IRIS
IRIS Home | Advanced Search
Searches using filters for organ/system affected are limited to effects (or tumor sites) used to derive the RfD, RfC, oral slope factor, or inhalation unit risk. Other effects associated with chemicals in the IRIS database that were not used as the basis for a toxicity value are not searchable with organ/system filters. IRIS Advanced Search searches only final IRIS assessments; to look for information on draft assessments, see Quick Check: Assessments in Development.
CHEMICAL NAME | CASRN | EXPOSURE ROUTE | ASSESSMENT TYPE | CRIT EFFECT TUMOR TYPE | WOE CHARACTERIZATION | TOXICITY VALUE TYPE | TOXICITY VALUE | |
---|---|---|---|---|---|---|---|---|
1 | Acenaphthene | 83-32-9 | Oral | Noncancer | Hepatotoxicity | n/a | RfD | 6 x 10 -2 mg/kg-day |
2 | Acenaphthylene | 208-96-8 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
3 | Acephate | 30560-19-1 | Oral | Noncancer | Inhibition of brain ChE | n/a | RfD | 4 x 10 -3 mg/kg-day |
4 | Acetaldehyde | 75-07-0 | Inhalation | Cancer | Nasal squamous cell carcinoma or adenocarcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 2.2 x 10 -6 per µg/m3 |
5 | Acetaldehyde | 75-07-0 | Inhalation | Noncancer | Degeneration of olfactory epithelium | n/a | RfC | 9 x 10 -3 mg/m3 |
6 | Acetochlor | 34256-82-1 | Oral | Noncancer | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | n/a | RfD | 2 x 10 -2 mg/kg-day |
7 | Acetone | 67-64-1 | Oral | Noncancer | Nephropathy | n/a | RfD | 9 x 10 -1 mg/kg-day |
8 | Acetonitrile | 75-05-8 | Inhalation | Noncancer | Mortality | n/a | RfC | 6 x 10 -2 mg/m3 |
9 | Acetophenone | 98-86-2 | Oral | Noncancer | General Toxicity | n/a | RfD | 1 x 10 -1 mg/kg-day |
10 | Acetyl chloride | 75-36-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
11 | Acifluorfen, sodium | 62476-59-9 | Oral | Noncancer | Mortality and kidney lesions | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
12 | Acrolein | 107-02-8 | Inhalation | Noncancer | Nasal lesions | n/a | RfC | 2 x 10 -5 mg/m3 |
13 | Acrolein | 107-02-8 | Oral | Noncancer | Decreased survival | n/a | RfD | 5 x 10 -4 mg/kg-day |
14 | Acrylamide | 79-06-1 | Oral | Cancer | thyroid tumors and tunica vaginalis mesotheliomas | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 5 x 10 -1 per mg/kg-day |
15 | Acrylamide | 79-06-1 | Inhalation | Cancer | thyroid tumors and tunica vaginalis mesotheliomas | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 1 x 10 -4 per µg/m3 |
16 | Acrylamide | 79-06-1 | Inhalation | Noncancer | Degenerative nerve changes | n/a | RfC | 6 x 10 -3 mg/m3 |
17 | Acrylamide | 79-06-1 | Oral | Noncancer | Degenerative nerve changes | n/a | RfD | 2 x 10 -3 mg/kg-day |
18 | Acrylic acid | 79-10-7 | Oral | Noncancer | Reduced pup weight | n/a | RfD | 5 x 10 -1 mg/kg-day |
19 | Acrylic acid | 79-10-7 | Inhalation | Noncancer | Degeneration of the nasal olfactory epithelium | n/a | RfC | 1 x 10 -3 mg/m3 |
20 | Acrylonitrile | 107-13-1 | Inhalation | Noncancer | Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells | n/a | RfC | 2 x 10 -3 mg/m3 |
21 | Acrylonitrile | 107-13-1 | Oral | Cancer | Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines) |
Oral Slope Factor | 5.4 x 10 -1 per mg/kg-day |
22 | Acrylonitrile | 107-13-1 | Inhalation | Cancer | Respiratory cancer | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines) |
Inhalation Unit Risk | 6.8 x 10 -5 per µg/m3 |
23 | Adiponitrile | 111-69-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
24 | Alachlor | 15972-60-8 | Oral | Noncancer | Hemosiderosis, hemolytic anemia | n/a | RfD | 1 x 10 -2 mg/kg-day |
25 | Alar | 1596-84-5 | Oral | Noncancer | No adverse effects | n/a | RfD | 1.5 x 10 -1 mg/kg-day |
26 | Aldicarb | 116-06-3 | Oral | Noncancer | Sweating as clinical sign of AChe inhibition | n/a | RfD | 1 x 10 -3 mg/kg-day |
27 | Aldicarb sulfone | 1646-88-4 | Oral | Noncancer | Brain ChE inhibition in females | n/a | RfD | 1 x 10 -3 mg/kg-day |
28 | Aldrin | 309-00-2 | Oral | Noncancer | Liver toxicity | n/a | RfD | 3 x 10 -5 mg/kg-day |
29 | Aldrin | 309-00-2 | Oral | Cancer | Liver carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.7 x 10 1 per mg/kg-day |
30 | Aldrin | 309-00-2 | Inhalation | Cancer | Liver carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 4.9 x 10 -3 per µg/m3 |
31 | Ally | 74223-64-6 | Oral | Noncancer | Decreased body weight | n/a | RfD | 2.5 x 10 -1 mg/kg-day |
32 | Allyl alcohol | 107-18-6 | Oral | Noncancer | Impaired renal function and increased liver and kidney weights | n/a | RfD | 5 x 10 -3 mg/kg-day |
33 | Allyl chloride | 107-05-1 | Inhalation | Noncancer | Functional and histological peripheral neurotoxicity | n/a | RfC | 1 x 10 -3 mg/m3 |
34 | Aluminum phosphide | 20859-73-8 | Oral | Noncancer | Body weight and clinical parameters | n/a | RfD | 4 x 10 -4 mg/kg-day |
35 | Amdro | 67485-29-4 | Oral | Noncancer | Increased organ weights | n/a | RfD | 3 x 10 -4 mg/kg-day |
36 | Ametryn | 834-12-8 | Oral | Noncancer | Liver toxicity | n/a | RfD | 9 x 10 -3 mg/kg-day |
37 | 4-Aminopyridine | 504-24-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
38 | Amitraz | 33089-61-1 | Oral | Noncancer | Increased mean blood sugar concentration; slight hypothermia | n/a | RfD | 2.5 x 10 -3 mg/kg-day |
39 | Ammonia | 7664-41-7 | Inhalation | Noncancer | Decreased lung function and respiratory symptoms | n/a | RfC | 5 x 10 -1 mg/m3 |
40 | Ammonium acetate | 631-61-8 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
41 | Ammonium methacrylate | 16325-47-6 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
42 | Ammonium sulfamate | 7773-06-0 | Oral | Noncancer | Decrease in body weight | n/a | RfD | 2 x 10 -1 mg/kg-day |
43 | Aniline | 62-53-3 | Inhalation | Noncancer | Methemoglobin increase, spleen toxicity | n/a | RfC | 1 x 10 -3 mg/m3 |
44 | Aniline | 62-53-3 | Oral | Cancer | Spleen, combined fibrosarcoma, stromal sarcoma, capsular sarcoma and hemangiosarcoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 5.7 x 10 -3 per mg/kg-day |
45 | Anthracene | 120-12-7 | Oral | Noncancer | No observed effects | n/a | RfD | 3 x 10 -1 mg/kg-day |
46 | Antimony | 7440-36-0 | Oral | Noncancer | Longevity, blood glucose, and cholesterol | n/a | RfD | 4 x 10 -4 mg/kg-day |
47 | Antimony trioxide | 1309-64-4 | Inhalation | Noncancer | Pulmonary toxicity, chronic interstitial inflammation | n/a | RfC | 2 x 10 -4 mg/m3 |
48 | Apollo | 74115-24-5 | Oral | Noncancer | Liver effects; organ weight changes | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
49 | Aramite | 140-57-8 | Inhalation | Cancer | Neoplastic liver nodules and carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 7.1 x 10 -6 per µg/m3 |
50 | Aramite | 140-57-8 | Oral | Cancer | Neoplastic liver nodules and carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.5 x 10 -2 per mg/kg-day |
51 | Aroclor 1016 | 12674-11-2 | Oral | Noncancer | Reduced birth weights | n/a | RfD | 7 x 10 -5 mg/kg-day |
52 | Aroclor 1254 | 11097-69-1 | Oral | Noncancer | Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes | n/a | RfD | 2 x 10 -5 mg/kg-day |
53 | Arsenic, Inorganic | 7440-38-2 | Inhalation | Cancer | Lung cancer | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 4.3 x 10 -3 per µg/m3 |
54 | Arsenic, Inorganic | 7440-38-2 | Oral | Cancer | Skin cancer | A (Human carcinogen) (1986 guidelines) |
Oral Slope Factor | 1.5 per mg/kg-day |
55 | Arsenic, Inorganic | 7440-38-2 | Oral | Noncancer | Hyperpigmentation, keratosis and possible vascular complications | n/a | RfD | 3 x 10 -4 mg/kg-day |
56 | Arsine | 7784-42-1 | Inhalation | Noncancer | Increased hemolysis, abnormal RBC morphology, and increased spleen weight | n/a | RfC | 5 x 10 -5 mg/m3 |
57 | Asbestos | 1332-21-4 | Inhalation | Cancer | Lung cancer and mesothelioma | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 2.3 x 10 -1 per f/mL |
58 | Assure | 76578-14-8 | Oral | Noncancer | Liver cell enlargement | n/a | RfD | 9 x 10 -3 mg/kg-day |
59 | Asulam | 3337-71-1 | Oral | Noncancer | Lower ovarian weight, lower liver/body weight | n/a | RfD | 5 x 10 -2 mg/kg-day |
60 | Atrazine | 1912-24-9 | Oral | Noncancer | Decreased body weight gain | n/a | RfD | 3.5 x 10 -2 mg/kg-day |
61 | Avermectin B1 | 65195-55-3 | Oral | Noncancer | Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth | n/a | RfD | 4 x 10 -4 mg/kg-day |
62 | Azobenzene | 103-33-3 | Oral | Cancer | Abdominal cavity sarcomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.1 x 10 -1 per mg/kg-day |
63 | Azobenzene | 103-33-3 | Inhalation | Cancer | Abdominal cavity sarcomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 3.1 x 10 -5 per µg/m3 |
64 | Barium and Compounds | 7440-39-3 | Oral | Noncancer | Nephropathy | n/a | RfD | 2 x 10 -1 mg/kg-day |
65 | Baygon | 114-26-1 | Oral | Noncancer | Mild cholinergic symptoms and RBD ChE inhibition | n/a | RfD | 4 x 10 -3 mg/kg-day |
66 | Bayleton | 43121-43-3 | Oral | Noncancer | Decreased body weight gain, erythrocyte count and hemoglobin level | n/a | RfD | 3 x 10 -2 mg/kg-day |
67 | Baythroid | 68359-37-5 | Oral | Noncancer | Decreased body weights in males, inflammatory foci in kidneys of females | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
68 | Benefin | 1861-40-1 | Oral | Noncancer | Depressed erythrocyte counts | n/a | RfD | 3 x 10 -1 mg/kg-day |
69 | Benomyl | 17804-35-2 | Oral | Noncancer | Decreased pup weanling weights | n/a | RfD | 5 x 10 -2 mg/kg-day |
70 | Bentazon (Basagran) | 25057-89-0 | Oral | Noncancer | Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs | n/a | RfD | 3 x 10 -2 mg/kg-day |
71 | Benz[a]anthracene | 56-55-3 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
72 | Benzaldehyde | 100-52-7 | Oral | Noncancer | Forestomach lesions, kidney toxicity | n/a | RfD | 1 x 10 -1 mg/kg-day |
73 | Benzene | 71-43-2 | Oral | Noncancer | Decreased lymphocyte count | n/a | RfD | 4 x 10 -3 mg/kg-day |
74 | Benzene | 71-43-2 | Inhalation | Cancer | Leukemia | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 7.8 x 10 -6 per µg/m3 |
75 | Benzene | 71-43-2 | Inhalation | Cancer | Leukemia | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 2.2 x 10 -6 per µg/m3 |
76 | Benzene | 71-43-2 | Oral | Cancer | Leukemia | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 5.5 x 10 -2 per mg/kg-day |
77 | Benzene | 71-43-2 | Oral | Cancer | Leukemia | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 1.5 x 10 -2 per mg/kg-day |
78 | Benzene | 71-43-2 | Inhalation | Noncancer | Decreased lymphocyte count | n/a | RfC | 3 x 10 -2 mg/m3 |
79 | Benzidine | 92-87-5 | Oral | Noncancer | Brain cell vacuolization; liver cell alterations in females | n/a | RfD | 3 x 10 -3 mg/kg-day |
80 | Benzidine | 92-87-5 | Oral | Cancer | Bladder tumors | A (Human carcinogen) (1986 guidelines) |
Oral Slope Factor | 2.3 x 10 2 per mg/kg-day |
81 | Benzidine | 92-87-5 | Inhalation | Cancer | Bladder tumors | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 6.7 x 10 -2 per µg/m3 |
82 | Benzo[a]pyrene (BaP) | 50-32-8 | Oral | Noncancer | Neurobehavioral changes | n/a | RfD | 3 x 10 -4 mg/kg-day |
83 | Benzo[a]pyrene (BaP) | 50-32-8 | Oral | Cancer | forestomach, esophagus, tongue, and larynx tumors | Carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 1 per mg/kg-day |
84 | Benzo[a]pyrene (BaP) | 50-32-8 | Inhalation | Cancer | Squamous cell neoplasia in the larynx, pharynx, trachea, nasal cavity, esophagus, and forestomach. | Carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 6 x 10 -4 per µg/m3 |
85 | Benzo[a]pyrene (BaP) | 50-32-8 | Inhalation | Noncancer | Reduced ovulation rate and ovary weight | n/a | RfC | 3 x 10 -6 mg/m3 |
86 | Benzo[a]pyrene (BaP) | 50-32-8 | Inhalation | Noncancer | Decreased embryo/fetal survival | n/a | RfC | 2 x 10 -6 mg/m3 |
87 | Benzo[a]pyrene (BaP) | 50-32-8 | Oral | Noncancer | Decreased ovarian follicles and ovary weight | n/a | RfD | 4 x 10 -4 mg/kg-day |
88 | Benzo[a]pyrene (BaP) | 50-32-8 | Oral | Noncancer | Decreased thymus weight and serum IgM | n/a | RfD | 2 x 10 -3 mg/kg-day |
89 | Benzo[b]fluoranthene | 205-99-2 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
90 | Benzo[g,h,i]perylene | 191-24-2 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
91 | Benzo[k]fluoranthene | 207-08-9 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
92 | Benzoic acid | 65-85-0 | Oral | Noncancer | No adverse effects observed | n/a | RfD | 4 mg/kg-day |
93 | Benzotrichloride | 98-07-7 | Oral | Cancer | Lung, adenocarcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.3 x 10 1 per mg/kg-day |
94 | Benzyl chloride | 100-44-7 | Oral | Cancer | Thyroid, C-cell adenoma/ carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.7 x 10 -1 per mg/kg-day |
95 | Beryllium and compounds | 7440-41-7 | Oral | Noncancer | Small intestinal lesions | n/a | RfD | 2 x 10 -3 mg/kg-day |
96 | Beryllium and compounds | 7440-41-7 | Inhalation | Cancer | Lung cancer | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines) Carcinogenic potential cannot be determined (1996 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 2.4 x 10 -3 per µg/m3 |
97 | Beryllium and compounds | 7440-41-7 | Inhalation | Noncancer | Beryllium sensitization and progression to CBD | n/a | RfC | 2 x 10 -5 mg/m3 |
98 | Bidrin | 141-66-2 | Oral | Noncancer | Decreased pup survival | n/a | RfD | 1 x 10 -4 mg/kg-day |
99 | Biphenthrin | 82657-04-3 | Oral | Noncancer | Tremors | n/a | RfD | 1.5 x 10 -2 mg/kg-day |
100 | Biphenyl | 92-52-4 | Oral | Cancer | Liver adenomas or carcinomas | Suggestive evidence of carcinogenic potential (2005 guidelines) |
Oral Slope Factor | 8 x 10 -3 per mg/kg-day |
101 | Biphenyl | 92-52-4 | Oral | Noncancer | Renal papillary mineralization in male F344 rats | n/a | RfD | 5 x 10 -1 mg/kg-day |
102 | Bis(2-chloro-1-methylethyl) ether | 108-60-1 | Oral | Noncancer | Decrease in hemoglobin and possible erythrocyte destruction | n/a | RfD | 4 x 10 -2 mg/kg-day |
103 | Bis(2-chloroethoxy)methane | 111-91-1 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
104 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Oral | Cancer | Hepatomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.1 per mg/kg-day |
105 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Inhalation | Cancer | Hepatomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 3.3 x 10 -4 per µg/m3 |
106 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Oral | Cancer | Respiratory tract tumors | A (Human carcinogen) (1986 guidelines) |
Oral Slope Factor | 2.2 x 10 2 per mg/kg-day |
107 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Inhalation | Cancer | Respiratory tract tumors | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 6.2 x 10 -2 per µg/m3 |
108 | Bisphenol A | 80-05-7 | Oral | Noncancer | Reduced mean body weight | n/a | RfD | 5 x 10 -2 mg/kg-day |
109 | Boron and Compounds | 7440-42-8 | Oral | Noncancer | Decreased fetal weight (developmental) | n/a | RfD | 2 x 10 -1 mg/kg-day |
110 | Bromate | 15541-45-4 | Oral | Noncancer | Renal effects: urothelial hyperplasia | n/a | RfD | 4 x 10 -3 mg/kg-day |
111 | Bromate | 15541-45-4 | Oral | Cancer | Testicular mesothelioma, renal tubular adenoma and carcinoma, and thyroid follicular cell adenoma and carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Carcinogenic potential cannot be determined (1996 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 7 x 10 -1 per mg/kg-day |
112 | Brominated dibenzofurans | None | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
113 | Bromobenzene | 108-86-1 | Oral | Noncancer | Hepatocellular cytomegaly in male B6C3F1 mice | n/a | RfD | 8 x 10 -3 mg/kg-day |
114 | Bromobenzene | 108-86-1 | Oral | Noncancer | Hepatocellular cytomegaly in male B6C3F1 mice | n/a | RfD | 2 x 10 -2 mg/kg-day |
115 | Bromobenzene | 108-86-1 | Inhalation | Noncancer | Hepatocellular cytomegaly in female B6C3F1 mice | n/a | RfC | 6 x 10 -2 mg/m3 |
116 | Bromobenzene | 108-86-1 | Inhalation | Noncancer | Hepatocellular cytomegaly in female B6C3F1 mice | n/a | RfC | 2 x 10 -1 mg/m3 |
117 | Bromochloromethane | 74-97-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
118 | Bromodichloromethane | 75-27-4 | Oral | Noncancer | Renal cytomegaly | n/a | RfD | 2 x 10 -2 mg/kg-day |
119 | Bromodichloromethane | 75-27-4 | Oral | Cancer | Kidney (tubular cell adenoma and tubular cell adenocarcinoma) | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 6.2 x 10 -2 per mg/kg-day |
120 | p-Bromodiphenyl ether | 101-55-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
121 | Bromoform | 75-25-2 | Oral | Noncancer | Hepatic lesions | n/a | RfD | 2 x 10 -2 mg/kg-day |
122 | Bromoform | 75-25-2 | Oral | Cancer | Neoplastic lesions in the large intestine | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 7.9 x 10 -3 per mg/kg-day |
123 | Bromoform | 75-25-2 | Inhalation | Cancer | Neoplastic lesions in the large intestine | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.1 x 10 -6 per µg/m3 |
124 | Bromomethane | 74-83-9 | Inhalation | Noncancer | Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity | n/a | RfC | 5 x 10 -3 mg/m3 |
125 | Bromomethane | 74-83-9 | Oral | Noncancer | Epithelial hyperplasia of the forestomach | n/a | RfD | 1.4 x 10 -3 mg/kg-day |
126 | Bromotrichloromethane | 75-62-7 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
127 | Bromoxynil | 1689-84-5 | Oral | Noncancer | No adverse effects | n/a | RfD | 2 x 10 -2 mg/kg-day |
128 | Bromoxynil octanoate | 1689-99-2 | Oral | Noncancer | No effects | n/a | RfD | 2 x 10 -2 mg/kg-day |
129 | 1,3-Butadiene | 106-99-0 | Inhalation | Cancer | Leukemia | Carcinogenic to humans (1999 guidelines) |
Inhalation Unit Risk | 3 x 10 -5 per µg/m3 |
130 | 1,3-Butadiene | 106-99-0 | Inhalation | Noncancer | Ovarian atrophy | n/a | RfC | 2 x 10 -3 mg/m3 |
131 | Butyl benzyl phthalate (BBP) | 85-68-7 | Oral | Noncancer | Significantly increased liver-to-body weight and liver-to-brain weight ratios | n/a | RfD | 2 x 10 -1 mg/kg-day |
132 | Butylate | 2008-41-5 | Oral | Noncancer | Increased relative liver weight in male dogs | n/a | RfD | 5 x 10 -2 mg/kg-day |
133 | t-Butylchloride | 507-20-0 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
134 | Butylphthalyl butylglycolate (BPBG) | 85-70-1 | Oral | Noncancer | No adverse effect | n/a | RfD | 1 mg/kg-day |
135 | Cacodylic acid | 75-60-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
136 | Cadmium | 7440-43-9 | Inhalation | Cancer | Lung, trachea, bronchus cancer deaths | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines) |
Inhalation Unit Risk | 1.8 x 10 -3 per µg/m3 |
137 | Cadmium | 7440-43-9 | Oral | Noncancer | Significant proteinuria | n/a | RfD | 1 x 10 -3 mg/kg-day |
138 | Cadmium | 7440-43-9 | Oral | Noncancer | Significant proteinuria | n/a | RfD | 5 x 10 -4 mg/kg-day |
139 | Calcium cyanide | 592-01-8 | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | n/a | RfD | 1 x 10 -3 mg/kg-day |
140 | Caprolactam | 105-60-2 | Oral | Noncancer | Reduced offspring body weight | n/a | RfD | 5 x 10 -1 mg/kg-day |
141 | Captafol | 2425-06-1 | Oral | Noncancer | Kidney and bladder toxicity | n/a | RfD | 2 x 10 -3 mg/kg-day |
142 | Captan | 133-06-2 | Oral | Noncancer | Decreased mean body weights | n/a | RfD | 1.3 x 10 -1 mg/kg-day |
143 | Carbaryl | 63-25-2 | Oral | Noncancer | Kidney and liver toxicity | n/a | RfD | 1 x 10 -1 mg/kg-day |
144 | Carbofuran | 1563-66-2 | Oral | Noncancer | RBC and plasma cholinesterase inhibition, and testicular and uterine effects | n/a | RfD | 5 x 10 -3 mg/kg-day |
145 | Carbon disulfide | 75-15-0 | Inhalation | Noncancer | Peripheral nervous system dysfunction | n/a | RfC | 7 x 10 -1 mg/m3 |
146 | Carbon disulfide | 75-15-0 | Oral | Noncancer | Fetal toxicity/ malformations | n/a | RfD | 1 x 10 -1 mg/kg-day |
147 | Carbon tetrachloride | 56-23-5 | Oral | Noncancer | Elevated serum SDH activity | n/a | RfD | 4 x 10 -3 mg/kg-day |
148 | Carbon tetrachloride | 56-23-5 | Oral | Cancer | Hepatocellular adenoma or carcinoma | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 7 x 10 -2 per mg/kg-day |
149 | Carbon tetrachloride | 56-23-5 | Inhalation | Noncancer | Fatty changes in the liver | n/a | RfC | 1 x 10 -1 mg/m3 |
150 | Carbon tetrachloride | 56-23-5 | Inhalation | Cancer | Pheochromocytoma | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 6 x 10 -6 per µg/m3 |
151 | Carbosulfan | 55285-14-8 | Oral | Noncancer | Decreased body weight | n/a | RfD | 1 x 10 -2 mg/kg-day |
152 | Carboxin | 5234-68-4 | Oral | Noncancer | Reduced weight gain, organ weight changes, increased mortality | n/a | RfD | 1 x 10 -1 mg/kg-day |
153 | Cerium Oxide and Cerium Compounds | 1306-38-3 | Inhalation | Noncancer | Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats | n/a | RfC | 9 x 10 -4 mg/m3 |
154 | Chloral hydrate | 302-17-0 | Oral | Noncancer | CNS depression and GI irritation in humans | n/a | RfD | 1 x 10 -1 mg/kg-day |
155 | Chloramben | 133-90-4 | Oral | Noncancer | Hepatocyte degeneration | n/a | RfD | 1.5 x 10 -2 mg/kg-day |
156 | Chlordane (Technical) | 12789-03-6 | Inhalation | Noncancer | Hepatic effects | n/a | RfC | 7 x 10 -4 mg/m3 |
157 | Chlordane (Technical) | 12789-03-6 | Oral | Noncancer | Hepatic necrosis | n/a | RfD | 5 x 10 -4 mg/kg-day |
158 | Chlordane (Technical) | 12789-03-6 | Inhalation | Cancer | Hepatocellular carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 1 x 10 -4 per µg/m3 |
159 | Chlordane (Technical) | 12789-03-6 | Oral | Cancer | Hepatocellular carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 3.5 x 10 -1 per mg/kg-day |
160 | Chlordecone (Kepone) | 143-50-0 | Oral | Noncancer | Renal lesions (glomerulosclerosis) in female Wistar rats | n/a | RfD | 3 x 10 -4 mg/kg-day |
161 | Chlordecone (Kepone) | 143-50-0 | Oral | Cancer | liver hepatocellular carcinoma | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 1 x 10 1 per mg/kg-day |
162 | Chlorimuron-ethyl | 90982-32-4 | Oral | Noncancer | Increase in WBC, decreased in RBC in females, increase in alkaline phosphatase in males | n/a | RfD | 2 x 10 -2 mg/kg-day |
163 | Chlorine | 7782-50-5 | Oral | Noncancer | No observed adverse effects | n/a | RfD | 1 x 10 -1 mg/kg-day |
164 | Chlorine cyanide | 506-77-4 | Oral | Noncancer | Weight loss, thyroid effects, and myelin degeneration | n/a | RfD | 5 x 10 -2 mg/kg-day |
165 | Chlorine dioxide | 10049-04-4 | Oral | Noncancer | Neurodevelopmental effects | n/a | RfD | 3 x 10 -2 mg/kg-day |
166 | Chlorine dioxide | 10049-04-4 | Inhalation | Noncancer | Vascular congestion and peribronchial edema | n/a | RfC | 2 x 10 -4 mg/m3 |
167 | Chlorite (sodium salt) | 7758-19-2 | Oral | Noncancer | Neurodevelopmental effects | n/a | RfD | 3 x 10 -2 mg/kg-day |
168 | 1-Chloro-1,1-difluoroethane | 75-68-3 | Inhalation | Noncancer | No adverse effects | n/a | RfC | 5 x 10 1 mg/m3 |
169 | 2-Chloroacetophenone | 532-27-4 | Inhalation | Noncancer | Squamous hyperplasia of the nasal respiratory epithelium | n/a | RfC | 3 x 10 -5 mg/m3 |
170 | p-Chloroaniline | 106-47-8 | Oral | Noncancer | Nonneoplastic lesions of splenic capsule | n/a | RfD | 4 x 10 -3 mg/kg-day |
171 | Chlorobenzene | 108-90-7 | Oral | Noncancer | Histopathologic changes in liver | n/a | RfD | 2 x 10 -2 mg/kg-day |
172 | Chlorobenzilate | 510-15-6 | Oral | Noncancer | Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) | n/a | RfD | 2 x 10 -2 mg/kg-day |
173 | 1-Chlorobutane | 109-69-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
174 | 2-Chlorobutane | 78-86-4 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
175 | Chlorocyclopentadiene | 41851-50-7 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
176 | Chlorodifluoromethane | 75-45-6 | Inhalation | Noncancer | Increased kidney, adrenal and pituitary weights | n/a | RfC | 5 x 10 1 mg/m3 |
177 | Chloroform | 67-66-3 | Inhalation | Cancer | Hepatocellular carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Likely to be carcinogenic to humans (1999 guidelines) Not likely to be carcinogenic to humans (1999 guidelines) |
Inhalation Unit Risk | 2.3 x 10 -5 per µg/m3 |
178 | Chloroform | 67-66-3 | Oral | Noncancer | Moderate/marked fatty cyst formation in the liver and elevated SGPT | n/a | RfD | 1 x 10 -2 mg/kg-day |
179 | Chloromethyl methyl ether (CMME) | 107-30-2 | None | Cancer | None | A (Human carcinogen) (1986 guidelines) |
NA | 0 NA |
180 | beta-Chloronaphthalene | 91-58-7 | Oral | Noncancer | Dyspnea, abnormal appearance, liver enlargement | n/a | RfD | 8 x 10 -2 mg/kg-day |
181 | 2-Chlorophenol | 95-57-8 | Oral | Noncancer | Reproductive effects | n/a | RfD | 5 x 10 -3 mg/kg-day |
182 | p-Chlorophenyl methyl sulfide | 123-09-1 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
183 | p-Chlorophenyl methyl sulfone | 98-57-7 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
184 | p-Chlorophenyl methyl sulfoxide | 934-73-6 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
185 | Chloroprene | 126-99-8 | Inhalation | Noncancer | Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively | n/a | RfC | 2 x 10 -2 mg/m3 |
186 | Chloroprene | 126-99-8 | Inhalation | Cancer | alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 3 x 10 -4 per µg/m3 |
187 | Chlorothalonil | 1897-45-6 | Oral | Noncancer | Renal tubular epithelial vacuolation | n/a | RfD | 1.5 x 10 -2 mg/kg-day |
188 | o-Chlorotoluene | 95-49-8 | Oral | Noncancer | Decrease in body weight gain | n/a | RfD | 2 x 10 -2 mg/kg-day |
189 | Chlorpropham | 101-21-3 | Oral | Noncancer | Kidney, spleen, liver, and bone marrow toxicity | n/a | RfD | 2 x 10 -1 mg/kg-day |
190 | Chlorsulfuron | 64902-72-3 | Oral | Noncancer | Decreased body weight | n/a | RfD | 5 x 10 -2 mg/kg-day |
191 | Chromium(III), insoluble salts | 16065-83-1 | Oral | Noncancer | No effects observed | n/a | RfD | 1.5 mg/kg-day |
192 | Chromium(VI) | 18540-29-9 | Oral | Noncancer | GI tract effects in mice and rats | n/a | RfD | 9 x 10 -4 mg/kg-day |
193 | Chromium(VI) | 18540-29-9 | Inhalation | Noncancer | Ulcerated nasal septum in humans | n/a | RfC | 3 x 10 -5 mg/m3 |
194 | Chromium(VI) | 18540-29-9 | Inhalation | Cancer | Lung cancer | Carcinogenic to humans (2005 guidelines) Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 1.1 x 10 -2 per µg/m3 |
195 | Chromium(VI) | 18540-29-9 | Oral | Cancer | Squamous cell carcinoma or squamous cell papilloma. | Carcinogenic to humans (2005 guidelines) Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 1.6 x 10 -1 per mg/kg-day |
196 | Chrysene | 218-01-9 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
197 | Coke oven emissions | None | Inhalation | Cancer | Respiratory cancer | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 6.2 x 10 -4 per µg/m3 |
198 | Copper | 7440-50-8 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
199 | Copper cyanide | 544-92-3 | Oral | Noncancer | Decreased body and organ weights, histopathologic alterations in liver and kidney | n/a | RfD | 5 x 10 -3 mg/kg-day |
200 | Creosote | 8001-58-9 | None | Cancer | None | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) (1986 guidelines) |
NA | 0 NA |
201 | Crotonaldehyde | 123-73-9 | None | Cancer | None | C (Possible human carcinogen) (1986 guidelines) |
NA | 0 NA |
202 | Cumene | 98-82-8 | Oral | Noncancer | Increased average kidney weight in female rats | n/a | RfD | 1 x 10 -1 mg/kg-day |
203 | Cumene | 98-82-8 | Inhalation | Noncancer | Increased kidney weights in female rats and adrenal weights in male and female rats | n/a | RfC | 4 x 10 -1 mg/m3 |
204 | Cyanide, free | 57-12-5 | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section 1.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | n/a | RfD | 6.3 x 10 -4 mg/kg-day |
205 | Cyanogen | 460-19-5 | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanogen is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | n/a | RfD | 1 x 10 -3 mg/kg-day |
206 | Cyanogen bromide | 506-68-3 | Oral | Noncancer | Weight loss, thyroid effects and myelin degeneration | n/a | RfD | 9 x 10 -2 mg/kg-day |
207 | Cyclohexane | 110-82-7 | Inhalation | Noncancer | Reduced pup weights in the F1 and F2 generations | n/a | RfC | 6 mg/m3 |
208 | Cyclohexanone | 108-94-1 | Oral | Noncancer | Body weight depression | n/a | RfD | 5 mg/kg-day |
209 | Cyclohexylamine | 108-91-8 | Oral | Noncancer | Testicular damage | n/a | RfD | 2 x 10 -1 mg/kg-day |
210 | Cyhalothrin/Karate | 68085-85-8 | Oral | Noncancer | Reduced body weight gain preceding pregnancy reduced body weight gain in offspring during weaning period | n/a | RfD | 5 x 10 -3 mg/kg-day |
211 | Cypermethrin | 52315-07-8 | Oral | Noncancer | G.I. tract disturbances | n/a | RfD | 1 x 10 -2 mg/kg-day |
212 | Cyromazine | 66215-27-8 | Oral | Noncancer | Hematologic effects | n/a | RfD | 7.5 x 10 -3 mg/kg-day |
213 | Dacthal | 1861-32-1 | Oral | Noncancer | Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females | n/a | RfD | 1 x 10 -2 mg/kg-day |
214 | Dalapon, sodium salt | 75-99-0 | Oral | Noncancer | Increased kidney body weight ratio | n/a | RfD | 3 x 10 -2 mg/kg-day |
215 | Danitol | 39515-41-8 | Oral | Noncancer | Tremors | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
216 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Oral | Noncancer | Neurobehavioral effects | n/a | RfD | 7 x 10 -3 mg/kg-day |
217 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Oral | Cancer | Liver neoplastic nodules or carcinoma (combined) | Suggestive evidence of carcinogenic potential (2005 guidelines) |
Oral Slope Factor | 7 x 10 -4 per mg/kg-day |
218 | Demeton | 8065-48-3 | Oral | Noncancer | ChE inhibition, optic nerve degeneration | n/a | RfD | 4 x 10 -5 mg/kg-day |
219 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Oral | Cancer | Hepatocellular carcinoma and adenoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.4 x 10 -2 per mg/kg-day |
220 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Oral | Noncancer | Increased relative liver weight | n/a | RfD | 2 x 10 -2 mg/kg-day |
221 | Di(2-ethylhexyl)adipate | 103-23-1 | Oral | Noncancer | Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size | n/a | RfD | 6 x 10 -1 mg/kg-day |
222 | Di(2-ethylhexyl)adipate | 103-23-1 | Oral | Cancer | Combined hepatocellular adenomas and carcinomas | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 1.2 x 10 -3 per mg/kg-day |
223 | Dibenz[a,h]anthracene | 53-70-3 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
224 | Dibenzofuran | 132-64-9 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
225 | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | Inhalation | Noncancer | Testicular effects | n/a | RfC | 2 x 10 -4 mg/m3 |
226 | 1,4-Dibromobenzene | 106-37-6 | Oral | Noncancer | Liver/body weight ratio and hepatic microsomal enzyme induction | n/a | RfD | 1 x 10 -2 mg/kg-day |
227 | Dibromochloromethane | 124-48-1 | Oral | Cancer | Hepatocellular adenoma or carcinoma | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 8.4 x 10 -2 per mg/kg-day |
228 | Dibromochloromethane | 124-48-1 | Oral | Noncancer | Hepatic lesions | n/a | RfD | 2 x 10 -2 mg/kg-day |
229 | Dibromodichloromethane | 594-18-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
230 | p,p'-Dibromodiphenyl ether | 2050-47-7 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
231 | 1,2-Dibromoethane | 106-93-4 | Oral | Cancer | Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas | Likely to be carcinogenic to humans (1999 guidelines) |
Oral Slope Factor | 1 mg/kg-day |
232 | 1,2-Dibromoethane | 106-93-4 | Oral | Cancer | Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas | Likely to be carcinogenic to humans (1999 guidelines) |
Oral Slope Factor | 2 per mg/kg-day |
233 | 1,2-Dibromoethane | 106-93-4 | Inhalation | Cancer | Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas | Likely to be carcinogenic to humans (1999 guidelines) |
Inhalation Unit Risk | 6 x 10 -4 per µg/m3 |
234 | 1,2-Dibromoethane | 106-93-4 | Inhalation | Cancer | Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas | Likely to be carcinogenic to humans (1999 guidelines) |
Inhalation Unit Risk | 3 x 10 -4 per µg/m3 |
235 | 1,2-Dibromoethane | 106-93-4 | Oral | Noncancer | Testicular atrophy, liver peliosis, and adrenal cortical degeneration | n/a | RfD | 9 x 10 -3 mg/kg-day |
236 | 1,2-Dibromoethane | 106-93-4 | Inhalation | Noncancer | Nasal inflammation | n/a | RfC | 9 x 10 -3 mg/m3 |
237 | Dibutyl phthalate (DBP) | 84-74-2 | Oral | Noncancer | Increased mortality | n/a | RfD | 1 x 10 -1 mg/kg-day |
238 | Dicamba | 1918-00-9 | Oral | Noncancer | Maternal (reduced weight gain) and fetal toxicity | n/a | RfD | 3 x 10 -2 mg/kg-day |
239 | Dichloroacetic acid | 79-43-6 | Oral | Noncancer | Lesions observed in the testes, cerebrum, cerebellum, and liver. | n/a | RfD | 4 x 10 -3 mg/kg-day |
240 | Dichloroacetic acid | 79-43-6 | Oral | Cancer | Hepatoadenoma and Hepatocarcinoma | Likely to be carcinogenic to humans (1999 guidelines) |
Oral Slope Factor | 5 x 10 -2 per mg/kg-day |
241 | 1,2-Dichlorobenzene | 95-50-1 | Oral | Noncancer | No adverse effects observed | n/a | RfD | 9 x 10 -2 mg/kg-day |
242 | 1,3-Dichlorobenzene | 541-73-1 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
243 | 1,4-Dichlorobenzene | 106-46-7 | Inhalation | Noncancer | Increased liver weights in P1 males | n/a | RfC | 8 x 10 -1 mg/m3 |
244 | 3,3'-Dichlorobenzidine | 91-94-1 | Oral | Cancer | Mammary adenocarcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 4.5 x 10 -1 per mg/kg-day |
245 | Dichlorodifluoromethane | 75-71-8 | Oral | Noncancer | Reduced body weight | n/a | RfD | 2 x 10 -1 mg/kg-day |
246 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | Oral | Cancer | Liver tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.4 x 10 -1 per mg/kg-day |
247 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | 72-55-9 | Oral | Cancer | Hepatocellular carcinomas, hepatomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 3.4 x 10 -1 per mg/kg-day |
248 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Inhalation | Cancer | Liver tumors, benign and malignant | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 9.7 x 10 -5 per µg/m3 |
249 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Oral | Cancer | Liver tumors, benign and malignant | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 3.4 x 10 -1 per mg/kg-day |
250 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Oral | Noncancer | Liver lesions | n/a | RfD | 5 x 10 -4 mg/kg-day |
251 | 1,1-Dichloroethane | 75-34-3 | None | Cancer | None | C (Possible human carcinogen) (1986 guidelines) |
NA | 0 NA |
252 | 1,2-Dichloroethane | 107-06-2 | Inhalation | Cancer | Hemangiosarcomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 2.6 x 10 -5 per µg/m3 |
253 | 1,2-Dichloroethane | 107-06-2 | Oral | Cancer | Hemangiosarcomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 9.1 x 10 -2 per mg/kg-day |
254 | cis-1,2-Dichloroethylene | 156-59-2 | Oral | Noncancer | Increased relative kidney weight in male rats | n/a | RfD | 2 x 10 -3 mg/kg-day |
255 | trans-1,2-Dichloroethylene | 156-60-5 | Oral | Noncancer | Decrease in number of antibody forming cells (AFCs) against sheep red blood cells (sRBCs) in male mice | n/a | RfD | 2 x 10 -2 mg/kg-day |
256 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Inhalation | Noncancer | Liver toxicity (fatty change) | n/a | RfC | 2 x 10 -1 mg/m3 |
257 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Oral | Noncancer | Liver toxicity (fatty change) | n/a | RfD | 5 x 10 -2 mg/kg-day |
258 | Dichloromethane | 75-09-2 | Oral | Cancer | Hepatocellular carcinomas or adenomas | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 2 x 10 -3 per mg/kg-day |
259 | Dichloromethane | 75-09-2 | Inhalation | Noncancer | Hepatic effects (hepatic vacuolation) | n/a | RfC | 6 x 10 -1 mg/m3 |
260 | Dichloromethane | 75-09-2 | Oral | Noncancer | Hepatic effects (hepatic vacuolation, liver foci) | n/a | RfD | 6 x 10 -3 mg/kg-day |
261 | Dichloromethane | 75-09-2 | Inhalation | Cancer | Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 1 x 10 -8 per µg/m3 |
262 | 2,4-Dichlorophenol | 120-83-2 | Oral | Noncancer | Decreased delayed hypersensitivity response | n/a | RfD | 3 x 10 -3 mg/kg-day |
263 | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) | 94-82-6 | Oral | Noncancer | Internal hemorrhage, mortality | n/a | RfD | 8 x 10 -3 mg/kg-day |
264 | 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Oral | Noncancer | Hematologic, hepatic and renal toxicity | n/a | RfD | 1 x 10 -2 mg/kg-day |
265 | 1,2-Dichloropropane | 78-87-5 | Inhalation | Noncancer | Hyperplasia of the nasal mucosa | n/a | RfC | 4 x 10 -3 mg/m3 |
266 | 2,3-Dichloropropanol | 616-23-9 | Oral | Noncancer | Myocardial degeneration, hepatotoxicity and nephrotoxicity | n/a | RfD | 3 x 10 -3 mg/kg-day |
267 | 1,3-Dichloropropene | 542-75-6 | Inhalation | Cancer | Bronchioalveolar adenoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 4 x 10 -6 per µg/m3 |
268 | 1,3-Dichloropropene | 542-75-6 | Inhalation | Noncancer | Hypertrophy/ hyperplasia of the nasal respiratory epithelium | n/a | RfC | 2 x 10 -2 mg/m3 |
269 | 1,3-Dichloropropene | 542-75-6 | Oral | Cancer | Hepatocellular adenoma/carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 5 x 10 -2 per mg/kg-day |
270 | 1,3-Dichloropropene | 542-75-6 | Oral | Noncancer | Chronic irritation | n/a | RfD | 3 x 10 -2 mg/kg-day |
271 | 1,3-Dichloropropene | 542-75-6 | Oral | Cancer | Urinary bladder carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 1 x 10 -1 per mg/kg-day |
272 | 1,3-Dichloropropene | 542-75-6 | Oral | Cancer | Hepatocellular adenoma/carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 5 x 10 -2 per mg/kg-day |
273 | Dichlorvos | 62-73-7 | Oral | Noncancer | Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males | n/a | RfD | 5 x 10 -4 mg/kg-day |
274 | Dichlorvos | 62-73-7 | Inhalation | Noncancer | Decreased brain cholinesterase activity | n/a | RfC | 5 x 10 -4 mg/m3 |
275 | Dichlorvos | 62-73-7 | Oral | Cancer | Forestomach tumors, pancreatic acinar adenoma, leukemia | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.9 x 10 -1 per mg/kg-day |
276 | Dieldrin | 60-57-1 | Inhalation | Cancer | Liver carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 4.6 x 10 -3 per µg/m3 |
277 | Dieldrin | 60-57-1 | Oral | Cancer | Liver carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.6 x 10 1 per mg/kg-day |
278 | Dieldrin | 60-57-1 | Oral | Noncancer | Liver lesions | n/a | RfD | 5 x 10 -5 mg/kg-day |
279 | Diesel engine exhaust | None | Inhalation | Noncancer | Pulmonary inflammation and histopathology | n/a | RfC | 5 x 10 -3 mg/m3 |
280 | Diethyl phthalate (DEP) | 84-66-2 | Oral | Noncancer | Decreased growth rate, food consumption and altered organ weights | n/a | RfD | 8 x 10 -1 mg/kg-day |
281 | Diethyl-p-nitrophenylphosphate | 311-45-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
282 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
283 | Difenzoquat | 43222-48-6 | Oral | Noncancer | Decreased body weight | n/a | RfD | 8 x 10 -2 mg/kg-day |
284 | Diflubenzuron | 35367-38-5 | Oral | Noncancer | Methemoglobin and sulfhemoglobin formation | n/a | RfD | 2 x 10 -2 mg/kg-day |
285 | 1,1-Difluoroethane | 75-37-6 | Inhalation | Noncancer | No adverse effects observed | n/a | RfC | 4 x 10 1 mg/m3 |
286 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | Oral | Noncancer | No effects related to treatment | n/a | RfD | 8 x 10 -2 mg/kg-day |
287 | Dimethipin | 55290-64-7 | Oral | Noncancer | Increased absolute and relative liver weight | n/a | RfD | 2 x 10 -2 mg/kg-day |
288 | Dimethoate | 60-51-5 | Oral | Noncancer | Brain ChE inhibition | n/a | RfD | 2 x 10 -4 mg/kg-day |
289 | Dimethyl phthalate | 131-11-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
290 | Dimethyl sulfate | 77-78-1 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
291 | Dimethyl terephthalate (DMT) | 120-61-6 | Oral | Noncancer | Chronic kidney inflammation | n/a | RfD | 1 x 10 -1 mg/kg-day |
292 | N-N-Dimethylaniline | 121-69-7 | Oral | Noncancer | Splenomegaly, increased splenic hemosiderosis and hematopoiesis | n/a | RfD | 2 x 10 -3 mg/kg-day |
293 | N,N-Dimethylformamide | 68-12-2 | Inhalation | Noncancer | Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities | n/a | RfC | 3 x 10 -2 mg/m3 |
294 | 2,4-Dimethylphenol | 105-67-9 | Oral | Noncancer | Clinical signs (lethargy, prostration, and ataxia) and hematological changes | n/a | RfD | 2 x 10 -2 mg/kg-day |
295 | 2,6-Dimethylphenol | 576-26-1 | Oral | Noncancer | Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) | n/a | RfD | 6 x 10 -4 mg/kg-day |
296 | 3,4-Dimethylphenol | 95-65-8 | Oral | Noncancer | Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen | n/a | RfD | 1 x 10 -3 mg/kg-day |
297 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | Oral | Noncancer | Cataract formation | n/a | RfD | 2 x 10 -3 mg/kg-day |
298 | m-Dinitrobenzene | 99-65-0 | Oral | Noncancer | Increased splenic weight | n/a | RfD | 1 x 10 -4 mg/kg-day |
299 | o-Dinitrobenzene | 528-29-0 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
300 | 2,4-Dinitrophenol | 51-28-5 | Oral | Noncancer | Cataract formation | n/a | RfD | 2 x 10 -3 mg/kg-day |
301 | 2,4-Dinitrotoluene | 121-14-2 | Oral | Noncancer | Neurotoxicity, Heinz bodies and biliary tract hyperplasia | n/a | RfD | 2 x 10 -3 mg/kg-day |
302 | 2,4-/2,6-Dinitrotoluene mixture | Various | Oral | Cancer | Liver: hepatocellular carcinomas, neoplastic nodules; mammary gland: adenomas, fibroadenomas, fibromas, adenocarcinomas/ carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 6.8 x 10 -1 per mg/kg-day |
303 | Dinoseb | 88-85-7 | Oral | Noncancer | Decreased fetal weight | n/a | RfD | 1 x 10 -3 mg/kg-day |
304 | 1,4-Dioxane | 123-91-1 | Oral | Noncancer | Liver and kidney toxicity | n/a | RfD | 3 x 10 -2 mg/kg-day |
305 | 1,4-Dioxane | 123-91-1 | Inhalation | Cancer | Multiple (nasal, liver, kidney, peritoneal, mammary gland, and Zymbal gland) | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 5 x 10 -6 per µg/m3 |
306 | 1,4-Dioxane | 123-91-1 | Oral | Cancer | Hepatocellular adenoma and carcinoma | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 1 x 10 -1 per mg/kg-day |
307 | 1,4-Dioxane | 123-91-1 | Inhalation | Noncancer | Atrophy and respiratory metaplasia of the olfactory epithelium | n/a | RfC | 3 x 10 -2 mg/m3 |
308 | Diphenamid | 957-51-7 | Oral | Noncancer | Liver toxicity | n/a | RfD | 3 x 10 -2 mg/kg-day |
309 | Diphenylamine | 122-39-4 | Oral | Noncancer | Decreased body weight gain, and increased liver and kidney weights | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
310 | 1,2-Diphenylhydrazine | 122-66-7 | Oral | Cancer | Hepatocellular carcinomas and neoplastic liver nodules | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 8 x 10 -1 per mg/kg-day |
311 | 1,2-Diphenylhydrazine | 122-66-7 | Inhalation | Cancer | Hepatocellular carcinomas and neoplastic liver nodules | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 2.2 x 10 -4 per µg/m3 |
312 | Diquat | 2764-72-9 | Oral | Noncancer | Minimal lens opacity and cataracts | n/a | RfD | 2.2 x 10 -3 mg/kg-day |
313 | Disulfoton | 298-04-4 | Oral | Noncancer | ChE inhibition, optic nerve degeneration | n/a | RfD | 4 x 10 -5 mg/kg-day |
314 | 1,4-Dithiane | 505-29-3 | Oral | Noncancer | Nasal olfactory lesions | n/a | RfD | 1 x 10 -2 mg/kg-day |
315 | Diuron | 330-54-1 | Oral | Noncancer | Abnormal pigments in blood | n/a | RfD | 2 x 10 -3 mg/kg-day |
316 | Dodine | 2439-10-3 | Oral | Noncancer | Thyroid toxicity | n/a | RfD | 4 x 10 -3 mg/kg-day |
317 | Endosulfan | 115-29-7 | Oral | Noncancer | Reduced body weight gain in males and females increased incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males | n/a | RfD | 6 x 10 -3 mg/kg-day |
318 | Endothall | 145-73-3 | Oral | Noncancer | Increased absolute and relative weights of stomach and small intestine | n/a | RfD | 2 x 10 -2 mg/kg-day |
319 | Endrin | 72-20-8 | Oral | Noncancer | Mild histological lesions in liver, occasional convulsions | n/a | RfD | 3 x 10 -4 mg/kg-day |
320 | Epichlorohydrin | 106-89-8 | Oral | Cancer | Papillomas and carcinomas of the forestomach | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 9.9 x 10 -3 per mg/kg-day |
321 | Epichlorohydrin | 106-89-8 | Inhalation | Cancer | Nasal cavity tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.2 x 10 -6 per µg/m3 |
322 | Epichlorohydrin | 106-89-8 | Inhalation | Noncancer | Changes in the nasal turbinates | n/a | RfC | 1 x 10 -3 mg/m3 |
323 | 1,2-Epoxybutane (EBU) | 106-88-7 | Inhalation | Noncancer | Degenerative lesions of the nasal cavity | n/a | RfC | 2 x 10 -2 mg/m3 |
324 | Ethephon | 16672-87-0 | Oral | Noncancer | Plasma ChE inhibition | n/a | RfD | 5 x 10 -3 mg/kg-day |
325 | Ethion | 563-12-2 | Oral | Noncancer | Plasma cholinesterase inhibition | n/a | RfD | 5 x 10 -4 mg/kg-day |
326 | 2-Ethoxyethanol | 110-80-5 | Inhalation | Noncancer | Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin | n/a | RfC | 2 x 10 -1 mg/m3 |
327 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Inhalation | Noncancer | Increased absolute kidney weight in female rats | n/a | RfC | 4 x 10 1 mg/m3 |
328 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Inhalation | Cancer | Hepatocellular adenomas and carcinomas | Suggestive evidence of carcinogenic potential (2005 guidelines) |
Inhalation Unit Risk | 8 x 10 -5 per mg/m3 |
329 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Oral | Noncancer | Increased absolute kidney weight in female rats | n/a | RfD | 1 mg/kg-day |
330 | Ethyl acetate | 141-78-6 | Oral | Noncancer | Mortality and body weight loss | n/a | RfD | 9 x 10 -1 mg/kg-day |
331 | Ethyl chloride | 75-00-3 | Inhalation | Noncancer | Delayed fetal ossification | n/a | RfC | 1 x 10 1 mg/m3 |
332 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | Oral | Noncancer | Degenerative cardiomyopathy | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
333 | Ethyl ether | 60-29-7 | Oral | Noncancer | Depressed body weights | n/a | RfD | 2 x 10 -1 mg/kg-day |
334 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | Oral | Noncancer | Neurotoxicity | n/a | RfD | 1 x 10 -5 mg/kg-day |
335 | Ethylbenzene | 100-41-4 | Oral | Noncancer | Liver and kidney toxicity | n/a | RfD | 1 x 10 -1 mg/kg-day |
336 | Ethylbenzene | 100-41-4 | Inhalation | Noncancer | Developmental toxicity | n/a | RfC | 1 mg/m3 |
337 | Ethylene diamine | 107-15-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
338 | Ethylene glycol | 107-21-1 | Oral | Noncancer | Kidney toxicity | n/a | RfD | 2 mg/kg-day |
339 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Oral | Noncancer | Hemosiderin deposition in the liver | n/a | RfD | 1 x 10 -1 mg/kg-day |
340 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Inhalation | Noncancer | Hemosiderin deposition in the liver | n/a | RfC | 1.6 mg/m3 |
341 | Ethylene oxide | 75-21-8 | Inhalation | Cancer | Lymphoid cancer, (female) breast cancer | Carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 3 x 10 -3 per µg/m3 |
342 | Ethylene thiourea (ETU) | 96-45-7 | Oral | Noncancer | Increased incidence of thyroid hyperplasia | n/a | RfD | 8 x 10 -5 mg/kg-day |
343 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | Oral | Noncancer | Kidney damage and reduced lifespan | n/a | RfD | 3 mg/kg-day |
344 | Express | 101200-48-0 | Oral | Noncancer | Elevated serum bilirubin and AST levels, increased urinary volume | n/a | RfD | 8 x 10 -3 mg/kg-day |
345 | Fenamiphos | 22224-92-6 | Oral | Noncancer | ChE inhibition | n/a | RfD | 2.5 x 10 -4 mg/kg-day |
346 | Fluometuron | 2164-17-2 | Oral | Noncancer | No adverse effects | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
347 | Fluoranthene | 206-44-0 | Oral | Noncancer | Nephropathy, increased liver weights, hematological alterations, and clinical effects | n/a | RfD | 4 x 10 -2 mg/kg-day |
348 | Fluorene | 86-73-7 | Oral | Noncancer | Decreased RBC, packed cell volume and hemoglobin | n/a | RfD | 4 x 10 -2 mg/kg-day |
349 | Fluorine (soluble fluoride) | 7782-41-4 | Oral | Noncancer | Objectionable dental fluorosis, a cosmetic effect | n/a | RfD | 6 x 10 -2 mg/kg-day |
350 | Fluridone | 59756-60-4 | Oral | Noncancer | Glomerulonephritis, atrophic testes, eye keratitis decreased body weight and organ weights | n/a | RfD | 8 x 10 -2 mg/kg-day |
351 | Flurprimidol | 56425-91-3 | Oral | Noncancer | Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) | n/a | RfD | 2 x 10 -2 mg/kg-day |
352 | Flutolanil | 66332-96-5 | Oral | Noncancer | Decreased body weight and body weight gains in both doses increased liver weights at high dose | n/a | RfD | 6 x 10 -2 mg/kg-day |
353 | Fluvalinate | 69409-94-5 | Oral | Noncancer | Decreases in body weight gain increase in plantar ulcer (females) | n/a | RfD | 1 x 10 -2 mg/kg-day |
354 | Folpet | 133-07-3 | Oral | Noncancer | Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) | n/a | RfD | 1 x 10 -1 mg/kg-day |
355 | Fonofos | 944-22-9 | Oral | Noncancer | Cholinesterase inhibition, cholinergic symptoms, and increased liver weight | n/a | RfD | 2 x 10 -3 mg/kg-day |
356 | Formaldehyde | 50-00-0 | Inhalation | Cancer | Nasopharyngeal cancer, sinonasal cancer, myeloid leukemia | Carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 1.1 x 10 -5 per µg/m3 |
357 | Formaldehyde | 50-00-0 | Inhalation | Noncancer | Decreased pulmonary function, prevalence of current asthma or degree of asthma control, and allergic conditions in children (See Note) | n/a | RfC | 7 x 10 -3 mg/m3 |
358 | Formaldehyde | 50-00-0 | Oral | Noncancer | Reduced weight gain, histopathology in rats | n/a | RfD | 2 x 10 -1 mg/kg-day |
359 | Fosetyl-al | 39148-24-8 | Oral | Noncancer | Slight testicular degeneration | n/a | RfD | 3 mg/kg-day |
360 | Furan | 110-00-9 | Oral | Noncancer | Hepatic lesions | n/a | RfD | 1 x 10 -3 mg/kg-day |
361 | Furfural | 98-01-1 | Oral | Noncancer | Mild hepatocellular vacuolization | n/a | RfD | 3 x 10 -3 mg/kg-day |
362 | Furmecyclox | 60568-05-0 | Oral | Cancer | Combined liver nodules and carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 3 x 10 -2 per mg/kg-day |
363 | Glufosinate-ammonium | 77182-82-2 | Oral | Noncancer | Increased absolute and relative kidney weights in males | n/a | RfD | 4 x 10 -4 mg/kg-day |
364 | Glycidaldehyde | 765-34-4 | Oral | Noncancer | Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects | n/a | RfD | 4 x 10 -4 mg/kg-day |
365 | Glyphosate | 1071-83-6 | Oral | Noncancer | Increased incidence of renal tubular dilation in F3b offspring | n/a | RfD | 1 x 10 -1 mg/kg-day |
366 | Haloxyfop-methyl | 69806-40-2 | Oral | Noncancer | Reduced relative kidney weights in F0, F1, and F2b adults; reduced fertility in the F1/F2b generation | n/a | RfD | 5 x 10 -5 mg/kg-day |
367 | Harmony | 79277-27-3 | Oral | Noncancer | Reduced body weight gains in males, reduced serum sodium in males and females | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
368 | Heptachlor | 76-44-8 | Inhalation | Cancer | Hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.3 x 10 -3 per µg/m3 |
369 | Heptachlor | 76-44-8 | Oral | Cancer | Hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 4.5 per mg/kg-day |
370 | Heptachlor | 76-44-8 | Oral | Noncancer | Liver weight increases in males | n/a | RfD | 5 x 10 -4 mg/kg-day |
371 | Heptachlor epoxide | 1024-57-3 | Oral | Noncancer | Increased liver-to-body weight ratio in both males and females | n/a | RfD | 1.3 x 10 -5 mg/kg-day |
372 | Heptachlor epoxide | 1024-57-3 | Inhalation | Cancer | Hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 2.6 x 10 -3 per µg/m3 |
373 | Heptachlor epoxide | 1024-57-3 | Oral | Cancer | Hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 9.1 per mg/kg-day |
374 | n-Heptane | 142-82-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
375 | Hexabromobenzene | 87-82-1 | Oral | Noncancer | Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins | n/a | RfD | 2 x 10 -3 mg/kg-day |
376 | Hexabromodiphenyl ether | 36483-60-0 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
377 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Oral | Noncancer | Neurobehavioral effects | n/a | RfD | 2 x 10 -4 mg/kg-day |
378 | Hexachlorobenzene | 118-74-1 | Oral | Noncancer | Liver effects | n/a | RfD | 8 x 10 -4 mg/kg-day |
379 | Hexachlorobenzene | 118-74-1 | Inhalation | Cancer | Hepatocellular carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 4.6 x 10 -4 per µg/m3 |
380 | Hexachlorobenzene | 118-74-1 | Oral | Cancer | Hepatocellular carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.6 per mg/kg-day |
381 | Hexachlorobutadiene | 87-68-3 | Inhalation | Cancer | Renal tubular adenomas and adenocarcinomas | C (Possible human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 2.2 x 10 -5 per µg/m3 |
382 | Hexachlorobutadiene | 87-68-3 | Oral | Cancer | Renal tubular adenomas and adenocarcinomas | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 7.8 x 10 -2 per mg/kg-day |
383 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Inhalation | Cancer | Hepatic nodules and hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.8 x 10 -3 per µg/m3 |
384 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Oral | Cancer | Hepatic nodules and hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 6.3 per mg/kg-day |
385 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Oral | Cancer | Hepatic nodules and hepatocellular carcinomas | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 1.8 per mg/kg-day |
386 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Inhalation | Cancer | Hepatic nodules and hepatocellular carcinomas | C (Possible human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 5.3 x 10 -4 per µg/m3 |
387 | delta-Hexachlorocyclohexane (delta-HCH) | 319-86-8 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
388 | epsilon-Hexachlorocyclohexane (epsilon-HC) | 6108-10-7 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
389 | gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | Oral | Noncancer | Liver and kidney toxicity | n/a | RfD | 3 x 10 -4 mg/kg-day |
390 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Inhalation | Cancer | Liver nodules and hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 5.1 x 10 -4 per µg/m3 |
391 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Oral | Cancer | Liver nodules and hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.8 per mg/kg-day |
392 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Oral | Noncancer | Chronic irritation | n/a | RfD | 6 x 10 -3 mg/kg-day |
393 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Inhalation | Noncancer | Suppurative inflammation of the nose | n/a | RfC | 2 x 10 -4 mg/m3 |
394 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Oral | Cancer | Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 6.2 x 10 3 per mg/kg-day |
395 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Inhalation | Cancer | Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.3 per µg/m3 |
396 | Hexachloroethane | 67-72-1 | Inhalation | Noncancer | Neurotoxicity (tremors and ruffled pelt) | n/a | RfC | 3 x 10 -2 mg/m3 |
397 | Hexachloroethane | 67-72-1 | Oral | Noncancer | Atrophy and degeneration of renal tubules | n/a | RfD | 7 x 10 -4 mg/kg-day |
398 | Hexachloroethane | 67-72-1 | Oral | Cancer | Renal adenomas and carcinomas (combined) | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 4 x 10 -2 per mg/kg-day |
399 | Hexachlorophene | 70-30-4 | Oral | Noncancer | Swollen salivary glands, status spongiosis in brain and optic nerve | n/a | RfD | 3 x 10 -4 mg/kg-day |
400 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Noncancer | Kidney medullary papillary necrosis in F344 rats | n/a | RfD | 1 x 10 -2 mg/kg-day |
401 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Noncancer | Suppurative prostatitis in F344 rats | n/a | RfD | 8 x 10 -4 mg/kg-day |
402 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Noncancer | Convulsions in F344 rats | n/a | RfD | 4 x 10 -3 mg/kg-day |
403 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Cancer | Liver (hepatocellular adenomas or carcinomas) and lung (alveolar/bronchiolar adenomas or carcinomas) | Suggestive evidence of carcinogenic potential (2005 guidelines) |
Oral Slope Factor | 8 x 10 -2 per mg/kg-day |
404 | 1,6-Hexamethylene diisocyanate | 822-06-0 | Inhalation | Noncancer | Degeneration of olfactory epithelium | n/a | RfC | 1 x 10 -5 mg/m3 |
405 | n-Hexane | 110-54-3 | Inhalation | Noncancer | Peripheral neuropathy (decreased MCV at 12 weeks) | n/a | RfC | 7 x 10 -1 mg/m3 |
406 | 2-Hexanone | 591-78-6 | Oral | Noncancer | Axonal swelling of the peripheral nerve | n/a | RfD | 5 x 10 -3 mg/kg-day |
407 | 2-Hexanone | 591-78-6 | Inhalation | Noncancer | Motor conduction velocity of the sciatic-tibial nerve | n/a | RfC | 3 x 10 -2 mg/m3 |
408 | Hexazinone | 51235-04-2 | Oral | Noncancer | Decreased body weight | n/a | RfD | 3.3 x 10 -2 mg/kg-day |
409 | Hydrazine/Hydrazine sulfate | 302-01-2 | Oral | Cancer | Hepatoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 3 per mg/kg-day |
410 | Hydrazine/Hydrazine sulfate | 302-01-2 | Inhalation | Cancer | Nasal cavity adenoma or adenocarcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 4.9 x 10 -3 per µg/m3 |
411 | Hydrogen Cyanide and Cyanide Salts | Various | Inhalation | Noncancer | Thyroid enlargement and altered iodide uptake | n/a | RfC | 8 x 10 -4 mg/m3 |
412 | Hydrogen Cyanide and Cyanide Salts | Various | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats | n/a | RfD | 6 x 10 -4 mg/kg-day |
413 | Hydrogen chloride | 7647-01-0 | Inhalation | Noncancer | Hyperplasia of nasal mucosa larynx and trachea | n/a | RfC | 2 x 10 -2 mg/m3 |
414 | Hydrogen sulfide | 7783-06-4 | Inhalation | Noncancer | Nasal lesions of the olfactory mucosa | n/a | RfC | 2 x 10 -3 mg/m3 |
415 | Imazalil | 35554-44-0 | Oral | Noncancer | Decreased body weight gain | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
416 | Imazaquin | 81335-37-7 | Oral | Noncancer | Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK | n/a | RfD | 2.5 x 10 -1 mg/kg-day |
417 | Indeno[1,2,3-cd]pyrene | 193-39-5 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
418 | Iprodione | 36734-19-7 | Oral | Noncancer | Increased RBC Heinz bodies; decreased prostate weight | n/a | RfD | 4 x 10 -2 mg/kg-day |
419 | Isobutyl alcohol | 78-83-1 | Oral | Noncancer | Hypoactivity and ataxia | n/a | RfD | 3 x 10 -1 mg/kg-day |
420 | Isophorone | 78-59-1 | Oral | Noncancer | Kidney pathology | n/a | RfD | 2 x 10 -1 mg/kg-day |
421 | Isophorone | 78-59-1 | Oral | Cancer | Preputial gland carcinoma | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 9.5 x 10 -4 per mg/kg-day |
422 | Isopropalin | 33820-53-0 | Oral | Noncancer | Reduced hemoglobin concentration, lowered hematocrits, and altered organ weights | n/a | RfD | 1.5 x 10 -2 mg/kg-day |
423 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | Oral | Noncancer | No adverse effects observed | n/a | RfD | 1 x 10 -1 mg/kg-day |
424 | Isoxaben | 82558-50-7 | Oral | Noncancer | Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight | n/a | RfD | 5 x 10 -2 mg/kg-day |
425 | Lactofen | 77501-63-4 | Oral | Noncancer | Increased absolute and relative liver weight; hepatocytomegaly in males | n/a | RfD | 2 x 10 -3 mg/kg-day |
426 | Lead and compounds (inorganic) | 7439-92-1 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
427 | Libby Amphibole Asbestos | 1318-09-8 | Inhalation | Noncancer | Localized pleural thickening | n/a | RfC | 9 x 10 -5 fiber/cc |
428 | Libby Amphibole Asbestos | 1318-09-8 | Inhalation | Cancer | Cancer mortality from lung cancer and mesothelioma | Carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 1.7 x 10 -1 per fiber/cc |
429 | Linuron | 330-55-2 | Oral | Noncancer | Abnormal blood pigment | n/a | RfD | 2 x 10 -3 mg/kg-day |
430 | Londax | 83055-99-6 | Oral | Noncancer | Liver effects | n/a | RfD | 2 x 10 -1 mg/kg-day |
431 | Malathion | 121-75-5 | Oral | Noncancer | RBC ChE depression | n/a | RfD | 2 x 10 -2 mg/kg-day |
432 | Maleic anhydride | 108-31-6 | Oral | Noncancer | Renal lesions | n/a | RfD | 1 x 10 -1 mg/kg-day |
433 | Maleic hydrazide | 123-33-1 | Oral | Noncancer | Renal dysfunction | n/a | RfD | 5 x 10 -1 mg/kg-day |
434 | Maneb | 12427-38-2 | Oral | Noncancer | Increased thyroid weight | n/a | RfD | 5 x 10 -3 mg/kg-day |
435 | Manganese | 7439-96-5 | Inhalation | Noncancer | Impairment of neurobehavioral function | n/a | RfC | 5 x 10 -5 mg/m3 |
436 | Manganese | 7439-96-5 | Oral | Noncancer | CNS effects | n/a | RfD | 1.4 x 10 -1 mg/kg-day |
437 | Mepiquat chloride | 24307-26-4 | Oral | Noncancer | Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects | n/a | RfD | 3 x 10 -2 mg/kg-day |
438 | Mercuric chloride (HgCl2) | 7487-94-7 | Oral | Noncancer | Autoimmune effects (autoimmune glomerulonephritis) | n/a | RfD | 3 x 10 -4 mg/kg-day |
439 | Mercury, elemental | 7439-97-6 | Inhalation | Noncancer | Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction | n/a | RfC | 3 x 10 -4 mg/m3 |
440 | Merphos | 150-50-5 | Oral | Noncancer | Ataxia, delayed neurotoxicity and weight loss | n/a | RfD | 3 x 10 -5 mg/kg-day |
441 | Merphos oxide | 78-48-8 | Oral | Noncancer | Ataxia, delayed neurotoxicity and weight loss | n/a | RfD | 3 x 10 -5 mg/kg-day |
442 | Metalaxyl | 57837-19-1 | Oral | Noncancer | Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio | n/a | RfD | 6 x 10 -2 mg/kg-day |
443 | Methacrylonitrile | 126-98-7 | Oral | Noncancer | Increased SGOT and SGPT levels | n/a | RfD | 1 x 10 -4 mg/kg-day |
444 | Methamidophos | 10265-92-6 | Oral | Noncancer | ChE inhibition | n/a | RfD | 5 x 10 -5 mg/kg-day |
445 | Methanol | 67-56-1 | Oral | Noncancer | Extra cervical ribs | n/a | RfD | 2 mg/kg-day |
446 | Methanol | 67-56-1 | Inhalation | Noncancer | Reduced brain weight in rat pups at 6 weeks of age | n/a | RfC | 2 x 10 1 mg/m3 |
447 | Methidathion | 950-37-8 | Oral | Noncancer | Liver toxicity | n/a | RfD | 1 x 10 -3 mg/kg-day |
448 | Methomyl | 16752-77-5 | Oral | Noncancer | Kidney and spleen pathology | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
449 | Methoxychlor | 72-43-5 | Oral | Noncancer | Excessive loss of litters | n/a | RfD | 5 x 10 -3 mg/kg-day |
450 | 2-Methoxyethanol | 109-86-4 | Inhalation | Noncancer | Testicular effects | n/a | RfC | 2 x 10 -2 mg/m3 |
451 | Methyl acrylate | 96-33-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
452 | Methyl chloride | 74-87-3 | Inhalation | Noncancer | Cerebellar lesions | n/a | RfC | 9 x 10 -2 mg/m3 |
453 | Methyl ethyl ketone (MEK) | 78-93-3 | Inhalation | Noncancer | Developmental toxicity (skeletal variations) | n/a | RfC | 5 mg/m3 |
454 | Methyl ethyl ketone (MEK) | 78-93-3 | Oral | Noncancer | Decreased pup body weight | n/a | RfD | 6 x 10 -1 mg/kg-day |
455 | Methyl isobutyl ketone (MIBK) | 108-10-1 | Inhalation | Noncancer | Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats. | n/a | RfC | 3 mg/m3 |
456 | Methyl methacrylate | 80-62-6 | Inhalation | Noncancer | Degeneration/ atrophy of olfactory epithelium (male rats) | n/a | RfC | 7 x 10 -1 mg/m3 |
457 | Methyl methacrylate | 80-62-6 | Oral | Noncancer | None | n/a | RfD | 1.4 mg/kg-day |
458 | Methyl parathion | 298-00-0 | Oral | Noncancer | RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs | n/a | RfD | 2.5 x 10 -4 mg/kg-day |
459 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | Inhalation | Noncancer | Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) | n/a | RfC | 3 mg/m3 |
460 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | Oral | Noncancer | Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights | n/a | RfD | 1 x 10 -2 mg/kg-day |
461 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | Oral | Noncancer | Increased absolute and relative kidney weights | n/a | RfD | 1 x 10 -3 mg/kg-day |
462 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | Oral | Noncancer | Kidney and liver toxicity | n/a | RfD | 5 x 10 -4 mg/kg-day |
463 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Inhalation | Noncancer | Hyperplasia of olfactory epithelium | n/a | RfC | 6 x 10 -4 mg/m3 |
464 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | Oral | Cancer | Thyroid, follicular cell carcinoma/ adenoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 4.6 x 10 -2 per mg/kg-day |
465 | Methylmercury (MeHg) | 22967-92-6 | Oral | Noncancer | Developmental neuropsychological impairment | n/a | RfD | 1 x 10 -4 mg/kg-day |
466 | Methylmercury (MeHg) | 22967-92-6 | Oral | Noncancer | Developmental neuropsychological impairment | n/a | RfD | 1 x 10 -4 mg/kg-day |
467 | 2-Methylnaphthalene | 91-57-6 | Oral | Noncancer | Pulmonary alveolar proteinosis | n/a | RfD | 4 x 10 -3 mg/kg-day |
468 | 2-Methylphenol | 95-48-7 | Oral | Noncancer | Decreased body weights and neurotoxicity | n/a | RfD | 5 x 10 -2 mg/kg-day |
469 | 3-Methylphenol | 108-39-4 | Oral | Noncancer | Decreased body weights and neurotoxicity | n/a | RfD | 5 x 10 -2 mg/kg-day |
470 | 4-Methylphenol | 106-44-5 | None | Cancer | None | C (Possible human carcinogen) (1986 guidelines) |
NA | 0 NA |
471 | Metolachlor | 51218-45-2 | Oral | Noncancer | Decreased body weight gain, decreased pup weight and parental food consumption | n/a | RfD | 1.5 x 10 -1 mg/kg-day |
472 | Metribuzin | 21087-64-9 | Oral | Noncancer | Liver and kidney effects, decreased body weight, mortality | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
473 | Mirex | 2385-85-5 | Oral | Noncancer | Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles | n/a | RfD | 2 x 10 -4 mg/kg-day |
474 | Molinate | 2212-67-1 | Oral | Noncancer | Reproductive toxicity | n/a | RfD | 2 x 10 -3 mg/kg-day |
475 | Molybdenum | 7439-98-7 | Oral | Noncancer | Increased uric acid levels | n/a | RfD | 5 x 10 -3 mg/kg-day |
476 | Monochloramine | 10599-90-3 | Oral | Noncancer | No observed effects | n/a | RfD | 1 x 10 -1 mg/kg-day |
477 | Naled | 300-76-5 | Oral | Noncancer | Brain ChE inhibition | n/a | RfD | 2 x 10 -3 mg/kg-day |
478 | Naphthalene | 91-20-3 | Inhalation | Noncancer | Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively | n/a | RfC | 3 x 10 -3 mg/m3 |
479 | Naphthalene | 91-20-3 | Oral | Noncancer | Decreased mean terminal body weight in males | n/a | RfD | 2 x 10 -2 mg/kg-day |
480 | Napropamide | 15299-99-7 | Oral | Noncancer | Decreased body weight gain in parental animals and pups | n/a | RfD | 1 x 10 -1 mg/kg-day |
481 | Nickel carbonyl | 13463-39-3 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
482 | Nickel refinery dust | None | Inhalation | Cancer | Lung cancer | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 2.4 x 10 -4 per µg/m3 |
483 | Nickel subsulfide | 12035-72-2 | Inhalation | Cancer | Lung cancer | A (Human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 4.8 x 10 -4 per µg/m3 |
484 | Nickel, soluble salts | Various | Oral | Noncancer | Decreased body and organ weights | n/a | RfD | 2 x 10 -2 mg/kg-day |
485 | Nitrate | 14797-55-8 | Oral | Noncancer | Early clinical signs of methemoglobinemia in excess of 10% (0-3 months old infants formula) | n/a | RfD | 1.6 mg/kg-day |
486 | Nitrite | 14797-65-0 | Oral | Noncancer | Methemoglobinemia | n/a | RfD | 1 x 10 -1 mg/kg-day |
487 | Nitrobenzene | 98-95-3 | Oral | Noncancer | Increased methemoglobin levels | n/a | RfD | 2 x 10 -3 mg/kg-day |
488 | Nitrobenzene | 98-95-3 | Inhalation | Noncancer | Bronchiolization of the alveoli and olfactory degeneration | n/a | RfC | 9 x 10 -3 mg/m3 |
489 | Nitrobenzene | 98-95-3 | Inhalation | Cancer | Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 4 x 10 -5 per µg/m3 |
490 | Nitroguanidine | 556-88-7 | Oral | Noncancer | Reduced weight gain in female rats, maternal/ fetal toxicity in rats, and equivocal evidence of developmental toxicity in rabbits | n/a | RfD | 1 x 10 -1 mg/kg-day |
491 | 2-Nitropropane | 79-46-9 | Inhalation | Noncancer | Liver focal vacuolization and nodules | n/a | RfC | 2 x 10 -2 mg/m3 |
492 | N-Nitroso-N-methylethylamine | 10595-95-6 | Oral | Cancer | Hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.2 x 10 1 per mg/kg-day |
493 | N-Nitroso-di-n-butylamine | 924-16-3 | Inhalation | Cancer | Bladder and esophagus tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.6 x 10 -3 per µg/m3 |
494 | N-Nitroso-di-n-butylamine | 924-16-3 | Oral | Cancer | Bladder and esophagus tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 5.4 per mg/kg-day |
495 | N-Nitrosodi-N-propylamine | 621-64-7 | Oral | Cancer | Hepatocellular carcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 7 per mg/kg-day |
496 | N-Nitrosodiethanolamine | 1116-54-7 | Oral | Cancer | Hepatocellular carcinoma, cholangiocellular carcinoma and adenoma and neoplastic nodules | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.8 per mg/kg-day |
497 | N-Nitrosodiethylamine | 55-18-5 | Inhalation | Cancer | Liver tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 4.3 x 10 -2 per µg/m3 |
498 | N-Nitrosodiethylamine | 55-18-5 | Oral | Cancer | Liver tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.5 x 10 2 per mg/kg-day |
499 | N-Nitrosodimethylamine | 62-75-9 | Inhalation | Cancer | Liver tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1.4 x 10 -2 per µg/m3 |
500 | N-Nitrosodimethylamine | 62-75-9 | Oral | Cancer | Liver tumors | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 5.1 x 10 1 per mg/kg-day |
501 | N-Nitrosodiphenylamine | 86-30-6 | Oral | Cancer | Transitional cell carcinoma of the bladder | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 4.9 x 10 -3 per mg/kg-day |
502 | N-Nitrosopyrrolidine | 930-55-2 | Inhalation | Cancer | Hepatocellular carcinoma and adenoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 6.1 x 10 -4 per µg/m3 |
503 | N-Nitrosopyrrolidine | 930-55-2 | Oral | Cancer | Hepatocellular carcinoma and adenoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.1 per mg/kg-day |
504 | Nonabromodiphenyl ether | 63936-56-1 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
505 | Norflurazon | 27314-13-2 | Oral | Noncancer | Liver and thyroid effects | n/a | RfD | 4 x 10 -2 mg/kg-day |
506 | NuStar | 85509-19-9 | Oral | Noncancer | Liver cell enlargement | n/a | RfD | 7 x 10 -4 mg/kg-day |
507 | Octabromodiphenyl ether | 32536-52-0 | Oral | Noncancer | Induction of hepatic enzymes; liver histopathology | n/a | RfD | 3 x 10 -3 mg/kg-day |
508 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | Oral | Noncancer | Hepatic lesions | n/a | RfD | 5 x 10 -2 mg/kg-day |
509 | Oryzalin | 19044-88-3 | Oral | Noncancer | Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights | n/a | RfD | 5 x 10 -2 mg/kg-day |
510 | Oxadiazon | 19666-30-9 | Oral | Noncancer | Increased levels of serum proteins and increased liver weights | n/a | RfD | 5 x 10 -3 mg/kg-day |
511 | Oxamyl | 23135-22-0 | Oral | Noncancer | Decreased body weight gain and food consumption | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
512 | Oxyfluorfen | 42874-03-3 | Oral | Noncancer | Increased absolute liver weight and nonneoplastic lesions | n/a | RfD | 3 x 10 -3 mg/kg-day |
513 | Paclobutrazol | 76738-62-0 | Oral | Noncancer | Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
514 | Paraquat | 1910-42-5 | Oral | Noncancer | Chronic pneumonitis | n/a | RfD | 4.5 x 10 -3 mg/kg-day |
515 | Parathion | 56-38-2 | None | Cancer | None | C (Possible human carcinogen) (1986 guidelines) |
NA | 0 NA |
516 | Pendimethalin | 40487-42-1 | Oral | Noncancer | Increase in serum alkaline phosphatase and liver weight, and hepatic lesions | n/a | RfD | 4 x 10 -2 mg/kg-day |
517 | Pentabromodiphenyl ether | 32534-81-9 | Oral | Noncancer | Induction of hepatic enzymes | n/a | RfD | 2 x 10 -3 mg/kg-day |
518 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | Oral | Noncancer | Neurobehavioral effects | n/a | RfD | 1 x 10 -4 mg/kg-day |
519 | Pentachlorobenzene | 608-93-5 | Oral | Noncancer | Liver and kidney toxicity | n/a | RfD | 8 x 10 -4 mg/kg-day |
520 | Pentachlorocyclopentadiene | 25329-35-5 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
521 | Pentachloronitrobenzene (PCNB) | 82-68-8 | Oral | Noncancer | Liver toxicity | n/a | RfD | 3 x 10 -3 mg/kg-day |
522 | Pentachlorophenol | 87-86-5 | Oral | Cancer | Hepatocellular adenomas or carcinomas and adrenal benign or malignant pheochromocytomas | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 4 x 10 -1 per mg/kg-day |
523 | Pentachlorophenol | 87-86-5 | Oral | Noncancer | Hepatotoxicity | n/a | RfD | 5 x 10 -3 mg/kg-day |
524 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | Oral | Noncancer | Radioactive iodide uptake inhibition (RAIU) in the thyroid | n/a | RfD | 7 x 10 -4 mg/kg-day |
525 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Decreased total T4 | n/a | RfD | 1 x 10 -2 mg/kg-day |
526 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Developmental delays | n/a | RfD | 6 x 10 -3 mg/kg-day |
527 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Developmental delays | n/a | RfD | 6 x 10 -3 mg/kg-day |
528 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Increased hepatocellular hypertrophy | n/a | RfD | 1 x 10 -3 mg/kg-day |
529 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Increased hepatocellular hypertrophy | n/a | RfD | 1 x 10 -2 mg/kg-day |
530 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) | n/a | RfD | 1 x 10 -3 mg/kg-day |
531 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Noncancer | Developmental delays | n/a | RfD | 6 x 10 -3 mg/kg-day |
532 | Perfluorodecanoic Acid (PFDA) | 335-76-2 | Oral | Noncancer | Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children | n/a | RfD | 2 x 10 -9 mg/kg-day |
533 | Perfluorodecanoic Acid (PFDA) | 335-76-2 | Oral | Noncancer | Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children | n/a | RfD | 2 x 10 -9 mg/kg-day |
534 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats | n/a | RfD | 5 x 10 -4 mg/kg-day |
535 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats | n/a | RfD | 4 x 10 -4 mg/kg-day |
536 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Increased hepatocellular hypertrophy in adult rats | n/a | RfD | 1 x 10 -3 mg/kg-day |
537 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats | n/a | RfD | 5 x 10 -4 mg/kg-day |
538 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats | n/a | RfD | 5 x 10 -3 mg/kg-day |
539 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats | n/a | RfD | 8 x 10 -4 mg/kg-day |
540 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Oral | Noncancer | Decreased total T4 in adult male Harlan Sprague-Dawley rats | n/a | RfD | 1 x 10 -3 mg/kg-day |
541 | Permethrin | 52645-53-1 | Oral | Noncancer | Increased liver weights | n/a | RfD | 5 x 10 -2 mg/kg-day |
542 | Phenanthrene | 85-01-8 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
543 | Phenmedipham | 13684-63-4 | Oral | Noncancer | No adverse effects | n/a | RfD | 2.5 x 10 -1 mg/kg-day |
544 | Phenol | 108-95-2 | Oral | Noncancer | Decreased maternal weight gain | n/a | RfD | 3 x 10 -1 mg/kg-day |
545 | m-Phenylenediamine | 108-45-2 | Oral | Noncancer | Increased relative and absolute liver weights and degenerative liver lesions | n/a | RfD | 6 x 10 -3 mg/kg-day |
546 | Phenylmercuric acetate | 62-38-4 | Oral | Noncancer | Renal damage | n/a | RfD | 8 x 10 -5 mg/kg-day |
547 | Phosgene | 75-44-5 | Inhalation | Noncancer | Collagen staining indicative of fibrosis | n/a | RfC | 3 x 10 -4 mg/m3 |
548 | Phosmet | 732-11-6 | Oral | Noncancer | Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition | n/a | RfD | 2 x 10 -2 mg/kg-day |
549 | Phosphine | 7803-51-2 | Inhalation | Noncancer | Decreased body weight | n/a | RfC | 3 x 10 -4 mg/m3 |
550 | Phosphine | 7803-51-2 | Oral | Noncancer | Body weight and clinical parameters | n/a | RfD | 3 x 10 -4 mg/kg-day |
551 | Phosphoric acid | 7664-38-2 | Inhalation | Noncancer | Bronchiolar fibrosis | n/a | RfC | 1 x 10 -2 mg/m3 |
552 | Phthalic anhydride | 85-44-9 | Oral | Noncancer | Lung and kidney histopathology | n/a | RfD | 2 mg/kg-day |
553 | Picloram | 1918-02-1 | Oral | Noncancer | Increased liver weights | n/a | RfD | 7 x 10 -2 mg/kg-day |
554 | Pirimiphos-methyl | 29232-93-7 | Oral | Noncancer | Transient plasma ChE depression | n/a | RfD | 1 x 10 -2 mg/kg-day |
555 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | Inhalation | Cancer | Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 1 x 10 -4 per µg/m3 |
556 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | Oral | Cancer | Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2 per mg/kg-day |
557 | Potassium cyanide | 151-50-8 | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | n/a | RfD | 2 x 10 -3 mg/kg-day |
558 | Potassium silver cyanide | 506-61-6 | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | n/a | RfD | 5 x 10 -3 mg/kg-day |
559 | Prochloraz | 67747-09-5 | Oral | Cancer | Liver adenoma/ carcinoma combined | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 1.5 x 10 -1 per mg/kg-day |
560 | Prochloraz | 67747-09-5 | Oral | Noncancer | Increase in SAP and liver weights, liver histopathology | n/a | RfD | 9 x 10 -3 mg/kg-day |
561 | Prometon | 1610-18-0 | Oral | Noncancer | No treatment related effects observed | n/a | RfD | 1.5 x 10 -2 mg/kg-day |
562 | Prometryn | 7287-19-6 | Oral | Noncancer | Liver and kidney degeneration and bone marrow atrophy | n/a | RfD | 4 x 10 -3 mg/kg-day |
563 | Pronamide | 23950-58-5 | Oral | Noncancer | No effects | n/a | RfD | 7.5 x 10 -2 mg/kg-day |
564 | Propachlor | 1918-16-7 | Oral | Noncancer | Decreased weight gain, food consumption increased relative liver weights | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
565 | Propanil | 709-98-8 | Oral | Noncancer | Increased relative spleen weight in females | n/a | RfD | 5 x 10 -3 mg/kg-day |
566 | Propargite | 2312-35-8 | Oral | Noncancer | Reduced body weight gain (maternal), increased resorption, reduced body weight (fetal), delayed ossification | n/a | RfD | 2 x 10 -2 mg/kg-day |
567 | Propargyl alcohol | 107-19-7 | Oral | Noncancer | Renal and hepatotoxicity | n/a | RfD | 2 x 10 -3 mg/kg-day |
568 | Propazine | 139-40-2 | Oral | Noncancer | Decrease in body weight | n/a | RfD | 2 x 10 -2 mg/kg-day |
569 | Propham | 122-42-9 | Oral | Noncancer | Increase in male spleen weight and ChE depression in females | n/a | RfD | 2 x 10 -2 mg/kg-day |
570 | Propiconazole | 60207-90-1 | Oral | Noncancer | Gastric mucosal irritation | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
571 | Propionaldehyde | 123-38-6 | Inhalation | Noncancer | Atrophy of olfactory epithelium | n/a | RfC | 8 x 10 -3 mg/m3 |
572 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | Inhalation | Noncancer | Mild reversible sedation | n/a | RfC | 2 mg/m3 |
573 | Propylene oxide | 75-56-9 | Oral | Cancer | Forestomach, squamous cell carcinoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 2.4 x 10 -1 per mg/kg-day |
574 | Propylene oxide | 75-56-9 | Inhalation | Cancer | Nasal cavity hemangioma or hemangiosarcoma | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 3.7 x 10 -6 per µg/m3 |
575 | Propylene oxide | 75-56-9 | Inhalation | Noncancer | Nest-like infolds of the nasal respiratory epithelium | n/a | RfC | 3 x 10 -2 mg/m3 |
576 | Pursuit | 81335-77-5 | Oral | Noncancer | Decreased packed cell volume, hemoglobin, erythrocytes in females | n/a | RfD | 2.5 x 10 -1 mg/kg-day |
577 | Pydrin | 51630-58-1 | Oral | Noncancer | Neurological dysfunction | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
578 | Pyrene | 129-00-0 | Oral | Noncancer | Kidney effects (renal tubular pathology, decreased kidney weights) | n/a | RfD | 3 x 10 -2 mg/kg-day |
579 | Pyridine | 110-86-1 | Oral | Noncancer | Increased liver weight | n/a | RfD | 1 x 10 -3 mg/kg-day |
580 | Quinalphos | 13593-03-8 | Oral | Noncancer | No adverse effects reported | n/a | RfD | 5 x 10 -4 mg/kg-day |
581 | Quinoline | 91-22-5 | Oral | Cancer | Hepatic hemangioendotheliomas or hemangiosarcomas | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 3 per mg/kg-day |
582 | Refractory ceramic fibers | None | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
583 | Resmethrin | 10453-86-8 | Oral | Noncancer | Reproductive toxicity | n/a | RfD | 3 x 10 -2 mg/kg-day |
584 | Rotenone | 83-79-4 | Oral | Noncancer | Reduced pup weight | n/a | RfD | 4 x 10 -3 mg/kg-day |
585 | Savey | 78587-05-0 | Oral | Noncancer | Hypertrophy of adrenal cortex (both sexes) hematologic effects (males) | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
586 | Selenious acid | 7783-00-8 | Oral | Noncancer | Clinical selenosis | n/a | RfD | 5 x 10 -3 mg/kg-day |
587 | Selenium and Compounds | 7782-49-2 | Oral | Noncancer | Clinical selenosis | n/a | RfD | 5 x 10 -3 mg/kg-day |
588 | Selenium sulfide | 7446-34-6 | None | Cancer | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
NA | 0 NA |
589 | Sethoxydim | 74051-80-2 | Oral | Noncancer | Mild anemia in males | n/a | RfD | 9 x 10 -2 mg/kg-day |
590 | Silver | 7440-22-4 | Oral | Noncancer | Argyria | n/a | RfD | 5 x 10 -3 mg/kg-day |
591 | Silver cyanide | 506-64-9 | Oral | Noncancer | Weight loss, thyroid effects, and myelin degeneration | n/a | RfD | 1 x 10 -1 mg/kg-day |
592 | Simazine | 122-34-9 | Oral | Noncancer | Reduction in weight gains hematological changes in females | n/a | RfD | 5 x 10 -3 mg/kg-day |
593 | Sodium azide | 26628-22-8 | Oral | Noncancer | Clinical sign (e.g., hunched postures) and reduced body weight | n/a | RfD | 4 x 10 -3 mg/kg-day |
594 | Sodium cyanide | 143-33-9 | Oral | Noncancer | Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | n/a | RfD | 1 x 10 -3 mg/kg-day |
595 | Sodium diethyldithiocarbamate | 148-18-5 | Oral | Noncancer | Reduced body weight | n/a | RfD | 3 x 10 -2 mg/kg-day |
596 | Sodium fluoroacetate | 62-74-8 | Oral | Noncancer | Increased heart weight in females and males; decreased testis weight and altered spermatogenesis in males. | n/a | RfD | 2 x 10 -5 mg/kg-day |
597 | Strontium | 7440-24-6 | Oral | Noncancer | Rachitic bone | n/a | RfD | 6 x 10 -1 mg/kg-day |
598 | Strychnine | 57-24-9 | Oral | Noncancer | Toxicity/histopathology | n/a | RfD | 3 x 10 -4 mg/kg-day |
599 | Styrene | 100-42-5 | Inhalation | Noncancer | CNS effects | n/a | RfC | 1 mg/m3 |
600 | Styrene | 100-42-5 | Oral | Noncancer | Red blood cell and liver effects | n/a | RfD | 2 x 10 -1 mg/kg-day |
601 | Systhane | 88671-89-0 | Oral | Noncancer | Testicular atrophy | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
602 | Tebuthiuron | 34014-18-1 | Oral | Noncancer | Depressed body weight gain in F1 females | n/a | RfD | 7 x 10 -2 mg/kg-day |
603 | Terbacil | 5902-51-2 | Oral | Noncancer | Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
604 | Terbutryn | 886-50-0 | Oral | Noncancer | Hematologic effects in females | n/a | RfD | 1 x 10 -3 mg/kg-day |
605 | Tetrabromodiphenyl ether | 40088-47-9 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
606 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | Oral | Noncancer | Neurobehavioral effects | n/a | RfD | 1 x 10 -4 mg/kg-day |
607 | 1,2,4,5-Tetrachlorobenzene | 95-94-3 | Oral | Noncancer | Kidney lesions | n/a | RfD | 3 x 10 -4 mg/kg-day |
608 | Tetrachlorocyclopentadiene | 695-77-2 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
609 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | Oral | Noncancer | Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates | n/a | RfD | 7 x 10 -10 mg/kg-day |
610 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | Oral | Noncancer | Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates | n/a | RfD | 7 x 10 -10 mg/kg-day |
611 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Inhalation | Cancer | Hepatocellular adenoma or carcinoma | C (Possible human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 7.4 x 10 -6 per µg/m3 |
612 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Oral | Noncancer | Mineralization of the kidneys in males, hepatic clear cell change in females | n/a | RfD | 3 x 10 -2 mg/kg-day |
613 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Oral | Cancer | Hepatocellular adenoma or carcinoma | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 2.6 x 10 -2 per mg/kg-day |
614 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Oral | Noncancer | Increased relative liver weight in rats | n/a | RfD | 2 x 10 -2 mg/kg-day |
615 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Oral | Noncancer | Increased relative liver weight in rats | n/a | RfD | 5 x 10 -2 mg/kg-day |
616 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Oral | Cancer | hepatocellular carcinomas | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 2 x 10 -1 per mg/kg-day |
617 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Oral | Noncancer | (See Note) | n/a | RfD | 6 x 10 -3 mg/kg-day |
618 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Oral | Cancer | Hepatocellular adenomas or carcinomas | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 2.1 x 10 -3 per mg/kg-day |
619 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Inhalation | Noncancer | (See Note) | n/a | RfC | 4 x 10 -2 mg/m3 |
620 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Inhalation | Cancer | Hepatocellular adenomas or carcinomas | Likely to be carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 2.6 x 10 -7 per µg/m3 |
621 | 2,3,4,6-Tetrachlorophenol | 58-90-2 | Oral | Noncancer | Increased liver weights and centrilobular hypertrophy | n/a | RfD | 3 x 10 -2 mg/kg-day |
622 | Tetrachlorovinphos | 961-11-5 | Oral | Noncancer | Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition | n/a | RfD | 3 x 10 -2 mg/kg-day |
623 | Tetraethyl lead | 78-00-2 | Oral | Noncancer | Histopathology of liver and thymus | n/a | RfD | 1 x 10 -7 mg/kg-day |
624 | Tetraethyldithiopyrophosphate | 3689-24-5 | Oral | Noncancer | Depressed RBC and plasma cholinesterase activity | n/a | RfD | 5 x 10 -4 mg/kg-day |
625 | 1,1,1,2-Tetrafluoroethane | 811-97-2 | Inhalation | Noncancer | Leydig cell hyperplasia | n/a | RfC | 8 x 10 1 mg/m3 |
626 | Tetrahydrofuran | 109-99-9 | Inhalation | Noncancer | Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) | n/a | RfC | 2 mg/m3 |
627 | Tetrahydrofuran | 109-99-9 | Oral | Noncancer | Decreased pup body weight gain | n/a | RfD | 9 x 10 -1 mg/kg-day |
628 | Thallium (I), soluble salts | Various | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
629 | Thallium acetate | 563-68-8 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
630 | Thallium carbonate | 6533-73-9 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
631 | Thallium chloride | 7791-12-0 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
632 | Thallium nitrate | 10102-45-1 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
633 | Thallium oxide | 1314-32-5 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
634 | Thallium selenite | 12039-52-0 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
635 | Thallium(I) sulfate | 7446-18-6 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
636 | Thiobencarb | 28249-77-6 | Oral | Noncancer | Decrease in body weight, increase in BUN | n/a | RfD | 1 x 10 -2 mg/kg-day |
637 | Thiophanate-methyl | 23564-05-8 | Oral | Noncancer | Decreased body weight, decreased spermatogenesis, and histological evidence of hyperthyroidism | n/a | RfD | 8 x 10 -2 mg/kg-day |
638 | Thiram | 137-26-8 | Oral | Noncancer | Neurotoxicity | n/a | RfD | 5 x 10 -3 mg/kg-day |
639 | Toluene | 108-88-3 | Inhalation | Noncancer | Neurological effects in occupationally-exposed workers | n/a | RfC | 5 mg/m3 |
640 | Toluene | 108-88-3 | Oral | Noncancer | Increased kidney weight | n/a | RfD | 8 x 10 -2 mg/kg-day |
641 | 2,4-/2,6-Toluene diisocyanate mixture (TDI) | 26471-62-5 | Inhalation | Noncancer | Chronic lung-function decline | n/a | RfC | 7 x 10 -5 mg/m3 |
642 | Toxaphene | 8001-35-2 | Inhalation | Cancer | Hepatocellular carcinomas and neoplastic nodules | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 3.2 x 10 -4 per µg/m3 |
643 | Toxaphene | 8001-35-2 | Oral | Cancer | Hepatocellular carcinomas and neoplastic nodules | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.1 per mg/kg-day |
644 | Tralomethrin | 66841-25-6 | Oral | Noncancer | Decreased body weight gain in males increased food and water consumption in males and females | n/a | RfD | 7.5 x 10 -3 mg/kg-day |
645 | Triallate | 2303-17-5 | Oral | Noncancer | Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females | n/a | RfD | 1.3 x 10 -2 mg/kg-day |
646 | Triasulfuron | 82097-50-5 | Oral | Noncancer | Centrilobular hepatocytomegaly in males | n/a | RfD | 1 x 10 -2 mg/kg-day |
647 | 1,2,4-Tribromobenzene | 615-54-3 | Oral | Noncancer | Increased liver-to-body weight ratio and hepatic microsomal enzyme induction | n/a | RfD | 5 x 10 -3 mg/kg-day |
648 | Tribromochloromethane | 594-15-0 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
649 | Tribromodiphenyl ether | 49690-94-0 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
650 | Tributyltin oxide (TBTO) | 56-35-9 | Oral | Noncancer | Immunosuppression | n/a | RfD | 3 x 10 -4 mg/kg-day |
651 | 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | 76-13-1 | Oral | Noncancer | Psychomotor impairment | n/a | RfD | 3 x 10 1 mg/kg-day |
652 | Trichloroacetic acid | 76-03-9 | Oral | Noncancer | Hepatocellular necrosis | n/a | RfD | 2 x 10 -2 mg/kg-day |
653 | Trichloroacetic acid | 76-03-9 | Oral | Cancer | Hepatocellular adenomas or carcinomas | Suggestive evidence of carcinogenic potential (2005 guidelines) |
Oral Slope Factor | 7 x 10 -2 per mg/kg-day |
654 | 1,2,4-Trichlorobenzene | 120-82-1 | Oral | Noncancer | Increased adrenal weights; vacuolization of zona fasciculata in the cortex | n/a | RfD | 1 x 10 -2 mg/kg-day |
655 | Trichlorocyclopentadiene | 77323-84-3 | None | Cancer | None | D (Not classifiable as to human carcinogenicity) (1986 guidelines) |
NA | 0 NA |
656 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Performance on neurobehavioral tests | n/a | RfC | 7 mg/m3 |
657 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Liver histopathologic changes | n/a | RfC | 5 mg/m3 |
658 | 1,1,1-Trichloroethane | 71-55-6 | Oral | Noncancer | Reduced body weight | n/a | RfD | 7 mg/kg-day |
659 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Performance on neurobehavioral tests | n/a | RfC | 9 mg/m3 |
660 | 1,1,1-Trichloroethane | 71-55-6 | Oral | Noncancer | Reduced body weight | n/a | RfD | 2 mg/kg-day |
661 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Performance on neurobehavioral tests | n/a | RfC | 7 mg/m3 |
662 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Performance on neurobehavioral tests | n/a | RfC | 6 mg/m3 |
663 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Performance on neurobehavioral tests | n/a | RfC | 5 mg/m3 |
664 | 1,1,1-Trichloroethane | 71-55-6 | Inhalation | Noncancer | Liver histopathologic changes | n/a | RfC | 5 mg/m3 |
665 | 1,1,2-Trichloroethane | 79-00-5 | Oral | Noncancer | Clinical serum chemistry (effects on erythrocytes and depressed humoral immune status) | n/a | RfD | 4 x 10 -3 mg/kg-day |
666 | 1,1,2-Trichloroethane | 79-00-5 | Inhalation | Cancer | Hepatocellular carcinoma | C (Possible human carcinogen) (1986 guidelines) |
Inhalation Unit Risk | 1.6 x 10 -5 per µg/m3 |
667 | 1,1,2-Trichloroethane | 79-00-5 | Oral | Cancer | Hepatocellular carcinoma | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 5.7 x 10 -2 per mg/kg-day |
668 | Trichloroethylene | 79-01-6 | Oral | Cancer | Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors | Carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 4.6 x 10 -2 per mg/kg-day |
669 | Trichloroethylene | 79-01-6 | Inhalation | Cancer | Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors | Carcinogenic to humans (2005 guidelines) |
Inhalation Unit Risk | 4.1 x 10 -6 per µg/m3 |
670 | Trichloroethylene | 79-01-6 | Oral | Noncancer | (See Note) | n/a | RfD | 5 x 10 -4 mg/kg-day |
671 | Trichloroethylene | 79-01-6 | Inhalation | Noncancer | (See Note) | n/a | RfC | 2 x 10 -3 mg/m3 |
672 | Trichlorofluoromethane | 75-69-4 | Oral | Noncancer | Survival and histopathology (pleuritis and pericarditis) | n/a | RfD | 3 x 10 -1 mg/kg-day |
673 | 2,4,5-Trichlorophenol | 95-95-4 | Oral | Noncancer | Liver and kidney pathology | n/a | RfD | 1 x 10 -1 mg/kg-day |
674 | 2,4,6-Trichlorophenol | 88-06-2 | Oral | Cancer | Leukemia | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Oral Slope Factor | 1.1 x 10 -2 per mg/kg-day |
675 | 2,4,6-Trichlorophenol | 88-06-2 | Inhalation | Cancer | Leukemia | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) (1986 guidelines) |
Inhalation Unit Risk | 3.1 x 10 -6 per µg/m3 |
676 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | Oral | Noncancer | Histopathological changes in liver | n/a | RfD | 8 x 10 -3 mg/kg-day |
677 | 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | 93-76-5 | Oral | Noncancer | Increased urinary coproporphyrins | n/a | RfD | 1 x 10 -2 mg/kg-day |
678 | 1,1,2-Trichloropropane | 598-77-6 | Oral | Noncancer | Mild lesions in liver, kidney and thyroid | n/a | RfD | 5 x 10 -3 mg/kg-day |
679 | 1,2,3-Trichloropropane | 96-18-4 | Oral | Noncancer | Increased absolute liver weight in male rats | n/a | RfD | 4 x 10 -3 mg/kg-day |
680 | 1,2,3-Trichloropropane | 96-18-4 | Oral | Cancer | alimentary system squamous cell neoplasms, liver hepatocellular adenomas or carcinomas, Harderian gland adenomas, uterine/cervix adenomas or carcinomas | Likely to be carcinogenic to humans (2005 guidelines) |
Oral Slope Factor | 3 x 10 1 per mg/kg-day |
681 | 1,2,3-Trichloropropane | 96-18-4 | Inhalation | Noncancer | peribronchial lymphoid hyperplasia in male rats | n/a | RfC | 3 x 10 -4 mg/m3 |
682 | Tridiphane | 58138-08-2 | Oral | Noncancer | Decreased fertility index and depressed body weight of dams | n/a | RfD | 3 x 10 -3 mg/kg-day |
683 | Triethylamine | 121-44-8 | Inhalation | Noncancer | Inflammation of the nasal passage | n/a | RfC | 7 x 10 -3 mg/m3 |
684 | Trifluralin | 1582-09-8 | Oral | Cancer | Combined renal pelvis carcinomas, urinary bladder papillomas and/or thyroid adenomas and carcinomas | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 7.7 x 10 -3 per mg/kg-day |
685 | Trifluralin | 1582-09-8 | Oral | Noncancer | Increased liver weights; increase in methemoglobin | n/a | RfD | 7.5 x 10 -3 mg/kg-day |
686 | 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfC | 6 x 10 -2 mg/m3 |
687 | 1,2,3-Trimethylbenzene | 526-73-8 | Oral | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfD | 4 x 10 -2 mg/kg-day |
688 | 1,2,3-Trimethylbenzene | 526-73-8 | Oral | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfD | 1 x 10 -2 mg/kg-day |
689 | 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Noncancer | Inflammatory lung lesions | n/a | RfC | 2 x 10 -1 mg/m3 |
690 | 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfC | 2 x 10 -1 mg/m3 |
691 | 1,2,3-Trimethylbenzene | 526-73-8 | Inhalation | Noncancer | Decreased segmented neutrophils | n/a | RfC | 6 x 10 -2 mg/m3 |
692 | 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Noncancer | Inflammatory lung lesions | n/a | RfC | 2 x 10 -1 mg/m3 |
693 | 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Noncancer | Decreased fetal weight | n/a | RfC | 4 mg/m3 |
694 | 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Noncancer | Decreased maternal weight | n/a | RfC | 3 mg/m3 |
695 | 1,2,4-Trimethylbenzene | 95-63-6 | Oral | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfD | 1 x 10 -2 mg/kg-day |
696 | 1,2,4-Trimethylbenzene | 95-63-6 | Oral | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfD | 4 x 10 -2 mg/kg-day |
697 | 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfC | 6 x 10 -2 mg/m3 |
698 | 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfC | 2 x 10 -1 mg/m3 |
699 | 1,2,4-Trimethylbenzene | 95-63-6 | Inhalation | Noncancer | Decreased clotting time | n/a | RfC | 8 x 10 -2 mg/m3 |
700 | 1,3,5-Trimethylbenzene | 108-67-8 | Inhalation | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfC | 6 x 10 -2 mg/m3 |
701 | 1,3,5-Trimethylbenzene | 108-67-8 | Oral | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfD | 1 x 10 -2 mg/kg-day |
702 | 1,3,5-Trimethylbenzene | 108-67-8 | Inhalation | Noncancer | Decreased fetal weight | n/a | RfC | 4 mg/m3 |
703 | 1,3,5-Trimethylbenzene | 108-67-8 | Inhalation | Noncancer | Decreased maternal weight | n/a | RfC | 4 x 10 -1 mg/m3 |
704 | 1,3,5-Trimethylbenzene | 108-67-8 | Oral | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfD | 4 x 10 -2 mg/kg-day |
705 | 1,3,5-Trimethylbenzene | 108-67-8 | Inhalation | Noncancer | Decreased pain sensitivity in male Wistar rats | n/a | RfC | 2 x 10 -1 mg/m3 |
706 | 2,2,4-Trimethylpentane | 540-84-1 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
707 | 1,3,5-Trinitrobenzene | 99-35-4 | Oral | Noncancer | Methemoglobinemia and spleen-erythroid cell hyperplasia | n/a | RfD | 3 x 10 -2 mg/kg-day |
708 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Oral | Noncancer | Liver effects | n/a | RfD | 5 x 10 -4 mg/kg-day |
709 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Oral | Cancer | Urinary bladder, transitional cell papilloma and transitional squamous cell carcinomas | C (Possible human carcinogen) (1986 guidelines) |
Oral Slope Factor | 3 x 10 -2 per mg/kg-day |
710 | Uranium, soluble salts | Various | Oral | Noncancer | Initial body weight loss moderate nephrotoxicity | n/a | RfD | 3 x 10 -3 mg/kg-day |
711 | Urea | 57-13-6 | None | Cancer | None | Inadequate information to assess carcinogenic potential (2005 guidelines) |
NA | 0 NA |
712 | Vanadium pentoxide | 1314-62-1 | Oral | Noncancer | Decreased hair cystine | n/a | RfD | 9 x 10 -3 mg/kg-day |
713 | Vernam | 1929-77-7 | Oral | Noncancer | Decreased body weight | n/a | RfD | 1 x 10 -3 mg/kg-day |
714 | Vinclozolin | 50471-44-8 | Oral | Noncancer | Organ weight changes (adrenal and kidney) | n/a | RfD | 2.5 x 10 -2 mg/kg-day |
715 | Vinyl acetate | 108-05-4 | Inhalation | Noncancer | Nasal epithelial lesions | n/a | RfC | 2 x 10 -1 mg/m3 |
716 | Vinyl bromide | 593-60-2 | Inhalation | Noncancer | Hypertrophy, basophilic and eosinophilic foci, in the liver | n/a | RfC | 3 x 10 -3 mg/m3 |
717 | Vinyl chloride | 75-01-4 | Inhalation | Cancer | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 8.8 x 10 -6 per µg/m3 |
718 | Vinyl chloride | 75-01-4 | Oral | Cancer | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 7.2 x 10 -1 per mg/kg-day |
719 | Vinyl chloride | 75-01-4 | Oral | Cancer | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 7.5 x 10 -1 per mg/kg-day |
720 | Vinyl chloride | 75-01-4 | Oral | Cancer | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 1.4 per mg/kg-day |
721 | Vinyl chloride | 75-01-4 | Inhalation | Cancer | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 4.4 x 10 -6 per µg/m3 |
722 | Vinyl chloride | 75-01-4 | Inhalation | Cancer | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 8.8 x 10 -6 per µg/m3 |
723 | Vinyl chloride | 75-01-4 | Oral | Cancer | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Oral Slope Factor | 1.5 per mg/kg-day |
724 | Vinyl chloride | 75-01-4 | Oral | Noncancer | Liver cell polymorphism | n/a | RfD | 3 x 10 -3 mg/kg-day |
725 | Vinyl chloride | 75-01-4 | Inhalation | Noncancer | Liver cell polymorphism | n/a | RfC | 1 x 10 -1 mg/m3 |
726 | Vinyl chloride | 75-01-4 | Inhalation | Cancer | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | A (Human carcinogen) (1986 guidelines) Known/likely human carcinogen (1996 guidelines) |
Inhalation Unit Risk | 4.4 x 10 -6 per µg/m3 |
727 | Warfarin | 81-81-2 | Oral | Noncancer | Increased prothrombin time | n/a | RfD | 3 x 10 -4 mg/kg-day |
728 | White phosphorus | 7723-14-0 | Oral | Noncancer | Parturition mortality; forelimb hair loss | n/a | RfD | 2 x 10 -5 mg/kg-day |
729 | Xylenes | 1330-20-7 | Oral | Noncancer | Decreased body weight, increased mortality | n/a | RfD | 2 x 10 -1 mg/kg-day |
730 | Xylenes | 1330-20-7 | Inhalation | Noncancer | Impaired motor coordination (decreased rotarod performance) | n/a | RfC | 1 x 10 -1 mg/m3 |
731 | Zinc and Compounds | 7440-66-6 | Oral | Noncancer | Decreases in erythrocyte Cu, Zn-superoxide dismutase (ESOD) activity in healthy adult male and female volunteers | n/a | RfD | 3 x 10 -1 mg/kg-day |
732 | Zinc cyanide | 557-21-1 | Oral | Noncancer | Weight loss, thyroid effects, and myelin degeneration | n/a | RfD | 5 x 10 -2 mg/kg-day |
733 | Zinc phosphide | 1314-84-7 | Oral | Noncancer | Reduction of food intake and body weight | n/a | RfD | 3 x 10 -4 mg/kg-day |
734 | Zineb | 12122-67-7 | Oral | Noncancer | Thyroid hyperplasia | n/a | RfD | 5 x 10 -2 mg/kg-day |
735 | n-Butanol | 71-36-3 | Oral | Noncancer | Hypoactivity and ataxia | n/a | RfD | 1 x 10 -1 mg/kg-day |
736 | tert-Butyl Alcohol (tBA) | 75-65-0 | Inhalation | Noncancer | Increased severity of nephropathy | n/a | RfC | 5 mg/m3 |
737 | tert-Butyl Alcohol (tBA) | 75-65-0 | Oral | Cancer | Renal adenomas and carcinomas, thyroid adenomas | Suggestive evidence of carcinogenic potential (2005 guidelines) |
Oral Slope Factor | 5 x 10 -4 per mg/kg-day |
738 | tert-Butyl Alcohol (tBA) | 75-65-0 | Oral | Noncancer | Increased severity of nephropathy | n/a | RfD | 4 x 10 -1 mg/kg-day |
CHEMICAL NAME | CASRN | PRINCIPAL CRITICAL EFFECT SYSTEM | PRINCIPAL CRITICAL DESCRIPTION | PRINCIPAL STUDY | STUDY CITATION | EXPERIMENTAL DOSE TYPE | POD VALUE | RFD VALUE | UNCERTAINTY FACTOR | MODIFYING FACTOR | STUDY CONFIDENCE | DATA CONFIDENCE | OVERALL CONFIDENCE | DOSE TYPE | DURATION | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Acenaphthene | 83-32-9 | Hepatic | Hepatotoxicity | Mouse oral subchronic study | U.S. EPA, 1989 | No Observable Adverse Effect Level | 175.0 mg/kg-day | 0.06 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
2 | Acephate | 30560-19-1 | Nervous | Inhibition of brain ChE | 90-day rat feeding study (LEL for male subjects) | Chevron Chemical Co., 1987a | Lowest Effect Level | 0.12 mg/kg-day | 0.004 mg/kg-day | 30 | 1 | Medium | High | High | Threshold | Chronic |
3 | Acetochlor | 34256-82-1 | Hematologic, Hepatic, Nervous, Reproductive, Urinary | Salivation, increased ALT and ornithine carbamyl transferase; significant increases in triglyceride and decreased blood glucose levels; histopathological changes in kidneys and testes of males | 1-year dog feeding study | ICI, Inc., 1988a | No Observable Adverse Effect Level | 2.0 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
4 | Acetone | 67-64-1 | Urinary | Nephropathy | Subchronic drinking water study in rats | Dietz, et., al, 1991 NTP, 1991 | No Observable Adverse Effect Level | 900.0 mg/kg-day | 0.9 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
5 | Acetophenone | 98-86-2 | Other | General Toxicity | Rat oral subchronic study | Hagen et al., 1967 | No Observable Adverse Effect Level | 423.0 mg/kg-day | 0.1 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
6 | Acifluorfen, sodium | 62476-59-9 | Developmental, Other, Urinary | Mortality and kidney lesions | 2-generation reproduction rat study | Rhone-Poulenc, Inc., 1986 | No Observed Effect Level | 1.25 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
7 | Acrolein | 107-02-8 | Other | Decreased survival | Chronic gavage rat study | Parent et. al., 1992a | No Observable Adverse Effect Level | 0.05 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | Medium | High | Medium/High | Threshold | Chronic |
8 | Acrylamide | 79-06-1 | Nervous | Degenerative nerve changes | Chronic rat study | Johnson et al. 1986 | Human Equivalent Dose | 0.053 mg/kg-day | 0.002 mg/kg-day | 30 | 1 | Medium/High | Medium/High | Medium/High | Threshold | Chronic |
9 | Acrylic acid | 79-10-7 | Developmental | Reduced pup weight | Rat reproductive study | BASF, 1993 | No Observable Adverse Effect Level | 53.0 mg/kg-day | 0.5 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
10 | Alachlor | 15972-60-8 | Hematologic, Other | Hemosiderosis, hemolytic anemia | 1-year dog feeding study | Monsanto Co., 1984a | No Observable Adverse Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
11 | Alar | 1596-84-5 | Other | No adverse effects | 3-generation reproduction rat study, 3-generation reproduction rat study | Uniroyal Chemical, 1966 | No Observed Effect Level | 15.0 mg/kg-day | 0.15 mg/kg-day | 100 | 1 | Low | Medium | Low | Threshold | Chronic |
12 | Aldicarb | 116-06-3 | Nervous | Sweating as clinical sign of AChe inhibition | Acute human oral exposure study | Rhone-Poulenc, 1992 | No Observable Adverse Effect Level | 0.01 mg/kg-day | 0.001 mg/kg-day | 10 | 1 | Medium | Medium | Medium | Threshold | Chronic |
13 | Aldicarb sulfone | 1646-88-4 | Nervous | Brain ChE inhibition in females | 1-year dog feeding study | Union Carbide Agricultural Products Co., 1987 | No Observable Adverse Effect Level | 0.11 mg/kg-day | 0.001 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
14 | Aldrin | 309-00-2 | Hepatic | Liver toxicity | Rat chronic feeding study | Fitzhugh et al., 1964 | Lowest Observable Adverse Effect Level | 0.025 mg/kg-day | 3e-05 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
15 | Ally | 74223-64-6 | Other | Decreased body weight | 2-year rat feeding/oncogenicity study | duPont, 1985a | No Observed Effect Level | 25.0 mg/kg-day | 0.25 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
16 | Allyl alcohol | 107-18-6 | Hepatic, Urinary | Impaired renal function and increased liver and kidney weights | Subchronic oral rat study (drinking water) | Carpanini et al., 1978 | No Observed Effect Level | 4.8 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
17 | Aluminum phosphide | 20859-73-8 | Other | Body weight and clinical parameters | Rat chronic oral study | Hackenburg, 1972 | No Observable Adverse Effect Level | 0.043 mg/kg-day | 0.0004 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
18 | Amdro | 67485-29-4 | Hepatic, Other | Increased organ weights | 26-week dog feeding study | American Cyanamid, 1980 | No Observed Effect Level | 0.33 mg/kg-day | 0.0003 mg/kg-day | 1000 | 1 | Medium | High | High | Threshold | Chronic |
19 | Ametryn | 834-12-8 | Hepatic | Liver toxicity | Rat subchronic oral gavage bioassay | Ciba-Geigy, 1961a | No Observed Effect Level | 8.6 mg/kg-day | 0.009 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
20 | Amitraz | 33089-61-1 | Hematologic | Increased mean blood sugar concentration; slight hypothermia | 2-year dog oral feeding study | Upjohn Co., 1972a | No Observed Effect Level | 0.25 mg/kg-day | 0.0025 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
21 | Ammonium sulfamate | 7773-06-0 | Other | Decrease in body weight | 90-day rat feeding study | Gupta et al., 1979 | No Observed Effect Level | 214.3 mg/kg-day | 0.2 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
22 | Anthracene | 120-12-7 | Other | No observed effects | Subchronic toxicity study in mice | U.S. EPA, 1989 | No Observed Effect Level | 1000.0 mg/kg-day | 0.3 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
23 | Antimony | 7440-36-0 | Hematologic, Other | Longevity, blood glucose, and cholesterol | Rat chronic oral bioassay | Schroeder et al., 1970 | Lowest Observable Adverse Effect Level | 0.35 mg/kg-day | 0.0004 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
24 | Apollo | 74115-24-5 | Endocrine, Hepatic | Liver effects; organ weight changes | 1-year feeding dog study | BFC Chemicals, Inc., 1984 | No Observed Effect Level | 1.25 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
25 | Aroclor 1016 | 12674-11-2 | Developmental | Reduced birth weights | Monkey reproductive bioassay | Barsotti and van Miller, 1984; Levin et al., 1988; Schantz et al., 1989, 1991 | No Observable Adverse Effect Level | 0.007 mg/kg-day | 7e-05 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
26 | Aroclor 1254 | 11097-69-1 | Dermal, Immune, Ocular | Ocular exudate, inflamed and prominent Meibomian glands, distorted growth of finger and toe nails; decreased antibody (IgG and IgM) response to sheep erythrocytes | Monkey clinical and immunologic studies | Arnold et al., 1994a,b; Tryphonas et al., 1989, 1991a,b | Lowest Observable Adverse Effect Level | 0.005 mg/kg-day | 2e-05 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
27 | Arsenic, Inorganic | 7440-38-2 | Cardiovascular, Dermal | Hyperpigmentation, keratosis and possible vascular complications | Human chronic oral exposure | Tseng, 1977; Tseng et al., 1968 | No Observable Adverse Effect Level | 0.0008 mg/kg-day | 0.0003 mg/kg-day | 3 | 1 | Medium | Medium | Medium | Threshold | Chronic |
28 | Assure | 76578-14-8 | Hepatic | Liver cell enlargement | 2-year rat feeding study (NOEL for male subjects) | duPont, 1985 | No Observed Effect Level | 0.9 mg/kg-day | 0.009 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
29 | Asulam | 3337-71-1 | Hepatic, Reproductive | Lower ovarian weight, lower liver/body weight | 2-generation reproduction rat study | Rhone-Poulenc, 1981a | Lowest Effect Level | 50.0 mg/kg-day | 0.05 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
30 | Atrazine | 1912-24-9 | Other | Decreased body weight gain | 2-year rat feeding study | Ciba-Geigy Corp., 1986 | No Observable Adverse Effect Level | 3.5 mg/kg-day | 0.035 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
31 | Avermectin B1 | 65195-55-3 | Developmental | Increased retinal folds in weanlings, decreased viability and lactation indices, decreased pup body weight, increase of dead pups at birth | 2-generation rat reproduction study | Merck and Co., 1984 | No Observed Effect Level | 0.12 mg/kg-day | 0.0004 mg/kg-day | 300 | 1 | Medium | High | High | Threshold | Chronic |
32 | Barium and Compounds | 7440-39-3 | Urinary | Nephropathy | 2-year drinking water study in mice | NTP (1994) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 63.0 mg/kg-day | 0.2 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
33 | Baygon | 114-26-1 | Nervous | Mild cholinergic symptoms and RBD ChE inhibition | Single-dose human study | Vandekar et al., 1971 | Lowest Effect Level | 0.36 mg/kg-day | 0.004 mg/kg-day | 100 | 1 | Low | Medium | Medium | Threshold | Chronic |
34 | Bayleton | 43121-43-3 | Hematologic, Other | Decreased body weight gain, erythrocyte count and hemoglobin level | 2-year rat dietary study | Mobay Chemical, 1978 | No Observed Effect Level | 2.5 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
35 | Baythroid | 68359-37-5 | Other, Urinary | Decreased body weights in males, inflammatory foci in kidneys of females | 2-year rat study, dietary | Mobay Chemical, 1983a | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
36 | Benefin | 1861-40-1 | Hematologic | Depressed erythrocyte counts | Dog chronic oral bioassay | Eli Lilly and Co., 1972 | No Observable Adverse Effect Level | 25.0 mg/kg-day | 0.3 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
37 | Benomyl | 17804-35-2 | Developmental | Decreased pup weanling weights | 3-generation reproduction rat study | du Pont, 1968a | No Observed Effect Level | 5.0 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
38 | Bentazon (Basagran) | 25057-89-0 | Hematologic | Blood loss into the gastrointestinal tract; coagulation defect in male and female dogs | 1 year dog feeding study | Allen et al., 1989 | No Observable Adverse Effect Level | 3.2 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
39 | Benzaldehyde | 100-52-7 | Gastrointestinal, Urinary | Forestomach lesions, kidney toxicity | Rat oral toxicity study (subchronic) | Kluwe et al., 1983 | No Observed Effect Level | 143.0 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
40 | Benzene | 71-43-2 | Immune | Decreased lymphocyte count | Human occupational inhalation study | Rothman et. al., 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.2 mg/kg-day | 0.004 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
41 | Benzidine | 92-87-5 | Hepatic, Nervous | Brain cell vacuolization; liver cell alterations in females | Mouse chronic oral bioassay | Littlefield et al., 1983 | Lowest Observable Adverse Effect Level | 2.7 mg/kg-day | 0.003 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
42 | Benzo[a]pyrene (BaP) | 50-32-8 | Developmental | Neurobehavioral changes | Gavage neurodevelopmental study in rats (postnatal days [PNDs] 5−11) | Chen et al. (2012) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.092 mg/kg-day | 0.0003 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Benchmark | Chronic |
43 | Benzo[a]pyrene (BaP) | 50-32-8 | Immune | Decreased thymus weight and serum IgM | Gavage subchronic (35 d) study in rats | De Jong et al. (1999) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.9 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | None | None | Low | Benchmark | Chronic |
44 | Benzo[a]pyrene (BaP) | 50-32-8 | Reproductive | Decreased ovarian follicles and ovary weight | Gavage subchronic (60 d) reproductive toxicity study in rats | Xu et al. (2010) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.37 mg/kg-day | 0.0004 mg/kg-day | 1000 | 1 | None | None | Medium | None | Chronic |
45 | Benzoic acid | 65-85-0 | Other | No adverse effects observed | Human daily per capita intakes | FDA, 1973; Selected Committee on Review of the GRAS List | No Observable Adverse Effect Level | 4.4 mg/kg-day | 4.0 mg/kg-day | 1 | 1 | Medium | Medium | Medium | Threshold | Chronic |
46 | Beryllium and compounds | 7440-41-7 | Gastrointestinal | Small intestinal lesions | Dog dietary study | Morgareidge et al., 1976 | Benchmark Dose | 0.46 mg/kg-day | 0.002 mg/kg-day | 300 | 1 | Medium | Low/Medium | Low/Medium | Threshold | Chronic |
47 | Bidrin | 141-66-2 | Reproductive | Decreased pup survival | 3-generation rat reproduction study | Shell Chemical, 1965a | No Observed Effect Level | 0.1 mg/kg-day | 0.0001 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
48 | Biphenthrin | 82657-04-3 | Nervous | Tremors | 1-year dog feeding study | FMC Corporation, 1985 | No Observed Effect Level | 1.5 mg/kg-day | 0.015 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
49 | Biphenyl | 92-52-4 | Urinary | Renal papillary mineralization in male F344 rats | 2-year dietary study | Umeda et al. (2002) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 13.9 mg/kg-day | 0.5 mg/kg-day | 30 | 10 | High | Medium/High | Medium/High | None | Chronic |
50 | Bis(2-chloro-1-methylethyl) ether | 108-60-1 | Hematologic | Decrease in hemoglobin and possible erythrocyte destruction | 104-week mouse study oral exposure (diet) | Mitsumori et al., 1979 | No Observable Adverse Effect Level | 35.8 mg/kg-day | 0.04 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
51 | Bisphenol A | 80-05-7 | Other | Reduced mean body weight | Rat chronic oral bioassay | NTP, 1982 | Lowest Observable Adverse Effect Level | 50.0 mg/kg-day | 0.05 mg/kg-day | 1000 | 1 | Medium | High | High | Threshold | Chronic |
52 | Boron and Compounds | 7440-42-8 | Developmental | Decreased fetal weight (developmental) | Rat dietary gestational exposure to boric acid | Price et al., 1996a; Heindel et al., 1992 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 10.3 mg/kg-day | 0.2 mg/kg-day | 66 | 1 | High | High | High | Benchmark | Chronic |
53 | Bromate | 15541-45-4 | Urinary | Renal effects: urothelial hyperplasia | Rat feeding study | DeAngelo et al., 1998 | No Observable Adverse Effect Level | 1.1 mg/kg-day | 0.004 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
54 | Bromobenzene | 108-86-1 | Hepatic | Hepatocellular cytomegaly in male B6C3F1 mice | 90-day oral gavage administration | NTP (1985b) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 24.1 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | None | Subchronic |
55 | Bromobenzene | 108-86-1 | Hepatic | Hepatocellular cytomegaly in male B6C3F1 mice | 90-day oral gavage administration | NTP (1985b) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 24.1 mg/kg-day | 0.008 mg/kg-day | 3000 | 1 | Medium | Low/Medium | Low/Medium | None | Chronic |
56 | Bromodichloromethane | 75-27-4 | Urinary | Renal cytomegaly | Chronic mouse gavage bioassay | NTP, 1986 | Lowest Observable Adverse Effect Level | 17.9 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
57 | Bromoform | 75-25-2 | Hepatic | Hepatic lesions | Rat, subchronic oral gavage bioassay | NTP, 1989 | No Observed Effect Level | 17.9 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
58 | Bromomethane | 74-83-9 | Gastrointestinal | Epithelial hyperplasia of the forestomach | Rat subchronic gavage study | Danse et al., 1984 | No Observable Adverse Effect Level | 1.4 mg/kg-day | 0.0014 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
59 | Bromoxynil | 1689-84-5 | Other | No adverse effects | 2-year rat feeding/ oncogenic study | Union Carbide, 1982 | No Observed Effect Level | 5.0 mg/kg-day | 0.02 mg/kg-day | 300 | 1 | Low | Medium | Medium | Threshold | Chronic |
60 | Bromoxynil octanoate | 1689-99-2 | Other | No effects | 2-year rat feeding study | Union Carbide, 1982 | No Observed Effect Level | 7.3 mg/kg-day | 0.02 mg/kg-day | 300 | 1 | Low | Medium | Medium | Threshold | Chronic |
61 | Butyl benzyl phthalate (BBP) | 85-68-7 | Hepatic | Significantly increased liver-to-body weight and liver-to-brain weight ratios | 6-month rat study oral exposure (diet) | NTP, 1985 | No Observable Adverse Effect Level | 159.0 mg/kg-day | 0.2 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
62 | Butylate | 2008-41-5 | Hepatic | Increased relative liver weight in male dogs | 12-month dog feeding study | Stauffer Chemical Co., 1987a | No Observable Adverse Effect Level | 5.0 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
63 | Butylphthalyl butylglycolate (BPBG) | 85-70-1 | Other | No adverse effect | Rat, chronic oral bioassay | B.F. Goodrich Co., 1950 | No Observed Effect Level | 1000.0 mg/kg-day | 1.0 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
64 | Cadmium | 7440-43-9 | Urinary | Significant proteinuria | Human studies involving chronic exposures | U.S. EPA, 1985 | No Observable Adverse Effect Level | 0.005 mg/kg-day | 0.0005 mg/kg-day | 10 | 1 | Not Available | High | High | Threshold | Chronic |
65 | Cadmium | 7440-43-9 | Urinary | Significant proteinuria | Human studies involving chronic exposures | U.S. EPA, 1985 | No Observable Adverse Effect Level | 0.01 mg/kg-day | 0.001 mg/kg-day | 10 | 1 | None | None | High | None | Chronic |
66 | Calcium cyanide | 592-01-8 | Reproductive | Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | None | None | None | None None | 0.001 mg/kg-day | None | None | None | None | None | None | Chronic |
67 | Caprolactam | 105-60-2 | Developmental | Reduced offspring body weight | Rat oral three generation reproduction study | Serotta et al., 1984 | No Observable Adverse Effect Level | 50.0 mg/kg-day | 0.5 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
68 | Captafol | 2425-06-1 | Urinary | Kidney and bladder toxicity | One-year dog feeding study | Ortho-Chevron, 1985a | Lowest Effect Level | 2.0 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | High | High | High | Threshold | Chronic |
69 | Captan | 133-06-2 | Other | Decreased mean body weights | One-generation and three-generation rat reproduction studies | Stauffer Chemical Co., 1982a Chevron Chemical Co., 1982 | No Observed Effect Level | 12.5 mg/kg-day | 0.13 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
70 | Carbaryl | 63-25-2 | Hepatic, Urinary | Kidney and liver toxicity | Rat chronic feeding study | Carpenter et al., 1961 | No Observable Adverse Effect Level | 9.6 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
71 | Carbofuran | 1563-66-2 | Nervous, Reproductive | RBC and plasma cholinesterase inhibition, and testicular and uterine effects | One-year dog feeding study | FMC Corp., 1983 | No Observed Effect Level | 0.5 mg/kg-day | 0.005 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
72 | Carbon disulfide | 75-15-0 | Developmental | Fetal toxicity/ malformations | Rabbit inhalation teratogenic study | Hardin et al., 1981 | No Observed Effect Level | 11.0 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
73 | Carbon tetrachloride | 56-23-5 | Hepatic | Elevated serum SDH activity | Subchronic oral rat study | Bruckner et al., 1986 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.9 mg/kg-day | 0.004 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
74 | Carbosulfan | 55285-14-8 | Other | Decreased body weight | 2-year rat feeding study | FMC, 1982a | No Observed Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
75 | Carboxin | 5234-68-4 | Other | Reduced weight gain, organ weight changes, increased mortality | 2-year rat feeding study | Uniroyal Chemical, 1969a | No Observed Effect Level | 10.0 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
76 | Chloral hydrate | 302-17-0 | Gastrointestinal, Nervous | CNS depression and GI irritation in humans | Subchronic human pharmacological information | Goodman and Gilman, 1985 | Lowest Observable Adverse Effect Level | 10.7 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
77 | Chloramben | 133-90-4 | Hepatic | Hepatocyte degeneration | 18-month feeding study in CD-1 mice | Union Carbide, 1978 | Lowest Effect Level | 15.0 mg/kg-day | 0.015 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
78 | Chlordane (Technical) | 12789-03-6 | Hepatic | Hepatic necrosis | Mouse 104-week oral study | Khasawinah and Grutsch, 1989a | No Observable Adverse Effect Level | 0.15 mg/kg-day | 0.0005 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
79 | Chlordecone (Kepone) | 143-50-0 | Urinary | Renal lesions (glomerulosclerosis) in female Wistar rats | 2-year feeding study | Larson et al., 1979 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.08 mg/kg-day | 0.0003 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Benchmark | Chronic |
80 | Chlorimuron-ethyl | 90982-32-4 | Hematologic | Increase in WBC, decreased in RBC in females, increase in alkaline phosphatase in males | 1-year dog study oral exposure (diet) | duPont, 1985 | No Observed Effect Level | 6.25 mg/kg-day | 0.02 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
81 | Chlorine | 7782-50-5 | None | No observed adverse effects | Rat chronic drinking water study | NTP, 1992 | No Observable Adverse Effect Level | 14.4 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
82 | Chlorine cyanide | 506-77-4 | Endocrine, Nervous, Other | Weight loss, thyroid effects, and myelin degeneration | Rat chronic oral study | Howard and Hanzal, 1955 | No Observable Adverse Effect Level | 25.3 mg/kg-day | 0.05 mg/kg-day | 100 | 5 | Medium | Medium | Medium | Threshold | Chronic |
83 | Chlorine dioxide | 10049-04-4 | Developmental, Nervous | Neurodevelopmental effects | Two-generation rat drinking water study | CMA, 1996 | No Observable Adverse Effect Level | 3.0 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | Medium | High | Medium/High | Threshold | Chronic |
84 | Chlorite (sodium salt) | 7758-19-2 | Developmental, Nervous | Neurodevelopmental effects | Two-generation rat drinking water study | CMA, 1996 | No Observable Adverse Effect Level | 3.0 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | Medium | High | Medium/High | Threshold | Chronic |
85 | p-Chloroaniline | 106-47-8 | Immune | Nonneoplastic lesions of splenic capsule | Rat, chronic oral bioassay | NCI, 1979 | Lowest Observable Adverse Effect Level | 12.5 mg/kg-day | 0.004 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
86 | Chlorobenzene | 108-90-7 | Hepatic | Histopathologic changes in liver | 13-week dog study, oral exposure (capsule) | Monsanto Co., 1967a; Knapp et al., 1971 | No Observable Adverse Effect Level | 19.0 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
87 | Chlorobenzilate | 510-15-6 | Nervous, Other | Decreased stool quantity, food consumption and body weight gains hyperirritability (maternal effects) | Rabbit teratology study | Ciba-Geigy Corp., 1984a | No Observed Effect Level | 5.0 mg/kg-day | 0.02 mg/kg-day | 300 | 1 | Low | Medium | Medium | Threshold | Chronic |
88 | Chloroform | 67-66-3 | Hepatic | Moderate/marked fatty cyst formation in the liver and elevated SGPT | Dog, chronic oral bioassay | Heywood et al., 1979 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
89 | beta-Chloronaphthalene | 91-58-7 | Hepatic, Other, Respiratory | Dyspnea, abnormal appearance, liver enlargement | Mouse subchronic oral gavage study | U.S. EPA, 1989 | No Observable Adverse Effect Level | 250.0 mg/kg-day | 0.08 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
90 | 2-Chlorophenol | 95-57-8 | Reproductive | Reproductive effects | Rat subchronic drinking water study | Exon and Koller, 1982 | No Observable Adverse Effect Level | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
91 | Chlorothalonil | 1897-45-6 | Urinary | Renal tubular epithelial vacuolation | 2-year dog feeding study | Diamond Shamrock Chemical, 1970a | No Observed Effect Level | 1.5 mg/kg-day | 0.015 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
92 | o-Chlorotoluene | 95-49-8 | Other | Decrease in body weight gain | 15-week rat study oral exposure (gavage) | Gibson et al., 1974a | No Observable Adverse Effect Level | 20.0 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
93 | Chlorpropham | 101-21-3 | Hematologic, Hepatic, Immune, Urinary | Kidney, spleen, liver, and bone marrow toxicity | 2-generation rat reproduction study | PPG Industries, 1983a | No Observed Effect Level | 50.0 mg/kg-day | 0.2 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
94 | Chlorsulfuron | 64902-72-3 | Other | Decreased body weight | 2-year rat study oral exposure (diet) | du Pont, 1980a | No Observed Effect Level | 5.0 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | High | High | High | None | Chronic |
95 | Chromium(III), insoluble salts | 16065-83-1 | Other | No effects observed | Rat chronic feeding study | Ivankovic and Preussman, 1975 | No Observable Adverse Effect Level | 1468.0 mg/kg-day | 1.5 mg/kg-day | 100 | 10 | Low | Low | Low | Threshold | Chronic |
96 | Chromium(VI) | 18540-29-9 | Gastrointestinal | GI tract effects in mice and rats | None | None | Human Equivalent Dose | 0.0911 mg/kg-day | 0.0009 mg/kg-day | 100 | None | None | None | Medium/High | None | Chronic |
97 | Copper cyanide | 544-92-3 | Hepatic, Other, Urinary | Decreased body and organ weights, histopathologic alterations in liver and kidney | Rat oral subchronic study | U.S. EPA, 1986 | No Observable Adverse Effect Level | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
98 | Cumene | 98-82-8 | Urinary | Increased average kidney weight in female rats | Rat oral gavage study | Wolf et al., 1956 | No Observable Adverse Effect Level | 110.0 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | Low | Medium | Low | Threshold | Chronic |
99 | Cyanide, free | 57-12-5 | Reproductive | Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanide, free is presented in section 1.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | Decreased cauda epididymis weight in rats in the subchronic oral study conducted by NTP (1993). A total UF of 3,000 was applied to the POD: 10 for the extrapolation from animals to humans (UFA), 10 for the extrapolation from a subchronic to chronic exposure duration (UFS) 10 for human intraspecies variability (UFH) and 3 to account for database deficiencies (UFD). | None | None | None None | 0.00063 mg/kg-day | 3000 | None | None | None | Low/Medium | None | Chronic |
100 | Cyanogen | 460-19-5 | Other | Decreased cauda epididymis weight in male F344/N rats. The RfD for cyanogen is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | None | None | None | None None | 0.001 mg/kg-day | None | None | None | None | None | None | Chronic |
101 | Cyanogen bromide | 506-68-3 | Endocrine, Nervous, Other | Weight loss, thyroid effects and myelin degeneration | Rat chronic oral study | Howard and Hanzal, 1955 | No Observable Adverse Effect Level | 44.0 mg/kg-day | 0.09 mg/kg-day | 100 | 5 | Medium | Medium | Low | Threshold | Chronic |
102 | Cyclohexanone | 108-94-1 | Other | Body weight depression | Chronic rat oral study | Lijinsky and Kovatch, 1986 | No Observable Adverse Effect Level | 462.0 mg/kg-day | 5.0 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
103 | Cyclohexylamine | 108-91-8 | Reproductive | Testicular damage | Rat chronic oral study | Gaunt et al., 1976 | No Observable Adverse Effect Level | 18.0 mg/kg-day | 0.2 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
104 | Cyhalothrin/Karate | 68085-85-8 | Developmental, Other | Reduced body weight gain preceding pregnancy reduced body weight gain in offspring during weaning period | 3-generation reproduction study in rats | Coopers Animal Health and Imperial Chemical Industries, 1984 | No Observed Effect Level | 0.5 mg/kg-day | 0.005 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
105 | Cypermethrin | 52315-07-8 | Gastrointestinal | G.I. tract disturbances | 1-year dog feeding study | ICI Americas, Inc., 1982a | No Observed Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
106 | Cyromazine | 66215-27-8 | Hematologic | Hematologic effects | 6-month dog study oral exposure (diet) | Ciba-Geigy, 1980 | No Observed Effect Level | 0.75 mg/kg-day | 0.0075 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
107 | Dacthal | 1861-32-1 | Endocrine, Hepatic, Ocular, Respiratory, Urinary | Effects on the lungs, liver, kidney, thyroid and thyroid hormones in males and females and eyes of females | 2-year rat feeding study | ISK Biotech Corp., 1993 | No Observable Adverse Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
108 | Dalapon, sodium salt | 75-99-0 | Urinary | Increased kidney body weight ratio | 2-year rat study oral exposure (diet) | Paynter et al., 1960 | No Observed Effect Level | 8.45 mg/kg-day | 0.03 mg/kg-day | 300 | 1 | Low | Low | Low | Threshold | Chronic |
109 | Danitol | 39515-41-8 | Nervous | Tremors | 1-year dog feeding study | Sumitomo Chemical Co., Ltd., 1984 | No Observable Adverse Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
110 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Nervous | Neurobehavioral effects | Single dose gavage study in mice | Viberg et al., 2003 | No Observable Adverse Effect Level | 2.22 mg/kg | 0.007 mg/kg-day | 300 | 1 | Low | Medium | Low | Threshold | Chronic |
111 | Demeton | 8065-48-3 | Nervous | ChE inhibition, optic nerve degeneration | 2-year feeding in rats (disulfoton) | Mobay Chemical, 1985 | Lowest Effect Level | 0.04 mg/kg-day | 4e-05 mg/kg-day | 1000 | 1 | High | Low | Low | Threshold | Chronic |
112 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Hepatic | Increased relative liver weight | Guinea pig subchronic-to-chronic oral bioassay | Carpenter et al., 1953 | Lowest Observable Adverse Effect Level | 19.0 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
113 | Di(2-ethylhexyl)adipate | 103-23-1 | Developmental, Hepatic, Musculoskeletal, Other, Urinary | Changes in body weight and liver weight increased liver weight of male and female parents reduced ossification and slightly dilated ureters in fetuses reduced offspring weight gain, total litter weight, and litter size | Rat teratogenicity feeding study one-generation rat reproductive study | ICI, 1988a,b | No Observable Adverse Effect Level | 170.0 mg/kg-day | 0.6 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
114 | 1,4-Dibromobenzene | 106-37-6 | Hepatic | Liver/body weight ratio and hepatic microsomal enzyme induction | Rat subchronic oral study | Carlson and Tardiff, 1977 | No Observable Adverse Effect Level | 10.0 mg/kg-day | 0.01 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
115 | Dibromochloromethane | 124-48-1 | Hepatic | Hepatic lesions | Rat, subchronic gavage bioassay | NTP, 1985 | No Observed Effect Level | 21.4 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
116 | 1,2-Dibromoethane | 106-93-4 | Endocrine, Hepatic, Reproductive | Testicular atrophy, liver peliosis, and adrenal cortical degeneration | Rat chronic oral gavage study | NCI, 1978 | Lowest Observable Adverse Effect Level | 27.0 mg/kg-day | 0.009 mg/kg-day | 3000 | 1 | Low/Medium | Low/Medium | Low/Medium | Benchmark | Chronic |
117 | Dibutyl phthalate (DBP) | 84-74-2 | Other | Increased mortality | Rat subchronic to chronic, oral bioassay | Smith, 1953 | No Observable Adverse Effect Level | 125.0 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
118 | Dicamba | 1918-00-9 | Developmental, Other | Maternal (reduced weight gain) and fetal toxicity | Rabbit developmental study | Velsicol Chemical, 1978 | No Observed Effect Level | 3.0 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
119 | Dichloroacetic acid | 79-43-6 | Hepatic, Nervous, Reproductive | Lesions observed in the testes, cerebrum, cerebellum, and liver. | Dog, Subchronic Oral | Cicmanec et. al., 1991 | Lowest Observable Adverse Effect Level | 12.5 mg/kg-day | 0.004 mg/kg-day | 3000 | 1 | High | Medium | Medium | Threshold | None |
120 | 1,2-Dichlorobenzene | 95-50-1 | Other | No adverse effects observed | 2-year rat study, oral exposure (gavage) | NTP, 1985 | No Observable Adverse Effect Level | 85.7 mg/kg-day | 0.09 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
121 | Dichlorodifluoromethane | 75-71-8 | Other | Reduced body weight | Rat chronic oral study | Sherman, 1974 | No Observable Adverse Effect Level | 15.0 mg/kg-day | 0.2 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
122 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Hepatic | Liver lesions | 27-week rat feeding study | Laug et al., 1950 | No Observed Effect Level | 0.05 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
123 | cis-1,2-Dichloroethylene | 156-59-2 | Urinary | Increased relative kidney weight in male rats | Subchronic oral rat study | McCauley et al. (1995, 1990) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 5.1 mg/kg-day | 0.002 mg/kg-day | 3000 | 1 | Medium | Low/Medium | Low | Threshold | Chronic |
124 | trans-1,2-Dichloroethylene | 156-60-5 | Immune | Decrease in number of antibody forming cells (AFCs) against sheep red blood cells (sRBCs) in male mice | Subchronic oral mouse study | Shopp et al. (1985) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 65.0 mg/kg-day | 0.02 mg/kg-day | 3000 | 1 | Medium | Low/Medium | Low | Threshold | Chronic |
125 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Hepatic | Liver toxicity (fatty change) | Rat chronic drinking water study | Quast et al., 1983 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 4.6 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
126 | Dichloromethane | 75-09-2 | Hepatic | Hepatic effects (hepatic vacuolation, liver foci) | 2-Year rat drinking water bioassay | Serota et al., 1986a | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.19 mg/kg-day | 0.006 mg/kg-day | 30 | 1 | High | Medium/High | High | None | Chronic |
127 | 2,4-Dichlorophenol | 120-83-2 | Immune | Decreased delayed hypersensitivity response | Rat, subchronic to chronic | Exon and Koller, 1985 | No Observed Effect Level | 0.3 mg/kg-day | 0.003 mg/kg-day | 100 | 1 | Low | Low | Low | Threshold | Chronic |
128 | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) | 94-82-6 | Other | Internal hemorrhage, mortality | Dog subchronic oral bioassay | Rhodia, Inc., 1969a | No Observable Adverse Effect Level | 8.0 mg/kg-day | 0.008 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
129 | 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | Hematologic, Hepatic, Urinary | Hematologic, hepatic and renal toxicity | 90-day rat oral bioassay and 1-year interim report from a 2-year rat oral bioassay | Dow Chemical Co., 1983 | No Observable Adverse Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
130 | 2,3-Dichloropropanol | 616-23-9 | Cardiovascular, Hepatic, Urinary | Myocardial degeneration, hepatotoxicity and nephrotoxicity | Rat oral subchronic study | U.S. EPA, 1989 | No Observable Adverse Effect Level | 10.0 mg/kg-day | 0.003 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
131 | 1,3-Dichloropropene | 542-75-6 | Gastrointestinal | Chronic irritation | Rat chronic feeding study | Stott et al., 1995 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.4 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
132 | Dichlorvos | 62-73-7 | Nervous | Plasma and RBC ChE inhibition in males and females brain ChE inhibition in males | 1-year dog feeding study | AMVAC Chemical Corp., 1990 | No Observable Adverse Effect Level | 0.05 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
133 | Dieldrin | 60-57-1 | Hepatic | Liver lesions | 2-year rat feeding study | Walker et al., 1969 | No Observable Adverse Effect Level | 0.005 mg/kg-day | 5e-05 mg/kg-day | 100 | 1 | Low | Medium | Medium | Threshold | Chronic |
134 | Diethyl phthalate (DEP) | 84-66-2 | Other | Decreased growth rate, food consumption and altered organ weights | Rat, subchronic oral feeding study | Brown et al., 1978 | No Observable Adverse Effect Level | 750.0 mg/kg-day | 0.8 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
135 | Difenzoquat | 43222-48-6 | Other | Decreased body weight | 2-year rat feeding study | American Cyanamid Co., 1975 | No Observed Effect Level | 25.0 mg/kg-day | 0.08 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
136 | Diflubenzuron | 35367-38-5 | Hematologic | Methemoglobin and sulfhemoglobin formation | One-year dog feeding study | Duphar, 1985 | No Observed Effect Level | 2.0 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
137 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | Other | No effects related to treatment | 90-day dog feeding study | U.S. DOD, 1980 | No Observed Effect Level | 75.0 mg/kg-day | 0.08 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
138 | Dimethipin | 55290-64-7 | Hepatic | Increased absolute and relative liver weight | 2-year rat feeding study | Uniroyal Chemical Co., 1981a | No Observed Effect Level | 2.0 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
139 | Dimethoate | 60-51-5 | Nervous | Brain ChE inhibition | 2-year rat feeding study | American Cyanamid Co., 1986a | No Observed Effect Level | 0.05 mg/kg-day | 0.0002 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
140 | Dimethyl terephthalate (DMT) | 120-61-6 | Urinary | Chronic kidney inflammation | Rat chronic dietary study | NCI, 1979 | Lowest Observable Adverse Effect Level | 125.0 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
141 | N-N-Dimethylaniline | 121-69-7 | Hematologic, Immune, Other | Splenomegaly, increased splenic hemosiderosis and hematopoiesis | Mouse subchronic gavage bioassay | Abdo et al., 1984 | Lowest Observable Adverse Effect Level | 22.32 mg/kg-day | 0.002 mg/kg-day | 10000 | 1 | Low | Low | Low | Threshold | Chronic |
142 | 2,4-Dimethylphenol | 105-67-9 | Hematologic, Nervous | Clinical signs (lethargy, prostration, and ataxia) and hematological changes | Mouse subchronic oral gavage | U.S. EPA, 1989 | No Observable Adverse Effect Level | 50.0 mg/kg-day | 0.02 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
143 | 3,4-Dimethylphenol | 95-65-8 | Cardiovascular, Hepatic, Immune, Other, Urinary | Changes in blood pressure and body weight histopathological changes in liver, kidney and spleen | Rat oral 1-year study | Veldre and Janes, 1979 | No Observed Effect Level | 1.4 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
144 | 2,6-Dimethylphenol | 576-26-1 | Hepatic, Immune, Other, Urinary | Body weight changes and histopathological changes of internal organs (liver, spleen and kidneys) | Rat subchronic toxicity study | Veldre and Janes, 1979 | No Observed Effect Level | 0.6 mg/kg-day | 0.0006 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
145 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | Ocular | Cataract formation | Adult human subchronic oral study | Horner, 1942 | Lowest Observable Adverse Effect Level | 2.0 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
146 | m-Dinitrobenzene | 99-65-0 | Immune | Increased splenic weight | Rat subchronic oral study | Cody et al., 1981 | No Observable Adverse Effect Level | 0.4 mg/kg-day | 0.0001 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
147 | 2,4-Dinitrophenol | 51-28-5 | Ocular | Cataract formation | Human chronic and subchronic exposures | Horner, 1942 | Lowest Observable Adverse Effect Level | 2.0 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
148 | 2,4-Dinitrotoluene | 121-14-2 | Hematologic, Hepatic, Nervous | Neurotoxicity, Heinz bodies and biliary tract hyperplasia | Dog feeding study, 2-year | Ellis et al., 1985 | No Observable Adverse Effect Level | 0.2 mg/kg-day | 0.002 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
149 | Dinoseb | 88-85-7 | Developmental | Decreased fetal weight | 3-generation rat reproduction study | Dow Chemical Co., 1981a | Lowest Effect Level | 1.0 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
150 | 1,4-Dioxane | 123-91-1 | Hepatic, Urinary | Liver and kidney toxicity | Chronic oral male rat study | Kociba et al. 1974 | No Observable Adverse Effect Level | 9.6 mg/kg-day | 0.03 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
151 | Diphenamid | 957-51-7 | Hepatic | Liver toxicity | 2-year dog feeding study | Upjohn Co., 1966a | No Observed Effect Level | 3.0 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
152 | Diphenylamine | 122-39-4 | Hepatic, Other, Urinary | Decreased body weight gain, and increased liver and kidney weights | 2-year dog feeding study | Thomas et al., 1967 | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
153 | Diquat | 2764-72-9 | Ocular | Minimal lens opacity and cataracts | Chronic rat study, dietary | Chevron Chemical, 1985 | No Observed Effect Level | 0.22 mg/kg-day | 0.0022 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
154 | Disulfoton | 298-04-4 | Nervous | ChE inhibition, optic nerve degeneration | 2-year rat study oral exposure (diet) | Mobay Chemical, 1985 | Lowest Effect Level | 0.04 mg/kg-day | 4e-05 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
155 | 1,4-Dithiane | 505-29-3 | Nervous, Respiratory | Nasal olfactory lesions | 90-day gavage rat study | Schieferstein et al., 1988 | Lowest Observable Adverse Effect Level | 105.0 mg/kg-day | 0.01 mg/kg-day | 10000 | 1 | Low | Low | Low | Threshold | Chronic |
156 | Diuron | 330-54-1 | Hematologic | Abnormal pigments in blood | 2-year dog feeding study | du Pont, 1964a | No Observed Effect Level | 0.625 mg/kg-day | 0.002 mg/kg-day | 300 | 1 | Low | Low | Low | Threshold | Chronic |
157 | Dodine | 2439-10-3 | Endocrine | Thyroid toxicity | 1-year dog feeding study | American Cyanamid, 1958 | No Observed Effect Level | 1.25 mg/kg-day | 0.004 mg/kg-day | 300 | 1 | Low | Low | Low | Threshold | Chronic |
158 | Endosulfan | 115-29-7 | Cardiovascular, Other, Urinary | Reduced body weight gain in males and females increased incidence of marked progressive glomerulonephrosis and blood vessel aneurysms in males | 2-year rat feeding study (NOAEL for males) | Hoechst Celanese Corp., 1989a | No Observable Adverse Effect Level | 0.6 mg/kg-day | 0.006 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
159 | Endothall | 145-73-3 | Gastrointestinal | Increased absolute and relative weights of stomach and small intestine | Two-year feeding study in dogs | Pennwalt Agchem., 1965 | No Observed Effect Level | 2.0 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
160 | Endrin | 72-20-8 | Hepatic, Nervous | Mild histological lesions in liver, occasional convulsions | Dog chronic oral bioassay | Velsicol Chemical Corporation, 1969 | No Observed Effect Level | 0.025 mg/kg-day | 0.0003 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
161 | Ethephon | 16672-87-0 | Nervous | Plasma ChE inhibition | 16-day human study | Union Carbide, 1977a | Lowest Effect Level | 0.5 mg/kg-day | 0.005 mg/kg-day | 100 | 1 | Low | Medium | Low | Threshold | Chronic |
162 | Ethion | 563-12-2 | Nervous | Plasma cholinesterase inhibition | Cholinesterase inhibition study in humans | FMC Corp., 1970 | No Observed Effect Level | 0.05 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
163 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Urinary | Increased absolute kidney weight in female rats | 2-year drinking water study in male and female F344 rats | Suzuki et al., 2012; JPEC, 2010a | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 28.8 mg/kg-day | 1.0 mg/kg-day | 30 | 1 | High | High | High | Benchmark | Chronic |
164 | Ethyl acetate | 141-78-6 | Other | Mortality and body weight loss | Rat oral subchronic study | U.S. EPA, 1986 | No Observed Effect Level | 900.0 mg/kg-day | 0.9 mg/kg-day | 1000 | 1 | High | Low | Low | Threshold | Chronic |
165 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | Cardiovascular | Degenerative cardiomyopathy | 2-generation reproduction rat study | PPG Industries, 1986a | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
166 | Ethyl ether | 60-29-7 | Other | Depressed body weights | Rat oral subchronic study | U.S. EPA, 1986 | No Observable Adverse Effect Level | 500.0 mg/kg-day | 0.2 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
167 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | Nervous | Neurotoxicity | 90-day hen delayed neurotoxicity bioassay | Morabani, Nissan, duPont and Velsicol, 1982 | No Observed Effect Level | 0.01 mg/kg-day | 1e-05 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
168 | Ethylbenzene | 100-41-4 | Hepatic, Urinary | Liver and kidney toxicity | Rat subchronic to chronic oral bioassay | Wolf et al., 1956 | No Observed Effect Level | 97.1 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
169 | Ethylene glycol | 107-21-1 | Urinary | Kidney toxicity | Chronic rat oral feeding study | DePass et al., 1986a | No Observable Adverse Effect Level | 200.0 mg/kg-day | 2.0 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
170 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Hematologic | Hemosiderin deposition in the liver | Chronic (rat and mouse) inhalation study | NTP (2000) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.4 mg/kg-day | 0.1 mg/kg-day | 10 | 1 | High | Medium/High | Medium/High | Threshold | Chronic |
171 | Ethylene thiourea (ETU) | 96-45-7 | Endocrine | Increased incidence of thyroid hyperplasia | Rat 24-month feeding study | Graham et al., 1975 | Lowest Observable Adverse Effect Level | 0.25 mg/kg-day | 8e-05 mg/kg-day | 3000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
172 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | Urinary | Kidney damage and reduced lifespan | Rat, chronic oral bioassay | Hodge et al., 1953 | No Observed Effect Level | 250.0 mg/kg-day | 3.0 mg/kg-day | 100 | 1 | Medium | Low | Low | Threshold | Chronic |
173 | Express | 101200-48-0 | Other, Urinary | Elevated serum bilirubin and AST levels, increased urinary volume | 1-year dog feeding study | du Pont, 1986a | No Observed Effect Level | 0.79 mg/kg-day | 0.008 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
174 | Fenamiphos | 22224-92-6 | Nervous | ChE inhibition | 2-year dog feeding study | Chemagro Corp., 1972a | No Observed Effect Level | 0.025 mg/kg-day | 0.00025 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
175 | Fluometuron | 2164-17-2 | Other | No adverse effects | 103-week rat feeding study | NCI, 1980 | No Observable Adverse Effect Level | 12.5 mg/kg-day | 0.013 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
176 | Fluoranthene | 206-44-0 | Hepatic, Urinary | Nephropathy, increased liver weights, hematological alterations, and clinical effects | Mouse subchronic study | U.S. EPA, 1988 | No Observable Adverse Effect Level | 125.0 mg/kg-day | 0.04 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
177 | Fluorene | 86-73-7 | Hematologic | Decreased RBC, packed cell volume and hemoglobin | Mouse subchronic study | U.S. EPA, 1989 | No Observable Adverse Effect Level | 125.0 mg/kg-day | 0.04 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
178 | Fluorine (soluble fluoride) | 7782-41-4 | Gastrointestinal | Objectionable dental fluorosis, a cosmetic effect | Epidemiologic study in children | Hodge, 1950, cited in Underwood, 1977 | No Observable Adverse Effect Level | 0.06 mg/kg-day | 0.06 mg/kg-day | 1 | 1 | High | High | High | Threshold | Chronic |
179 | Fluridone | 59756-60-4 | Ocular, Other, Reproductive, Urinary | Glomerulonephritis, atrophic testes, eye keratitis decreased body weight and organ weights | 2-year rat feeding study | Elanco Products, 1980a | No Observed Effect Level | 8.0 mg/kg-day | 0.08 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
180 | Flurprimidol | 56425-91-3 | Hepatic, Other | Increased incidence of hepatocellular changes including fatty change and vacuolation (M) increased susceptibility to stress factors (F) | 2-generation rat reproduction study | Eli Lilly and Co., 1986a | No Observed Effect Level | 1.8 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
181 | Flutolanil | 66332-96-5 | Hepatic, Other, Reproductive | Decreased body weight and body weight gains in both doses increased liver weights at high dose | 3-generation reproduction and teratology study in rats | NOR-AM Chemical Co., 1982a | Lowest Effect Level | 63.7 mg/kg-day | 0.06 mg/kg-day | 1000 | 1 | Low | Medium | Medium | Threshold | Chronic |
182 | Fluvalinate | 69409-94-5 | Dermal, Other | Decreases in body weight gain increase in plantar ulcer (females) | 2-year feeding/ oncogenicity study in rats | Zoecon, 1984 | No Observed Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
183 | Folpet | 133-07-3 | Hepatic, Other | Decreased body weight gain, altered serum chemistry parameters (decreased serum cholesterol, total protein, and serum albumin and globulin levels) | Chronic oral toxicity study in dogs | Chevron Chemical, 1986 | No Observed Effect Level | 10.0 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
184 | Fonofos | 944-22-9 | Hepatic, Nervous | Cholinesterase inhibition, cholinergic symptoms, and increased liver weight | 2-year dog feeding study | Stauffer Chemical Co., 1969 | No Observed Effect Level | 0.2 mg/kg-day | 0.002 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
185 | Formaldehyde | 50-00-0 | Gastrointestinal, Other, Urinary | Reduced weight gain, histopathology in rats | Rat 2-year bioassay | Til et al., 1989 | No Observable Adverse Effect Level | 15.0 mg/kg-day | 0.2 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
186 | Fosetyl-al | 39148-24-8 | Reproductive | Slight testicular degeneration | 2-year dog feeding study | Rhone-Poulenc, 1981a | No Observed Effect Level | 250.0 mg/kg-day | 3.0 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
187 | Furan | 110-00-9 | Hepatic | Hepatic lesions | Mouse subchronic oral study | NTP, 1982 | No Observable Adverse Effect Level | 1.4 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
188 | Furfural | 98-01-1 | Hepatic | Mild hepatocellular vacuolization | Rat oral subchronic study | NTP, 1981a | Lowest Observable Adverse Effect Level | 7.9 mg/kg-day | 0.003 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
189 | Glufosinate-ammonium | 77182-82-2 | Urinary | Increased absolute and relative kidney weights in males | 13-week rat feeding study | Hoescht AG, 1982a | No Observed Effect Level | 0.4 mg/kg-day | 0.0004 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
190 | Glycidaldehyde | 765-34-4 | Endocrine, Hematologic, Other, Urinary | Weight gain retardation, enlarged adrenals, hydropic renal pelvis and hematopoietic effects | Rat subchronic inhalation study | Hine et al., 1961 | No Observable Adverse Effect Level | 1.09 mg/kg-day | 0.0004 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
191 | Glyphosate | 1071-83-6 | Developmental, Urinary | Increased incidence of renal tubular dilation in F3b offspring | 3-generation rat reproduction study | Monsanto Co., 1981a | No Observed Effect Level | 10.0 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
192 | Haloxyfop-methyl | 69806-40-2 | Reproductive, Urinary | Reduced relative kidney weights in F0, F1, and F2b adults; reduced fertility in the F1/F2b generation | 3-generation rat reproduction study | Dow Chemical U.S.A., 1985a | No Observed Effect Level | 0.005 mg/kg-day | 5e-05 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
193 | Harmony | 79277-27-3 | Other | Reduced body weight gains in males, reduced serum sodium in males and females | 2-year rat feeding study | du Pont, 1986a | No Observed Effect Level | 1.25 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
194 | Heptachlor | 76-44-8 | Hepatic | Liver weight increases in males | 2-year rat feeding study | Velsicol Chemical, 1955a | No Observed Effect Level | 0.15 mg/kg-day | 0.0005 mg/kg-day | 300 | 1 | Low | Low | Low | Threshold | Chronic |
195 | Heptachlor epoxide | 1024-57-3 | Hepatic | Increased liver-to-body weight ratio in both males and females | 60-week dog feeding study | Dow Chemical Co., 1958 | Lowest Effect Level | 0.0125 mg/kg-day | 1.3e-05 mg/kg-day | 1000 | 1 | Low | Medium | Low | Threshold | Chronic |
196 | Hexabromobenzene | 87-82-1 | Hepatic | Induced serum carboxylesterase activity, increased relative liver weight, increased liver porphyrins | Rat dietary subchronic study | Mendoza et al., 1977 | No Observable Adverse Effect Level | 2.0 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
197 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Nervous | Neurobehavioral effects | Single dose gavage study in mice | Viberg et al. 2003 | No Observable Adverse Effect Level | 0.45 mg/kg | 0.0002 mg/kg-day | 3000 | 1 | Low | Low | Low | Benchmark | Chronic |
198 | Hexachlorobenzene | 118-74-1 | Hepatic | Liver effects | Rat chronic feeding study | Arnold et al., 1985 | No Observable Adverse Effect Level | 0.08 mg/kg-day | 0.0008 mg/kg-day | 100 | 1 | Medium | High | Medium | Threshold | Chronic |
199 | gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | Hepatic, Urinary | Liver and kidney toxicity | Rat, subchronic oral bioassay (NOAEL for females) | Zoecon Corp., 1983 | No Observable Adverse Effect Level | 0.33 mg/kg-day | 0.0003 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
200 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Gastrointestinal | Chronic irritation | Rat subchronic gavage bioassay | Abdo et al., 1984 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 6.0 mg/kg-day | 0.006 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
201 | Hexachloroethane | 67-72-1 | Urinary | Atrophy and degeneration of renal tubules | 16-week subchronic dietary exposure study, male F344 rats | Gorzinski et al., 1985 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.728 mg/kg-day | 0.0007 mg/kg-day | 1000 | 1 | High | Low/Medium | Low/Medium | Threshold | Chronic |
202 | Hexachlorophene | 70-30-4 | Gastrointestinal, Nervous | Swollen salivary glands, status spongiosis in brain and optic nerve | 13-week dog feeding study | Nationwide Chemical Corp., 1974 | Lowest Effect Level | 0.75 mg/kg-day | 0.0003 mg/kg-day | 3000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
203 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Urinary | Kidney medullary papillary necrosis in F344 rats | 2-year rat feeding study | Levine et al., 1983 | No Observable Adverse Effect Level | 3.9 mg/kg-day | 0.01 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
204 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Nervous | Convulsions in F344 rats | 90-day oral gavage study in F344 rats | Crouse et al., 2006 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.3 mg/kg-day | 0.004 mg/kg-day | 300 | 1 | Medium | None | Medium | Benchmark | Chronic |
205 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Reproductive | Suppurative prostatitis in F344 rats | 2-year rat feeding study | Levine et al., 1983 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.23 mg/kg-day | 0.0008 mg/kg-day | 300 | 1 | Low | Low | Low | Benchmark | Chronic |
206 | 2-Hexanone | 591-78-6 | Nervous | Axonal swelling of the peripheral nerve | 13-Month drinking water study in rats | O'Donoghue et al., 1978 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Medium | Low/Medium | Medium | Benchmark | Chronic |
207 | Hexazinone | 51235-04-2 | Other | Decreased body weight | 2-year rat feeding study | du Pont, 1977 | No Observed Effect Level | 10.0 mg/kg-day | 0.033 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
208 | Hydrogen Cyanide and Cyanide Salts | Various | Reproductive | Decreased cauda epididymis weight in male F344/N rats | 13-Week drinking water study | NTP, 1993 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.9 mg/kg-day | 0.0006 mg/kg-day | 3000 | 1 | Medium | Low/Medium | Low/Medium | Benchmark | Chronic |
209 | Imazalil | 35554-44-0 | Other | Decreased body weight gain | 2-year dog feeding study | Penwalt Corp., 1977 | No Observed Effect Level | 1.25 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
210 | Imazaquin | 81335-37-7 | Hematologic, Hepatic, Immune, Other | Decreased body weight gain, skeletal myopathy, slight anemia, bone marrow hyperplasia, elevated serum SGOT, SGPT, CPK | One-year dog feeding study | American Cyanamid, 1984a | No Observed Effect Level | 25.0 mg/kg-day | 0.25 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
211 | Iprodione | 36734-19-7 | Hematologic, Reproductive | Increased RBC Heinz bodies; decreased prostate weight | 1-year dog feeding study | Rhone-Poulenc, 1984 | No Observed Effect Level | 4.2 mg/kg-day | 0.04 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
212 | Isobutyl alcohol | 78-83-1 | Nervous | Hypoactivity and ataxia | Rat oral subchronic study | U.S. EPA, 1986 | No Observed Effect Level | 316.0 mg/kg-day | 0.3 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
213 | Isophorone | 78-59-1 | Urinary | Kidney pathology | 90-day dog feeding study | Nor-Am Agricultural Products, Inc., 1972a | No Observed Effect Level | 150.0 mg/kg-day | 0.2 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
214 | Isopropalin | 33820-53-0 | Hematologic, Other | Reduced hemoglobin concentration, lowered hematocrits, and altered organ weights | 90-day rat feeding study | Elanco Products, 1969a | No Observed Effect Level | 15.0 mg/kg-day | 0.015 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
215 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | Other | No adverse effects observed | Rat drinking water study 90-day | Mecler, 1981 | No Observable Adverse Effect Level | 279.0 mg/kg-day | 0.1 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
216 | Isoxaben | 82558-50-7 | Cardiovascular, Hepatic, Urinary | Increased BUN; decreased serum AP and AST; decreased food consumption efficiency; increased heart/body weight | 2-year rat feeding study (NOEL for males) | Elanco Products, 1985a | No Observed Effect Level | 5.0 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
217 | Lactofen | 77501-63-4 | Hepatic | Increased absolute and relative liver weight; hepatocytomegaly in males | 78-week oncogenic study in mice | PPG Industries, 1985a | Lowest Effect Level | 1.5 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | High | High | High | Threshold | Chronic |
218 | Linuron | 330-55-2 | Hematologic | Abnormal blood pigment | 2-year dog feeding study | du Pont, 1962 | Lowest Effect Level | 0.625 mg/kg-day | 0.002 mg/kg-day | 300 | 1 | Medium | High | High | Threshold | Chronic |
219 | Londax | 83055-99-6 | Hepatic | Liver effects | 1-year dog feeding study (NOEL for females) | du Pont, 1986a | No Observed Effect Level | 19.9 mg/kg-day | 0.2 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
220 | Malathion | 121-75-5 | Nervous | RBC ChE depression | Subchronic human feeding study | Moeller and Rider, 1962 | No Observed Effect Level | 0.23 mg/kg-day | 0.02 mg/kg-day | 10 | 1 | Medium | Medium | Medium | Threshold | Chronic |
221 | Maleic anhydride | 108-31-6 | Urinary | Renal lesions | Rat oral chronic study | U.S. EPA, 1983 | No Observable Adverse Effect Level | 10.0 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
222 | Maleic hydrazide | 123-33-1 | Urinary | Renal dysfunction | 2-year rat feeding study | Uniroyal Chemical Co., 1981 | Lowest Effect Level | 500.0 mg/kg-day | 0.5 mg/kg-day | 1000 | 1 | Low | Medium | Medium | Threshold | Chronic |
223 | Maneb | 12427-38-2 | Endocrine | Increased thyroid weight | 6-month monkey feeding study | Rohm and Haas Co., 1977; Maneb Task Force, 1986 | No Observed Effect Level | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
224 | Manganese | 7439-96-5 | Nervous | CNS effects | Human chronic ingestion data | NRC, 1989; Freeland- Graves et al., 1987; WHO, 1973 | No Observable Adverse Effect Level | 0.14 mg/kg-day | 0.14 mg/kg-day | 1 | 1 | Medium | Medium | Medium | Threshold | Chronic |
225 | Mepiquat chloride | 24307-26-4 | Hematologic, Nervous, Other | Sedation and tonoclonic spasms decreased food intake and body weights hematologic effects | 90-day dog feeding study | BASF Wyandotte Chemical, 1977a | No Observed Effect Level | 25.0 mg/kg-day | 0.03 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
226 | Mercuric chloride (HgCl2) | 7487-94-7 | Immune, Urinary | Autoimmune effects (autoimmune glomerulonephritis) | Rat subchronic feeding and subcutaneous studies | U.S. EPA, 1987 | Lowest Observable Adverse Effect Level | 0.317 mg/kg-day | 0.0003 mg/kg-day | 1000 | 1 | Not Available | High | High | Threshold | Chronic |
227 | Merphos | 150-50-5 | Nervous, Other | Ataxia, delayed neurotoxicity and weight loss | 90-day hen delayed neurotoxicity study | Abou-Donia et al., 1980 | No Observed Effect Level | 0.1 mg/kg-day | 3e-05 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
228 | Merphos oxide | 78-48-8 | Nervous, Other | Ataxia, delayed neurotoxicity and weight loss | 90-day hen delayed neurotoxicity study | Abou-Donia et al., 1979 | No Observed Effect Level | 0.1 mg/kg-day | 3e-05 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
229 | Metalaxyl | 57837-19-1 | Hepatic | Increased serum alkaline phosphatase levels and increased liver-to-brain weight ratio | 6-month dog feeding study | Ciba-Geigy, 1981a | No Observed Effect Level | 6.25 mg/kg-day | 0.06 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
230 | Methacrylonitrile | 126-98-7 | Hepatic | Increased SGOT and SGPT levels | Dog subchronic study | Pozzani et al., 1968 | No Observable Adverse Effect Level | 0.34 mg/kg-day | 0.0001 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
231 | Methamidophos | 10265-92-6 | Nervous | ChE inhibition | One-year dog feeding study | Mobay Chemical, 1984a | Lowest Effect Level | 0.05 mg/kg-day | 5e-05 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
232 | Methanol | 67-56-1 | Developmental | Extra cervical ribs | CD-1 mice, Inhalation developmental toxicity study exposure during gestation days GD7-GD17 | Rogers et al. (1993b) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 43.1 mg/L | 2.0 mg/kg-day | 100 | 1 | High | Medium | Medium/High | None | Chronic |
233 | Methidathion | 950-37-8 | Hepatic | Liver toxicity | 2-year dog feeding study | Ciba-Geigy, 1967 | No Observed Effect Level | 0.1 mg/kg-day | 0.001 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
234 | Methomyl | 16752-77-5 | Immune, Urinary | Kidney and spleen pathology | 2-year feeding study dogs | du Pont, 1968a | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
235 | Methoxychlor | 72-43-5 | Developmental | Excessive loss of litters | Rabbit teratology study | Kincaid Enterprises, 1986 | No Observed Effect Level | 5.01 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
236 | Methyl ethyl ketone (MEK) | 78-93-3 | Developmental | Decreased pup body weight | Multigeneration reproductive developmental rat drinking water study | Cox et al., 1975 | Lowest Effect Dose | 639.0 mg/kg-day | 0.6 mg/kg-day | 1000 | 1 | Low/Medium | Low | Low | Threshold | Chronic |
237 | Methyl methacrylate | 80-62-6 | Other | None | Rat drinking water study | Borzelleca et al., 1964 | No Observable Adverse Effect Level | 136.0 mg/kg-day | 1.4 mg/kg-day | 100 | 1 | Low/Medium | Low/Medium | Low/Medium | Threshold | Chronic |
238 | Methyl parathion | 298-00-0 | Hematologic, Nervous | RBC, ChE inhibition; reduced hemoglobin, hematocrit and RBCs | 2-year rat feeding study | Monsanto Co., 1984 | No Observed Effect Level | 0.025 mg/kg-day | 0.00025 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
239 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | Hepatic, Other, Reproductive, Urinary | Male reproductive toxicity and other effects (including decreased body weight gain), increased liver and kidney weights | 13-week dog feeding study | Rhodia, Inc., 1970a | No Observed Effect Level | 12.0 mg/kg-day | 0.01 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
240 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | Urinary | Increased absolute and relative kidney weights | 90-day rat feeding study | BASF Aktiegesellschaft, 1985 | No Observed Effect Level | 3.0 mg/kg-day | 0.001 mg/kg-day | 3000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
241 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | Hepatic, Urinary | Kidney and liver toxicity | 1-year dog feeding study | Industry Task Force on MCPA, 1986a | No Observed Effect Level | 0.15 mg/kg-day | 0.0005 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
242 | Methylmercury (MeHg) | 22967-92-6 | Developmental, Nervous | Developmental neuropsychological impairment | Human epidemiological studies | Grandjean et al., 1997 Budtz-Jorgensen et al., 1999a | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.00086 mg/kg-day | 0.0001 mg/kg-day | 10 | 1 | High | High | High | None | Chronic |
243 | Methylmercury (MeHg) | 22967-92-6 | Developmental, Nervous | Developmental neuropsychological impairment | Human epidemiological studies | Grandjean et al., 1997 Budtz-Jorgensen et al., 1999a | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.0015 mg/kg-day | 0.0001 mg/kg-day | 10 | 1 | High | High | High | None | Chronic |
244 | 2-Methylnaphthalene | 91-57-6 | Respiratory | Pulmonary alveolar proteinosis | B6C3F1 male and female mice 81-week dietary study | Murata et al. (1997) | Benchmark Dose | 4.7 mg/kg-day | 0.004 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
245 | 2-Methylphenol | 95-48-7 | Nervous, Other | Decreased body weights and neurotoxicity | 90-day oral subchronic neurotoxicity study in rats | U.S. EPA, 1986, 1987 | No Observable Adverse Effect Level | 50.0 mg/kg-day | 0.05 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
246 | 3-Methylphenol | 108-39-4 | Nervous | Decreased body weights and neurotoxicity | 90-day oral subchronic neurotoxicity study in rats | U.S. EPA, 1986, 1987 | No Observable Adverse Effect Level | 50.0 mg/kg-day | 0.05 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
247 | Metolachlor | 51218-45-2 | Other, Reproductive | Decreased body weight gain, decreased pup weight and parental food consumption | 2-year rat feeding study | Ciba-Geigy, 1983 | No Observed Effect Level | 15.0 mg/kg-day | 0.15 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
248 | Metribuzin | 21087-64-9 | Hepatic, Other, Urinary | Liver and kidney effects, decreased body weight, mortality | 2-year feeding study in dogs | Mobay Chemical, 1974a | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
249 | Mirex | 2385-85-5 | Endocrine, Hepatic | Liver cytomegaly, fatty metamorphosis, angiectasis; thyroid cystic follicles | Rat chronic dietary feeding study | NTP, 1990 | No Observable Adverse Effect Level | 0.07 mg/kg-day | 0.0002 mg/kg-day | 300 | 1 | High | High | High | Threshold | Chronic |
250 | Molinate | 2212-67-1 | Reproductive | Reproductive toxicity | Rat fertility study (gavage) | Stauffer Chemical Co., 1981 | No Observed Effect Level | 0.2 mg/kg-day | 0.002 mg/kg-day | 100 | 1 | Medium | Low | Low | Threshold | Chronic |
251 | Molybdenum | 7439-98-7 | Urinary | Increased uric acid levels | Human 6-year to lifetime dietary exposure study | Koval'skiy et al., 1961 | Lowest Observable Adverse Effect Level | 0.14 mg/kg-day | 0.005 mg/kg-day | 30 | 1 | Medium | Medium | Medium | Threshold | Chronic |
252 | Monochloramine | 10599-90-3 | Other | No observed effects | Rat chronic oral study | NTP, 1992 | No Observable Adverse Effect Level | 9.5 mg/kg-day | 0.1 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
253 | Naled | 300-76-5 | Nervous | Brain ChE inhibition | 2-year rat study, dietary | Chevron Chemical Co., 1984a | No Observed Effect Level | 0.2 mg/kg-day | 0.002 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
254 | Naphthalene | 91-20-3 | Other | Decreased mean terminal body weight in males | Subchronic oral rat study | BCL, 1980a | No Observable Adverse Effect Level | 71.0 mg/kg-day | 0.02 mg/kg-day | 3000 | 1 | High | Low | Low | Threshold | Chronic |
255 | Napropamide | 15299-99-7 | Reproductive | Decreased body weight gain in parental animals and pups | 3-generation rat reproduction study | Stauffer Chemical Co., 1978a | No Observed Effect Level | 30.0 mg/kg-day | 0.1 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
256 | Nickel, soluble salts | Various | Other | Decreased body and organ weights | Rat chronic oral study | Ambrose et al., 1976 | No Observable Adverse Effect Level | 5.0 mg/kg-day | 0.02 mg/kg-day | 300 | 1 | Low | Medium | Medium | Threshold | Chronic |
257 | Nitrate | 14797-55-8 | Hematologic | Early clinical signs of methemoglobinemia in excess of 10% (0-3 months old infants formula) | Human epidemiological surveys | Bosch et al., 1950; Walton, 1951 | No Observable Adverse Effect Level | 1.6 mg/kg-day | 1.6 mg/kg-day | 1 | 1 | High | High | High | Threshold | Chronic |
258 | Nitrite | 14797-65-0 | Hematologic | Methemoglobinemia | Infant chronic exposure to drinking water | Walton, 1951 | No Observed Effect Level | 1.0 mg/kg-day | 0.1 mg/kg-day | 1 | 10 | High | High | High | Threshold | Chronic |
259 | Nitrobenzene | 98-95-3 | Hematologic | Increased methemoglobin levels | Subchronic rat study | NTP, 1983 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.8 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
260 | Nitroguanidine | 556-88-7 | Developmental, Other | Reduced weight gain in female rats, maternal/ fetal toxicity in rats, and equivocal evidence of developmental toxicity in rabbits | 90-day rat study oral exposure (diet) | Morgan et al., 1988 Coppes et al., 1988a, b | No Observable Adverse Effect Level | 316.0 mg/kg-day | 0.1 mg/kg-day | 3000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
261 | Norflurazon | 27314-13-2 | Endocrine, Hepatic | Liver and thyroid effects | 6-month dog feeding study | Sandoz-Wander, 1973 | No Observed Effect Level | 3.75 mg/kg-day | 0.04 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
262 | NuStar | 85509-19-9 | Hepatic | Liver cell enlargement | 1-year dog feeding study | du Pont, 1985 | No Observed Effect Level | 0.2 mg/kg-day | 0.0007 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
263 | Octabromodiphenyl ether | 32536-52-0 | Hepatic | Induction of hepatic enzymes; liver histopathology | Subchronic, rat, oral (gavage) | Carlson, 1980 | No Observable Adverse Effect Level | 2.51 mg/kg-day | 0.003 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
264 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | Hepatic | Hepatic lesions | 13-week rat feeding study | U.S. DOD, 1985a | No Observable Adverse Effect Level | 50.0 mg/kg-day | 0.05 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
265 | Oryzalin | 19044-88-3 | Endocrine, Hepatic, Urinary | Increases in serum cholesterol, alkaline phosphatase, and relative liver and kidney weights, and decreases in alanine transaminase and adrenal weights | 1-year dog feeding study | Eli Lilly Co., 1986 | No Observed Effect Level | 5.0 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
266 | Oxadiazon | 19666-30-9 | Hematologic, Hepatic | Increased levels of serum proteins and increased liver weights | 2-year rat feeding study | Rhone-Poulenc, 1981 | No Observed Effect Level | 0.5 mg/kg-day | 0.005 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
267 | Oxamyl | 23135-22-0 | Other | Decreased body weight gain and food consumption | 2-year rat feeding/ oncogenic study | du Pont, 1972a | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | Low | Medium | Medium | Threshold | Chronic |
268 | Oxyfluorfen | 42874-03-3 | Hepatic | Increased absolute liver weight and nonneoplastic lesions | 20-month mouse feeding study | Rohm & Haas, 1977a | No Observed Effect Level | 0.3 mg/kg-day | 0.003 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
269 | Paclobutrazol | 76738-62-0 | Hepatic | Elevated liver weights, serum cholesterol, hepatic aminopyrine N-demethylase activity, and alanine transaminase levels | 90-day rat feeding study | ICI Americas, Inc., 1983a | No Observed Effect Level | 12.5 mg/kg-day | 0.013 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
270 | Paraquat | 1910-42-5 | Respiratory | Chronic pneumonitis | 1-year dog feeding study | Chevron Chemical Company, 1983a | No Observed Effect Level | 0.45 mg/kg-day | 0.0045 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
271 | Pendimethalin | 40487-42-1 | Hepatic | Increase in serum alkaline phosphatase and liver weight, and hepatic lesions | 2-year dog feeding study | American Cyanamid, 1979 | No Observed Effect Level | 12.5 mg/kg-day | 0.04 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
272 | Pentabromodiphenyl ether | 32534-81-9 | Hepatic | Induction of hepatic enzymes | Subchronic, rat, oral (gavage) | Carlson, 1980 | No Observable Adverse Effect Level | 1.77 mg/kg-day | 0.002 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
273 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | Nervous | Neurobehavioral effects | Single dose gavage study in mice | Viberg et al. (2004a) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.29 mg/kg | 0.0001 mg/kg-day | 3000 | 1 | Low | Low | Low | Benchmark | Chronic |
274 | Pentachlorobenzene | 608-93-5 | Hepatic, Urinary | Liver and kidney toxicity | Subchronic rat oral bioassay (including weanlings) | Linder et al., 1980 | Lowest Observable Adverse Effect Level | 8.3 mg/kg-day | 0.0008 mg/kg-day | 10000 | 1 | Medium | Low | Low | Threshold | Chronic |
275 | Pentachloronitrobenzene (PCNB) | 82-68-8 | Hepatic | Liver toxicity | 2-year dog feeding study | Olin Mathieson Corp., 1968a | No Observed Effect Level | 0.75 mg/kg-day | 0.003 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
276 | Pentachlorophenol | 87-86-5 | Hepatic | Hepatotoxicity | 1-Year beagle dog study | Mecler, 1996 | Lowest Observable Adverse Effect Level | 1.5 mg/kg-day | 0.005 mg/kg-day | 300 | 1 | Medium | High | Medium | Threshold | Chronic |
277 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | Endocrine | Radioactive iodide uptake inhibition (RAIU) in the thyroid | Adult human volunteers | Greer et al. (2002) | No Observed Effect Level | 0.007 mg/kg-day | 0.0007 mg/kg-day | 10 | 1 | Medium/High | Medium | High | Threshold | Chronic |
278 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Endocrine | Decreased total T4 | 90-day oral gavage study in male Sprague-Dawley rats | BUTENHOFF, 2012 | No Observable Adverse Effect Level | 1.27 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | Medium | Low/Medium | Threshold | Subchronic |
279 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Endocrine, Hepatic | Increased hepatocellular hypertrophy (Liver), Decreased total T4 (Thyroid) | 90-day oral gavage study in male Sprague-Dawley rats | BUTENHOFF, 2012 | No Observable Adverse Effect Level | 1.27 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
280 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Developmental | Developmental delays | Gestational oral gavage study in female CD-1 mice | DAS, 2008 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.62 mg/kg-day | 0.006 mg/kg-day | 100 | 1 | High | Medium | Low/Medium | Benchmark | Chronic |
281 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Hepatic | Increased hepatocellular hypertrophy | 90-day oral gavage study in male Sprague-Dawley rats | BUTENHOFF, 2012 | No Observable Adverse Effect Level | 1.27 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
282 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Developmental | Developmental delays | Gestational oral gavage study in female CD-1 mice | DAS, 2008 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.62 mg/kg-day | 0.006 mg/kg-day | 100 | 1 | High | Medium | Low/Medium | Benchmark | Subchronic |
283 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Developmental | Developmental delays | Gestational oral gavage study in female CD-1 mice | DAS, 2008 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.62 mg/kg-day | 0.006 mg/kg-day | 100 | 1 | High | Medium | Low/Medium | Benchmark | Subchronic |
284 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Hepatic | Increased hepatocellular hypertrophy | 90-day oral gavage study in male Sprague-Dawley rats | BUTENHOFF, 2012 | No Observable Adverse Effect Level | 1.27 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Subchronic |
285 | Perfluorodecanoic Acid (PFDA) | 335-76-2 | Developmental, Immune | Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children | Birth cohort study of children in the Faroe Islands | Wikstrom, 2020 | None | None None | 2e-09 mg/kg-day | 30 | 1 | Medium | Low/Medium | Medium | Threshold | Subchronic |
286 | Perfluorodecanoic Acid (PFDA) | 335-76-2 | Developmental, Immune | Decreased serum antibody concentrations for tetanus and diphtheria in children; Decreased birth weight in male and female children | Birth cohort study of children in the Faroe Island | Wikstrom, 2020 | None | None None | 2e-09 mg/kg-day | 30 | 1 | Medium | Low/Medium | Medium | Threshold | Chronic |
287 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Hepatic | Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats | 90-day oral gavage study in male and female Sprague-Dawley rats | Loveless, 2009 | Benchmark Dose | 0.11 mg/kg-day | 0.0004 mg/kg-day | 300 | 1 | High | Medium | Medium | Benchmark | Chronic |
288 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Hematologic | Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats | 2 year cancer gavage bioassay in male and female Sprague-Dawley rats | Klaunig, 2015 | Benchmark Dose | 0.52 mg/kg-day | 0.005 mg/kg-day | 100 | 1 | High | Medium | Medium | Benchmark | Chronic |
289 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Developmental | Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats | One-generation reproductive gavage study in Sprague-Dawley rats | Loveless, 2009 | Benchmark Dose | 0.048 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | High | Medium | Medium | Benchmark | Subchronic |
290 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Hepatic | Increased hepatocellular hypertrophy in adult rats | Increased hepatocellular hypertrophy in adult male Crl:CD Sprague‑Dawley rats | Loveless, 2009 | Benchmark Dose | 0.11 mg/kg-day | 0.001 mg/kg-day | 100 | 1 | High | Medium | Medium | Benchmark | Subchronic |
291 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Hematologic | Decreased red blood cells in adult female Crl:CD Sprague‑Dawley rats | 90 day gavage study in male and female Sprague-Dawley rats | Chengelis, 2009 | Benchmark Dose | 0.078 mg/kg-day | 0.0008 mg/kg-day | 100 | 1 | High | Low/Medium | Low/Medium | Benchmark | Subchronic |
292 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Endocrine | Decreased total T4 in adult male Harlan Sprague-Dawley rats | 28 day gavage study in male and female Harlan Sprague-Dawley rats | NTP, 2018 | Benchmark Dose | 0.029 mg/kg-day | 0.001 mg/kg-day | 300 | 1 | High | Medium | Medium | Benchmark | Subchronic |
293 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Developmental | Decreased postnatal (PND 0) body weight in F1 Sprague‑Dawley male and female rats | One-generation reproductive gavage study in Sprague-Dawley rats | Loveless, 2009 | Benchmark Dose | 0.048 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | High | Medium | Medium | Benchmark | Chronic |
294 | Permethrin | 52645-53-1 | Hepatic | Increased liver weights | 2-year rat feeding study | FMC Corp., 1977 | No Observed Effect Level | 5.0 mg/kg-day | 0.05 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
295 | Phenmedipham | 13684-63-4 | Other | No adverse effects | 2-year rat feeding/ carcinogenicity study | Nor-Am Agricultural Products, Inc., 1980a | No Observable Adverse Effect Level | 25.0 mg/kg-day | 0.25 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
296 | Phenol | 108-95-2 | Other | Decreased maternal weight gain | Rat developmental study | Argus Research Laboratories, 1997 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 93.0 mg/kg-day | 0.3 mg/kg-day | 300 | 1 | Medium | Medium/High | Medium/High | Threshold | Chronic |
297 | m-Phenylenediamine | 108-45-2 | Hepatic | Increased relative and absolute liver weights and degenerative liver lesions | Rat oral subchronic study | Hofer et al., 1982 | No Observed Effect Level | 6.0 mg/kg-day | 0.006 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
298 | Phenylmercuric acetate | 62-38-4 | Urinary | Renal damage | Rat oral chronic study | Fitzhugh et al., 1950 | No Observable Adverse Effect Level | 0.0084 mg/kg-day | 8e-05 mg/kg-day | 100 | 1 | Medium | Low | Low | Threshold | Chronic |
299 | Phosmet | 732-11-6 | Hepatic, Nervous, Other | Reduced body weight (males), liver cell vacuolation, cholinesterase inhibition | 2-year rat feeding study | Stauffer Chemical, 1967 | No Observed Effect Level | 2.0 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
300 | Phosphine | 7803-51-2 | Other | Body weight and clinical parameters | Rat chronic oral study | Hackenburg, 1972 | No Observed Effect Level | 0.026 mg/kg-day | 0.0003 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
301 | Phthalic anhydride | 85-44-9 | Respiratory, Urinary | Lung and kidney histopathology | Chronic mouse oral study | NCI, 1979 | Lowest Observable Adverse Effect Level | 1562.0 mg/kg-day | 2.0 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
302 | Picloram | 1918-02-1 | Hepatic | Increased liver weights | 6-month dog feeding study | Dow Chemical, 1982a | No Observed Effect Level | 7.0 mg/kg-day | 0.07 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
303 | Pirimiphos-methyl | 29232-93-7 | Nervous | Transient plasma ChE depression | 56-day human feeding study | ICI Americas, 1976a | No Observed Effect Level | 0.25 mg/kg-day | 0.01 mg/kg-day | 25 | 1 | High | High | High | Threshold | Chronic |
304 | Potassium cyanide | 151-50-8 | Reproductive | Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | None | None | None | None None | 0.002 mg/kg-day | None | None | None | None | None | None | Chronic |
305 | Potassium silver cyanide | 506-61-6 | Reproductive | Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | None | None | None | None None | 0.005 mg/kg-day | None | None | None | None | None | None | Chronic |
306 | Prochloraz | 67747-09-5 | Hepatic | Increase in SAP and liver weights, liver histopathology | 2-year dog feeding study | FBC Limited, 1981 | No Observed Effect Level | 0.9 mg/kg-day | 0.009 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
307 | Prometon | 1610-18-0 | Other | No treatment related effects observed | Subchronic rat feeding study | Ciba-Geigy, 1982a | No Observable Adverse Effect Level | 15.0 mg/kg-day | 0.015 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
308 | Prometryn | 7287-19-6 | Hematologic, Hepatic, Immune, Urinary | Liver and kidney degeneration and bone marrow atrophy | 106-week dog feeding study | Ciba-Geigy, 1965a | No Observed Effect Level | 3.75 mg/kg-day | 0.004 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
309 | Pronamide | 23950-58-5 | Other | No effects | 2-year dog feeding study | Rohm & Haas, Co., 1970a | No Observed Effect Level | 7.5 mg/kg-day | 0.075 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
310 | Propachlor | 1918-16-7 | Hepatic, Other | Decreased weight gain, food consumption increased relative liver weights | 90-day feeding study in rats | Monsanto Co., 1964a | No Observed Effect Level | 13.3 mg/kg-day | 0.013 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
311 | Propanil | 709-98-8 | Immune | Increased relative spleen weight in females | 2-year rat feeding study | Rohm and Haas Co., 1964a | No Observed Effect Level | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
312 | Propargite | 2312-35-8 | Developmental, Musculoskeletal, Other | Reduced body weight gain (maternal), increased resorption, reduced body weight (fetal), delayed ossification | Rabbit developmental toxicity study (NOEL maternal and fetotoxic) | Uniroyal Chemical, 1982 | No Observed Effect Level | 2.0 mg/kg-day | 0.02 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
313 | Propargyl alcohol | 107-19-7 | Hepatic, Urinary | Renal and hepatotoxicity | Rat oral subchronic study | U.S. EPA, 1987 | No Observable Adverse Effect Level | 5.0 mg/kg-day | 0.002 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
314 | Propazine | 139-40-2 | Other | Decrease in body weight | 2-year rat feeding study | Ciba-Geigy, 1980a | No Observed Effect Level | 5.0 mg/kg-day | 0.02 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
315 | Propham | 122-42-9 | Immune, Nervous | Increase in male spleen weight and ChE depression in females | 90-day rat feeding study | PPG Industries, 1979 | No Observed Effect Level | 50.0 mg/kg-day | 0.02 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
316 | Propiconazole | 60207-90-1 | Gastrointestinal | Gastric mucosal irritation | 1-year dog feeding study | Ciba Geigy, 1985a | No Observed Effect Level | 1.25 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
317 | Pursuit | 81335-77-5 | Hematologic | Decreased packed cell volume, hemoglobin, erythrocytes in females | 1-year dog study oral exposure (diet) | American Cyanamid Co., 1987a | No Observed Effect Level | 25.0 mg/kg-day | 0.25 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
318 | Pydrin | 51630-58-1 | Nervous | Neurological dysfunction | 13-week rat feeding study | Shell Development Co., 1984 | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
319 | Pyrene | 129-00-0 | Urinary | Kidney effects (renal tubular pathology, decreased kidney weights) | Mouse subchronic oral bioassay | U.S. EPA, 1989 | No Observable Adverse Effect Level | 75.0 mg/kg-day | 0.03 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
320 | Pyridine | 110-86-1 | Hepatic | Increased liver weight | 90-day rat oral gavage study | U.S. EPA, 1986 | No Observable Adverse Effect Level | 1.0 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
321 | Quinalphos | 13593-03-8 | Other | No adverse effects reported | Two-year dog feeding study | Sandoz, Ltd., 1980a | No Observed Effect Level | 0.05 mg/kg-day | 0.0005 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
322 | Resmethrin | 10453-86-8 | Reproductive | Reproductive toxicity | 3-generation rat reproduction study | Penwick Corp., 1979a | Lowest Effect Level | 25.0 mg/kg-day | 0.03 mg/kg-day | 1000 | 1 | High | High | High | Threshold | Chronic |
323 | Rotenone | 83-79-4 | Developmental | Reduced pup weight | 2-generation rat reproduction study | U.S. Fish and Wildlife Service, 1983 | No Observed Effect Level | 0.38 mg/kg-day | 0.004 mg/kg-day | 100 | 1 | Medium | Medium | Medium | None | Chronic |
324 | Savey | 78587-05-0 | Endocrine, Hematologic | Hypertrophy of adrenal cortex (both sexes) hematologic effects (males) | 1-year dog feeding study | du Pont, 1984a | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
325 | Selenious acid | 7783-00-8 | Dermal, Hematologic, Nervous | Clinical selenosis | Human epidemiological study | Yang et al., 1989b | No Observable Adverse Effect Level | 0.015 mg/kg-day | 0.005 mg/kg-day | 3 | 1 | Medium | High | High | Threshold | Chronic |
326 | Selenium and Compounds | 7782-49-2 | Dermal, Hematologic, Nervous | Clinical selenosis | Human epidemiological study | Yang et al., 1989b | No Observable Adverse Effect Level | 0.015 mg/kg-day | 0.005 mg/kg-day | 3 | 1 | Medium | High | High | Threshold | Chronic |
327 | Sethoxydim | 74051-80-2 | Hematologic | Mild anemia in males | 1-year dog study oral exposure (diet) (NOEL for males) | BASF Corporation, 1984 | No Observed Effect Level | 8.86 mg/kg-day | 0.09 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
328 | Silver | 7440-22-4 | Dermal | Argyria | 2- to 9-year human i.v. study | Gaul and Staud, 1935 | Lowest Observable Adverse Effect Level | 0.014 mg/kg-day | 0.005 mg/kg-day | 3 | 1 | Medium | Low | Low | Threshold | Chronic |
329 | Silver cyanide | 506-64-9 | Endocrine, Nervous, Other | Weight loss, thyroid effects, and myelin degeneration | Rat chronic oral study | Howard and Hanzal, 1955 | No Observable Adverse Effect Level | 55.7 mg/kg-day | 0.1 mg/kg-day | 100 | 5 | Medium | Low | Low | Threshold | Chronic |
330 | Simazine | 122-34-9 | Hematologic, Other | Reduction in weight gains hematological changes in females | 2-year rat feeding study | Ciba-Geigy Corp., 1988a | No Observable Adverse Effect Level | 0.52 mg/kg-day | 0.005 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
331 | Sodium azide | 26628-22-8 | Other | Clinical sign (e.g., hunched postures) and reduced body weight | Rat oral subchronic study | NCI, 1981 | No Observable Adverse Effect Level | 3.57 mg/kg-day | 0.004 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
332 | Sodium cyanide | 143-33-9 | Reproductive | Decreased cauda epididymis weight in male F344/N rats. The RfD for potassium cyanide is presented in section I.A.3 of the hydrogen cyanide and cyanide salts IRIS Summary. | None | None | None | None None | 0.001 mg/kg-day | None | None | None | None | None | None | Chronic |
333 | Sodium diethyldithiocarbamate | 148-18-5 | Other | Reduced body weight | Rat subchronic oral study | Sunderman et al., 1967 | No Observed Effect Level | 30.0 mg/kg-day | 0.03 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
334 | Sodium fluoroacetate | 62-74-8 | Cardiovascular, Reproductive | Increased heart weight in females and males; decreased testis weight and altered spermatogenesis in males. | 13-week rat oral study (gavage) | U.S. EPA, 1988 | No Observable Adverse Effect Level | 0.05 mg/kg-day | 2e-05 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
335 | Strontium | 7440-24-6 | Musculoskeletal | Rachitic bone | 20-day, 9-week, and 3-year oral studies in young and adult rats | Storey, 1961; Marie et al., 1985; Skoryna, 1981 | No Observable Adverse Effect Level | 190.0 mg/kg-day | 0.6 mg/kg-day | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
336 | Strychnine | 57-24-9 | Other | Toxicity/histopathology | Rat oral short-term to subchronic study | Seidl and Zbinden, 1982 | Lowest Observable Adverse Effect Level | 2.5 mg/kg-day | 0.0003 mg/kg-day | 10000 | 1 | Low | Low | Low | Threshold | Chronic |
337 | Styrene | 100-42-5 | Hematologic, Hepatic | Red blood cell and liver effects | Dog subchronic oral study | Quast et al., 1979 | No Observable Adverse Effect Level | 200.0 mg/kg-day | 0.2 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
338 | Systhane | 88671-89-0 | Reproductive | Testicular atrophy | 2-year chronic rat feeding study | Rohm and Haas, 1986a | No Observed Effect Level | 2.49 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
339 | Tebuthiuron | 34014-18-1 | Other | Depressed body weight gain in F1 females | 2-generation rat reproduction study | Elanco Products, 1981 | No Observed Effect Level | 7.0 mg/kg-day | 0.07 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
340 | Terbacil | 5902-51-2 | Endocrine, Hepatic | Increase in thyroid/body weight ratio; slight increase in liver weights; elevated alkaline phosphatase | 2-year dog feeding study | duPont, 1967a | No Observed Effect Level | 1.25 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
341 | Terbutryn | 886-50-0 | Hematologic | Hematologic effects in females | 2-year rat feeding study | Ciba-Geigy, 1980a | No Observed Effect Level | 0.1 mg/kg-day | 0.001 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
342 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | Nervous | Neurobehavioral effects | Single dose gavage study in mice | Eriksson et al., 2001 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.35 mg/kg | 0.0001 mg/kg-day | 3000 | 1 | Low | Low | Low | Benchmark | Chronic |
343 | 1,2,4,5-Tetrachlorobenzene | 95-94-3 | Urinary | Kidney lesions | Rat oral subchronic study | Chu et al., 1984 | No Observable Adverse Effect Level | 0.34 mg/kg-day | 0.0003 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
344 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | Developmental, Endocrine, Reproductive | Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates | Epidemiologic cohort study | Mocarelli et al., 2008 / Baccarelli et al., 2008 | Lowest Observable Adverse Effect Level | 2e-08 mg/kg-day | 7e-10 mg/kg-day | 30 | 1 | High | High | High | None | Chronic |
345 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | Reproductive | Decreased sperm count and motility in men exposed to TCDD as boys / Increased TSH in neonates | Epidemiologic cohort study | Mocarelli et al., (2008) / Baccarelli et al., (2008) | Lowest Observable Adverse Effect Level | 2e-08 mg/kg-day | 7e-10 mg/kg-day | 30 | None | High | High | High | None | None |
346 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Hepatic, Urinary | Mineralization of the kidneys in males, hepatic clear cell change in females | Rat, chronic oral gavage study | NTP, 1983 | Lowest Observable Adverse Effect Level | 89.3 mg/kg-day | 0.03 mg/kg-day | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
347 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Hepatic | Increased relative liver weight in rats | Subchronic dietary study | NTP (2004) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 15.0 mg/kg-day | 0.05 mg/kg-day | 300 | 1 | High | Medium | Medium | None | Chronic |
348 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Hepatic | Increased relative liver weight in rats | Subchronic dietary study | NTP (2004) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 15.0 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
349 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Nervous, Ocular | (See Note) | None | None | None | None None | 0.006 mg/kg-day | None | None | Medium | Medium | Medium | None | Chronic |
350 | 2,3,4,6-Tetrachlorophenol | 58-90-2 | Hepatic | Increased liver weights and centrilobular hypertrophy | Rat oral subchronic study | U.S. EPA, 1986 | No Observable Adverse Effect Level | 25.0 mg/kg-day | 0.03 mg/kg-day | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
351 | Tetrachlorovinphos | 961-11-5 | Hepatic, Nervous, Other, Urinary | Reduced body weight gain, increased liver and kidney weights, and RBC ChE inhibition | Two-year dog feeding study | Shell Chemical Co., 1968 | No Observed Effect Level | 3.13 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
352 | Tetraethyl lead | 78-00-2 | Hepatic, Immune | Histopathology of liver and thymus | Rat subchronic study | Schepers, 1964 | Lowest Observable Adverse Effect Level | 0.0012 mg/kg-day | 1e-07 mg/kg-day | 10000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
353 | Tetraethyldithiopyrophosphate | 3689-24-5 | Nervous | Depressed RBC and plasma cholinesterase activity | Rat subchronic oral study | Kimmerle and Klimmer, 1974 | No Observed Effect Level | 0.5 mg/kg-day | 0.0005 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
354 | Tetrahydrofuran | 109-99-9 | Developmental | Decreased pup body weight gain | Rat two-generation reproduction study | Hellwig et al. (2002)/BASF (1996) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 928.0 mg/kg-day | 0.9 mg/kg-day | 1000 | 1 | Medium | Low | Low/Medium | None | Chronic |
355 | Thiobencarb | 28249-77-6 | Other, Urinary | Decrease in body weight, increase in BUN | 2-year rat feeding study | Chevron Chemical, 1984a | No Observed Effect Level | 1.0 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
356 | Thiophanate-methyl | 23564-05-8 | Endocrine, Other, Reproductive | Decreased body weight, decreased spermatogenesis, and histological evidence of hyperthyroidism | 2-year rat feeding study | Pennwalt Corp., 1972a | No Observed Effect Level | 8.0 mg/kg-day | 0.08 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
357 | Thiram | 137-26-8 | Nervous | Neurotoxicity | 2-year rat feeding study | duPont, 1954 | No Observed Effect Level | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
358 | Toluene | 108-88-3 | Urinary | Increased kidney weight | 13-week gavage study in rats | NTP, 1990 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 238.0 mg/kg-day | 0.08 mg/kg-day | 3000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
359 | Tralomethrin | 66841-25-6 | Other | Decreased body weight gain in males increased food and water consumption in males and females | 2-year rat feeding study | Roussel UCLAF, 1984 | No Observed Effect Level | 0.75 mg/kg-day | 0.0075 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
360 | Triallate | 2303-17-5 | Hepatic, Other | Increased hemosiderin deposition, serum alkaline phosphatase, and liver weight in females | 2-year dog feeding study | Monsanto, 1979 | No Observable Adverse Effect Level | 1.275 mg/kg-day | 0.013 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
361 | Triasulfuron | 82097-50-5 | Hepatic | Centrilobular hepatocytomegaly in males | 2-year mouse feeding/carcinogenicity study | Ciba-Geigy Corporation, 1988 | No Observed Effect Level | 1.2 mg/kg-day | 0.01 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
362 | 1,2,4-Tribromobenzene | 615-54-3 | Hepatic | Increased liver-to-body weight ratio and hepatic microsomal enzyme induction | Rat oral subchronic study | Carlson and Tardiff, 1977 | No Observable Adverse Effect Level | 5.0 mg/kg-day | 0.005 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
363 | Tributyltin oxide (TBTO) | 56-35-9 | Immune | Immunosuppression | 18-month immunotoxicity study in rats | Vos et al., 1990 | Benchmark Dose | 0.03 mg/kg-day | 0.0003 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
364 | 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | 76-13-1 | Nervous | Psychomotor impairment | Epidemiologic study: human occupational exposure | Imbus and Adkins, 1972 | No Observable Adverse Effect Level | 273.0 mg/kg-day | 30.0 mg/kg-day | 10 | 1 | Low | Low | Low | Threshold | Chronic |
365 | Trichloroacetic acid | 76-03-9 | Hepatic | Hepatocellular necrosis | 60-week drinking water exposure study, male B6C3F1 mice | DeAngelo et al., 2008 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 18.0 mg/kg-day | 0.02 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | None | Chronic |
366 | 1,2,4-Trichlorobenzene | 120-82-1 | Endocrine | Increased adrenal weights; vacuolization of zona fasciculata in the cortex | Rat reproductive study | Robinson et al., 1981 | No Observable Adverse Effect Level | 14.8 mg/kg-day | 0.01 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
367 | 1,1,1-Trichloroethane | 71-55-6 | Other | Reduced body weight | 90-Day mouse dietary study | NTP (2000) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 2155.0 mg/kg-day | 2.0 mg/kg-day | 1000 | 1 | High | Low/Medium | Low/Medium | Benchmark | Chronic |
368 | 1,1,1-Trichloroethane | 71-55-6 | Other | Reduced body weight | 90-Day mouse dietary study | NTP (2000) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 2155.0 mg/kg-day | 7.0 mg/kg-day | 300 | 1 | Medium | Low/Medium | Low/Medium | None | Subchronic |
369 | 1,1,2-Trichloroethane | 79-00-5 | Hematologic, Immune | Clinical serum chemistry (effects on erythrocytes and depressed humoral immune status) | Mouse subchronic drinking water study | White et al., 1985 Sanders et al., 1985 | No Observable Adverse Effect Level | 3.9 mg/kg-day | 0.004 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
370 | Trichloroethylene | 79-01-6 | Developmental, Immune | (See Note) | None | None | None | None None | 0.0005 mg/kg-day | None | 1 | High | High | High | None | Chronic |
371 | Trichlorofluoromethane | 75-69-4 | Cardiovascular, Other, Respiratory | Survival and histopathology (pleuritis and pericarditis) | Cancer bioassay studies in rats and mice | NCI, 1978 | Lowest Observable Adverse Effect Level | 349.0 mg/kg-day | 0.3 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
372 | 2,4,5-Trichlorophenol | 95-95-4 | Hepatic, Urinary | Liver and kidney pathology | Rat oral subchronic study | McCollister et al., 1961 | No Observed Effect Level | 100.0 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
373 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | Hepatic | Histopathological changes in liver | Dog chronic oral bioassay | Mullison, 1966; Gehring and Betso, 1978 | No Observed Effect Level | 0.75 mg/kg-day | 0.008 mg/kg-day | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
374 | 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | 93-76-5 | Urinary | Increased urinary coproporphyrins | 2-year rat feeding study | Kociba et al., 1979 | No Observable Adverse Effect Level | 3.0 mg/kg-day | 0.01 mg/kg-day | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
375 | 1,1,2-Trichloropropane | 598-77-6 | Endocrine, Hepatic, Urinary | Mild lesions in liver, kidney and thyroid | Rat oral subchronic study | Villeneuve et al., 1985 | No Observed Effect Level | 15.0 mg/kg-day | 0.005 mg/kg-day | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
376 | 1,2,3-Trichloropropane | 96-18-4 | Hepatic | Increased absolute liver weight in male rats | 2-year bioassay | NTP, 1993 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 1.1 mg/kg-day | 0.004 mg/kg-day | 300 | 1 | High | Medium/High | Medium/High | Benchmark | Chronic |
377 | Tridiphane | 58138-08-2 | Other, Reproductive | Decreased fertility index and depressed body weight of dams | Rat, 2-generation reproduction study | Dow Chemical, 1984 | No Observed Effect Level | 0.33 mg/kg-day | 0.003 mg/kg-day | 100 | 1 | Medium | High | High | Threshold | Chronic |
378 | Trifluralin | 1582-09-8 | Hematologic, Hepatic | Increased liver weights; increase in methemoglobin | 12-month dog feeding study | Hoechst Aktiengesellschaft, 1984a | No Observed Effect Level | 0.75 mg/kg-day | 0.0075 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
379 | 1,2,4-Trimethylbenzene | 95-63-6 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.5 mg/kg-day | 0.04 mg/kg-day | 100 | 1 | None | None | Low | Benchmark | Subchronic |
380 | 1,2,4-Trimethylbenzene | 95-63-6 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.5 mg/kg-day | 0.01 mg/kg-day | 300 | 1 | Low/Medium | Low/Medium | Low | Benchmark | Chronic |
381 | 1,2,3-Trimethylbenzene | 526-73-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.5 mg/kg-day | 0.04 mg/kg-day | 100 | 1 | Low | Low | Low | Benchmark | Subchronic |
382 | 1,2,3-Trimethylbenzene | 526-73-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.5 mg/kg-day | 0.01 mg/kg-day | 300 | 1 | Low/Medium | Low/Medium | Low | Benchmark | Chronic |
383 | 1,3,5-Trimethylbenzene | 108-67-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.5 mg/kg-day | 0.01 mg/kg-day | 300 | 1 | Low/Medium | Low/Medium | Low | Benchmark | Chronic |
384 | 1,3,5-Trimethylbenzene | 108-67-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 3.5 mg/kg-day | 0.04 mg/kg-day | 100 | 1 | Low | Low | Low | Benchmark | Subchronic |
385 | 1,3,5-Trinitrobenzene | 99-35-4 | Hematologic | Methemoglobinemia and spleen-erythroid cell hyperplasia | Rat 2-year dietary study | Reddy et al., 1996, 1997 | No Observable Adverse Effect Level | 2.68 mg/kg-day | 0.03 mg/kg-day | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
386 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Hepatic | Liver effects | 26-week dog feeding study | U.S. DOD, 1983 | Lowest Observable Adverse Effect Level | 0.5 mg/kg-day | 0.0005 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
387 | Uranium, soluble salts | Various | Other, Urinary | Initial body weight loss moderate nephrotoxicity | 30-day oral rabbit bioassay (diet) | Maynard and Hodge, 1949 | Lowest Observable Adverse Effect Level | 2.8 mg/kg-day | 0.003 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
388 | Vanadium pentoxide | 1314-62-1 | Dermal | Decreased hair cystine | Rat chronic oral study | Stokinger et al., 1953 | No Observable Adverse Effect Level | 0.89 mg/kg-day | 0.009 mg/kg-day | 100 | 1 | Low | Low | Low | Threshold | Chronic |
389 | Vernam | 1929-77-7 | Other | Decreased body weight | 2-generation reproduction rat study | Stauffer Chemical Co., 1983 | No Observed Effect Level | 1.0 mg/kg-day | 0.001 mg/kg-day | 1000 | 1 | High | Low | Low | Threshold | Chronic |
390 | Vinclozolin | 50471-44-8 | Endocrine, Urinary | Organ weight changes (adrenal and kidney) | 6-month dog feeding study | BASF Corp., 1982 | No Observed Effect Level | 2.5 mg/kg-day | 0.025 mg/kg-day | 100 | 1 | High | High | High | Threshold | Chronic |
391 | Vinyl chloride | 75-01-4 | Hepatic | Liver cell polymorphism | Rat chronic feeding study | Til et al., 1983, 1991 | No Observable Adverse Effect Level | 0.09 mg/kg-day | 0.003 mg/kg-day | 30 | 1 | High | Medium/High | Medium | Threshold | Chronic |
392 | Warfarin | 81-81-2 | Hematologic | Increased prothrombin time | Human clinical studies | Huff, 1985 | Lowest Observable Adverse Effect Level | 0.029 mg/kg-day | 0.0003 mg/kg-day | 100 | 1 | Low | Low | Low | Threshold | Chronic |
393 | White phosphorus | 7723-14-0 | Dermal, Reproductive | Parturition mortality; forelimb hair loss | Reproductive rat study | Condray, 1985 | No Observable Adverse Effect Level | 0.015 mg/kg-day | 2e-05 mg/kg-day | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
394 | Xylenes | 1330-20-7 | Other | Decreased body weight, increased mortality | Chronic F344/N rat study, Oral gavage exposure | NTP, 1986 | No Observable Adverse Effect Level | 179.0 mg/kg-day | 0.2 mg/kg-day | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
395 | Zinc and Compounds | 7440-66-6 | Hematologic, Immune | Decreases in erythrocyte Cu, Zn-superoxide dismutase (ESOD) activity in healthy adult male and female volunteers | None | Yadrick et al., 1989, Fischer et al., 1984, Davis et al., 2000, Milne et al., 2001 | Lowest Observable Adverse Effect Level | 0.91 mg/kg-day | 0.3 mg/kg-day | 3 | 1 | Medium/High | High | Medium/High | Threshold | Chronic |
396 | Zinc cyanide | 557-21-1 | Endocrine, Nervous, Other | Weight loss, thyroid effects, and myelin degeneration | Rat chronic oral study | Howard and Hanzal, 1955 | No Observable Adverse Effect Level | 24.3 mg/kg-day | 0.05 mg/kg-day | 100 | 5 | Medium | Medium | Medium | Threshold | Chronic |
397 | Zinc phosphide | 1314-84-7 | Other | Reduction of food intake and body weight | Rat subchronic oral study | Bai et al, 1980 | Lowest Observable Adverse Effect Level | 3.48 mg/kg-day | 0.0003 mg/kg-day | 10000 | 1 | Medium | Low | Low | Threshold | Chronic |
398 | Zineb | 12122-67-7 | Endocrine | Thyroid hyperplasia | Rat, chronic oral bioassay | Blackwell-Smith et al., 1953 | Lowest Observable Adverse Effect Level | 25.0 mg/kg-day | 0.05 mg/kg-day | 500 | 1 | Medium | Medium | Medium | Threshold | Chronic |
399 | n-Butanol | 71-36-3 | Nervous | Hypoactivity and ataxia | Rat oral subchronic study | U.S. EPA, 1986 | No Observable Adverse Effect Level | 125.0 mg/kg-day | 0.1 mg/kg-day | 1000 | 1 | High | Low | Low | Threshold | Chronic |
400 | tert-Butyl Alcohol (tBA) | 75-65-0 | Urinary | Increased severity of nephropathy | 2-year drinking water study in female rats | NTP 1995 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 43.2 mg/kg-day | 0.4 mg/kg-day | 100 | 1 | High | Medium | Medium | Benchmark | Chronic |
CHEMICAL NAME | CASRN | PRINCIPAL CRITICAL EFFECT SYSTEM | PRINCIPAL CRITICAL DESCRIPTION | PRINCIPAL STUDY | STUDY CITATION | EXPERIMENTAL DOSE TYPE | POD VALUE | RFC VALUE | UNCERTAINTY FACTOR | MODIFYING FACTOR | STUDY CONFIDENCE | DATA CONFIDENCE | OVERALL CONFIDENCE | DOSE TYPE | DURATION | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Acetaldehyde | 75-07-0 | Nervous, Respiratory | Degeneration of olfactory epithelium | Short-term rat inhalation studies | Appleman et al., 1986 1982 | No Observable Adverse Effect Level | 8.7 mg/m3 | 0.009 mg/m3 | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
2 | Acetonitrile | 75-05-8 | Other | Mortality | Mouse subchronic/chronic inhalation studies | NTP, 1996 | No Observable Adverse Effect Level | 60.0 mg/m3 | 0.06 mg/m3 | 100 | 10 | Medium | Medium | Medium | Threshold | Chronic |
3 | Acrolein | 107-02-8 | Respiratory | Nasal lesions | Subchronic rat inhalation study | Feron et. al., 1978 | Lowest Observable Adverse Effect Level | 0.02 mg/m3 | 2e-05 mg/m3 | 1000 | 1 | Medium | Low/Medium | Medium | Threshold | Chronic |
4 | Acrylamide | 79-06-1 | Nervous | Degenerative nerve changes | Chronic rat study | Johnson et al. 1986 | Human Equivalent Concentration | 0.18 mg/m3 | 0.006 mg/m3 | 30 | 1 | Medium/High | Low/Medium | Medium | Threshold | Chronic |
5 | Acrylic acid | 79-10-7 | Nervous, Respiratory | Degeneration of the nasal olfactory epithelium | Mouse subchronic inhalation study | Miller et al., 1981a | Lowest Observable Adverse Effect Level | 0.33 mg/m3 | 0.001 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
6 | Acrylonitrile | 107-13-1 | Respiratory | Degeneration and inflammation of nasal respiratory epithelium; hyperplasia of mucous secreting cells | Rat 2-year inhalation study | Quast et al., 1980 | Lowest Observable Adverse Effect Level | 1.9 mg/m3 | 0.002 mg/m3 | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
7 | Allyl chloride | 107-05-1 | Nervous | Functional and histological peripheral neurotoxicity | Rabbit subchronic inhalation study | Lu et al., 1982 | No Observable Adverse Effect Level | 3.6 mg/m3 | 0.001 mg/m3 | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
8 | Ammonia | 7664-41-7 | Respiratory | Decreased lung function and respiratory symptoms | Occupational epidemiology studies | Holness et al. (1989), supported by Rahman et al. (2007), Ballal et al. (1998), and Ali et al. (2001) | No Observable Adverse Effect Level | 4.9 mg/m3 | 0.5 mg/m3 | 10 | 1 | Medium | Medium | Medium | Threshold | Chronic |
9 | Aniline | 62-53-3 | Hematologic | Methemoglobin increase, spleen toxicity | 20-26 week inhalation rat, guinea pig and mouse study | Oberst et al., 1956 | No Observable Adverse Effect Level | 3.4 mg/m3 | 0.001 mg/m3 | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
10 | Antimony trioxide | 1309-64-4 | Respiratory | Pulmonary toxicity, chronic interstitial inflammation | Rat 1-year inhalation toxicity study | Newton et al., 1994 | Benchmark Concentration | 0.074 mg/m3 | 0.0002 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
11 | Arsine | 7784-42-1 | Hematologic, Immune | Increased hemolysis, abnormal RBC morphology, and increased spleen weight | 13-week rat and mouse and 28-day hamster inhalation study | Blair et al., 1990a,b | No Observable Adverse Effect Level | 0.014 mg/m3 | 5e-05 mg/m3 | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
12 | Benzene | 71-43-2 | Immune | Decreased lymphocyte count | Human occupational inhalation study | Rothman et. al., 1996 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 8.2 mg/m3 | 0.03 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
13 | Benzo[a]pyrene (BaP) | 50-32-8 | Developmental | Decreased embryo/fetal survival | Developmental toxicity study in rats (GDs 11−20) | Archibong et al. (2002) | Lowest Observable Adverse Effect Level | 0.0046 mg/m3 | 2e-06 mg/m3 | 3000 | 1 | Low/Medium | Low | Low/Medium | Threshold | Chronic |
14 | Benzo[a]pyrene (BaP) | 50-32-8 | Reproductive | Reduced ovulation rate and ovary weight | Premating study in rats (14 d) | Archibong et al. (2012) | Lowest Observable Adverse Effect Level | 0.0091 mg/m3 | 3e-06 mg/m3 | 3000 | 1 | None | None | Low/Medium | Threshold | Chronic |
15 | Beryllium and compounds | 7440-41-7 | Immune, Respiratory | Beryllium sensitization and progression to CBD | Occupational study | Kreiss et al., 1996 | Lowest Observable Adverse Effect Level | 0.0002 mg/m3 | 2e-05 mg/m3 | 10 | 1 | Medium | Medium | Medium | Threshold | Chronic |
16 | Bromobenzene | 108-86-1 | Hepatic | Hepatocellular cytomegaly in female B6C3F1 mice | 13-week inhalation study | NTP (1985d) | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 63.0 mg/m3 | 0.06 mg/m3 | 1000 | 1 | Medium | Low/Medium | Low/Medium | None | Chronic |
17 | Bromobenzene | 108-86-1 | Hepatic | Hepatocellular cytomegaly in female B6C3F1 mice | 13-week inhalation study | NTP (1985d) | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 63.0 mg/m3 | 0.2 mg/m3 | 300 | 1 | Medium | Medium | Medium | None | Subchronic |
18 | Bromomethane | 74-83-9 | Nervous, Respiratory | Degenerative and proliferative lesions of the olfactory epithelium of the nasal cavity | Rat 29-month inhalation study | Reuzel et al., 1987, 1991 | Lowest Observable Adverse Effect Level | 0.48 mg/m3 | 0.005 mg/m3 | 100 | 1 | Medium | High | High | Threshold | Chronic |
19 | 1,3-Butadiene | 106-99-0 | Reproductive | Ovarian atrophy | 2-year mouse inhalation study | NTP, 1993 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 1.98 mg/m3 | 0.002 mg/m3 | 1000 | 1 | High | High | Medium | Threshold | Chronic |
20 | Carbon disulfide | 75-15-0 | Nervous | Peripheral nervous system dysfunction | Occupational study | Johnson et al., 1983 | Benchmark Concentration | 19.7 mg/m3 | 0.7 mg/m3 | 30 | 1 | Medium | Medium | Medium | Threshold | Chronic |
21 | Carbon tetrachloride | 56-23-5 | Hepatic | Fatty changes in the liver | Chronic inhalation toxicity study in rats | Nagano et al., 2007b, JBRC, 1998 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 14.3 mg/m3 | 0.1 mg/m3 | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
22 | Cerium Oxide and Cerium Compounds | 1306-38-3 | Respiratory | Increased incidence of alveolar epithelial hyperplasia in the lungs of male and female rats | Subchronic inhalation study | BRL, 1994 (unpublished study) | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 0.86 mg/m3 | 0.0009 mg/m3 | 1000 | 1 | Medium | Low | Low | Benchmark | Chronic |
23 | Chlordane (Technical) | 12789-03-6 | Hepatic | Hepatic effects | Rat subchronic inhalation study | Khasawinah et al., 1989a | No Observable Adverse Effect Level | 0.65 mg/m3 | 0.0007 mg/m3 | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
24 | Chlorine dioxide | 10049-04-4 | Cardiovascular, Respiratory | Vascular congestion and peribronchial edema | 60-day rat inhalation study | Paulet and Desbrousses, 1972 | Lowest Observable Adverse Effect Level | 0.64 mg/m3 | 0.0002 mg/m3 | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
25 | 1-Chloro-1,1-difluoroethane | 75-68-3 | Other | No adverse effects | 2-year rat inhalation study | Seckar et al., 1986 | No Observable Adverse Effect Level | 14710.0 mg/m3 | 50.0 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
26 | 2-Chloroacetophenone | 532-27-4 | Respiratory | Squamous hyperplasia of the nasal respiratory epithelium | Chronic rat inhalation study | NTP, 1990 | Lowest Observable Adverse Effect Level | 0.03 mg/m3 | 3e-05 mg/m3 | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
27 | Chlorodifluoromethane | 75-45-6 | Endocrine, Urinary | Increased kidney, adrenal and pituitary weights | Chronic rat inhalation study | Tinston et al., 1981a | No Observable Adverse Effect Level | 5260.0 mg/m3 | 50.0 mg/m3 | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
28 | Chloroprene | 126-99-8 | Immune, Nervous, Respiratory | Increase in incidence of olfactory atrophy, alveolar hyperplasia, and splenic hematopoietic proliferation in male F344/N rats, female F344/N rats, and female B6C3F1 mice, respectively | 2-year chronic inhalation study | NTP, 1998 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 2.0 mg/m3 | 0.02 mg/m3 | 100 | 1 | High | Medium/High | Medium/High | Threshold | Chronic |
29 | Chromium(VI) | 18540-29-9 | Respiratory | Ulcerated nasal septum in humans | None | None | Lowest Observable Adverse Effect Level | 0.0034 mg/m3 | 3e-05 mg/m3 | 100 | None | None | None | Medium | None | Chronic |
30 | Cumene | 98-82-8 | Endocrine, Urinary | Increased kidney weights in female rats and adrenal weights in male and female rats | Rat 13-week inhalation study | Cushman et al., 1995 | No Observable Adverse Effect Level | 435.0 mg/m3 | 0.4 mg/m3 | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
31 | Cyclohexane | 110-82-7 | Developmental | Reduced pup weights in the F1 and F2 generations | Rat, 2-generation reproductive/developmental toxicity study | DuPont HLR, 1997a | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 1822.0 mg/m3 | 6.0 mg/m3 | 300 | 1 | High | Low/Medium | Low/Medium | Threshold | None |
32 | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | Reproductive | Testicular effects | 13-week subchronic rabbit inhalation study | Rao et al., 1982 | No Observable Adverse Effect Level | 0.17 mg/m3 | 0.0002 mg/m3 | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
33 | 1,2-Dibromoethane | 106-93-4 | Respiratory | Nasal inflammation | Mouse chronic inhalation study | NTP, 1982 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 2.8 mg/m3 | 0.009 mg/m3 | 300 | 1 | Medium | Medium | Medium | Benchmark | Chronic |
34 | 1,4-Dichlorobenzene | 106-46-7 | Hepatic | Increased liver weights in P1 males | Rat multigeneration reproductive study | Chlorobenzene Producers Assn., 1986 | No Observable Adverse Effect Level | 75.0 mg/m3 | 0.8 mg/m3 | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
35 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Hepatic | Liver toxicity (fatty change) | Rat chronic inhalation study | Quast et al., 1986 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 6.9 mg/m3 | 0.2 mg/m3 | 30 | 1 | High | Medium | Medium | Threshold | Chronic |
36 | Dichloromethane | 75-09-2 | Hepatic | Hepatic effects (hepatic vacuolation) | 2-Year rat inhalation bioassay | Nitschke et al. (1988a) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 17.2 mg/m3 | 0.6 mg/m3 | 30 | 1 | High | Medium/High | Medium/High | None | Chronic |
37 | 1,2-Dichloropropane | 78-87-5 | Respiratory | Hyperplasia of the nasal mucosa | Rat 13-week inhalation study | Nitschke et al., 1988 | Lowest Observable Adverse Effect Level | 1.3 mg/m3 | 0.004 mg/m3 | 300 | 1 | High | Medium | Medium | Threshold | None |
38 | 1,3-Dichloropropene | 542-75-6 | Respiratory | Hypertrophy/ hyperplasia of the nasal respiratory epithelium | Chronic inhalation study in B6C3F1 mice | Lomax et al., 1989 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 0.72 mg/m3 | 0.02 mg/m3 | 30 | 1 | High | High | High | Threshold | Chronic |
39 | Dichlorvos | 62-73-7 | Nervous | Decreased brain cholinesterase activity | Carworth Farm E strain rat chronic inhalation study | Blair et al., 1976 | No Observable Adverse Effect Level | 0.05 mg/m3 | 0.0005 mg/m3 | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
40 | Diesel engine exhaust | None | Respiratory | Pulmonary inflammation and histopathology | Rat chronic inhalation study | Ishinishi et. al., (1988) | No Observable Adverse Effect Level | 0.144 mg/m3 | 0.005 mg/m3 | 30 | 1 | Medium | Medium | Medium | Threshold | Chronic |
41 | 1,1-Difluoroethane | 75-37-6 | Other | No adverse effects observed | 2-year inhalation study | McAlack and Schneider, 1982 | No Observable Adverse Effect Level | 12051.0 mg/m3 | 40.0 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
42 | N,N-Dimethylformamide | 68-12-2 | Hepatic | Digestive disturbances and minimal hepatic changes suggestive of liver abnormalities | Human occupational studies | Cirla et al., 1984; Catenacci et al., 1984 | Lowest Observable Adverse Effect Level | 7.9 mg/m3 | 0.03 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
43 | 1,4-Dioxane | 123-91-1 | Nervous, Respiratory | Atrophy and respiratory metaplasia of the olfactory epithelium | Chronic inhalation male rat study | Kasai et al. 2009 | Lowest Observable Adverse Effect Level | 32.2 mg/m3 | 0.03 mg/m3 | 1000 | 1 | Medium | Medium | Medium | None | Chronic |
44 | Epichlorohydrin | 106-89-8 | Respiratory | Changes in the nasal turbinates | Rat and mouse 90-day inhalation study | Quast et al., 1979a | No Observable Adverse Effect Level | 0.36 mg/m3 | 0.001 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
45 | 1,2-Epoxybutane (EBU) | 106-88-7 | Respiratory | Degenerative lesions of the nasal cavity | 2-year mouse inhalation study | NTP, 1988 | Lowest Observable Adverse Effect Level | 4.8 mg/m3 | 0.02 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
46 | 2-Ethoxyethanol | 110-80-5 | Hematologic, Reproductive | Decreased testis weight, seminiferous tubule degeneration and decreased hemoglobin | New Zealand White Rabbit subchronic toxicity study | Barbee et al., 1984 | No Observable Adverse Effect Level | 68.0 mg/m3 | 0.2 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
47 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Urinary | Increased absolute kidney weight in female rats | 2-year inhalation study in male and female F344 rats | Saito et al., 2013; JPEC, 2010b | No Observable Adverse Effect Level | 1110.0 mg/m3 | 40.0 mg/m3 | 30 | 1 | Medium | High | Medium | Threshold | Chronic |
48 | Ethyl chloride | 75-00-3 | Developmental, Musculoskeletal | Delayed fetal ossification | Mouse developmental inhalation study | Scortichini et al., 1986 | No Observable Adverse Effect Level | 4000.0 mg/m3 | 10.0 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
49 | Ethylbenzene | 100-41-4 | Developmental | Developmental toxicity | Rat and rabbit developmental inhalation studies | Andrew et al., 1981; Hardin et al., 1981 | No Observable Adverse Effect Level | 434.0 mg/m3 | 1.0 mg/m3 | 300 | 1 | Low | Low | Low | Threshold | Chronic |
50 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Hematologic | Hemosiderin deposition in the liver | Chronic (rat and mouse) inhalation study | NTP (2000) | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 16.0 mg/m3 | 1.6 mg/m3 | 10 | 1 | High | Medium/High | Medium/High | Threshold | Chronic |
51 | Formaldehyde | 50-00-0 | Respiratory | Decreased pulmonary function, prevalence of current asthma or degree of asthma control, and allergic conditions in children (See Note) | None | None | None | None None | 0.007 mg/m3 | None | None | None | None | High | None | Chronic |
52 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Respiratory | Suppurative inflammation of the nose | Chronic inhalation study in B6C3F1 mice | NTP, 1994 | No Observable Adverse Effect Level | 0.024 mg/m3 | 0.0002 mg/m3 | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
53 | Hexachloroethane | 67-72-1 | Nervous | Neurotoxicity (tremors and ruffled pelt) | 6-week subchronic inhalation study, male and female Sprague-Dawley rats | Weeks et al., 1979 | No Observable Adverse Effect Level | 83.0 mg/m3 | 0.03 mg/m3 | 3000 | 1 | Low | Low | Low | Threshold | Chronic |
54 | 1,6-Hexamethylene diisocyanate | 822-06-0 | Nervous, Respiratory | Degeneration of olfactory epithelium | Rat chronic inhalation study | Mobay, Inc., 1989 | No Observable Adverse Effect Level | 0.001 mg/m3 | 1e-05 mg/m3 | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
55 | n-Hexane | 110-54-3 | Nervous | Peripheral neuropathy (decreased MCV at 12 weeks) | Rat subchronic inhalation study | Huang et al., 1989 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 215.0 mg/m3 | 0.7 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
56 | 2-Hexanone | 591-78-6 | Nervous | Motor conduction velocity of the sciatic-tibial nerve | Subchronic inhalation study in monkeys | Johnson et al., 1977 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 90.0 mg/m3 | 0.03 mg/m3 | 3000 | 1 | Medium | Low | Low | Benchmark | Chronic |
57 | Hydrogen Cyanide and Cyanide Salts | Various | Endocrine | Thyroid enlargement and altered iodide uptake | Epidemiology study | El Ghawabi et al., 1975 | Lowest Observable Adverse Effect Level | 2.5 mg/m3 | 0.0008 mg/m3 | 3000 | 1 | Medium | Low/Medium | Low/Medium | Threshold | Chronic |
58 | Hydrogen chloride | 7647-01-0 | Respiratory | Hyperplasia of nasal mucosa larynx and trachea | Rat chronic inhalation study | Sellakumar et al., 1994; Albert et al., 1982 | Lowest Observable Adverse Effect Level | 6.1 mg/m3 | 0.02 mg/m3 | 300 | 1 | Low | Low | Low | Threshold | Chronic |
59 | Hydrogen sulfide | 7783-06-4 | Nervous, Respiratory | Nasal lesions of the olfactory mucosa | Rat Subchronic Inhalation Study | Brenneman et. al., 2000 | No Observable Adverse Effect Level | 0.64 mg/m3 | 0.002 mg/m3 | 300 | 1 | Medium | Medium/High | Medium/High | Threshold | Chronic |
60 | Libby Amphibole Asbestos | 1318-09-8 | Respiratory | Localized pleural thickening | Occupational epidemiology study | Rohs et al. (2008) | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 0.026 fiber/cc | 9e-05 fiber/cc | 300 | 1 | Medium | Medium | Medium | None | Chronic |
61 | Manganese | 7439-96-5 | Nervous | Impairment of neurobehavioral function | Occupational exposure to manganese dioxide | Roels et al., 1992 | Lowest Observable Adverse Effect Level | 0.05 mg/m3 | 5e-05 mg/m3 | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
62 | Mercury, elemental | 7439-97-6 | Nervous | Hand tremor; increases in memory disturbances; slight subjective and objective evidence of autonomic dysfunction | Human occupational inhalation studies | Fawer et al., 1983; Piikivi and Tolonen, 1989; Piikivi and Hanninen, 1989; Piikivi, 1989; Ngim et al., 1992; Liang et al., 1993 | Lowest Observable Adverse Effect Level | 0.009 mg/m3 | 0.0003 mg/m3 | 30 | 1 | Medium | Medium | Medium | Threshold | Chronic |
63 | Methanol | 67-56-1 | Developmental, Nervous | Reduced brain weight in rat pups at 6 weeks of age | Male Sprague-Dawley rats, Developmental inhalation exposure through gestation and 3, 6 or 8 weeks postnatal | NEDO (1987) | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 858.0 mg-hr/L | 20.0 mg/m3 | 100 | 1 | High | Medium | Medium/High | None | Chronic |
64 | 2-Methoxyethanol | 109-86-4 | Reproductive | Testicular effects | Subchronic inhalation studies in male New Zealand White Rabbits and Sprague-Dawley rats | Miller et al., 1983 | No Observable Adverse Effect Level | 17.0 mg/m3 | 0.02 mg/m3 | 1000 | 1 | Medium | Medium | Medium | Threshold | Chronic |
65 | Methyl chloride | 74-87-3 | Nervous | Cerebellar lesions | Mouse 11-day continuous inhalation study | Landry et al., 1983, 1985 | No Observable Adverse Effect Level | 94.6 mg/m3 | 0.09 mg/m3 | 1000 | 1 | High | Medium | Medium | Threshold | Chronic |
66 | Methyl ethyl ketone (MEK) | 78-93-3 | Developmental, Musculoskeletal | Developmental toxicity (skeletal variations) | Mouse developmental study | Schwetz et al., 1991 | Lowest Effect Concentration | 1517.0 mg/m3 | 5.0 mg/m3 | 300 | 1 | High | Medium | Medium | Threshold | Chronic |
67 | Methyl isobutyl ketone (MIBK) | 108-10-1 | Developmental, Musculoskeletal | Reduced fetal body weight, skeletal variations, and increased fetal death in mice, and skeletal variations in rats. | Rat and mouse developmental inhalation study | Tyl et. al., 1987 | No Observable Adverse Effect Level | 1026.0 mg/m3 | 3.0 mg/m3 | 300 | 1 | Medium | Low/Medium | Low/Medium | Threshold | Chronic |
68 | Methyl methacrylate | 80-62-6 | Nervous, Respiratory | Degeneration/ atrophy of olfactory epithelium (male rats) | Rat chronic inhalation study | Hazelton Laboratories 1979a Lomax, 1992 Lomax et al., 1997 | Benchmark Concentration | 7.2 mg/m3 | 0.7 mg/m3 | 10 | 1 | High | Medium/High | Medium/High | Threshold | Chronic |
69 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | Hepatic, Ocular, Other, Urinary | Increased absolute and relative liver and kidney weights and increased severity of spontaneous renal lesions (females), increased prostration (females), and swollen periocular tissue (males and females) | Chronic rat 24-month inhalation study | Chun et al., 1992 | No Observable Adverse Effect Level | 259.0 mg/m3 | 3.0 mg/m3 | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
70 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Nervous, Respiratory | Hyperplasia of olfactory epithelium | Rat inhalation studies | Reuzel et al., 1990, 1994b | Benchmark Concentration | 0.06 mg/m3 | 0.0006 mg/m3 | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
71 | Naphthalene | 91-20-3 | Nervous, Respiratory | Nasal effects: hyperplasia and metaplasia in respiratory and olfactory epithelium, respectively | Chronic mouse inhalation study | NTP, 1992a | Lowest Observable Adverse Effect Level | 9.3 mg/m3 | 0.003 mg/m3 | 3000 | 1 | Medium | Low/Medium | Medium | Threshold | Chronic |
72 | Nitrobenzene | 98-95-3 | Nervous, Respiratory | Bronchiolization of the alveoli and olfactory degeneration | Chronic mouse study | CIIT, 1993 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 0.26 mg/m3 | 0.009 mg/m3 | 30 | 1 | High | High | Medium | None | Chronic |
73 | 2-Nitropropane | 79-46-9 | Hepatic | Liver focal vacuolization and nodules | Rat chronic inhalation study | Griffin et al., 1980, 1981; Angus Chemical Co., 1985a, b | Lowest Observable Adverse Effect Level | 16.0 mg/m3 | 0.02 mg/m3 | 1000 | 1 | Low | Low | Low | Threshold | Chronic |
74 | Phosgene | 75-44-5 | Respiratory | Collagen staining indicative of fibrosis | Subchronic inhalation study in rats | Kodavanti et al., 1997 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 0.03 mg/m3 | 0.0003 mg/m3 | 100 | 1 | Medium | Medium | Medium | Benchmark | Chronic |
75 | Phosphine | 7803-51-2 | Other | Decreased body weight | Mouse subchronic inhalation study | Barbosa et al., 1994 | No Observable Adverse Effect Level | 0.25 mg/m3 | 0.0003 mg/m3 | 1000 | 1 | Medium | Low | Low | Threshold | Chronic |
76 | Phosphoric acid | 7664-38-2 | Respiratory | Bronchiolar fibrosis | 13-week rat inhalation study | Aranyi et al., 1988a | Benchmark Concentration | 3.4 mg/m3 | 0.01 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
77 | Propionaldehyde | 123-38-6 | Nervous, Respiratory | Atrophy of olfactory epithelium | Subchronic inhalation study in rats | Union Carbide, 1993 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 8.0 mg/m3 | 0.008 mg/m3 | 1000 | 1 | Low/Medium | Low | Low/Medium | Benchmark | Chronic |
78 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | Nervous | Mild reversible sedation | Rat/rabbit subchronic inhalation study | Landry et al., 1983 | No Observable Adverse Effect Level | 658.0 mg/m3 | 2.0 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
79 | Propylene oxide | 75-56-9 | Respiratory | Nest-like infolds of the nasal respiratory epithelium | 2-year rat chronic inhalation study | Kuper et al., 1988 | Lowest Observable Adverse Effect Level | 2.9 mg/m3 | 0.03 mg/m3 | 100 | 1 | Medium | Medium | Medium | Threshold | Chronic |
80 | Styrene | 100-42-5 | Nervous | CNS effects | Occupational study | Mutti et al., 1984 | No Observable Adverse Effect Level | 34.0 mg/m3 | 1.0 mg/m3 | 30 | 1 | Medium | Medium | Medium | Threshold | Chronic |
81 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Nervous, Ocular | (See Note) | None | None | None | None None | 0.04 mg/m3 | None | None | Medium | Medium | Medium | None | Chronic |
82 | 1,1,1,2-Tetrafluoroethane | 811-97-2 | Reproductive | Leydig cell hyperplasia | Rat chronic inhalation study | Collins et al., 1995 | Benchmark Concentration | 8200.0 mg/m3 | 80.0 mg/m3 | 100 | 1 | High | Medium | Medium | Threshold | Chronic |
83 | Tetrahydrofuran | 109-99-9 | Hepatic, Nervous | Increased liver weight and centrilobular cytomegaly, CNS effects (narcosis) | Subchronic mouse study | NTP (1998) | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 246.0 mg/m3 | 2.0 mg/m3 | 100 | 1 | High | Medium/High | Medium/High | None | Chronic |
84 | Toluene | 108-88-3 | Nervous | Neurological effects in occupationally-exposed workers | Multiple human studies | Abbate et al., 1993, Boey et al., 1997, Cavalleri et al., 2000, Eller et al., 1999, Foo et al., 1990, Murata et al., 1993, Nakatsuka et al., 1992, Neubert et al., 2001, Vrca et al., 1995, Zavalic et al., 1998a | No Observable Adverse Effect Level | 46.0 mg/m3 | 5.0 mg/m3 | 10 | 1 | High | High | High | Threshold | Chronic |
85 | 2,4-/2,6-Toluene diisocyanate mixture (TDI) | 26471-62-5 | Respiratory | Chronic lung-function decline | Prospective occupational study | Diem et al., 1982 | No Observable Adverse Effect Level | 0.002 mg/m3 | 7e-05 mg/m3 | 30 | 1 | Medium | Medium | Medium | Threshold | Chronic |
86 | 1,1,1-Trichloroethane | 71-55-6 | Nervous | Performance on neurobehavioral tests | Human subjects exposed for 3.5 hr | Mackay et al. (1987) | Lowest Observable Adverse Effect Level | 950.0 mg/m3 | 7.0 mg/m3 | 100 | 1 | Medium | Medium | Medium | None | None |
87 | 1,1,1-Trichloroethane | 71-55-6 | Hepatic | Liver histopathologic changes | 2-Year inhalation rat study, 14-Week inhalation mouse study | Quast et al. (1988, 1984), McNutt et al. (1975) | No Observable Adverse Effect Level | 1553.0 mg/m3 | 5.0 mg/m3 | 100 | 1 | Low | Medium | Medium | None | Subchronic |
88 | 1,1,1-Trichloroethane | 71-55-6 | Hepatic | Liver histopathologic changes | 2-Year inhalation rat study, 14-Week inhalation mouse study | Quast et al. (1988, 1984), McNutt et al. (1975) | No Observable Adverse Effect Level | 1553.0 mg/m3 | 5.0 mg/m3 | 100 | 1 | Low | Medium | Medium | None | Chronic |
89 | 1,1,1-Trichloroethane | 71-55-6 | Nervous | Performance on neurobehavioral tests | Human subjects exposed for 3.5 hr | Mackay et al. (1987) | Lowest Observable Adverse Effect Level | 950.0 mg/m3 | 9.0 mg/m3 | 100 | 1 | Medium | Medium | Medium | None | None |
90 | 1,1,1-Trichloroethane | 71-55-6 | Nervous | Performance on neurobehavioral tests | Human subjects exposed for 3.5 hr | Mackay et al. (1987) | Lowest Observable Adverse Effect Level | 950.0 mg/m3 | 7.0 mg/m3 | 100 | 1 | Medium | Medium | Medium | None | None |
91 | 1,1,1-Trichloroethane | 71-55-6 | Nervous | Performance on neurobehavioral tests | Human subjects exposed for 3.5 hr | Mackay et al. (1987) | Lowest Observable Adverse Effect Level | 950.0 mg/m3 | 6.0 mg/m3 | 100 | 1 | Medium | Medium | Medium | None | None |
92 | 1,1,1-Trichloroethane | 71-55-6 | Nervous | Performance on neurobehavioral tests | Human subjects exposed for 3.5 hr | Mackay et al. (1987) | Lowest Observable Adverse Effect Level | 526.0 mg/m3 | 5.0 mg/m3 | 100 | 1 | Medium | Medium | Medium | None | None |
93 | Trichloroethylene | 79-01-6 | Developmental, Immune | (See Note) | None | None | None | None None | 0.002 mg/m3 | None | None | High | High | High | None | Chronic |
94 | 1,2,3-Trichloropropane | 96-18-4 | Respiratory | peribronchial lymphoid hyperplasia in male rats | 13-week inhalation Study | Johannsen et al., 1988 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 0.9 mg/m3 | 0.0003 mg/m3 | 3000 | 1 | Low/Medium | Low | Low | Benchmark | Chronic |
95 | Triethylamine | 121-44-8 | Respiratory | Inflammation of the nasal passage | 28-week rat inhalation study | Lynch et al., 1990 | No Observable Adverse Effect Level | 19.5 mg/m3 | 0.007 mg/m3 | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
96 | 1,2,4-Trimethylbenzene | 95-63-6 | Hematologic | Decreased clotting time | Korsak and Rydzyński | 1996 | No Observable Adverse Effect Level | 24.3 mg/m3 | 0.08 mg/m3 | 300 | 1 | None | None | Low/Medium | None | Chronic |
97 | 1,2,4-Trimethylbenzene | 95-63-6 | Respiratory | Inflammatory lung lesions | Korsak et al. | 2000a | No Observable Adverse Effect Level | 61.65 mg/m3 | 0.2 mg/m3 | 300 | 1 | None | None | Low/Medium | None | Chronic |
98 | 1,2,4-Trimethylbenzene | 95-63-6 | Developmental | Decreased fetal weight | Saillenfait et al. | 2005 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 395.16 mg/m3 | 4.0 mg/m3 | 100 | 1 | None | None | Low/Medium | Benchmark | Chronic |
99 | 1,2,4-Trimethylbenzene | 95-63-6 | Other | Decreased maternal weight | Saillenfait et al. | 2005 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 758.06 mg/m3 | 3.0 mg/m3 | 300 | 1 | None | None | Low/Medium | None | Chronic |
100 | 1,2,4-Trimethylbenzene | 95-63-6 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 18.15 mg/m3 | 0.06 mg/m3 | 300 | 1 | Low/Medium | Low/Medium | Low/Medium | Benchmark | Chronic |
101 | 1,2,3-Trimethylbenzene | 526-73-8 | Respiratory | Inflammatory lung lesions | Korsak et al. | 2000b | No Observable Adverse Effect Level | 66.56 mg/m3 | 0.2 mg/m3 | 300 | 1 | None | None | Low/Medium | None | Chronic |
102 | 1,2,4-Trimethylbenzene | 95-63-6 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 18.15 mg/m3 | 0.2 mg/m3 | 100 | 1 | None | None | Low/Medium | Benchmark | Subchronic |
103 | 1,2,3-Trimethylbenzene | 526-73-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 18.15 mg/m3 | 0.2 mg/m3 | 100 | 1 | None | None | Low/Medium | Benchmark | Subchronic |
104 | 1,2,3-Trimethylbenzene | 526-73-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 18.15 mg/m3 | 0.06 mg/m3 | 300 | 1 | Low/Medium | Low/Medium | Low/Medium | Benchmark | Chronic |
105 | 1,3,5-Trimethylbenzene | 108-67-8 | Developmental | Decreased fetal weight | Saillenfait et al. | 2005 | No Observable Adverse Effect Level | 367.75 mg/m3 | 4.0 mg/m3 | 100 | 1 | Low/Medium | Low/Medium | Low/Medium | None | Chronic |
106 | 1,3,5-Trimethylbenzene | 108-67-8 | Other | Decreased maternal weight | Saillenfait et al. | 2005 | No Observable Adverse Effect Level | 124.25 mg/m3 | 0.4 mg/m3 | 300 | 1 | None | None | Low/Medium | None | Chronic |
107 | 1,3,5-Trimethylbenzene | 108-67-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Dose based on the LED10 (Lowest Effective Dose) | 18.15 mg/m3 | 0.2 mg/m3 | 100 | 1 | Low/Medium | Low/Medium | Low/Medium | Threshold | Subchronic |
108 | 1,3,5-Trimethylbenzene | 108-67-8 | Nervous | Decreased pain sensitivity in male Wistar rats | Korsak and Rydzyński | 1996 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 18.15 mg/m3 | 0.06 mg/m3 | 300 | 1 | Low/Medium | Low/Medium | Low/Medium | Threshold | Chronic |
109 | 1,2,3-Trimethylbenzene | 526-73-8 | Hematologic | Decreased segmented neutrophils | Korsak et al. | 2000b | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 16.65 mg/m3 | 0.06 mg/m3 | 300 | 1 | None | None | Low/Medium | Benchmark | Chronic |
110 | Vinyl acetate | 108-05-4 | Nervous, Respiratory | Nasal epithelial lesions | Chronic inhalation study in rats and mice | Owen, 1988 Beems, 1988 Dreef-van der Meulen, 1988 | No Observable Adverse Effect Level | 5.0 mg/m3 | 0.2 mg/m3 | 30 | 1 | High | High | High | Threshold | Chronic |
111 | Vinyl bromide | 593-60-2 | Hepatic | Hypertrophy, basophilic and eosinophilic foci, in the liver | Chronic rat inhalation study | Benya et al., 1982; Busey, 1979 | Lowest Observable Adverse Effect Level | 7.7 mg/m3 | 0.003 mg/m3 | 3000 | 1 | Medium | Low | Low | Threshold | Chronic |
112 | Vinyl chloride | 75-01-4 | Hepatic | Liver cell polymorphism | Rat chronic feeding study | Til et al., 1983, 1991 | No Observable Adverse Effect Level | 2.5 mg/m3 | 0.1 mg/m3 | 30 | 1 | High | Medium/High | Medium | Threshold | Chronic |
113 | Xylenes | 1330-20-7 | Nervous | Impaired motor coordination (decreased rotarod performance) | Subchronic inhalation study in male rats | Korsak et. al., 1994 | No Observable Adverse Effect Level | 39.0 mg/m3 | 0.1 mg/m3 | 300 | 1 | Medium | Medium | Medium | Threshold | Chronic |
114 | tert-Butyl Alcohol (tBA) | 75-65-0 | Urinary | Increased severity of nephropathy | Route-to-route extrapolation from 2-year drinking water study | NTP 1995 | Benchmark Concentration based on the LEC10 (Lowest Effective Concentration) | 491.0 mg/m3 | 5.0 mg/m3 | 100 | 1 | High | Medium | Medium | None | Chronic |
CHEMICAL NAME | CASRN | ROUTE | WOE DESCRIPTION | WOE TITLE | WOE NARRITIVE | |
---|---|---|---|---|---|---|
1 | Acenaphthylene | 208-96-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
2 | Acephate | 30560-19-1 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | The classification is based on increased incidence of hepatocellular carcinomas and adenomas in female mice. |
3 | Acetaldehyde | 75-07-0 | None | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on increased incidence of nasal tumors in male and female rats and laryngeal tumors in male and female hamsters after inhalation exposure. |
4 | Acetone | 67-64-1 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | In accordance with the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) data are inadequate for an assessment of the human carcinogenic potential of acetone. |
5 | Acetonitrile | 75-05-8 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the carcinogenic potential of ACN following inhalation, oral, or dermal exposure is best characterized as "cannot be determined because the existing evidence is composed of conflicting data (e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm any concern)." |
6 | Acetonitrile | 75-05-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the carcinogenic potential of ACN following inhalation, oral, or dermal exposure is best characterized as "cannot be determined because the existing evidence is composed of conflicting data (e.g., some evidence is suggestive of carcinogenic effects, but other equally pertinent evidence does not confirm any concern)." |
7 | Acetophenone | 98-86-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and no animal data. |
8 | Acetyl chloride | 75-36-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data or animal data. |
9 | Acrolein | 107-02-8 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the potential carcinogenicity of acrolein cannot be determined because the existing data are inadequate for an assessment of human carcinogenic potential for either the oral or inhalation route of exposure. There are no adequate human studies of the carcinogenic potential of acrolein. Collectively, experimental studies provide inadequate evidence that acrolein causes cancer in laboratory animals. |
10 | Acrylamide | 79-06-1 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | In accordance with the Guidelines for Carcinogen Risk Assessment U.S. EPA, 2005, acrylamide (AA) is characterized as "likely to be carcinogenic to humans." |
11 | Acrylonitrile | 107-13-1 | Undefined | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | The observation of a statistically significant increase in incidence of lung cancer in exposed workers and observation of tumors, generally astrocytomas in the brain, in studies in two rat strains exposed by various routes (drinking water, gavage, and inhalation) forms the basis for this classification. |
12 | Adiponitrile | 111-69-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human and no animal cancer data were available. Adiponitrile was negative for mutagenicity in Salmonella with and without activation. |
13 | Aldicarb | 116-06-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Aldicarb was not found to induce statistically significant increases in tumor incidence in mice or rats in feeding studies or mice in a skin painting study. In the feeding studies there were, however, significant trends in pituitary tumors in female rats and fibrosarcomas in the male mouse. This evidence, together with the fact that less than maximum tolerated doses were used, indicates that the available assays are inadequate to assess the carcinogenic potential of aldicarb. |
14 | Aldrin | 309-00-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Orally administered aldrin produced significant increases in tumor responses in three different strains of mice in both males and females. Tumor induction has been observed for structurally related chemicals, including dieldrin, a metabolite. |
15 | Allyl chloride | 107-05-1 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Classification is based on a low (but biologically important) incidence of forestomach tumors in female mice and positive results in a variety of genetic toxicity tests. Allyl chloride is an alkylating agent and structurally related to probable human carcinogens. |
16 | 4-Aminopyridine | 504-24-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
17 | Ammonium acetate | 631-61-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data |
18 | Ammonium methacrylate | 16325-47-6 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data |
19 | Aniline | 62-53-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Induction of tumors of the spleen and the body cavity in two strains of rat, and some supporting genetic toxicological evidence. |
20 | Anthracene | 120-12-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
21 | Apollo | 74115-24-5 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on an increase in thyroid gland follicular cell tumors in male rats and supportive findings in pituitary/thyroid hormone activity. |
22 | Aramite | 140-57-8 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient data from animal bioassays including increased incidence of liver tumors and/or neoplastic nodules in three strains of male and female rats and males of one strain of mice, and extrahepatic biliary system tumors in dogs following chronic oral exposure. |
23 | Arsenic, Inorganic | 7440-38-2 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on sufficient evidence from human data. An increased lung cancer mortality was observed in multiple human populations exposed primarily through inhalation. Also, increased mortality from multiple internal organ cancers (liver, kidney, lung, and bladder) and an increased incidence of skin cancer were observed in populations consuming drinking water high in inorganic arsenic. |
24 | Asbestos | 1332-21-4 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Observation of increased mortality and incidence of lung cancer, mesotheliomas and gastrointestinal cancer in occupationally exposed workers are consistent across investigators and study populations. Animal studies by inhalation in two strains of rats showed similar findings for lung cancer and mesotheliomas. Animal evidence for carcinogenicity via ingestion is limited (male rats fed intermediate-range chrysotile fibers; i.e., >10 um length, developed benign polyps), and epidemiologic data in this regard are inadequate. |
25 | Assure | 76578-14-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate animal data. |
26 | Azobenzene | 103-33-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Azobenzene induced invasive sarcomas in the spleen and other abdominal organs in male and female F344 rats following dietary administration. It is genotoxic and may be converted to benzidine, a known human carcinogen, under the acidic conditions in the stomach. |
27 | Barium and Compounds | 7440-39-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, barium would be classified as Group D, not classifiable as to human carcinogenicity. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), barium is considered not likely to be carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined following inhalation exposure. |
28 | Barium and Compounds | 7440-39-3 | Oral | Not likely to be carcinogenic to humans | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, barium would be classified as Group D, not classifiable as to human carcinogenicity. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), barium is considered not likely to be carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined following inhalation exposure. |
29 | Barium and Compounds | 7440-39-3 | Inhalation | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, barium would be classified as Group D, not classifiable as to human carcinogenicity. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), barium is considered not likely to be carcinogenic to humans following oral exposure and its carcinogenic potential cannot be determined following inhalation exposure. |
30 | Bentazon (Basagran) | 25057-89-0 | Undefined | E (Evidence of non-carcinogenicity for humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, Bentazon would be classified as evidence of non-carcinogenicity for humans, or a Group E chemical. Under EPA's proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), Bentazon would be characterized as not likely to be carcinogenic to humans by any route of exposure. |
31 | Bentazon (Basagran) | 25057-89-0 | Undefined | Not likely to be carcinogenic to humans | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, Bentazon would be classified as evidence of non-carcinogenicity for humans, or a Group E chemical. Under EPA's proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), Bentazon would be characterized as not likely to be carcinogenic to humans by any route of exposure. |
32 | Benz[a]anthracene | 56-55-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient data from animal bioassays. Benz[a]anthracene produced tumors in mice exposed by gavage; intraperitoneal, subcutaneous or intramuscular injection; and topical application. Benz[a]anthracene produced mutations in bacteria and in mammalian cells, and transformed mammalian cells in culture. |
33 | Benzene | 71-43-2 | Undefined | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Benzene is classified as a "known" human carcinogen (Category A) under the Risk Assessment Guidelines of 1986. Under the proposed revised Carcinogen Risk Assessment Guidelines (U.S. EPA, 1996), benzene is characterized as a known human carcinogen for all routes of exposure based upon convincing human evidence as well as supporting evidence from animal studies. (U.S. EPA, 1979, 1985, 1998; ATSDR, 1997). |
34 | Benzene | 71-43-2 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Benzene is classified as a "known" human carcinogen (Category A) under the Risk Assessment Guidelines of 1986. Under the proposed revised Carcinogen Risk Assessment Guidelines (U.S. EPA, 1996), benzene is characterized as a known human carcinogen for all routes of exposure based upon convincing human evidence as well as supporting evidence from animal studies. (U.S. EPA, 1979, 1985, 1998; ATSDR, 1997). |
35 | Benzidine | 92-87-5 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Observation of increased incidence of bladder cancer and bladder cancer-related deaths in exposed workers |
36 | Benzo[a]pyrene (BaP) | 50-32-8 | None | Carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), benzo[a]pyrene is “carcinogenic to humans” based on strong and consistent evidence in animals and humans. |
37 | Benzo[b]fluoranthene | 205-99-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient data from animal bioassays. Benzo[b]fluoranthene produced tumors in mice after lung implantation, intraperitoneal (i.p.) or subcutaneous (s.c.) injection, and skin painting. |
38 | Benzo[g,h,i]perylene | 191-24-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate animal data from lung implant, skin-painting and subcutaneous injection bioassays. |
39 | Benzo[k]fluoranthene | 207-08-9 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient data from animal bioassays. Benzo[k]fluoranthene produced tumors after lung implantation in mice and when administered with a promoting agent in skin-painting studies. Equivocal results have been found in a lung adenoma assay in mice. Benzo[k]fluoranthene is mutagenic in bacteria. |
40 | Benzoic acid | 65-85-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and inadequate data from animal bioassays |
41 | Benzotrichloride | 98-07-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and sufficient evidence of carcinogenicity in animals; namely, significantly increased incidences of benign and malignant tumors at multiple sites in one strain of female mice treated orally, dermally, and by inhalation. There is also evidence of mutagenicity in a variety of test systems. |
42 | Benzyl chloride | 100-44-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and sufficient evidence of carcinogenicity in animals; namely significantly increased incidences of benign and malignant tumors at multiple sites in both sexes of mice and a significant increase in thyroid tumors in female rats. There was evidence of mutagenicity in a variety of test systems. |
43 | Beryllium and compounds | 7440-41-7 | Inhalation | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined. |
44 | Beryllium and compounds | 7440-41-7 | Oral | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined. |
45 | Beryllium and compounds | 7440-41-7 | Undefined | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | B1; probable human carcinogen. Based on the limited evidence of carcinogenicity in humans exposed to airborne beryllium (lung cancer) and sufficient evidence of carcinogenicity in animals (lung cancer in rats and monkeys inhaling beryllium, lung tumors in rats exposed to beryllium via intratracheal instillation, and osteosarcomas in rabbits and possibly mice receiving intravenous or intramedullary injection), beryllium is reclassified from a B2 (inadequate human data) to a B1 probable human carcinogen (limited human data) using criteria of the 1986 Guidelines for Carcinogen Risk Assessment. Using the 1996 proposed Guidelines for Carcinogen Risk Assessment, inhaled beryllium would be characterized as a "likely" carcinogen in humans, and the human carcinogenic potential of ingested beryllium cannot be determined. |
46 | Biphenyl | 92-52-4 | None | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for biphenyl provides “suggestive evidence of carcinogenic potential” based on increased incidence of urinary bladder tumors (transitional cell papillomas and carcinomas) in male F344 rats (Umeda et al., 2002) and liver tumors (hepatocellular adenomas and carcinomas) in female BDF1 mice (Umeda et al., 2005) exposed to biphenyl in the diet for 104 weeks, as well as information on mode of carcinogenic action. The carcinogenic potential of biphenyl in humans has not been investigated. |
47 | Bis(2-chloroethoxy)methane | 111-91-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data. |
48 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Positive carcinogenicity results in two strains of mice and evidence of mutagenicity |
49 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Statistically significant increases in lung tumors (oat cell carcinomas) observed in six studies of exposed workers and bioassay data from rats and mice. |
50 | Boron and Compounds | 7440-42-8 | Oral | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), data are inadequate for an assessment of human carcinogenic potential for boron. |
51 | Bromate | 15541-45-4 | Inhalation | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route. |
52 | Bromate | 15541-45-4 | Oral | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route. |
53 | Bromate | 15541-45-4 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the current Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986), bromate would be classified as B2, probable human carcinogen. Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), bromate should be evaluated as a likely human carcinogen by the oral route of exposure. Insufficient data are available to evaluate the human carcinogenic potential of bromate by the inhalation route. |
54 | Brominated dibenzofurans | None | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No data in humans or animals |
55 | Bromobenzene | 108-86-1 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of bromobenzene. |
56 | Bromochloromethane | 74-97-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on the lack of data regarding the carcinogenicity of bromochloromethane in humans or animals; however, there are data indicative of genotoxic effects and structural relationships to halogenated methanes classified as B2 probable human carcinogens. |
57 | Bromodichloromethane | 75-27-4 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and sufficient evidence of carcinogenicity in two animal species (mice and rats) as shown by increased incidence of kidney tumors and tumors of the large intestine in male and female rats, kidney tumors in male mice, and liver tumors in female mice. |
58 | p-Bromodiphenyl ether | 101-55-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and inadequate animal data. |
59 | Bromoform | 75-25-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and sufficient evidence of carcinogenicity in animals, namely an increased incidence of tumors after oral administration of bromoform in rats and intraperitoneal administration in mice. Bromoform is genotoxic in several assay systems. Also, bromoform is structurally related to other trihalomethanes (e.g., chloroform, bromodichloromethane, dibromochloromethane) which have been verified as either probable or possible carcinogens. |
60 | Bromomethane | 74-83-9 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Inadequate human and animal data: a single mortality study from which direct exposure associations could not be deduced and studies in several animal species with too few animals, too brief exposure or observation time for adequate power. Bromomethane has shown genotoxicity. |
61 | Bromotrichloromethane | 75-62-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data regarding the carcinogenicity of bromotrichloromethane in humans or animals. |
62 | 1,3-Butadiene | 106-99-0 | Undefined | Carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under EPA's 1999 Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), 1,3-butadiene is characterized as carcinogenic to humans by inhalation. This characterization is supported by the total weight of evidence provided by the following: (1) sufficient evidence from epidemiologic studies of the majority of U.S. workers occupationally exposed to 1,3-butadiene, either to the monomer or to the polymer by inhalation, showing increased lymphohematopoietic cancers and a dose-response relationship for leukemias in polymer workers (see Section II.A.2), (2) sufficient evidence in laboratory animal studies showing that 1,3-butadiene causes tumors at multiple sites in mice and rats by inhalation (see Section II.A.3), and (3) numerous studies consistently demonstrating that 1,3-butadiene is metabolized into genotoxic metabolites by experimental animals and humans (see Section II.A.4). The specific mechanisms of 1,3-butadiene-induced carcinogenesis are unknown however, the scientific evidence strongly suggests that the carcinogenic effects are mediated by genotoxic metabolites of 1,3-butadiene, i.e., the monoepoxide, the diepoxide, and the epoxydiol. |
63 | Butyl benzyl phthalate (BBP) | 85-68-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on statistically significant increase in mononuclear cell leukemia in female rats; the response in male rats was inconclusive and there was no such response in mice. |
64 | t-Butylchloride | 507-20-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human carcinogenicity data and inadequate animal data. |
65 | Cacodylic acid | 75-60-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and inadequate data in animals |
66 | Cadmium | 7440-43-9 | Undefined | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Limited evidence from occupational epidemiologic studies of cadmium is consistent across investigators and study populations. There is sufficient evidence of carcinogenicity in rats and mice by inhalation and intramuscular and subcutaneous injection. Seven studies in rats and mice wherein cadmium salts (acetate, sulfate, chloride) were administered orally have shown no evidence of carcinogenic response. |
67 | Carbon tetrachloride | 56-23-5 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), carbon tetrachloride is "likely to be carcinogenic to humans." |
68 | Cerium Oxide and Cerium Compounds | 1306-38-3 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | In accordance with U.S. EPA (2005a) Guidelines for Carcinogen Risk Assessment, there is "inadequate information to assess the carcinogenic potential" of cerium in humans. |
69 | Chloral hydrate | 302-17-0 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the 1986 cancer guidelines (U.S. EPA, 1986), chloral hydrate is assigned to Group C, possible human carcinogen. Under the 1996 proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), chloral hydrate shows suggestive evidence of human carcinogenicity by the oral route of exposure. There are no carcinogenicity data from humans. |
70 | Chloral hydrate | 302-17-0 | Oral | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the 1986 cancer guidelines (U.S. EPA, 1986), chloral hydrate is assigned to Group C, possible human carcinogen. Under the 1996 proposed guidelines for carcinogen risk assessment (U.S. EPA, 1996), chloral hydrate shows suggestive evidence of human carcinogenicity by the oral route of exposure. There are no carcinogenicity data from humans. |
71 | Chlordane (Technical) | 12789-03-6 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the 1996 Proposed Guidelines, chlordane would be characterized as a likely carcinogen by all routes of exposure. |
72 | Chlordane (Technical) | 12789-03-6 | Undefined | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the 1996 Proposed Guidelines, chlordane would be characterized as a likely carcinogen by all routes of exposure. |
73 | Chlordecone (Kepone) | 143-50-0 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the U.S. EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), chlordecone is "likely to be carcinogenic to humans" based on data from an oral cancer bioassay in rats and mice demonstrating an increase in the incidence of hepatocellular carcinomas in both sexes of both species (NCI, 1976a, b). |
74 | Chlorine dioxide | 10049-04-4 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located. |
75 | Chlorine dioxide | 10049-04-4 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the current guidelines (U.S. EPA, 1986), chlorine dioxide is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorine dioxide cannot be determined because no satisfactory human or animal studies assessing the chronic carcinogenic potential of chlorine dioxide have been located. |
76 | Chlorite (sodium salt) | 7758-19-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the current guidelines (U.S. EPA, 1986), chlorite is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorite cannot be determined because of a lack of human data and limitations in animal studies. |
77 | Chlorite (sodium salt) | 7758-19-2 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the current guidelines (U.S. EPA, 1986), chlorite is classified as Group D; not classifiable as to human carcinogenicity because of inadequate data in humans and animals. Under the draft Carcinogen Assessment Guidelines (U.S. EPA, 1996), the human carcinogenicity of chlorite cannot be determined because of a lack of human data and limitations in animal studies. |
78 | Chlorobenzene | 108-90-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data, inadequate animal data and predominantly negative genetic toxicity data in bacterial, yeast, and mouse lymphoma cells. |
79 | 2-Chlorobutane | 78-86-4 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human carcinogenicity data and inadequate animal data. |
80 | 1-Chlorobutane | 109-69-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human carcinogenicity data and inadequate animal data. |
81 | Chlorocyclopentadiene | 41851-50-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Lack of data concerning carcinogenicity in humans or animals. |
82 | Chloroform | 67-66-3 | Undefined | Likely to be carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996; U.S. EPA, 1999), chloroform is likely to be carcinogenic to humans by all routes of exposure under high-exposure conditions that lead to cytotoxicity and regenerative hyperplasia in susceptible tissues (U.S. EPA, 1998a,b). Chloroform is not likely to be carcinogenic to humans by any route of exposure under exposure conditions that do not cause cytotoxicity and cell regeneration. This weight-of-evidence conclusion is based on: 1) observations in animals exposed by both oral and inhalation pathways which indicate that sustained or repeated cytotoxicity with secondary regenerative hyperplasia precedes, and is probably required for, hepatic and renal neoplasia; 2) there are no epidemiological data specific to chloroform and, at most, equivocal epidemiological data related to drinking water exposures that cannot necessarily be negative, although there are some scattered positive results that generally have limitations such as excessively high dose or with confounding factors. Thus, the weigh-of-evidence of the genotoxicity data on chloroform supports a conclusion that chloroform is not strongly mutagenic, and the genotoxicity is not likely to be the predominant mode of action underlying the carcinogenic potential of chloroform. Although no cancer data exist for exposures via the dermal pathway, the weight-of-evidence conclusion is considered to be applicable to this pathway as well, because chloroform absorbed through the skin and into the blood is expected to be metabolized and to cause toxicity in much the same way as chloroform absorbed by other exposure routes. |
83 | Chloroform | 67-66-3 | Undefined | Not likely to be carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996; U.S. EPA, 1999), chloroform is likely to be carcinogenic to humans by all routes of exposure under high-exposure conditions that lead to cytotoxicity and regenerative hyperplasia in susceptible tissues (U.S. EPA, 1998a,b). Chloroform is not likely to be carcinogenic to humans by any route of exposure under exposure conditions that do not cause cytotoxicity and cell regeneration. This weight-of-evidence conclusion is based on: 1) observations in animals exposed by both oral and inhalation pathways which indicate that sustained or repeated cytotoxicity with secondary regenerative hyperplasia precedes, and is probably required for, hepatic and renal neoplasia; 2) there are no epidemiological data specific to chloroform and, at most, equivocal epidemiological data related to drinking water exposures that cannot necessarily be negative, although there are some scattered positive results that generally have limitations such as excessively high dose or with confounding factors. Thus, the weigh-of-evidence of the genotoxicity data on chloroform supports a conclusion that chloroform is not strongly mutagenic, and the genotoxicity is not likely to be the predominant mode of action underlying the carcinogenic potential of chloroform. Although no cancer data exist for exposures via the dermal pathway, the weight-of-evidence conclusion is considered to be applicable to this pathway as well, because chloroform absorbed through the skin and into the blood is expected to be metabolized and to cause toxicity in much the same way as chloroform absorbed by other exposure routes. |
84 | Chloroform | 67-66-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996; U.S. EPA, 1999), chloroform is likely to be carcinogenic to humans by all routes of exposure under high-exposure conditions that lead to cytotoxicity and regenerative hyperplasia in susceptible tissues (U.S. EPA, 1998a,b). Chloroform is not likely to be carcinogenic to humans by any route of exposure under exposure conditions that do not cause cytotoxicity and cell regeneration. This weight-of-evidence conclusion is based on: 1) observations in animals exposed by both oral and inhalation pathways which indicate that sustained or repeated cytotoxicity with secondary regenerative hyperplasia precedes, and is probably required for, hepatic and renal neoplasia; 2) there are no epidemiological data specific to chloroform and, at most, equivocal epidemiological data related to drinking water exposures that cannot necessarily be negative, although there are some scattered positive results that generally have limitations such as excessively high dose or with confounding factors. Thus, the weigh-of-evidence of the genotoxicity data on chloroform supports a conclusion that chloroform is not strongly mutagenic, and the genotoxicity is not likely to be the predominant mode of action underlying the carcinogenic potential of chloroform. Although no cancer data exist for exposures via the dermal pathway, the weight-of-evidence conclusion is considered to be applicable to this pathway as well, because chloroform absorbed through the skin and into the blood is expected to be metabolized and to cause toxicity in much the same way as chloroform absorbed by other exposure routes. |
85 | Chloromethyl methyl ether (CMME) | 107-30-2 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | The observation of an increased incidence of respiratory cancer in exposed workers and the observation of respiratory tumors in mice, rats, and hamsters exposed by inhalation forms the basis for this classification. |
86 | p-Chlorophenyl methyl sulfide | 123-09-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human or animal studies found in the available literature |
87 | p-Chlorophenyl methyl sulfone | 98-57-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human or animal studies found in the available literature |
88 | p-Chlorophenyl methyl sulfoxide | 934-73-6 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human or animal studies found in the available literature |
89 | Chloroprene | 126-99-8 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is evidence that chloroprene is "likely to be carcinogenic to humans" |
90 | Chromium(III), insoluble salts | 16065-83-1 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), trivalent chromium is most appropriately designated a Group D -- Not classified as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (EPA, 1996), there are inadequate data to determine the potential carcinogenicity of trivalent chromium, as discussed below. However, the classification of hexavalent chromium as a known human carcinogen raises a concern for the carcinogenic potential of trivalent chromium. |
91 | Chromium(III), insoluble salts | 16065-83-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), trivalent chromium is most appropriately designated a Group D -- Not classified as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (EPA, 1996), there are inadequate data to determine the potential carcinogenicity of trivalent chromium, as discussed below. However, the classification of hexavalent chromium as a known human carcinogen raises a concern for the carcinogenic potential of trivalent chromium. |
92 | Chromium(VI) | 18540-29-9 | Oral | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), Cr(VI) is “likely to be carcinogenic” via oral exposure based on sufficiently supported [laboratory] animal studies relevant to humans. This assessment maintains the previous conclusion (U.S. EPA, 1998) that Cr(VI) is “carcinogenic to humans” via inhalation exposure. |
93 | Chromium(VI) | 18540-29-9 | Inhalation | Carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), Cr(VI) is “likely to be carcinogenic” via oral exposure based on sufficiently supported [laboratory] animal studies relevant to humans. This assessment maintains the previous conclusion (U.S. EPA, 1998) that Cr(VI) is “carcinogenic to humans” via inhalation exposure. |
94 | Chrysene | 218-01-9 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and sufficient data from animal bioassays. Chrysene produced carcinomas and malignant lymphoma in mice after intraperitoneal injection and skin carcinomas in mice following dermal exposure. Chrysene produced chromosomal abnormalities in hamsters and mouse germ cells after gavage exposure, positive responses in bacterial gene mutation assays and transformed mammalian cells exposed in culture. |
95 | Coke oven emissions | None | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Studies of coke oven workers have shown increased risk of mortality from cancer of the lung, trachea and bronchus; cancer of the kidney; cancer of the prostate; and cancer at all sites combined. In animals, extracts and condensates of coke oven emissions were found to be carcinogenic in both inhalation studies and skin-painting bioassays. The mutagenicity of whole extracts and condensates, as well as their individual components, provides supportive evidence for carcinogenicity. |
96 | Copper | 7440-50-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | There are no human data, inadequate animal data from assays of copper compounds, and equivocal mutagenicity data. |
97 | Creosote | 8001-58-9 | Undefined | B1 (Probable human carcinogen - based on limited evidence of carcinogenicity in humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Limited evidence of the association between occupational creosote contact and subsequent tumor formation, sufficient evidence of local and distant tumor formation after dermal application to mice, and some evidence of mutagenic activity, as well as the well-documented carcinogenicity of other coal tar products to humans. |
98 | Crotonaldehyde | 123-73-9 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and an increased incidence of hepatocellular carcinomas and hepatic neoplastic nodules (combined) in male F344 rats. The possible carcinogenicity of crotonaldehyde is supported by genotoxic activity and the expected reactivity of croton oil and aldehyde. Crotonaldehyde is also a suspected metabolite of N-nitrosopyrrolidine, a probable human carcinogen. |
99 | Cumene | 98-82-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that the carcinogenic potential of cumene cannot be determined because no adequate data, such as well-conducted long-term animal studies or reliable human epidemiological studies, are available for any assessment. |
100 | Cumene | 98-82-8 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under the proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that the carcinogenic potential of cumene cannot be determined because no adequate data, such as well-conducted long-term animal studies or reliable human epidemiological studies, are available for any assessment. |
101 | Cyanide, free | 57-12-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Pertinent data regarding carcinogenicity have not been located in the available literature. |
102 | Cyclohexane | 110-82-7 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Cyclohexane is characterized as "Data are inadequate for an assessment of human carcinogenic potential" (U.S. EPA, 1999). |
103 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Undefined | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for decabromodiphenyl ether provides suggestive evidence of carcinogenic potential. |
104 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Orally administered DEHP produced significant dose-related increases in liver tumor responses in rats and mice of both sexes. |
105 | Di(2-ethylhexyl)adipate | 103-23-1 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on an absence of human data and increased incidence of liver tumors in female mice. Except for a positive dominant lethal assay, there was no evidence of genotoxicity; this compound does, however, exhibit structural relationships to other nongenotoxic compounds classified as probable and possible human carcinogens. |
106 | Dibenz[a,h]anthracene | 53-70-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient data from animal bioassays. Dibenz[a,h]anthracene produced carcinomas in mice following oral or dermal exposure and injection site tumors in several species following subcutaneous or intramuscular administration. Dibenz[a,h]anthracene has induced DNA damage and gene mutations in bacteria as well as gene mutations and transformation in several types of mammalian cell cultures. |
107 | Dibenzofuran | 132-64-9 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and no animal data for dibenzofuran alone. |
108 | Dibromochloromethane | 124-48-1 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and limited evidence of carcinogenicity in animals; namely, positive carcinogenic evidence in B6C3Fl mice (males and females), together with positive mutagenicity data, and structural similarity to other trihalomethanes, which are known animal carcinogens. |
109 | Dibromodichloromethane | 594-18-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on the lack of data regarding the carcinogenicity of dibromodichloromethane in humans or animals. |
110 | p,p'-Dibromodiphenyl ether | 2050-47-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
111 | 1,2-Dibromoethane | 106-93-4 | Undefined | Likely to be carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), 2-dibromoethane is considered "likely to be carcinogenic to humans" based on strong evidence of carcinogenicity in animals and inconclusive evidence of carcinogenicity in an exposed human population. |
112 | Dibutyl phthalate (DBP) | 84-74-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Pertinent data regarding carcinogenicity was not located in the available literature. |
113 | Dichloroacetic acid | 79-43-6 | Undefined | Likely to be carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | EPA believes that DCA is likely to be a carcinogen in humans. |
114 | 1,2-Dichlorobenzene | 95-50-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and evidence of both negative and positive trends for carcinogenic responses in rats and mice. |
115 | 1,3-Dichlorobenzene | 541-73-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data, no animal data and limited genetic data. |
116 | 3,3'-Dichlorobenzidine | 91-94-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on statistically significantly increased tumor incidences in rats, mice and dogs. Additional support is provided by positive evidence of genotoxicity and structural relationship to the known human bladder carcinogen benzidine. |
117 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on an increased incidence of lung tumors in male and female mice, liver tumors in male mice and thyroid tumors in male rats. DDD is structurally similar to, and is a known metabolite of DDT, a probable human carcinogen. |
118 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | 72-55-9 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of liver tumors including carcinomas in two strains of mice and in hamsters and of thyroid tumors in female rats by diet. |
119 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Observation of tumors (generally of the liver) in seven studies in various mouse strains and three studies in rats. DDT is structurally similar to other probable carcinogens, such as DDD and DDE. |
120 | 1,2-Dichloroethane | 107-06-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on the induction of several tumor types in rats and mice treated by gavage and lung papillomas in mice after topical application |
121 | 1,1-Dichloroethane | 75-34-3 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and limited evidence of carcinogenicity in two animal species (rats and mice) as shown by an increased incidence of mammary gland adenocarcinomas and hemangiosarcomas in female rats and an increased incidence of hepatocellular carcinomas and benign uterine polyps in mice. |
122 | cis-1,2-Dichloroethylene | 156-59-2 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of cis-1,2-DCE. |
123 | trans-1,2-Dichloroethylene | 156-60-5 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of trans-1,2-DCE. |
124 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the 1986 cancer guidelines (U.S. EPA, 1986), 1,1-DCE is assigned to Group C, possible human carcinogen. Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes 1,1-DCE exhibits suggestive evidence of carcinogenicity but not sufficient evidence to assess human carcinogenic potential following inhalation exposure in studies in rodents. Male mice developed kidney tumors at one exposure in a lifetime bioassay, a finding tempered by the absence of similar results in female mice or male or female rats and by the enzymatic differences (i.e., CYP2E1) between male mice and female mice, male and female rats, and human kidney cells. Limited evidence of genotoxicity has been reported in bacterial systems with metabolic activation. The data for 1,1-DCE are inadequate for an assessment of human carcinogenic potential by the oral route, based on the absence of statistically or biologically significant tumors in limited bioassays in rats and mice balanced against the suggestive evidence in male mice in a single bioassay by inhalation and the limited evidence of genotoxicity. The human epidemiological results on the carcinogenicity of 1,1-DCE are too limited to draw useful conclusions. EPA concludes that the results of kidney tumors in one sex and one exposure in a single species of rodents are too limited to support an exposure-response assessment. |
125 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Inhalation | Suggestive evidence of carcinogenicity, but not sufficient to assess human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the 1986 cancer guidelines (U.S. EPA, 1986), 1,1-DCE is assigned to Group C, possible human carcinogen. Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes 1,1-DCE exhibits suggestive evidence of carcinogenicity but not sufficient evidence to assess human carcinogenic potential following inhalation exposure in studies in rodents. Male mice developed kidney tumors at one exposure in a lifetime bioassay, a finding tempered by the absence of similar results in female mice or male or female rats and by the enzymatic differences (i.e., CYP2E1) between male mice and female mice, male and female rats, and human kidney cells. Limited evidence of genotoxicity has been reported in bacterial systems with metabolic activation. The data for 1,1-DCE are inadequate for an assessment of human carcinogenic potential by the oral route, based on the absence of statistically or biologically significant tumors in limited bioassays in rats and mice balanced against the suggestive evidence in male mice in a single bioassay by inhalation and the limited evidence of genotoxicity. The human epidemiological results on the carcinogenicity of 1,1-DCE are too limited to draw useful conclusions. EPA concludes that the results of kidney tumors in one sex and one exposure in a single species of rodents are too limited to support an exposure-response assessment. |
126 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | Oral | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the 1986 cancer guidelines (U.S. EPA, 1986), 1,1-DCE is assigned to Group C, possible human carcinogen. Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes 1,1-DCE exhibits suggestive evidence of carcinogenicity but not sufficient evidence to assess human carcinogenic potential following inhalation exposure in studies in rodents. Male mice developed kidney tumors at one exposure in a lifetime bioassay, a finding tempered by the absence of similar results in female mice or male or female rats and by the enzymatic differences (i.e., CYP2E1) between male mice and female mice, male and female rats, and human kidney cells. Limited evidence of genotoxicity has been reported in bacterial systems with metabolic activation. The data for 1,1-DCE are inadequate for an assessment of human carcinogenic potential by the oral route, based on the absence of statistically or biologically significant tumors in limited bioassays in rats and mice balanced against the suggestive evidence in male mice in a single bioassay by inhalation and the limited evidence of genotoxicity. The human epidemiological results on the carcinogenicity of 1,1-DCE are too limited to draw useful conclusions. EPA concludes that the results of kidney tumors in one sex and one exposure in a single species of rodents are too limited to support an exposure-response assessment. |
127 | Dichloromethane | 75-09-2 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Following U.S. EPA (2005) Guidelines for Carcinogen Risk Assessment, dichloromethane is "likely to be carcinogenic in humans," based predominantly on evidence of carcinogenicity at two sites in 2-year bioassays in male and female B6C3F1 mice (liver and lung tumors) with inhalation exposure (NTP, 1986) and at one site in male B6C3F1 mice (liver tumors) with drinking water exposure (Serota et al., 1986b; Hazleton Laboratories, 1983). |
128 | 1,3-Dichloropropene | 542-75-6 | Undefined | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Although the available human data are inadequate, 1,3-dichloropropene is characterized as "likely" to be a human carcinogen in accordance with the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996). |
129 | 1,3-Dichloropropene | 542-75-6 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Although the available human data are inadequate, 1,3-dichloropropene is characterized as "likely" to be a human carcinogen in accordance with the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996). |
130 | Dichlorvos | 62-73-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Significant increases in forestomach tumors in female and male B6C3F1 mice and leukemias and pancreatic acinar adenomas in Fischer 344 rats. Supporting evidence included observation of tumors at other sites in the rat and observation of mutagenicity for both dichlorvos and a major metabolite dichloroacetaldehyde. A structurally related material, dichloropropene, also induces forestomach tumors in rodents. |
131 | Dieldrin | 60-57-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Dieldrin is carcinogenic in seven strains of mice when administered orally. Dieldrin is structurally related to compounds (aldrin, chlordane, heptachlor, heptachlor epoxide, and chlorendic acid) which produce tumors in rodents. |
132 | Diesel engine exhaust | None | Undefined | Likely to be carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Using U.S. EPA's revised draft 1999 Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), diesel exhaust (DE) is likely to be carcinogenic to humans by inhalation from environmental exposures. |
133 | Diethyl phthalate (DEP) | 84-66-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Pertinent data regarding carcinogenicity were not located in the available literature. |
134 | Diethyl-p-nitrophenylphosphate | 311-45-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
135 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human or animal carcinogenic studies found in the available literature. |
136 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No data from cancer bioassays or epidemiological studies are available. |
137 | Dimethipin | 55290-64-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Classification is based on an elevated combined incidence of pulmonary adenomas/carcinomas in male, but not in female, CD-1 mice. A rat study is undergoing further evaluation. |
138 | Dimethyl phthalate | 131-11-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Pertinent data regarding carcinogenicity was not located in the available literature. |
139 | Dimethyl sulfate | 77-78-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Classification is based on induction of local carcinomas following inhalation and subcutaneous exposures in rats, tumor induction in rats following prenatal exposure, and evidence suggestive of carcinogenicity in hamsters and mice by inhalation. Dimethyl sulfate alkylates cellular macromolecules and is genotoxic. |
140 | m-Dinitrobenzene | 99-65-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data in humans and animals. |
141 | o-Dinitrobenzene | 528-29-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data in humans and animals. |
142 | 2,4-/2,6-Dinitrotoluene mixture | Various | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on multiple benign and malignant tumor types at multiple sites in both sexes of rats (2 strains) and malignant renal tumors in male mice. The classification is supported by evidence of mutagenicity. |
143 | Dinoseb | 88-85-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Dinoseb was not observed to be carcinogenic in two inadequate studies in rats and in mice. In a third study, an increase in benign liver tumors in female mice was not considered to be treatment-related. The increase was much lower in the high dose than the mid dose, there were no decreases in time to tumor, nor any evidence of any of the potentially predisposing lesions in the liver such as hypertrophy, hyperplasia or degeneration which are often associated with known hepatocellular carcinogens. |
144 | 1,4-Dioxane | 123-91-1 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), 1,4-dioxane is characterized as "likely to be carcinogenic to humans." |
145 | 1,2-Diphenylhydrazine | 122-66-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Positive results of studies in both rats and mice form the basis for this classification. Two apparently negative studies lack information on compound purity, experimental design, and statistical treatment. |
146 | 1,4-Dithiane | 505-29-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data in humans and animals. |
147 | Endrin | 72-20-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Oral administration of endrin did not produce carcinogenic effects in either sex of two strains of rats and three strains of mice. An NCI bioassay was suggestive of responses in male and female rats although NCI reported a no evidence conclusion. The inadequacies of several of the bioassays call into question the strength of the reported negative findings. These inadequacies and the suggestive responses in the NCI bioassay do not support a Group E classification; rather a Group D classification best reflects the equivocal data. |
148 | Epichlorohydrin | 106-89-8 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Human data are inadequate. Multiple studies in rats and mice administered epichlorohydrin by various routes were positive. As epichlorohydrin is a strong alkylating agent, tumors are produced at the site of application. |
149 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Inhalation | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), ethyl tertiary butyl ether has “suggestive evidence of carcinogenic potential" for the inhalation route and “inadequate information to assess carcinogenic potential” for the oral route. |
150 | Ethylbenzene | 100-41-4 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Nonclassifiable due to lack of animal bioassays and human studies. |
151 | Ethylene diamine | 107-15-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate animal data. |
152 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | Undefined | Not likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), EGBE is deemed "not likely to be carcinogenic to humans" at environmental concentrations at or below the RfD and RfC, based on laboratory animal evidence, mode-of-action information, and limited human study information. |
153 | Ethylene oxide | 75-21-8 | Inhalation | Carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), ethylene oxide is "carcinogenic to humans" by the inhalation route of exposure, based on (1) strong, but less than conclusive on its own, epidemiological evidence of lymphohematopoietic cancers and breast cancer in EtO exposed workers, (2) extensive evidence of carcinogenicity in laboratory animals, including lymphohematopoietic cancers in rats and mice and mammary carcinomas in mice following inhalation exposure, (3) clear evidence that EtO is genotoxic and sufficient weight of evidence to support a mutagenic mode of action for EtO carcinogenicity, and (4) strong evidence that the key precursor events are anticipated to occur in humans and progress to tumors, including evidence of chromosome damage in humans exposed to EtO. |
154 | Fluoranthene | 206-44-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
155 | Fluorene | 86-73-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
156 | Folpet | 133-07-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Folpet has induced carcinoma and adenoma of the duodenum (an unusual site) in both sexes of both CD-1 and B6C3F1 mice. Folpet is also mutagenic in several in vitro assays and is a structural analogue of captan, which has been shown to induce carcinoma in the duodenum of two mouse strains. |
157 | Fomesafen | 72178-02-0 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Fomesafen produced liver adenomas and carcinomas in both sexes of Charles River CD-1 mice. |
158 | Formaldehyde | 50-00-0 | Inhalation | Carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), formaldehyde is “carcinogenic to humans by the inhalation route of exposure”. This conclusion is independently supported by three sets of evidence, namely evidence integration (aka “weight of evidence”) judgments that the evidence demonstrates that formaldehyde inhalation causes nasopharyngeal cancer, sinonasal cancer, and myeloid leukemia, in exposed humans (see the IRIS Toxicological Review for details on the human, animal, and/or mechanistic evidence that supports each of these three judgments). |
159 | Fosetyl-al | 39148-24-8 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of urinary bladder tumors (adenomas/carcinomas combined) in male rats. No increase in tumor incidence occurred in female rats or in mice of either sex. |
160 | Furmecyclox | 60568-05-0 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Dose-related increased incidence of neoplastic nodules, carcinomas and combined neoplasic nodules/carcinomas in the liver of female rats and increased incidence of liver nodules and carcinomas and urothelial tumors of the bladder in male rats. |
161 | Glycidaldehyde | 765-34-4 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and an increased incidence of malignant tumors in rats and mice following subcutaneous injection of glycidaldehyde and of skin carcinomas following dermal application to mice. Glycidaldehyde shows mutagenic activity in many assay systems and is known to be highly reactive because of the epoxide and the aldehyde groups. A number of structurally related epoxide compounds are also carcinogenic in experimental animals, including the analogues glycidol and propylene oxide. |
162 | Glyphosate | 1071-83-6 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Inadequate evidence for oncogenicity in animals. Glyphosate was originally classified as C, possible human carcinogen, on the basis of increased incidence of renal tumors in mice. Following independent review of the slides the classification was changed to D on the basis of a lack of statistical significance and uncertainty as to a treatment-related effect. |
163 | Heptachlor | 76-44-8 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Inadequate human data, but sufficient evidence exist from studies in which benign and malignant liver tumors were induced in three strains of mice of both sexes. Several structurally related compounds are liver carcinogens. |
164 | Heptachlor epoxide | 1024-57-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Sufficient evidence exists from rodent studies in which liver carcinomas were induced in two strains of mice of both sexes and in CFN female rats. Several structurally related compounds are liver carcinogens. |
165 | n-Heptane | 142-82-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
166 | Hexabromodiphenyl ether | 36483-60-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
167 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4',5,5'-hexabromodiphenyl ether. |
168 | Hexachlorobenzene | 118-74-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Hexachlorobenzene, when administered orally, has been shown to induce tumors in the liver, thyroid and kidney in three rodent species. |
169 | Hexachlorobutadiene | 87-68-3 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Observation of renal neoplasms in male and female rats in one study. |
170 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Dietary alpha-HCH has been shown to cause increased incidence of liver tumors in five mouse strains and in Wistar rats. |
171 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increases in benign liver tumors in CF1 mice fed beta-HCH |
172 | delta-Hexachlorocyclohexane (delta-HCH) | 319-86-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
173 | epsilon-Hexachlorocyclohexane (epsilon-HC) | 6108-10-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
174 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Assays in four strains of mice have yielded positive carcinogenicity results for t-HCH administered in the diet. |
175 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Undefined | Not likely to be carcinogenic to humans | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | According to the existing Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986a), evaluation of the weight-of-evidence for carcinogenicity to humans indicates that HCCPD is most appropriately categorized as Group E, Evidence of Noncarcinogenicity to Humans, via inhalation exposure. In accordance with U.S. EPA's Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), HCCPD is not likely to be a human carcinogen by the inhalation route based on current data indicating no evidence of cancer in well-conducted bioassays in two species of rodents; the absence of increased deaths from cancer in the limited human occupational studies available; and lack of mutagenicity in a variety of test systems. |
176 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | Undefined | E (Evidence of non-carcinogenicity for humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | According to the existing Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986a), evaluation of the weight-of-evidence for carcinogenicity to humans indicates that HCCPD is most appropriately categorized as Group E, Evidence of Noncarcinogenicity to Humans, via inhalation exposure. In accordance with U.S. EPA's Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), HCCPD is not likely to be a human carcinogen by the inhalation route based on current data indicating no evidence of cancer in well-conducted bioassays in two species of rodents; the absence of increased deaths from cancer in the limited human occupational studies available; and lack of mutagenicity in a variety of test systems. |
177 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Hepatic tumors in mice and rats by gavage |
178 | Hexachloroethane | 67-72-1 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the U.S. EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005b), HCE is "likely to be carcinogenic to humans" based on evidence of multiple tumor types in both sexes of rats and mice (NTP, 1989 NCI, 1978). |
179 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | None | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is suggestive evidence of carcinogenic potential for RDX based on evidence of benign and malignant tumors in the liver and lungs of B6C3F1 mice or F344 rats. |
180 | n-Hexane | 110-54-3 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the emGuidelines for Carcinogen Risk Assessment/em (U.S. EPA, 2005b), there is eminadequate information to assess the carcinogenic potential of n-hexane./em |
181 | 2-Hexanone | 591-78-6 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for 2-hexanone is "inadequate to assess human carcinogenic potential." |
182 | Hydrazine/Hydrazine sulfate | 302-01-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Tumors have been induced in mice, rats and hamsters following oral, inhalation or intraperitoneal administration of hydrazine and sulfate. Hydrazine is mutagenic in numerous assays. |
183 | Hydrogen Cyanide and Cyanide Salts | Various | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the U.S. EPA (2005a) Guidelines for Carcinogen Risk Assessment, there is "inadequate information to assess the carcinogenic potential" of cyanide. |
184 | Hydrogen sulfide | 7783-06-4 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), data are inadequate for an assessment of the carcinogenic potential of hydrogen sulfide. |
185 | Indeno[1,2,3-cd]pyrene | 193-39-5 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient data from animal bioassays. Indeno[1,2,3-cd]pyrene produced tumors in mice following lung implants, subcutaneous injection and dermal exposure. Indeno[1,2,3-cd]pyrene tested positive in bacterial gene mutation assays. |
186 | Isophorone | 78-59-1 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data in humans; limited evidence of carcinogenicity of one tumor type in one sex of one animal species as shown by an increase of preputial gland carcinomas in male rats. The apparent renal tubular cell tumor in the male rat is associated with alpha-2u-globulin, considered to be of questionable relevance to humans. |
187 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data in humans and animals. |
188 | Isoxaben | 82558-50-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on a statistically significant increased incidence of benign liver tumors in one species. |
189 | Lead and compounds (inorganic) | 7439-92-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Sufficient animal evidence. Ten rat bioassays and one mouse assay have shown statistically significant increases in renal tumors with dietary and subcutaneous exposure to several soluble lead salts. Animal assays provide reproducible results in several laboratories, in multiple rat strains with some evidence of multiple tumor sites. Short term studies show that lead affects gene expression. Human evidence is inadequate. |
190 | Libby Amphibole Asbestos | 1318-09-8 | Inhalation | Carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the EPA Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), Libby Amphibole asbestos (LAA) is "carcinogenic to humans" following inhalation exposure based on epidemiologic evidence that shows a convincing association between exposure to LAA fibers and increased lung cancer and mesothelioma mortality. |
191 | Linuron | 330-55-2 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Limited evidence indicated linuron produced increases in both testicular hyperplasia and adenomas in male rats in three separate studies. Hepatocellular adenomas were observed in female mice in a single study at the highest dose group tested; the tumors were benign and showed no progression toward malignancy. |
192 | Manganese | 7439-96-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Existing studies are inadequate to assess the carcinogenicity of manganese. |
193 | Mercuric chloride (HgCl2) | 7487-94-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on the absence of data in humans and limited evidence of carcinogenicity in rats and mice. Focal papillary hyperplasia and squamous cell papillomas in the forestomach as well as thyroid follicular cell adenomas and carcinomas were observed in male rats gavaged with mercuric chloride for 2 years. The relevance of the forestomach papillomas to assessment of cancer in humans is questionable because no evidence indicated that the papillomas progressed to malignancy. The relevance of the increase in thyroid tumors has also been questioned because these tumors are generally considered to be secondary to hyperplasia; this effect was not observed in the high-dose males. It should also be noted that the authors considered the doses used in the study to exceed the MTD for male rats. In the same study, evidence for increases in squamous cell papillomas in the forestomach of female rats was equivocal. In a second study, equivocal evidence for renal adenomas and adenocarcinomas was observed in male mice; there was a significant positive trend. This tumor type is rare in mice, and the increase in incidence was statistically significant when compared with historic controls. Two other nonpositive lifetime rodent studies were considered inadequate. Mercuric chloride showed mixed results in a number of genotoxicity assays. |
194 | Mercury, elemental | 7439-97-6 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human and animal data. Epidemiologic studies failed to show a correlation between exposure to elemental mercury vapor and carcinogenicity; the findings in these studies were confounded by possible or known concurrent exposures to other chemicals, including human carcinogens, as well as lifestyle factors (e.g., smoking). Findings from genotoxicity tests are severely limited and provide equivocal evidence that mercury adversely affects the number or structure of chromosomes in human somatic cells. |
195 | Methidathion | 950-37-8 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of liver adenomas, carcinomas, and combined adenomas and carcinomas in male mice. There was no shortening of time to tumor. Short-term tests and structure/activity study were not supportive of a higher classification. |
196 | Methoxychlor | 72-43-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Human data are unavailable, and animal evidence is inconclusive. |
197 | Methyl acrylate | 96-33-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate evidence of carcinogenicity in animals and no human data. |
198 | Methyl chloride | 74-87-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), methyl chloride is most appropriately designated a Group D - Not classifiable as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the available data suggest that methyl chloride would be classified as an agent whose carcinogenic potential cannot be determined. |
199 | Methyl chloride | 74-87-3 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Applying the criteria for evaluating the overall weight-of-evidence for carcinogenicity to humans outlined in EPA's guidelines for carcinogen risk assessment (U.S. EPA, 1986), methyl chloride is most appropriately designated a Group D - Not classifiable as to its human carcinogenicity. Using the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), the available data suggest that methyl chloride would be classified as an agent whose carcinogenic potential cannot be determined. |
200 | Methyl ethyl ketone (MEK) | 78-93-3 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes the data are inadequate for an assessment of human carcinogenic potential of MEK. Studies of humans chronically exposed to MEK are inconclusive, and MEK has not been tested for carcinogenicity in animals by the oral or inhalation routes. |
201 | Methyl isobutyl ketone (MIBK) | 108-10-1 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the draft revised cancer guidelines (U.S. EPA, 1999), the data for MIBK are inadequate for an assessment of human carcinogenic potential. No data were located regarding the existence of an association between cancer and MIBK exposure in humans, but studies of the in vivo and in vitro genotoxicity of MIBK overwhelmingly provided negative responses. |
202 | Methyl methacrylate | 80-62-6 | Undefined | Not likely to be carcinogenic to humans | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, MMA would be classified as evidence of non-carcinogenicity for humans or a Group E chemical. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), MMA is considered not likely to be carcinogenic to humans by any route of exposure because it has been evaluated in four well-conducted chronic inhalation studies in three appropriate animal species without demonstrating carcinogenic effects. |
203 | Methyl methacrylate | 80-62-6 | Undefined | E (Evidence of non-carcinogenicity for humans) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under EPA's 1986 Guidelines for Carcinogen Risk Assessment, MMA would be classified as evidence of non-carcinogenicity for humans or a Group E chemical. Under the Proposed Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 1996), MMA is considered not likely to be carcinogenic to humans by any route of exposure because it has been evaluated in four well-conducted chronic inhalation studies in three appropriate animal species without demonstrating carcinogenic effects. |
204 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under U.S. EPA's 1996 Proposed Guidelines for Carcinogen Risk Assessment, the carcinogenic potential of MDI/PMDI would be characterized as "cannot be determined," but for which there is suggestive evidence that raises concern for carcinogenic effects. |
205 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Under U.S. EPA's 1996 Proposed Guidelines for Carcinogen Risk Assessment, the carcinogenic potential of MDI/PMDI would be characterized as "cannot be determined," but for which there is suggestive evidence that raises concern for carcinogenic effects. |
206 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Sufficient evidence from animal experiments: thyroid tumors in male and female rats, and liver carcinoma/adenoma in the female mice with a significant positive trend in male mice. There is evidence of mutagenic activity. There are no human data. |
207 | Methylmercury (MeHg) | 22967-92-6 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate data in humans and limited evidence of carcinogenicity in animals. Male ICR and B6C3F1 mice exposed to methylmercuric chloride in the diet had an increased incidence of renal adenomas, adenocarcinomas and carcinomas. The tumors were observed at a single site and in a single species and single sex. The renal epithelial cell hyperplasia and tumors were observed only in the presence of profound nephrotoxicity and were suggested to be a consequence of reparative changes in the cells. Several nonpositive cancer bioassays were also reported. Although genotoxicity test data suggest that methylmercury is capable of producing chromosomal and nuclear damage, there are also nonpositive genotoxicity data. |
208 | 2-Methylnaphthalene | 91-57-6 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the draft revised guidelines for carcinogen risk assessment (U.S. EPA, 1999), EPA concludes the data are inadequate for an assessment of human carcinogenic potential of 2-methylnaphthalene. Based on the absence of data concerning the carcinogenic potential of 2-methylnaphthalene in humans and limited equivocal evidence in animals. |
209 | 3-Methylphenol | 108-39-4 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on an increased incidence of skin papillomas in mice in an initiation-promotion study. The three cresol isomers produced positive results in genetic toxicity studies both alone and in combination. |
210 | 4-Methylphenol | 106-44-5 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on an increased incidence of skin papillomas in mice in an initiation-promotion study. The three cresol isomers produced positive results in genetic toxicity studies both alone and in combination. |
211 | 2-Methylphenol | 95-48-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on an increased incidence of skin papillomas in mice in an initiation-promotion study. The three cresol isomers produced positive results in genetic toxicity studies both alone and in combination. |
212 | Metolachlor | 51218-45-2 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Classification is based on the appearance of proliferative liver lesions (combined neoplastic nodules and carcinomas) at highest dose tested (3000 ppm) in female rats. |
213 | Metribuzin | 21087-64-9 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and inadequate evidence ffom animal bioassays. Metribuzin did not increase the incidence of tumors in a lifetime dietary study using CD-1 mice when compared with both concurrent and historic controls. In a 2-year feeding study in Wistar rats, no significant differences in neoplastic findings between the test and control groups were found. Short-term studies in bacteria and mammalian systems suggest that metribuzin is not mutagenic. |
214 | Monochloramine | 10599-90-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and equivocal evidence of carcinogenicity from animal bioassays. A 2-year bioassay showed a marginal increase in mononuclear cell leukemia in female F344/N rats. No evidence of carcinogenic activity was reported in male rats or in male or female B6C3F1 mice. Genotoxicity studies, both in vitro and in vivo, gave negative results. |
215 | Naphthalene | 91-20-3 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Using criteria of the 1986 Guidelines for Carcinogen Risk Assessment, naphthalene is classified in Group C, a possible human carcinogen. This is based on the inadequate data of carcinogenicity in humans exposed to naphthalene via the oral and inhalation routes, and the limited evidence of carcinogenicity in animals via the inhalation route. Using the 1996 Proposed Guidelines for Carcinogen Risk Assessment, the human carcinogenic potential of naphthalene via the oral or inhalation routes "cannot be determined" at this time based on human and animal data; however, there is suggestive evidence (observations of benign respiratory tumors and one carcinoma in female mice only exposed to naphthalene by inhalation [NTP, 1992a]). Additional support includes increase in respiratory tumors associated with exposure to 1-methylnaphthalene. |
216 | Naphthalene | 91-20-3 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Using criteria of the 1986 Guidelines for Carcinogen Risk Assessment, naphthalene is classified in Group C, a possible human carcinogen. This is based on the inadequate data of carcinogenicity in humans exposed to naphthalene via the oral and inhalation routes, and the limited evidence of carcinogenicity in animals via the inhalation route. Using the 1996 Proposed Guidelines for Carcinogen Risk Assessment, the human carcinogenic potential of naphthalene via the oral or inhalation routes "cannot be determined" at this time based on human and animal data; however, there is suggestive evidence (observations of benign respiratory tumors and one carcinoma in female mice only exposed to naphthalene by inhalation [NTP, 1992a]). Additional support includes increase in respiratory tumors associated with exposure to 1-methylnaphthalene. |
217 | Nickel carbonyl | 13463-39-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based upon the observation of pulmonary carcinomas and malignant tumors at various sites in rats administered nickel carbonyl by inhalation and intravenous injection, respectively. Nickel administered as nickel carbonyl binds to DNA. |
218 | Nickel refinery dust | None | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Human data in which exposure to nickel refinery dust caused lung and nasal tumors in sulfide nickel matte refinery workers in several epidemiologic studies in different countries, and on animal data in which carcinomas were produced in rats by inhalation and injection. |
219 | Nickel subsulfide | 12035-72-2 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased risks of lung and nasal cancer in humans exposed to nickel refinery dust, most of which was believed to have been nickel subsulfide; increased tumor incidences in animals by several routes of administration in several animal species and strains; and positive results in genotoxicity assays form the basis for this classification. |
220 | Nitrobenzene | 98-95-3 | Combined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), nitrobenzene is classified as "likely to be carcinogenic to humans" by any route of exposure. |
221 | Nitroguanidine | 556-88-7 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Pertinent data regarding carcinogenicity have not been located in the available literature. |
222 | N-Nitroso-N-methylethylamine | 10595-95-6 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of tumors of the liver and other sites in two rat strains |
223 | N-Nitroso-di-n-butylamine | 924-16-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidences of several tumor types in rats, mice, and hamsters exposed by various routes. |
224 | N-Nitrosodi-N-propylamine | 621-64-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased tumor incidence at multiple sites in two rodent species and in monkeys administered the compound by various routes |
225 | N-Nitrosodiethanolamine | 1116-54-7 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of liver tumors and tumors at other sites in three strains of rats and in hamsters |
226 | N-Nitrosodiethylamine | 55-18-5 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Induction of tumors at multiple sites in both rodent and nonrodent species exposed by various routes. |
227 | N-Nitrosodimethylamine | 62-75-9 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Induction of tumors at multiple sites in both rodents and nonrodent mammals exposed by various routes. |
228 | N-Nitrosodiphenylamine | 86-30-6 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of bladder tumors in male and female rats and reticulum cell sarcomas in mice, and structural relationship to carcinogenic nitrosamines |
229 | N-Nitrosopyrrolidine | 930-55-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Tumors at more than one site have been observed in two rodent species administered nitrosopyrrolidine orally. |
230 | Nonabromodiphenyl ether | 63936-56-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
231 | Octabromodiphenyl ether | 32536-52-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
232 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No cancer bioassays or epidemiological studies are available. |
233 | Oryzalin | 19044-88-3 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Oryzalin produced tumors (generally benign) at multiple sites in male and female rats. It is structurally related to 2,4-diaminoanisole sulfate which causes malignant tumors at similar sites. |
234 | Paraquat | 1910-42-5 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Paraquat produced squamous cell carcinoma, an uncommon tumor, in the head region in both sexes of Fischer 344 rats. |
235 | Parathion | 56-38-2 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased adrenal cortical tumors in female and male Osborne-Mendel rats and positive trends for thyroid follicular adenomas and pancreatic islet-cell carcinomas in male rats in one study. |
236 | Pentabromodiphenyl ether | 32534-81-9 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and animal data available. |
237 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4',5-pentabromodiphenyl ether (BDE-99). |
238 | Pentachlorobenzene | 608-93-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
239 | Pentachlorocyclopentadiene | 25329-35-5 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Lack of data concerning carcinogenicity to humans or animals. |
240 | Pentachlorophenol | 87-86-5 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), PCP is "likely to be carcinogenic to humans." |
241 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | Undefined | Not likely to be carcinogenic to humans | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under U.S. EPAs 1999 Draft Revised Guidelines for Carcinogen Risk Assessment, perchlorate is not likely to pose a risk of thyroid cancer in humans, at least at doses below those necessary to alter thyroid hormone homeostasis, based on the hormonally-mediated mode of action in rodent studies and species differences in thyroid function. |
242 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | Oral | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | None |
243 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | Combined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | None |
244 | Phenanthrene | 85-01-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from a single gavage study in rats and skin painting and injection studies in mice. |
245 | Phenol | 108-95-2 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the data regarding the carcinogenicity of phenol via the oral, inhalation, and dermal exposure routes are inadequate for an assessment of human carcinogenic potential. Phenol was negative in oral carcinogenicity studies in rats and mice, but questions remain regarding increased leukemia in male rats in the bioassay as well as the positive gene mutation data and the positive results in dermal initiation/promotion studies at doses at or above the maximum tolerated dose (MTD). No inhalation studies of an appropriate duration exist. Therefore, no quantitative assessment of carcinogenic potential via any route is possible. |
246 | Phenol | 108-95-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), the data regarding the carcinogenicity of phenol via the oral, inhalation, and dermal exposure routes are inadequate for an assessment of human carcinogenic potential. Phenol was negative in oral carcinogenicity studies in rats and mice, but questions remain regarding increased leukemia in male rats in the bioassay as well as the positive gene mutation data and the positive results in dermal initiation/promotion studies at doses at or above the maximum tolerated dose (MTD). No inhalation studies of an appropriate duration exist. Therefore, no quantitative assessment of carcinogenic potential via any route is possible. |
247 | Phosgene | 75-44-5 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005b), there is inadequate information to assess carcinogenic potential of phosgene. A single epidemiology study was not considered adequate for evaluating carcinogenic potential in humans, and no animal cancer bioassays of phosgene have been conducted. |
248 | Phosphine | 7803-51-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate data in animals and no tumor data in humans. While phospine has not been associated with cancer in humans, there is some evidence of chromosomal damage (transient chromatid deletions, gaps and breaks, persistent chromosomal translocations). A relationship between these genetic effects and the development of cancer in humans is sometimes postulated. |
249 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | A 1996 study found liver tumors in female rats exposed to Aroclors 1260, 1254, 1242, and 1016, and in male rats exposed to 1260. These mixtures contain overlapping groups of congeners that, together, span the range of congeners most often found in environmental mixtures. Earlier studies found high, statistically significant incidences of liver tumors in rats ingesting Aroclor 1260 or Clophen A 60 (Kimbrough et al., 1975 Norback and Weltman, 1985 Schaeffer et al., 1984). Mechanistic studies are beginning to identify several congeners that have dioxin-like activity and may promote tumors by different modes of action. PCBs are absorbed through ingestion, inhalation, and dermal exposure, after which they are transported similarly through the circulation. This provides a reasonable basis for expecting similar internal effects from different routes of environmental exposure. Information on relative absorption rates suggests that differences in toxicity across exposure routes are small. The human studies are being updated currently available evidence is inadequate, but suggestive. |
250 | Prochloraz | 67747-09-5 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Statistically significantly increased incidence and dose-related trend in liver adenomas and carcinomas (combined) in both sexes of one strain of mouse. |
251 | Propionaldehyde | 123-38-6 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" for propionaldehyde. |
252 | Propylene oxide | 75-56-9 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and an increased incidence of benign and malignant tumors at the site of exposure in two species of animals, when exposed by subcutaneous injection, by inhalation, and by gavage. There was also evidence of mutagenicity in a variety of test systems. Propylene oxide is structurally similar to other chemicals that demonstrate carcinogenic activity in animals. |
253 | Pyrene | 129-00-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and inadequate data from animal bioassays. |
254 | Quinoline | 91-22-5 | Undefined | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | Quinoline is considered likely to be carcinogenic in humans in accordance with proposed EPA carcinogen risk assessment guidelines (U.S. EPA, 1996) on the basis of observations of exposure-related increased incidence of an unusual malignant tumor in multiple strains of rats and mice, multiple experiments using oral, i.p. and s.c. dosing at an early age. This determination is supported by studies that demonstrate that quinoline is genotoxic. |
255 | Quinoline | 91-22-5 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Quinoline is considered likely to be carcinogenic in humans in accordance with proposed EPA carcinogen risk assessment guidelines (U.S. EPA, 1996) on the basis of observations of exposure-related increased incidence of an unusual malignant tumor in multiple strains of rats and mice, multiple experiments using oral, i.p. and s.c. dosing at an early age. This determination is supported by studies that demonstrate that quinoline is genotoxic. |
256 | Refractory ceramic fibers | None | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and sufficient evidence from animal studies. Chronic inhalation studies showed that several types of RCFs induced mesotheliomas and lung tumors in rats and hamsters. Administration of RCFs by intraperitoneal/intrapleural injection or intratracheal instillation also caused peritoneal/pleural mesotheliomas or lung tumors in rats and hamsters. |
257 | Selenious acid | 7783-00-8 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and inadequate evidence of carcinogenicity in animals. The evidence for various selenium compounds in animal and mutagenicity studies is conflicting and difficult to interpret; however, evidence for selenium sulfide is sufficient for a B2 (probable human carcinogen) classification. |
258 | Selenium and Compounds | 7782-49-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate human data and inadequate evidence of carcinogenicity in animals. The evidence for various selenium compounds in animal and mutagenicity studies is conflicting and difficult to interpret; however, evidence for selenium sulfide is sufficient for a B2 (probable human carcinogen) classification. |
259 | Selenium sulfide | 7446-34-6 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on inadequate data from human studies and sufficient evidence in animals. When administered orally, selenium sulfide produced hepatocellular carcinomas in both sexes of F344 rats and female B6C3F1 mice and alveolar/bronchiolar carcinomas or adenomas in female B6C3F1 mice. |
260 | Silver | 7440-22-4 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | In animals, local sarcomas have been induced after implantation of foils and discs of silver. However, the interpretation of these findings has been questioned due to the phenomenon of solid-state carcinogenesis in which even insoluble solids such as plastic have been shown to result in local fibrosarcomas. |
261 | Tetrabromodiphenyl ether | 40088-47-9 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
262 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of 2,2',4,4'-tetrabromodiphenyl ether (BDE-47). |
263 | Tetrachlorocyclopentadiene | 695-77-2 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Lack of data concerning carcinogenicity in humans or animals. |
264 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a) 1,1,2,2-tetrachloroethane is "likely to be carcinogenic to humans." |
265 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Increased incidence of combined hepatocellular adenomas and carcinomas in female mice; inadequate evidence from human studies. |
266 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Following EPA (2005a) Guidelines for Carcinogen Risk Assessment, tetrachloroethylene is "likely to be carcinogenic in humans by all routes of exposure." |
267 | Tetrahydrofuran | 109-99-9 | Undefined | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for THF provides "suggestive evidence of carcinogenic potential." |
268 | Thallium (I), soluble salts | Various | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
269 | Thallium acetate | 563-68-8 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
270 | Thallium carbonate | 6533-73-9 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
271 | Thallium chloride | 7791-12-0 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
272 | Thallium nitrate | 10102-45-1 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
273 | Thallium oxide | 1314-32-5 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
274 | Thallium selenite | 12039-52-0 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
275 | Thallium(I) sulfate | 7446-18-6 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for thallium and compounds provides "inadequate information to assess carcinogenic potential." |
276 | Toluene | 108-88-3 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess the carcinogenic potential of toluene because studies of humans chronically exposed to toluene are inconclusive, toluene was not carcinogenic in adequate inhalation cancer bioassays of rats and mice exposed for life (CIIT, 1980 NTP, 1990 Huff, 2003), and increased incidences of mammary cancer and leukemia were reported in a lifetime rat oral bioassay at a dose level of 500 mg/kg-day but not at 800 mg/kg-day (Maltoni et al., 1997). |
277 | Toxaphene | 8001-35-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | The classification is based on increased incidence of hepatocellular tumors in mice and thyroid tumors in rats and is supported by mutagenicity in Salmonella. |
278 | Tribromochloromethane | 594-15-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human or animal cancer data. |
279 | Tribromodiphenyl ether | 49690-94-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | No human data and no animal data available. |
280 | Tributyltin oxide (TBTO) | 56-35-9 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | There are no data in humans concerning development of cancer following exposure to tributyltin oxide (TBTO). Cancer bioassays following oral exposure have been conducted in rats and mice. Because of the questionable data from the bioassay in rats, EPA assigns TBTO to the "cannot be determined" category [U.S. EPA, 1996 (proposed)]. |
281 | Tributyltin oxide (TBTO) | 56-35-9 | Undefined | Carcinogenic potential cannot be determined | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | There are no data in humans concerning development of cancer following exposure to tributyltin oxide (TBTO). Cancer bioassays following oral exposure have been conducted in rats and mice. Because of the questionable data from the bioassay in rats, EPA assigns TBTO to the "cannot be determined" category [U.S. EPA, 1996 (proposed)]. |
282 | Trichloroacetic acid | 76-03-9 | Undefined | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (Cancer Guidelines) (U.S. EPA, 2005a), there is suggestive evidence of carcinogenic potential for TCA based on significantly increased incidences of liver tumors in male B6C3F1 mice exposed via drinking water for 52–104 weeks (DeAngelo et al., 2008 Bull et al., 2002, 1990 Herren-Freund et al., 1987) and female B6C3F1 mice exposed for 51 or 82 weeks (Pereira, 1996), and lack of treatment-related tumors in a study of male F344/N rats following lifetime exposure in drinking water (DeAngelo et al., 1997). |
283 | 1,2,4-Trichlorobenzene | 120-82-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | A dermal exposure study in mice was found inadequate for drawing conclusions as to carcinogenicity in humans. |
284 | Trichlorocyclopentadiene | 77323-84-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Lack of data concerning carcinogenicity in humans or animals. |
285 | 1,1,2-Trichloroethane | 79-00-5 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Hepatocellular carcinomas and pheochromocytomas in one strain of mice forms the basis for this classification. Carcinogenicity was not shown in rats. 1,1,2-Trichloroethane is structurally related to 1,2-dichloroethane, a probable human carcinogen. |
286 | 1,1,1-Trichloroethane | 71-55-6 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), the database for 1,1,1-trichloroethane provides "inadequate information to assess carcinogenic potential." |
287 | Trichloroethylene | 79-01-6 | Undefined | Carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Following U.S. EPA (2005b) Guidelines for Carcinogen Risk Assessment, TCE is characterized as "carcinogenic to humans" by all routes of exposure. |
288 | 2,4,6-Trichlorophenol | 88-06-2 | Undefined | B2 (Probable human carcinogen - based on sufficient evidence of carcinogenicity in animals) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human data and sufficient evidence in animals; namely, increased incidence of lymphomas or leukemias in male rats and hepatocellular adenomas or carcinomas in male and female mice. |
289 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Human data are not available and the available animal cancer bioassay studies are considered to be inadequate. |
290 | 1,2,3-Trichloropropane | 96-18-4 | Undefined | Likely to be carcinogenic to humans | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogenic Risk Assessment (U.S. EPA, 2005), 1,2,3-trichloropropane is "likely to be carcinogenic to humans", based on a statistically significant and dose-related increase in the formation of multiple tumors in both sexes of two species from an NTP (1993) chronic oral bioassay. |
291 | Trifluralin | 1582-09-8 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Classification is based on the induction of urinary tract tumors (renal pelvis carcinomas and urinary bladder papillomas) and thyroid tumors (adenomas/carcinomas combined) in one animal species (F344 rats) in one study. Trifluralin is structurally similar to ethalfluralin, a carcinogen in the rat. |
292 | 1,3,5-Trimethylbenzene | 108-67-8 | None | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA 2005), there is “inadequate information to assess carcinogenic potential” of TMBs. This characterization is based on the fact that there is no information regarding the carcinogenicity of TMBs in humans and that the only animal study available on the carcinogenicity of 1,2,4‑TMB observed no statistically significant carcinogenic effects. No studies regarding the carcinogenicity of 1,2,3‑TMB or 1,3,5‑TMB were identified in the available scientific literature. |
293 | 1,2,4-Trimethylbenzene | 95-63-6 | None | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA 2005), there is “inadequate information to assess carcinogenic potential” of TMBs. This characterization is based on the fact that there is no information regarding the carcinogenicity of TMBs in humans and that the only animal study available on the carcinogenicity of 1,2,4‑TMB observed no statistically significant carcinogenic effects. No studies regarding the carcinogenicity of 1,2,3‑TMB or 1,3,5‑TMB were identified in the available scientific literature. |
294 | 1,2,3-Trimethylbenzene | 526-73-8 | None | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA 2005), there is “inadequate information to assess carcinogenic potential” of TMBs. This characterization is based on the fact that there is no information regarding the carcinogenicity of TMBs in humans and that the only animal study available on the carcinogenicity of 1,2,4‑TMB observed no statistically significant carcinogenic effects. No studies regarding the carcinogenicity of 1,2,3‑TMB or 1,3,5‑TMB were identified in the available scientific literature. |
295 | 2,2,4-Trimethylpentane | 540-84-1 | Oral | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | In accordance with the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is inadequate information to assess carcinogenic potential for 2,2,4-trimethylpentane. |
296 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Undefined | C (Possible human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Evidence of human carcinogenicity is inadequate. Urinary bladder papilloma and carcinoma were observed in female Fischer 344 rats. Mutagenic activity was observed in Salmonella with and without metabolic activation. |
297 | Urea | 57-13-6 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005a), there is "inadequate information to assess the carcinogenic potential" of urea. |
298 | Vinyl chloride | 75-01-4 | Undefined | Known/likely human carcinogen | Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996) | On the basis of sufficient evidence for carcinogenicity in human epidemiology studies, VC is considered to best fit the weight-of-evidence Category "A," according to current EPA Risk Assessment Guidelines (U.S. EPA, 1986). Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that VC is a known human carcinogen by the inhalation route of exposure, based on human epidemiological data, and by analogy the oral route because of positive animal bioassay data as well as pharmacokinetic data allowing dose extrapolation across routes. VC is also considered highly likely to be carcinogenic by the dermal route because it is well absorbed and acts systemically. |
299 | Vinyl chloride | 75-01-4 | Undefined | A (Human carcinogen) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | On the basis of sufficient evidence for carcinogenicity in human epidemiology studies, VC is considered to best fit the weight-of-evidence Category "A," according to current EPA Risk Assessment Guidelines (U.S. EPA, 1986). Under the Proposed Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1996), it is concluded that VC is a known human carcinogen by the inhalation route of exposure, based on human epidemiological data, and by analogy the oral route because of positive animal bioassay data as well as pharmacokinetic data allowing dose extrapolation across routes. VC is also considered highly likely to be carcinogenic by the dermal route because it is well absorbed and acts systemically. |
300 | White phosphorus | 7723-14-0 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no data in humans or animals. |
301 | Xylenes | 1330-20-7 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Draft Revised Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999), data are inadequate for an assessment of the carcinogenic potential of xylenes. Adequate human data on the carcinogenicity of xylenes are not available, and the available animal data are inconclusive as to the ability of xylenes to cause a carcinogenic response. Evaluations of the genotoxic effects of xylenes have consistently given negative results. |
302 | Zinc and Compounds | 7440-66-6 | Undefined | Inadequate information to assess carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal. |
303 | Zinc and Compounds | 7440-66-6 | Undefined | Data are inadequate for an assessment of human carcinogenic potential | Revised Draft Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1999) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal. |
304 | Zinc and Compounds | 7440-66-6 | Undefined | Not applicable. This substance was not assessed using the 1986 cancer guidelines (U.S. EPA, 1986). | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal. |
305 | Zinc and Compounds | 7440-66-6 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Under the Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), there is inadequate information to assess carcinogenic potential of zinc, because studies of humans occupationally-exposed to zinc are inadequate or inconclusive, adequate animal bioassays of the possible carcinogenicity of zinc are not available, and results of genotoxic tests of zinc have been equivocal. |
306 | n-Butanol | 71-36-3 | Undefined | D (Not classifiable as to human carcinogenicity) | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 1986) | Based on no human and no animal cancer data. |
307 | tert-Butyl Alcohol (tBA) | 75-65-0 | None | Suggestive evidence of carcinogenic potential | Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005) | Under EPA’s Guidelines for Carcinogen Risk Assessment (U.S. EPA, 2005), tert-butyl alcohol has “suggestive evidence of carcinogenic potential” for all routes of exposure based on some evidence in animals. |
CHEMICAL NAME | CAS REG DISPLAY | CA ROUTE | TUMOR SITE | PT DESC | PRECURSOR TUMOR | PT STUDY SUBJECT | STUDY ROUTE CODE | STUDY ROUTE QUALIFIER | STUDY CITATION DESC | SLOPEFACTOR VALUE | SF MUTAGENIC MODE OF ACTION | UNIT RISK VALUE | UR MUTAGENIC MODE OF ACTION | UR EXTRAP METHOD | PT FOOTNOTE | E4 VALUE | E5 VALUE | E6 VALUE | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | Acephate | 30560-19-1 | Oral | Hepatic | Liver adenomas and carcinomas | Tumor | Mouse/ CD-1, female | Oral | Diet | Chevron Chemical, 1982a | 8.7 x 10 -3 per mg/kg-day | No | 2.5 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 4 x 10 2 µg/L | 4 x 10 1 µg/L | 4 µg/L |
2 | Acetaldehyde | 75-07-0 | Inhalation | Respiratory | Nasal squamous cell carcinoma or adenocarcinoma | Tumor | Rat/SPF Wistar, male | Inhalation | None | Woutersen and Appleman, 1984 | None | No | 2.2 x 10 -6 per µg/m3 | No | Linearized multistage-variable exposure input form (extra risk) | None | 5 x 10 1 µg/m3 | 5 µg/m3 | 5 x 10 -1 µg/m3 |
3 | Acrylamide | 79-06-1 | Oral | Endocrine, Reproductive | thyroid tumors and tunica vaginalis mesotheliomas | Tumor | Rat/Fischer 344, males | Oral | drinking water | Johnson et al., 1986 | 5 x 10 -1 per mg/kg-day | No | None | No | Multistage model with linear extrapolation from the point of departure (BMDL), summed risk. | ADAF -- EPA has concluded that acrylamide is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
4 | Acrylamide | 79-06-1 | Inhalation | Endocrine, Reproductive | thyroid tumors and tunica vaginalis mesotheliomas | Tumor | Rat/Fischer 344, males | Oral | drinking water | Johnson et al., 1986 | None | No | 1 x 10 -4 per µg/m3 | No | Multistage model with linear extrapolation from the point of departure (BMDL), summed risk. | ADAF -- EPA has concluded that acrylamide is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
5 | Acrylonitrile | 107-13-1 | Inhalation | Respiratory | Respiratory cancer | Tumor | Humans | Inhalation | None | O'Berg, 1980 | None | No | 6.8 x 10 -5 per µg/m3 | No | Average relative risk | None | 1 µg/m3 | 1 x 10 -1 µg/m3 | 1 x 10 -2 µg/m3 |
6 | Acrylonitrile | 107-13-1 | Oral | Gastrointestinal, Nervous, Other | Brain and spinal cord astrocytomas, Zymbal gland carcinomas and stomach papillomas/ carcinomas | Tumor | Rats (Spartan Sprague-Dawley, males Fischer 344, males Sprague-Dawley, males) | Oral | Drinking water | Biodynamics, 1980a,b Quast et al., 1980a | 5.4 x 10 -1 per mg/kg-day | No | 1.5 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 µg/L | 6 x 10 -1 µg/L | 6 x 10 -2 µg/L |
7 | Aldrin | 309-00-2 | Inhalation | Hepatic | Liver carcinoma | Tumor | Mouse/C3H (Davis); mouse/B6C3F1, male (NCI) | Oral | Diet | Davis, 1965, NCI, 1978 | None | No | 4.9 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 | 2 x 10 -4 µg/m3 |
8 | Aldrin | 309-00-2 | Oral | Hepatic | Liver carcinoma | Tumor | Mouse/C3H (Davis); mouse/B6C3F1, male (NCI) | Oral | Drin | Davis, 1965, NCI, 1978 | 1.7 x 10 1 per mg/kg-day | No | 4.9 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L | 2 x 10 -3 µg/L |
9 | Aniline | 62-53-3 | Oral | Immune | Spleen, combined fibrosarcoma, stromal sarcoma, capsular sarcoma and hemangiosarcoma | Tumor | Rat/CD-F, male | Oral | Diet | CIIT, 1982 | 5.7 x 10 -3 per mg/kg-day | No | 1.6 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 x 10 2 µg/L | 6 x 10 1 µg/L | 6 µg/L |
10 | Aramite | 140-57-8 | Oral | Hepatic | Neoplastic liver nodules and carcinomas | Tumor | Rat/ FDRL, male and female | Oral | Diet | Popper et al., 1960; Oser and Oser, 1962 | 2.5 x 10 -2 per mg/kg-day | No | 7.1 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 2 µg/L | 1 x 10 1 µg/L | 1 µg/L |
11 | Aramite | 140-57-8 | Inhalation | Hepatic | Neoplastic liver nodules and carcinomas | Tumor | Rat/ FDRL, male and female | Oral | Diet | Popper et al., 1960; Oser and Oser, 1962 | None | No | 7.1 x 10 -6 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/m3 | 1 µg/m3 | 1 x 10 -1 µg/m3 |
12 | Arsenic, Inorganic | 7440-38-2 | Inhalation | Respiratory | Lung cancer | Tumor | Human, male | Inhalation | Occupational exposure | Brown and Chu, 1983a,b,c; Lee-Feldstein, 1983; Higgins, 1982; Enterline and Marsh, 1982 | None | No | 4.3 x 10 -3 per µg/m3 | No | Absolute-risk linear model | None | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 | 2 x 10 -4 µg/m3 |
13 | Arsenic, Inorganic | 7440-38-2 | Oral | Dermal | Skin cancer | Tumor | Human | Oral | Drinking water | Tseng, 1977; Tseng et al., 1968; U.S. EPA, 1988 | 1.5 per mg/kg-day | No | 5 x 10 -5 per µg/L | No | Time- and dose-related formulation of the multistage model | None | 2 µg/L | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L |
14 | Asbestos | 1332-21-4 | Inhalation | Respiratory | Lung cancer and mesothelioma | Tumor | Human | Inhalation | Occupational exposure | Selikoff et al., 1979; Peto et al., 1982; Seidman et al., 1979; Peto, 1980; Finkelstein, 1983 | None | No | 2.3 x 10 -1 per f/mL | No | Additive risk of lung cancer and mesothelioma, using relative risk model for lung cancer and absolute risk model for mesothelioma | None | 4 x 10 -4 f/mL | 4 x 10 -5 f/mL | 4 x 10 -6 f/mL |
15 | Azobenzene | 103-33-3 | Oral | Other | Abdominal cavity sarcomas | Tumor | Rats/ F344, female | Oral | Diet | NCI, 1979 | 1.1 x 10 -1 per mg/kg-day | No | 3.1 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 x 10 1 µg/L | 3 µg/L | 3 x 10 -1 µg/L |
16 | Azobenzene | 103-33-3 | Inhalation | Other | Abdominal cavity sarcomas | Tumor | Rats/ F344, female | Oral | Diet | NCI, 1979 | None | No | 3.1 x 10 -5 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 3 µg/m3 | 3 x 10 -1 µg/m3 | 3 x 10 -2 µg/m3 |
17 | Benzene | 71-43-2 | Oral | Hematologic | Leukemia | Tumor | Human | Inhalation | Occupational exposure | Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump, 1994 U. S. EPA, 1998 U.S. EPA, 1999 | 1.5 x 10 -2 per mg/kg-day | No | 4.4 x 10 -7 per µg/L | No | Linear extrapolation of human occupational data | None | 1 x 10 2 µg/L | 1 x 10 1 µg/L | 1 µg/L |
18 | Benzene | 71-43-2 | Inhalation | Hematologic | Leukemia | Tumor | Human | Inhalation | None | Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump and Allen, 1984 Crump, 1992, 1994 U.S. EPA, 1998 | None | No | 7.8 x 10 -6 per µg/m3 | No | Low-dose linearity utilizing maximum likelihood estimates | None | 4.5 x 10 1 µg/m3 | 4.5 µg/m3 | 4.5 x 10 -1 µg/m3 |
19 | Benzene | 71-43-2 | Oral | Hematologic | Leukemia | Tumor | Human | Inhalation | Occupational exposure | Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump, 1994 U. S. EPA, 1998 U.S. EPA, 1999 | 5.5 x 10 -2 per mg/kg-day | No | 1.6 x 10 -6 per µg/L | No | Linear extrapolation of human occupational data | None | 1 x 10 3 µg/L | 1 x 10 2 µg/L | 1 x 10 1 µg/L |
20 | Benzene | 71-43-2 | Inhalation | Hematologic | Leukemia | Tumor | Human | Inhalation | None | Rinsky et al., 1981, 1987 Paustenbach et al., 1993 Crump and Allen, 1984 Crump, 1992, 1994 U.S. EPA, 1998 | None | No | 2.2 x 10 -6 per µg/m3 | No | Low-dose linearity utilizing maximum likelihood estimates | None | 1.3 x 10 1 µg/m3 | 1.3 µg/m3 | 1.3 x 10 -1 µg/m3 |
21 | Benzidine | 92-87-5 | Inhalation | Urinary | Bladder tumors | Tumor | Human | Inhalation | Occupational exposure | Zavon, 1973 | None | No | 6.7 x 10 -2 per µg/m3 | No | One-hit with time factor, extra risk | None | 2 x 10 -3 µg/m3 | 2 x 10 -4 µg/m3 | 2 x 10 -5 µg/m3 |
22 | Benzidine | 92-87-5 | Oral | Urinary | Bladder tumors | Tumor | Human | Inhalation | Occupational exposure | Zavon, 1973 | 2.3 x 10 2 per mg/kg-day | No | 6.7 x 10 -3 per µg/L | No | One-hit with time factor, extra risk | None | 2 x 10 -2 µg/L | 2 x 10 -3 µg/L | 2 x 10 -4 µg/L |
23 | Benzo[a]pyrene (BaP) | 50-32-8 | Inhalation | Gastrointestinal, Respiratory | Squamous cell neoplasia in the larynx, pharynx, trachea, nasal cavity, esophagus, and forestomach. | Tumor | male hamsters | Inhalation | None | Thyssen et al., 1981 | None | Yes | 6 x 10 -4 per µg/m3 | Yes | Time-to-tumor dose-response model with linear extrapolation from the POD ((BMCL10(HED)) associated with 10% extra cancer risk. | ADAF -- EPA has concluded that benzo[a]pyrene is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
24 | Benzo[a]pyrene (BaP) | 50-32-8 | Oral | Gastrointestinal | forestomach, esophagus, tongue, and larynx tumors | Tumor | male and female Wistar rats female B6C3F1 mice | Oral | Gavage Diet | Kroese et al. 2001; Beland and Culp, 1998 | 1 per mg/kg-day | Yes | None | Yes | Time-to-tumor dose-response model with linear extrapolation from the POD (BMDL10(HED)) associated with 10% extra cancer risk. | ADAF -- EPA has concluded that benzo[a]pyrene is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
25 | Benzotrichloride | 98-07-7 | Oral | Respiratory | Lung, adenocarcinoma | Tumor | Mouse/ ICR, female | Oral | Gavage, sesame oil | Fukuda et al., 1978 | 1.3 x 10 1 per mg/kg-day | No | 3.6 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 x 10 -1 µg/L | 3 x 10 -2 µg/L | 3 x 10 -3 µg/L |
26 | Benzyl chloride | 100-44-7 | Oral | Endocrine | Thyroid, C-cell adenoma/ carcinoma | Tumor | Rat/Fischer 344, female | Oral | Gavage, corn oil | Lijinsky, 1986 | 1.7 x 10 -1 per mg/kg-day | No | 4.9 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 x 10 1 µg/L | 2 µg/L | 2 x 10 -1 µg/L |
27 | Beryllium and compounds | 7440-41-7 | Inhalation | Respiratory | Lung cancer | Tumor | Human, male | Inhalation | Occupational exposure | Wagoner et al., 1980 | None | No | 2.4 x 10 -3 per µg/m3 | No | Relative risk | None | 4 x 10 -2 µg/m3 | 4 x 10 -3 µg/m3 | 4 x 10 -4 µg/m3 |
28 | Biphenyl | 92-52-4 | Oral | Hepatic | Liver adenomas or carcinomas | Tumor | female BDF1 mice | Oral | Diet | Umeda et al., 2005 | 8 x 10 -3 per mg/kg-day | None | 2.3 x 10 -7 per µg/L | None | Multistage model with linear extrapolation from the POD (LED10). | None | 4.3 x 10 2 µg/L | 4.3 x 10 1 µg/L | 4 µg/L |
29 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Inhalation | Hepatic | Hepatomas | Tumor | Mouse/(C57B1/6 x C3H/AnF)F1, male | Oral | Gavage followed by diet | Innes et al., 1969 | None | No | 3.3 x 10 -4 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 3 x 10 -1 µg/m3 | 3 x 10 -2 µg/m3 | 3 x 10 -3 µg/m3 |
30 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | Oral | Hepatic | Hepatomas | Tumor | Mouse/(C57B1/6 x C3H/AnF)F1, male | Oral | Gavage followed by diet | Innes et al., 1969 | 1.1 per mg/kg-day | No | 3.3 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 µg/L | 3 x 10 -1 µg/L | 3 x 10 -2 µg/L |
31 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Oral | Respiratory | Respiratory tract tumors | Tumor | Rat/Sprague-Dawley, male | Inhalation | None | Kuschner et al., 1975 | 2.2 x 10 2 per mg/kg-day | No | 6.2 x 10 -3 per µg/L | No | Linearized multistage procedure, extra risk | None | 1.6 x 10 -2 µg/L | 1.6 x 10 -3 µg/L | 1.6 x 10 -4 µg/L |
32 | Bis(chloromethyl)ether (BCME) | 542-88-1 | Inhalation | Respiratory | Respiratory tract tumors | Tumor | Rat/Sprague-Dawley, male | Inhalation | None | Kuschner et al., 1975 | None | No | 6.2 x 10 -2 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 1.6 x 10 -3 µg/m3 | 1.6 x 10 -4 µg/m3 | 1.6 x 10 -5 µg/m3 |
33 | Bromate | 15541-45-4 | Oral | Endocrine, Reproductive, Urinary | Testicular mesothelioma, renal tubular adenoma and carcinoma, and thyroid follicular cell adenoma and carcinoma | Tumor | F344 rats, male | Oral | Drinking water | DeAngelo et al., 1998 | 7 x 10 -1 per mg/kg-day | No | 2 x 10 -5 per µg/L | No | Time-to-tumor, Weibull | None | 5 µg/L | 5 x 10 -1 µg/L | 5 x 10 -2 µg/L |
34 | Bromodichloromethane | 75-27-4 | Oral | Urinary | Kidney (tubular cell adenoma and tubular cell adenocarcinoma) | Tumor | B6C3F1 mice, male | Oral | Gavage, corn oil | NTP, 1987 | 6.2 x 10 -2 per mg/kg-day | No | 1.8 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 x 10 1 µg/L | 6 µg/L | 6 x 10 -1 µg/L |
35 | Bromoform | 75-25-2 | Inhalation | Gastrointestinal | Neoplastic lesions in the large intestine | Tumor | F344/N rat, female | Oral | Gavage in corn oil | NTP, 1988 | None | No | 1.1 x 10 -6 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 9 x 10 1 µg/m3 | 9 µg/m3 | 9 x 10 -1 µg/m3 |
36 | Bromoform | 75-25-2 | Oral | Gastrointestinal | Neoplastic lesions in the large intestine | Tumor | F344/N rat, female | Oral | Gavage in corn oil | NTP, 1988 | 7.9 x 10 -3 per mg/kg-day | No | 2.3 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 4 x 10 2 µg/L | 4 x 10 1 µg/L | 4 µg/L |
37 | 1,3-Butadiene | 106-99-0 | Inhalation | Hematologic | Leukemia | Tumor | Human | Inhalation | None | Health Canada, 1998; U.S. EPA, 2002 | None | No | 3 x 10 -5 per µg/m3 | No | Linear extrapolation from LEC01 (0.254 ppm); LEC01 derived from linear relative rate model (RR = 1 + (B)(x)) using lifetable analysis with leukemia incidence data; an adjustment factor of 2 was applied. | None | 3 µg/m3 | 3 x 10 -1 µg/m3 | 3 x 10 -2 µg/m3 |
38 | Cadmium | 7440-43-9 | Inhalation | Respiratory | Lung, trachea, bronchus cancer deaths | Tumor | Human/ white male | Inhalation | Exposure in the workplace | Thun et al., 1985 | None | No | 1.8 x 10 -3 per µg/m3 | No | Two stage; only first affected by exposure; extra risk | None | 6 x 10 -2 µg/m3 | 6 x 10 -3 µg/m3 | 6 x 10 -4 µg/m3 |
39 | Carbon tetrachloride | 56-23-5 | Inhalation | Endocrine | Pheochromocytoma | Tumor | Male BDF1 mouse | Inhalation | None | Nagano et al. 2007b, JBRC 1998 | None | No | 6 x 10 -6 per µg/m3 | No | Log-probit model with linear extrapolation from the POD (LEC10). | None | 1.7 x 10 1 µg/m3 | 1.7 µg/m3 | 1.7 x 10 -1 µg/m3 |
40 | Carbon tetrachloride | 56-23-5 | Oral | Hepatic | Hepatocellular adenoma or carcinoma | Tumor | Female BDF1 mouse | Inhalation | route-to-route extrapolation, PBPK modeling | Nagano et al., 2007b, JBRC, 1998 | 7 x 10 -2 per mg/kg-day | No | 2 x 10 -6 per µg/L | No | Multistage model with linear extrapolation from the POD (LED10). | None | 5 x 10 1 µg/L | 5 µg/L | 5 x 10 -1 µg/L |
41 | Chlordane (Technical) | 12789-03-6 | Oral | Hepatic | Hepatocellular carcinoma | Tumor | Mouse/ CD-1 (IRDC); mouse/ B6C3F1(NCI); mouse/ ICR (Khasawinah and Grutsch) | Oral | Diet | IRDC, 1973; NCI, 1977; Khasawinah and Grutsch, 1989b | 3.5 x 10 -1 per mg/kg-day | No | 1 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/L | 1 µg/L | 1 x 10 -1 µg/L |
42 | Chlordane (Technical) | 12789-03-6 | Inhalation | Hepatic | Hepatocellular carcinoma | Tumor | Mouse/ CD-1 (IRDC); mouse/ B6C3F1(NCI); mouse/ ICR (Khasawinah and Grutsch) | Oral | Diet | IRDC, 1973; NCI, 1977; Khasawinah and Grutsch, 1989b | None | No | 1 x 10 -4 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 1 µg/m3 | 1 x 10 -1 µg/m3 | 1 x 10 -2 µg/m3 |
43 | Chlordecone (Kepone) | 143-50-0 | Oral | Hepatic | liver hepatocellular carcinoma | Tumor | B6C3F1 mice | Oral | dietary | NCI (1976a) | 1 x 10 1 per mg/kg-day | No | 3 x 10 -4 per µg/L | No | Multistage-Weibull model (implemented in TOX_RISK) with linear extrapolation from the POD (BMDL10). | None | 3.3 x 10 -1 µg/L | 3.3 x 10 -2 µg/L | 3.3 x 10 -3 µg/L |
44 | Chloroform | 67-66-3 | Inhalation | Hepatic | Hepatocellular carcinoma | Tumor | Mouse, B6C3F1, female | Oral | Gavage | NCI, 1976 | None | No | 2.3 x 10 -5 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 4 µg/m3 | 4 x 10 -1 µg/m3 | 4 x 10 -2 µg/m3 |
45 | Chloroprene | 126-99-8 | Inhalation | Dermal, Gastrointestinal, Hepatic, Ocular, Other, Reproductive, Respiratory | alveolar/ bronchiolar adenoma or carcinoma hemangioma/ hemangiosarcoma (all organs) mammary gland adenocarcinoma, carcinoma, or adenoacanthoma forestomach squamous cell papilloma or carcinoma hepatocellular adenoma or carcinoma Harderian gland adenoma or carcinoma skin sarcoma and Zymbal's gland carcinoma | Tumor | female B6C3F1 mice | Inhalation | None | NTP, 1998 | None | No | 3 x 10 -4 per µg/m3 | No | Multistage model with linear extrapolation from the point of departure (BMDL), summed risk. | ADAF -- EPA has concluded that chloroprene is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
46 | Chromium(VI) | 18540-29-9 | Inhalation | Respiratory | Lung cancer | Tumor | None | None | None | None | None | No | 1.1 x 10 -2 per µg/m3 | No | Linear extrapolation from LEC01 derived from Cox proportional hazard model with 5 year lag using lifetable analysis. | ADAF – EPA has concluded that Cr(VI) is carcinogenic by a mutagenic mode of action. Lifetime exposure IUR for human lung cancer, after application of ADAFs: 0.018 per µg Cr(VI)/m3 | None | None | None |
47 | Chromium(VI) | 18540-29-9 | Oral | Gastrointestinal | Squamous cell carcinoma or squamous cell papilloma. | None | None | None | None | NTP, 2008 | 1.6 x 10 -1 per mg/kg-day | None | None | None | HEDs calculated using BW3/4 scaling | ADAF – EPA has concluded that Cr(VI) is carcinogenic by a mutagenic mode of action. Lifetime exposure OSF for squamous cell carcinomas or squamous cell papillomas in the female rat tongue or oral mucosa, after application of the age-dependent adjustment factors at constant dose: 0.26 per mg/kg-d | None | None | None |
48 | Coke oven emissions | None | Inhalation | Respiratory | Respiratory cancer | Tumor | Human, male | Inhalation | Occupational | Mazumdar et al., 1975; Land, 1976 | None | No | 6.2 x 10 -4 per µg/m3 | No | Linearized multistage procedure | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
49 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | Oral | Hepatic | Liver neoplastic nodules or carcinoma (combined) | Tumor | Male F344/N rats | Oral | diet | NTP (1986) | 7 x 10 -4 per mg/kg-day | No | 2 x 10 -8 per µg/L | No | Multistage model with linear extrapolation from the point of departure (LED12). | None | 5 x 10 3 µg/L | 5 x 10 2 µg/L | 5 x 10 1 µg/L |
50 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | Oral | Hepatic | Hepatocellular carcinoma and adenoma | Tumor | Mouse/ B6C3F1, male | Oral | Diet | NTP, 1982 | 1.4 x 10 -2 per mg/kg-day | No | 4 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 x 10 2 µg/L | 3 x 10 1 µg/L | 3 µg/L |
51 | Di(2-ethylhexyl)adipate | 103-23-1 | Oral | Hepatic | Combined hepatocellular adenomas and carcinomas | Tumor | Mouse/ B6C3F1, female | Oral | Diet | NTP, 1982 | 1.2 x 10 -3 per mg/kg-day | No | 3.4 x 10 -8 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 x 10 3 µg/L | 3 x 10 2 µg/L | 3 x 10 1 µg/L |
52 | Dibromochloromethane | 124-48-1 | Oral | Hepatic | Hepatocellular adenoma or carcinoma | Tumor | Mouse/ B6C3F1, female | Oral | Gavage | NTP, 1985 | 8.4 x 10 -2 per mg/kg-day | No | 2.4 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 4 x 10 1 µg/L | 4 µg/L | 4 x 10 -1 µg/L |
53 | 1,2-Dibromoethane | 106-93-4 | Inhalation | Other, Reproductive, Respiratory | Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas | Tumor | Rat/ Fischer 344, male | Inhalation | None | NTP, 1982 | None | No | 6 x 10 -4 per µg/m3 | No | Multistage-Weibull model linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
54 | 1,2-Dibromoethane | 106-93-4 | Oral | Endocrine, Gastrointestinal, Other | Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas | Tumor | Rat/Osborne-Mendel, male | Oral | gavage | NCI, 1978 | 2 per mg/kg-day | None | 6 x 10 -5 per µg/L | None | Multistage model with Poly-3 adjusted incidence data linear extrapolation from lower 95% confidence limit on dose associated with extra risk (adjusted for background) at point of departure at lower end of data range. | None | 2 µg/L | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L |
55 | 1,2-Dibromoethane | 106-93-4 | Oral | Endocrine, Gastrointestinal, Other | Forestomach tumors, hemangiosarcomas, thyroid follicular cell adenomas or carcinomas | Tumor | Rat/Osborne-Mendel, male | Oral | gavage | NCI, 1978 | 1 mg/kg-day | None | None | None | Multistage model with Poly-3 adjusted incidence data central tendency estimate | None | None | None | None |
56 | 1,2-Dibromoethane | 106-93-4 | Inhalation | Other, Reproductive, Respiratory | Nasal cavity (includes adenoma, adenocarcinoma, papillary adenoma, squamous cell carcinoma, and or/papilloma), hemangiosarcomas, mesotheliomas | Tumor | Rat/ Fischer 344, male | Inhalation | None | NTP, 1982 | None | No | 3 x 10 -4 per µg/m3 | No | Multistage model with Poly-3 adjusted incidence data central tendency estimate | None | None | None | None |
57 | Dichloroacetic acid | 79-43-6 | Oral | Hepatic | Hepatoadenoma and Hepatocarcinoma | Tumor | Male B6C3F1 mice | Oral | drinking water | DeAngelo et. al., 1999 | 5 x 10 -2 per mg/kg-day | No | 1.4 x 10 -6 per µg/L | No | Multistage model with Benchmark Dose Modeling | None | 7 x 10 1 µg/L | 7 µg/L | 7 x 10 -1 µg/L |
58 | 3,3'-Dichlorobenzidine | 91-94-1 | Oral | Reproductive | Mammary adenocarcinoma | Tumor | Rat/ ChR-CD, female | Oral | Diet | Stula et al., 1975 | 4.5 x 10 -1 per mg/kg-day | No | 1.3 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 8 µg/L | 8 x 10 -1 µg/L | 8 x 10 -2 µg/L |
59 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | Oral | Hepatic | Liver tumors | Tumor | Mouse/ CF-1, males | Oral | Diet | Tomatis et al., 1974 | 2.4 x 10 -1 per mg/kg-day | No | 6.9 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/L | 1 µg/L | 1 x 10 -1 µg/L |
60 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | 72-55-9 | Oral | Hepatic | Hepatocellular carcinomas, hepatomas | Tumor | Mouse/ B6C3F1; mouse/ CF-1; hamsters/ Syrian Golden | Oral | Diet | NCI, 1978; Tomatis et al., 1974; Rossi et al., 1983 | 3.4 x 10 -1 per mg/kg-day | No | 9.7 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/L | 1 µg/L | 1 x 10 -1 µg/L |
61 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Inhalation | Hepatic | Liver tumors, benign and malignant | Tumor | Mouse/ CF-1; Mouse/ BALB/C; Rat/ MRC Porton; Rat/ Wistar | Oral | Diet | Turusov et al., 1973; Terracini et al., 1973; Thorpe and Walker, 1973; Tomatis and Turusov, 1975; Cabral et al., 1982; Rossi et al., 1977 | None | No | 9.7 x 10 -5 per µg/m3 | No | Linear multistage procedure, extra risk | None | 1 µg/m3 | 1 x 10 -1 µg/m3 | 1 x 10 -2 µg/m3 |
62 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | Oral | Hepatic | Liver tumors, benign and malignant | Tumor | Mouse/ CF-1; Mouse/ BALB/C; Rat/ MRC Porton; Rat/ Wistar | Oral | Diet | Turusov et al., 1973; Terracini et al., 1973; Thorpe and Walker, 1973; Tomatis and Turusov, 1975; Cabral et al., 1982; Rossi et al., 1977 | 3.4 x 10 -1 per mg/kg-day | No | 9.7 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/L | 1 µg/L | 1 x 10 -1 µg/L |
63 | 1,2-Dichloroethane | 107-06-2 | Inhalation | Other | Hemangiosarcomas | Tumor | Rat/ Osborne-Mendel, male | Oral | Gavage | NCI, 1978 | None | No | 2.6 x 10 -5 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 4 µg/m3 | 4 x 10 -1 µg/m3 | 4 x 10 -2 µg/m3 |
64 | 1,2-Dichloroethane | 107-06-2 | Oral | Other | Hemangiosarcomas | Tumor | Rat/ Osborne-Mendel, male | Oral | Gavage | NCI, 1978 | 9.1 x 10 -2 per mg/kg-day | No | 2.6 x 10 -6 per µg/L | No | Linearized multistage procedure with time-to-death analysis, extra risk | None | 4 x 10 1 µg/L | 4 µg/L | 4 x 10 -1 µg/L |
65 | Dichloromethane | 75-09-2 | Inhalation | Hepatic, Respiratory | Hepatocellular carcinomas or adenomas, bronchoalveolar carcinomas or adenomas | Tumor | Male B6C3F1 mice | Inhalation | None | Mennear et al., 1988; NTP, 1986 | None | Yes | 1 x 10 -8 per µg/m3 | Yes | Multistage model with linear extrapolation from the point of departure (BMDL10). | ADAF -- EPA has concluded that dichloromethane is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
66 | Dichloromethane | 75-09-2 | Oral | Hepatic | Hepatocellular carcinomas or adenomas | Tumor | Male B6C3F1 mice | Oral | drinking water | Serota et al., 1986b | 2 x 10 -3 per mg/kg-day | Yes | None | Yes | Multistage model with linear extrapolation from the point of departure (BMDL10). | ADAF -- EPA has concluded that dichloromethane is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
67 | 1,3-Dichloropropene | 542-75-6 | Oral | Hepatic | Hepatocellular adenoma/carcinoma | Tumor | male rat | Oral | dietary | Stott et al., 1995 | 5 x 10 -2 per mg/kg-day | No | 1 x 10 -6 per µg/L | No | Linearized multistage model, extra risk | None | 8 x 10 1 µg/L | 8 µg/L | 8 x 10 -1 µg/L |
68 | 1,3-Dichloropropene | 542-75-6 | Oral | Hepatic | Hepatocellular adenoma/carcinoma | Tumor | male rat | Oral | gavage | NTP, 1985 | 5 x 10 -2 per mg/kg-day | No | 2 x 10 -6 per µg/L | No | Linearized multistage model, extra risk | None | 7 x 10 1 µg/L | 7 µg/L | 7 x 10 -1 µg/L |
69 | 1,3-Dichloropropene | 542-75-6 | Oral | Urinary | Urinary bladder carcinoma | Tumor | female mouse | Oral | gavage | NTP, 1985 | 1 x 10 -1 per mg/kg-day | No | 3 x 10 -6 per µg/L | No | Linearized multistage model, extra risk | None | 4 x 10 1 µg/L | 4 µg/L | 4 x 10 -1 µg/L |
70 | 1,3-Dichloropropene | 542-75-6 | Inhalation | Respiratory | Bronchioalveolar adenoma | Tumor | Male mouse | Inhalation | None | Lomax et al., 1989 | None | No | 4 x 10 -6 per µg/m3 | No | Linearized multistage model, extra risk | None | 2 x 10 1 µg/m3 | 2 µg/m3 | 2 x 10 -1 µg/m3 |
71 | Dichlorvos | 62-73-7 | Oral | Endocrine, Gastrointestinal, Hematologic | Forestomach tumors, pancreatic acinar adenoma, leukemia | Tumor | Mouse and rat | Oral | Gavage | NTP, 1986a,b | 2.9 x 10 -1 per mg/kg-day | No | 8.3 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/L | 1 µg/L | 1 x 10 -1 µg/L |
72 | Dieldrin | 60-57-1 | Inhalation | Hepatic | Liver carcinoma | Tumor | Mouse | Oral | Diet | Davis (1965), reevaluated by Reuber, 1974 (cited in Epstein, 1975a); Walker et al., 1972; Thorpe and Walker, 1973; NCI, 1978a,b; Tennekes et al., 1981; Meierhenry et al., 1983 | None | No | 4.6 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 | 2 x 10 -4 µg/m3 |
73 | Dieldrin | 60-57-1 | Oral | Hepatic | Liver carcinoma | Tumor | Mouse | Oral | Diet | Davis (1965), reevaluated by Reuber, 1974 (cited in Epstein, 1975a); Walker et al., 1972; Thorpe and Walker, 1973; NCI, 1978a,b; Tennekes et al., 1981; Meierhenry et al., 1983 | 1.6 x 10 1 per mg/kg-day | No | 4.6 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L | 2 x 10 -3 µg/L |
74 | 2,4-/2,6-Dinitrotoluene mixture | Various | Oral | Hepatic, Reproductive | Liver: hepatocellular carcinomas, neoplastic nodules; mammary gland: adenomas, fibroadenomas, fibromas, adenocarcinomas/ carcinomas | Tumor | Rat/Sprague-Dawley, female | Oral | Diet | Ellis et al., 1979 | 6.8 x 10 -1 per mg/kg-day | No | 1.9 x 10 -5 per µg/L | No | Linearized multistage procedure | None | 5 µg/L | 5 x 10 -1 µg/L | 5 x 10 -2 µg/L |
75 | 1,4-Dioxane | 123-91-1 | Inhalation | Gastrointestinal, Hepatic, Other, Reproductive, Respiratory, Urinary | Multiple (nasal, liver, kidney, peritoneal, mammary gland, and Zymbal gland) | Precursor | Male F344 rats | Inhalation | None | Kasai et al. 2009 | None | None | 5 x 10 -6 per µg/m3 | None | Multi-tumor dose-response model with linear extrapolation from the POD (BMDL10HED) associated with 10% extra cancer risk. | None | None | None | None |
76 | 1,4-Dioxane | 123-91-1 | Oral | Hepatic | Hepatocellular adenoma and carcinoma | Tumor | Female BDF1 mouse | Oral | Drinking water | Kano et al. 2009 | 1 x 10 -1 per mg/kg-day | No | 2.9 x 10 -6 per µg/L | No | Log-logistic model with linear extrapolation from the POD (BMDL50HED) associated with 50% extra cancer risk. | None | 3.5 x 10 1 µg/L | 3.5 µg/L | 3.5 x 10 -1 µg/L |
77 | 1,2-Diphenylhydrazine | 122-66-7 | Inhalation | Hepatic | Hepatocellular carcinomas and neoplastic liver nodules | Tumor | Rat/Fisher 344, male | Oral | Diet | NCI, 1979 | None | No | 2.2 x 10 -4 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 5 x 10 -1 µg/m3 | 5 x 10 -2 µg/m3 | 5 x 10 -3 µg/m3 |
78 | 1,2-Diphenylhydrazine | 122-66-7 | Oral | Hepatic | Hepatocellular carcinomas and neoplastic liver nodules | Tumor | Rat/Fisher 344, male | Oral | Diet | NCI, 1979 | 8 x 10 -1 per mg/kg-day | No | 2.2 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 5 µg/L | 5 x 10 -1 µg/L | 5 x 10 -2 µg/L |
79 | Epichlorohydrin | 106-89-8 | Oral | Gastrointestinal | Papillomas and carcinomas of the forestomach | Tumor | Rat/Wistar, male | Oral | Drinking water | Konishi et al., 1980 | 9.9 x 10 -3 per mg/kg-day | No | 2.8 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 x 10 2 µg/L | 3 x 10 1 µg/L | 3 µg/L |
80 | Epichlorohydrin | 106-89-8 | Inhalation | Respiratory | Nasal cavity tumors | Tumor | Rat/Sprague-Dawley, male | Inhalation | None | Laskin et al., 1980 | None | No | 1.2 x 10 -6 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 8 x 10 1 µg/m3 | 8 µg/m3 | 8 x 10 -1 µg/m3 |
81 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | Inhalation | Hepatic | Hepatocellular adenomas and carcinomas | None | Male and female F344 rats | Inhalation | 2-year inhalation bioassay | Saito et al. 2013; JPEC, 2010b | None | None | 8 x 10 -5 per mg/m3 | None | Linear extrapolation from the POD ((BMCL10(HED)) associated with 10% extra cancer risk. | None | None | None | None |
82 | Ethylene oxide | 75-21-8 | Inhalation | Immune, Reproductive | Lymphoid cancer, (female) breast cancer | Tumor | Human occupational epidemiology study: NIOSH study of sterilizer workers | Inhalation | None | Steenland et al., 2003, 2004 | None | Yes | 3 x 10 -3 per µg/m3 | Yes | Linear extrapolation. Two-piece linear spline model with knot at 1,600 ppm × days for lymphoid cancer. Two-piece linear spline model with knot at 5,750 ppm × days for breast cancer incidence in females. POD of 1% extra risk was used for both cancer types. | ADAF -- EPA has concluded that ethylene oxide is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
83 | Folpet | 133-07-3 | Oral | Gastrointestinal | Digestive tract tumors (adenoma and/ or adenocarcinoma) | Tumor | Mouse/CD1, males and females | Oral | Diet | Chevron, 1982 | 3.5 x 10 -3 per mg/kg-day | No | 1 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 3 µg/L | 1 x 10 2 µg/L | 1 x 10 1 µg/L |
84 | Fomesafen | 72178-02-0 | Oral | Hepatic | Liver adenomas and carcinomas | Tumor | Mice/ CD-1; males | Oral | Diet | Huntingdon, 1985 | 1.9 x 10 -1 per mg/kg-day | No | 5.4 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 x 10 1 µg/L | 2 µg/L | 2 x 10 -1 µg/L |
85 | Formaldehyde | 50-00-0 | Inhalation | Hematologic, Respiratory | Nasopharyngeal cancer, sinonasal cancer, myeloid leukemia | Tumor | None | Inhalation | None | None | None | No | 1.1 x 10 -5 per µg/m3 | No | Based on nasopharyngeal cancer (NPC) incidence (Beane Freeman, 2013), linear low-dose extrapolation from the 95% lower bound on the exposure level associated with the extra risk level serving as the benchmark response and application of age-dependent adjustment factors (ADAFs) due to an operant mutagenic mode-of-action (MOA) for nasal cancers (see Section 3.2.5 of the Toxicological Review). Confidence in the IUR is Medium (see Section 5.2 of the Toxicological Review). | The IUR is based on NPC alone, although it was concluded that the evidence demonstrates that formaldehyde inhalation also causes myeloid leukemia and sinonasal cancer (see Section 5.2 of the Toxicological Review for details). Thus, the IUR may underestimate the actual total cancer risk. Less-than-lifetime exposure scenarios with a very large fraction of exposure during adulthood may not warrant ADAF adjustment, and one may choose to use the unadjusted unit risk estimate of 7.4 × 10-6 per µg/m3 or the adult-based estimate of 6.4 × 10-6 per µg/m3 (see Section 5.2.4 of the Toxicological Review). | 8 µg/m3 | 8 x 10 -1 µg/m3 | 8 x 10 -2 µg/m3 |
86 | Furmecyclox | 60568-05-0 | Oral | Hepatic | Combined liver nodules and carcinomas | Tumor | Rat/Sprague-Dawley OF-A, female | Oral | Diet | BASF Wyandotte, 1984a | 3 x 10 -2 per mg/kg-day | No | 8.6 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 2 µg/L | 1 x 10 1 µg/L | 1 µg/L |
87 | Heptachlor | 76-44-8 | Oral | Hepatic | Hepatocellular carcinomas | Tumor | Mouse/C3H; mouse/B6C3F1 | Oral | Diet | Davis, 1965; NCI, 1977 | 4.5 per mg/kg-day | No | 1.3 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 8 x 10 -1 µg/L | 8 x 10 -2 µg/L | 8 x 10 -3 µg/L |
88 | Heptachlor | 76-44-8 | Inhalation | Hepatic | Hepatocellular carcinomas | Tumor | Mouse/C3H; mouse/B6C3F1 | Oral | Diet | Davis, 1965; NCI, 1977 | None | No | 1.3 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 8 x 10 -2 µg/m3 | 8 x 10 -3 µg/m3 | 8 x 10 -4 µg/m3 |
89 | Heptachlor epoxide | 1024-57-3 | Inhalation | Hepatic | Hepatocellular carcinomas | Tumor | Mouse/C3H (Davis); mouse/CD1 (Velsicol) | Oral | Diet | Davis, 1965; Velsicol, 1973 | None | No | 2.6 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 4 x 10 -2 µg/m3 | 4 x 10 -3 µg/m3 | 4 x 10 -4 µg/m3 |
90 | Heptachlor epoxide | 1024-57-3 | Oral | Hepatic | Hepatocellular carcinomas | Tumor | Mouse/C3H (Davis); mouse/CD1 (Velsicol) | Oral | Diet | Davis, 1965; Velsicol, 1973 | 9.1 per mg/kg-day | No | 2.6 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 4 x 10 -1 µg/L | 4 x 10 -2 µg/L | 4 x 10 -3 µg/L |
91 | Hexachlorobenzene | 118-74-1 | Inhalation | Hepatic | Hepatocellular carcinoma | Tumor | Rat/Sprague-Dawley, female | Oral | Diet | Erturk et al., 1986 | None | No | 4.6 x 10 -4 per µg/m3 | No | Linearized multistage, extra risk | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
92 | Hexachlorobenzene | 118-74-1 | Oral | Hepatic | Hepatocellular carcinoma | Tumor | Rat/Sprague-Dawley, female | Oral | Diet | Erturk et al., 1986 | 1.6 per mg/kg-day | No | 4.6 x 10 -5 per µg/L | No | Linearized multistage, extra risk | None | 2 µg/L | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L |
93 | Hexachlorobutadiene | 87-68-3 | Inhalation | Urinary | Renal tubular adenomas and adenocarcinomas | Tumor | Rat, Sprague-Dawley, male | Oral | Diet | Kociba et al., 1977 | None | No | 2.2 x 10 -5 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 5 µg/m3 | 5 x 10 -1 µg/m3 | 5 x 10 -2 µg/m3 |
94 | Hexachlorobutadiene | 87-68-3 | Oral | Urinary | Renal tubular adenomas and adenocarcinomas | Tumor | Rat, Sprague-Dawley, male | Oral | Diet | Kociba et al., 1977 | 7.8 x 10 -2 per mg/kg-day | No | 2.2 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 5 x 10 1 µg/L | 5 µg/L | 5 x 10 -1 µg/L |
95 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Inhalation | Hepatic | Hepatic nodules and hepatocellular carcinomas | Tumor | Mouse/dd, male | Oral | Diet | Ito et al., 1973a | None | No | 1.8 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 6 x 10 -2 µg/m3 | 6 x 10 -3 µg/m3 | 6 x 10 -4 µg/m3 |
96 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | Oral | Hepatic | Hepatic nodules and hepatocellular carcinomas | Tumor | Mouse/dd, male | Oral | Diet | Ito et al., 1973a | 6.3 per mg/kg-day | No | 1.8 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 x 10 -1 µg/L | 6 x 10 -2 µg/L | 6 x 10 -3 µg/L |
97 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Inhalation | Hepatic | Hepatic nodules and hepatocellular carcinomas | Tumor | Mouse/CF1, male | Oral | Diet | Thorpe and Walker, 1973 | None | No | 5.3 x 10 -4 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
98 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | Oral | Hepatic | Hepatic nodules and hepatocellular carcinomas | Tumor | Mouse/CF1, male | Oral | Diet | Thorpe and Walker, 1973 | 1.8 per mg/kg-day | No | 5.3 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 µg/L | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L |
99 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Inhalation | Hepatic | Liver nodules and hepatocellular carcinomas | Tumor | Mouse/Swiss, male | Oral | Diet | Munir et al., 1983 | None | No | 5.1 x 10 -4 per µg/m3 | No | Linearized multistage procedure | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
100 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | Oral | Hepatic | Liver nodules and hepatocellular carcinomas | Tumor | Mouse/Swiss, male | Oral | Diet | Munir et al., 1983 | 1.8 per mg/kg-day | No | 5.1 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 µg/L | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L |
101 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Oral | Hepatic | Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) | Tumor | Mouse/B6C3F1, male; rat/ Osborne-Mendel, female | Oral | Gavage | NTP, 1980a | 6.2 x 10 3 per mg/kg-day | No | 1.8 x 10 -1 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 x 10 -4 µg/L | 6 x 10 -5 µg/L | 6 x 10 -6 µg/L |
102 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | Inhalation | Hepatic | Liver tumors (adenomas and carcinomas; neoplastic nodules and hepatocellular carcinomas) | Tumor | Mouse/B6C3F1, male; rat/ Osborne-Mendel, female | Oral | Gavage | NTP, 1980a | None | No | 1.3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 8 x 10 -5 µg/m3 | 8 x 10 -6 µg/m3 | 8 x 10 -7 µg/m3 |
103 | Hexachloroethane | 67-72-1 | Oral | Urinary | Renal adenomas and carcinomas (combined) | Tumor | Male F344 rats | Oral | None | NTP (1989) | 4 x 10 -2 per mg/kg-day | No | 1 x 10 -6 per µg/L | No | The multistage model with linear extrapolation from the point of departure (LED10). | None | 9 x 10 1 µg/L | 9 µg/L | 9 x 10 -1 µg/L |
104 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | Oral | Hepatic, Respiratory | Liver (hepatocellular adenomas or carcinomas) and lung (alveolar/bronchiolar adenomas or carcinomas) | Tumor | Mouse/B6C3F1, female | Oral | Diet | Lish et al., 1984 | 8 x 10 -2 per mg/kg-day | No | None | No | Linear extrapolation from the POD (BMDL10-HED) associated with a 10% extra cancer risk | None | None | None | None |
105 | Hydrazine/Hydrazine sulfate | 302-01-2 | Inhalation | Respiratory | Nasal cavity adenoma or adenocarcinoma | Tumor | Rat/F344, male | Inhalation | None | MacEwen et al., 1981 | None | No | 4.9 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 | 2 x 10 -4 µg/m3 |
106 | Hydrazine/Hydrazine sulfate | 302-01-2 | Oral | Hepatic | Hepatoma | Tumor | Mouse, CBA/Cb/Se; male | Oral | Gavage (hydrazine sulfate in water) | Biancifiori, 1970 | 3 per mg/kg-day | No | 8.5 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 µg/L | 1 x 10 -1 µg/L | 1 x 10 -2 µg/L |
107 | Isophorone | 78-59-1 | Oral | Reproductive | Preputial gland carcinoma | Tumor | Rat/ F344/N, male | Oral | Gavage | NTP, 1986 | 9.5 x 10 -4 per mg/kg-day | No | 2.7 x 10 -8 per µg/L | No | Linearized multistage procedure, extra risk | None | 4 x 10 3 µg/L | 4 x 10 2 µg/L | 4 x 10 1 µg/L |
108 | Libby Amphibole Asbestos | 1318-09-8 | Inhalation | Respiratory | Cancer mortality from lung cancer and mesothelioma | Tumor | Humans | Inhalation | None | Sullivan, 2007 | None | None | 1.7 x 10 -1 per fiber/cc | None | Linear low dose extrapolation below the POD. | None | 5.9 x 10 -4 fiber/cc | 5.9 x 10 -5 fiber/cc | 5.9 x 10 -6 fiber/cc |
109 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | Oral | Endocrine | Thyroid, follicular cell carcinoma/ adenoma | Tumor | Rat/ F344, female | Oral | Diet | NCI, 1979a | 4.6 x 10 -2 per mg/kg-day | No | 1.3 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 8 x 10 1 µg/L | 8 µg/L | 8 x 10 -1 µg/L |
110 | Nickel refinery dust | None | Inhalation | Respiratory | Lung cancer | Tumor | Human: refinery and nonrefinery workers | Inhalation | None | Enterline and Marsh, 1982; Chovil et al., 1981; Peto et al., 1984; Magnus et al., 1982 | None | No | 2.4 x 10 -4 per µg/m3 | No | Additive and multiplicative | None | 4 x 10 -1 µg/m3 | 4 x 10 -2 µg/m3 | 4 x 10 -3 µg/m3 |
111 | Nickel subsulfide | 12035-72-2 | Inhalation | Respiratory | Lung cancer | Tumor | Human: refinery and nonrefinery workers | Inhalation | None | Enterline and Marsh, 1982; Chovil et al., 1981; Peto et al., 1984; Magnus et al., 1982 | None | No | 4.8 x 10 -4 per µg/m3 | No | Additive and multiplicative | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
112 | Nitrobenzene | 98-95-3 | Inhalation | Endocrine, Hepatic, Urinary | Liver hepatocellular adenomas or carcinomas, kidney tubular adenomas or carcinomas, thyroid follicular cell adenomas or carcinomas | Tumor | Rat/F344 (male) | Inhalation | None | CIIT (1993) | None | No | 4 x 10 -5 per µg/m3 | No | Multistage model with linear extrapolation from the POD (LEC10). | None | 2.5 µg/m3 | 2.5 x 10 -1 µg/m3 | 2.5 x 10 -2 µg/m3 |
113 | N-Nitroso-N-methylethylamine | 10595-95-6 | Oral | Hepatic | Hepatocellular carcinomas | Tumor | Rat/ BD, sex not specified | Oral | Drinking water | Druckrey, 1967; Druckrey et al., 1967 | 2.2 x 10 1 per mg/kg-day | No | 6.3 x 10 -4 per µg/L | No | One-hit | None | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L | 2 x 10 -3 µg/L |
114 | N-Nitroso-di-n-butylamine | 924-16-3 | Inhalation | Gastrointestinal, Urinary | Bladder and esophagus tumors | Tumor | Mouse/ C57B16, males | Oral | Drinking water | Bertram and Craig, 1970 | None | No | 1.6 x 10 -3 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 6 x 10 -2 µg/m3 | 6 x 10 -3 µg/m3 | 6 x 10 -4 µg/m3 |
115 | N-Nitroso-di-n-butylamine | 924-16-3 | Oral | Gastrointestinal, Urinary | Bladder and esophagus tumors | Tumor | Mouse/ C57B16, males | Oral | Drinking water | Bertram and Craig, 1970 | 5.4 per mg/kg-day | No | 1.6 x 10 -4 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 x 10 -1 µg/L | 6 x 10 -2 µg/L | 6 x 10 -3 µg/L |
116 | N-Nitrosodi-N-propylamine | 621-64-7 | Oral | Hepatic | Hepatocellular carcinomas | Tumor | Rat/ BD, sex not specified | Oral | Drinking water | Druckrey, 1967; Druckrey et al., 1967 | 7 per mg/kg-day | No | 2 x 10 -4 per µg/L | No | One-hit | None | 5 x 10 -1 µg/L | 5 x 10 -2 µg/L | 5 x 10 -3 µg/L |
117 | N-Nitrosodiethanolamine | 1116-54-7 | Oral | Hepatic | Hepatocellular carcinoma, cholangiocellular carcinoma and adenoma and neoplastic nodules | Tumor | Rat/ F344, female | Oral | Drinking water | Lijinsky and Kovatch, 1985 | 2.8 per mg/kg-day | No | 8 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 µg/L | 1 x 10 -1 µg/L | 1 x 10 -2 µg/L |
118 | N-Nitrosodiethylamine | 55-18-5 | Inhalation | Hepatic | Liver tumors | Tumor | Rat/Colworth, female | Oral | Drinking water | Peto et al., 1984 | None | No | 4.3 x 10 -2 per µg/m3 | No | Weibull, extra risk | None | 2 x 10 -3 µg/m3 | 2 x 10 -4 µg/m3 | 2 x 10 -5 µg/m3 |
119 | N-Nitrosodiethylamine | 55-18-5 | Oral | Hepatic | Liver tumors | Tumor | Rat/Colworth, female | Oral | Drinking water | Peto et al., 1984 | 1.5 x 10 2 per mg/kg-day | No | 4.3 x 10 -3 per µg/L | No | Weibull, extra risk | None | 2 x 10 -2 µg/L | 2 x 10 -3 µg/L | 2 x 10 -4 µg/L |
120 | N-Nitrosodimethylamine | 62-75-9 | Oral | Hepatic | Liver tumors | Tumor | Rat/ Colworth, female | Oral | Drinking water | Peto et al., 1984 | 5.1 x 10 1 per mg/kg-day | No | 1.4 x 10 -3 per µg/L | No | Weibull, extra risk | None | 7 x 10 -2 µg/L | 7 x 10 -3 µg/L | 7 x 10 -4 µg/L |
121 | N-Nitrosodimethylamine | 62-75-9 | Inhalation | Hepatic | Liver tumors | Tumor | Rat/ Colworth, female | Oral | Drinking water | Peto et al., 1984 | None | No | 1.4 x 10 -2 per µg/m3 | No | Weibull, extra risk | None | 7 x 10 -3 µg/m3 | 7 x 10 -4 µg/m3 | 7 x 10 -5 µg/m3 |
122 | N-Nitrosodiphenylamine | 86-30-6 | Oral | Urinary | Transitional cell carcinoma of the bladder | Tumor | Rat/ F344, female | Oral | Drinking water | NCI, 1979 | 4.9 x 10 -3 per mg/kg-day | No | 1.4 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 7 x 10 2 µg/L | 7 x 10 1 µg/L | 7 µg/L |
123 | N-Nitrosopyrrolidine | 930-55-2 | Oral | Hepatic | Hepatocellular carcinoma and adenoma | Tumor | Rat/ Sprague-Dawley, male and female | Oral | Diet | Preussmann et al., 1977 | 2.1 per mg/kg-day | No | 6.1 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 2 µg/L | 2 x 10 -1 µg/L | 2 x 10 -2 µg/L |
124 | N-Nitrosopyrrolidine | 930-55-2 | Inhalation | Hepatic | Hepatocellular carcinoma and adenoma | Tumor | Rat/ Sprague-Dawley, male and female | Oral | Diet | Preussmann et al., 1977 | None | No | 6.1 x 10 -4 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 2 x 10 -1 µg/m3 | 2 x 10 -2 µg/m3 | 2 x 10 -3 µg/m3 |
125 | Pentachlorophenol | 87-86-5 | Oral | Endocrine, Hepatic | Hepatocellular adenomas or carcinomas and adrenal benign or malignant pheochromocytomas | Tumor | Male B6C3F1 mice | Oral | Diet | NTP, 1989 | 4 x 10 -1 per mg/kg-day | No | 1.1 x 10 -5 per µg/L | No | Multistage model with linear extrapolation from the POD (LED10). | None | 9 µg/L | 9 x 10 -1 µg/L | 9 x 10 -2 µg/L |
126 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | Inhalation | Hepatic | Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas | Tumor | Female Sprague-Dawley rats | Oral | Diet | Brunner et al., 1996; Norback and Weltman, 1985 | None | No | 1 x 10 -4 per µg/m3 | No | Linear extrapolation below LED10; route-to-route extrapolation from the oral slope factor | For inhalation of an aerosol or dust contaminated with PCBs, see the IRIS Summary for information on the appropriate inhalation unit risk. | 1 µg/m3 | 1 x 10 -1 µg/m3 | 1 x 10 -2 µg/m3 |
127 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | Oral | Hepatic | Liver hepatocellular adenomas, carcinomas, cholangiomas, or cholangiocarcinomas | Tumor | Female Sprague-Dawley rats | Oral | Diet | Brunner et al., 1996 Norback and Weltman, 1985 | 2 per mg/kg-day | None | None | None | Linear extrapolation below LED10s | Cancer potency of PCB mixtures is determined by a tiered approach that depends on exposure matrix and route, type of congener present, and lifestage. See IRIS Summary for specific factors used to select appropriate slope factor. High risk and persistence: 2 per mg/kg-day; Low risk and persistence: 0.4 per mg/kg-day; Lowest risk and persistence: 0.07 per mg/kg-day. | None | None | None |
128 | Prochloraz | 67747-09-5 | Oral | Hepatic | Liver adenoma/ carcinoma combined | Tumor | Mouse/ CD-1, male and female | Oral | Diet | Nor-Am Chemical Co., 1983 | 1.5 x 10 -1 per mg/kg-day | No | 4.3 x 10 -6 per µg/L | No | Male mice: time-to-tumor linearized multistage procedure in dose, Weibull in time. Female mice: linearized multistage procedure | None | 2 x 10 1 µg/L | 2 µg/L | 2 x 10 -1 µg/L |
129 | Propylene oxide | 75-56-9 | Inhalation | Respiratory | Nasal cavity hemangioma or hemangiosarcoma | Tumor | Mouse/ B6C3F1, male | Inhalation | None | NTP, 1985 Renne et al., 1986 | None | No | 3.7 x 10 -6 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 3 x 10 1 µg/m3 | 3 µg/m3 | 3 x 10 -1 µg/m3 |
130 | Propylene oxide | 75-56-9 | Oral | Gastrointestinal | Forestomach, squamous cell carcinoma | Tumor | Rat/ Sprague-Dawley, female | Oral | Gavage, salad oil | Dunkelberg, 1982 | 2.4 x 10 -1 per mg/kg-day | No | 6.8 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/L | 1 µg/L | 1 x 10 -1 µg/L |
131 | Quinoline | 91-22-5 | Oral | Hepatic | Hepatic hemangioendotheliomas or hemangiosarcomas | Tumor | Male Sprague-Dawley rats | Oral | Dietary | Hirao et al., 1976 | 3 per mg/kg-day | No | 9 x 10 -5 per µg/L | No | Time-to-tumor, multistage-Weibull | None | 1 µg/L | 1 x 10 -1 µg/L | 1 x 10 -2 µg/L |
132 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Oral | Hepatic | Hepatocellular adenoma or carcinoma | Tumor | Mouse/B6C3F1, female | Oral | Gavage | NTP, 1983 | 2.6 x 10 -2 per mg/kg-day | No | 7.4 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 2 µg/L | 1 x 10 1 µg/L | 1 µg/L |
133 | 1,1,1,2-Tetrachloroethane | 630-20-6 | Inhalation | Hepatic | Hepatocellular adenoma or carcinoma | Tumor | Mouse/B6C3F1, female | Oral | Gavage | NTP, 1983 | None | No | 7.4 x 10 -6 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 1 x 10 1 µg/m3 | 1 µg/m3 | 1 x 10 -1 µg/m3 |
134 | 1,1,2,2-Tetrachloroethane | 79-34-5 | Oral | Hepatic | hepatocellular carcinomas | Tumor | female B6C3F1 mice | Oral | gavage | NCI, 1978 | 2 x 10 -1 per mg/kg-day | No | 6 x 10 -6 per µg/L | No | Multistage model with linear extrapolation from the point of departure (LED10). | None | 1.7 x 10 1 µg/L | 1.7 µg/L | 1.7 x 10 -1 µg/L |
135 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Inhalation | Hepatic | Hepatocellular adenomas or carcinomas | Tumor | Male Crj:BDF1 mice | Inhalation | None | JISA, 1993 | 0.0 | None | 2.6 x 10 -7 per µg/m3 | None | Multistage model with linear extrapolation from the point of departure (BMCL10), followed by extrapolation to humans using the PBPK model of Chiu and Ginsberg (2011). | None | 4 x 10 2 µg/m3 | 4 x 10 1 µg/m3 | 4 µg/m3 |
136 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | Oral | Hepatic | Hepatocellular adenomas or carcinomas | Tumor | Male Crj:BDF1 mice | Inhalation | None | JISA, 1993 | 2.1 x 10 -3 per mg/kg-day | No | 6.1 x 10 -8 per µg/L | No | Multistage model (with linear extrapolation from the point of departure (BMDL10), followed by route-to-route extrapolation to the oral route and interspecies extrapolation using the PBPK model of Chiu and Ginsberg (2011). | None | 2 x 10 3 µg/L | 2 x 10 2 µg/L | 2 x 10 1 µg/L |
137 | Toxaphene | 8001-35-2 | Inhalation | Hepatic | Hepatocellular carcinomas and neoplastic nodules | Tumor | Mouse/B6C3F1, males | Oral | Diet | Litton Bionetics, 1978 | None | No | 3.2 x 10 -4 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 3 x 10 -1 µg/m3 | 3 x 10 -2 µg/m3 | 3 x 10 -3 µg/m3 |
138 | Toxaphene | 8001-35-2 | Oral | Hepatic | Hepatocellular carcinomas and neoplastic nodules | Tumor | Mouse/B6C3F1, males | Oral | Diet | Litton Bionetics, 1978 | 1.1 per mg/kg-day | No | 3.2 x 10 -5 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 µg/L | 3 x 10 -1 µg/L | 3 x 10 -2 µg/L |
139 | Trichloroacetic acid | 76-03-9 | Oral | Hepatic | Hepatocellular adenomas or carcinomas | Tumor | Male B6C3F1 mice | Oral | drinking water | DeAngelo et al. (2008) | 7 x 10 -2 per mg/kg-day | No | 2 x 10 -6 per µg/L | No | Multistage model with linear extrapolation from the POD (LED10). | None | 5 x 10 1 µg/L | 5 µg/L | 5 x 10 -1 µg/L |
140 | 1,1,2-Trichloroethane | 79-00-5 | Oral | Hepatic | Hepatocellular carcinoma | Tumor | Mouse/ B6C3F1 | Oral | Gavage | NCI, 1978 | 5.7 x 10 -2 per mg/kg-day | No | 1.6 x 10 -6 per µg/L | No | Linearized multistage procedure, extra risk | None | 6 x 10 1 µg/L | 6 µg/L | 6 x 10 -1 µg/L |
141 | 1,1,2-Trichloroethane | 79-00-5 | Inhalation | Hepatic | Hepatocellular carcinoma | Tumor | Mouse/ B6C3F1 | Oral | Gavage | NCI, 1978 | None | No | 1.6 x 10 -5 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 6 µg/m3 | 6 x 10 -1 µg/m3 | 6 x 10 -2 µg/m3 |
142 | Trichloroethylene | 79-01-6 | Inhalation | Hematologic, Hepatic, Urinary | Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors | Tumor | Human (epidemiological studies) | Inhalation | None | Charbotel et al. 2006 EPA, 2011 Raaschou-Nielsen et al., 2003 | None | Yes | 4.1 x 10 -6 per µg/m3 | Yes | Low-dose linear extrapolation from the point of departure (LEC01) with a factor of 4 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk | ADAF -- EPA has concluded that trichloroethylene is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the inhalation unit risk is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
143 | Trichloroethylene | 79-01-6 | Oral | Hematologic, Hepatic, Urinary | Renal cell carcinoma, non-Hodgkin's lymphoma, and liver tumors | Tumor | Human (epidemiological studies) | Inhalation | (route-to-route extrapolation to Oral) | Charbotel et al., 2006 EPA, 2011 Raaschou-Nielsen et al., 2003 | 4.6 x 10 -2 per mg/kg-day | Yes | None | Yes | PBPK model-based route-to-route extrapolation of the inhalation unit risk estimate for kidney cancer with a factor of 5 applied to include non-Hodgkin's lymphoma (NHL) and liver cancer risks, combined risk | ADAF -- EPA has concluded that trichloroethylene is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
144 | 2,4,6-Trichlorophenol | 88-06-2 | Oral | Hematologic | Leukemia | Tumor | Rat/F344, male | Oral | Diet | NCI, 1979 | 1.1 x 10 -2 per mg/kg-day | No | 3.1 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 3 x 10 2 µg/L | 3 x 10 1 µg/L | 3 µg/L |
145 | 2,4,6-Trichlorophenol | 88-06-2 | Inhalation | Hematologic | Leukemia | Tumor | Rat/F344, male | Oral | Diet | NCI, 1979 | None | No | 3.1 x 10 -6 per µg/m3 | No | Linearized multistage procedure, extra risk | None | 3 x 10 1 µg/m3 | 3 µg/m3 | 3 x 10 -1 µg/m3 |
146 | 1,2,3-Trichloropropane | 96-18-4 | Oral | Gastrointestinal, Hepatic, Ocular, Reproductive | alimentary system squamous cell neoplasms, liver hepatocellular adenomas or carcinomas, Harderian gland adenomas, uterine/cervix adenomas or carcinomas | Tumor | B6C3F1 mice (female) | Oral | Oral gavage | NTP, 1993 | 3 x 10 1 per mg/kg-day | No | None | No | Multistage-Weibull model with linear extrapolation from the point of departure (BMDL10). | ADAF -- EPA has concluded that 1,2,3-trichloropropane is carcinogenic by a mutagenic mode of action. Application of age-dependent adjustment factors (ADAFs) to the oral slope factor is recommended in combination with appropriate exposure data when assessing risk associated with early-life exposure. | None | None | None |
147 | Trifluralin | 1582-09-8 | Oral | Endocrine, Urinary | Combined renal pelvis carcinomas, urinary bladder papillomas and/or thyroid adenomas and carcinomas | Tumor | Rat/F344, male | Oral | Diet | Emmerson et al., 1980 | 7.7 x 10 -3 per mg/kg-day | No | 2.2 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 5 x 10 2 µg/L | 5 x 10 1 µg/L | 5 µg/L |
148 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | Oral | Urinary | Urinary bladder, transitional cell papilloma and transitional squamous cell carcinomas | Tumor | Rat/Fischer 344, female | Oral | Diet | U.S. DOD, 1984a | 3 x 10 -2 per mg/kg-day | No | 9 x 10 -7 per µg/L | No | Linearized multistage procedure, extra risk | None | 1 x 10 2 µg/L | 1 x 10 1 µg/L | 1 µg/L |
149 | Vinyl chloride | 75-01-4 | Inhalation | Hepatic | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | Tumor | Female Sprague-Dawley rats | Inhalation | None | Maltoni et al. (1981, 1984) | None | No | 4.4 x 10 -6 per µg/m3 | No | LMS method | None | 2.3 x 10 1 µg/m3 | 2.3 µg/m3 | 2.3 x 10 -1 µg/m3 |
150 | Vinyl chloride | 75-01-4 | Inhalation | Hepatic | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | Tumor | Female Sprague-Dawley rats | Inhalation | None | Maltoni et al. (1981, 1984) | None | No | 8.8 x 10 -6 per µg/m3 | No | LMS method | None | None | None | None |
151 | Vinyl chloride | 75-01-4 | Inhalation | Hepatic | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | Tumor | Female Sprague-Dawley rats | Inhalation | None | Maltoni et al. (1981, 1984) | None | No | 4.4 x 10 -6 per µg/m3 | No | LED 10/ linear method | None | None | None | None |
152 | Vinyl chloride | 75-01-4 | Oral | Hepatic | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | Tumor | Female Wistar rats | Oral | Diet | Feron et al., 1981 | 1.5 per mg/kg-day | No | 4.2 x 10 -5 per µg/L | No | LED 10/ linear method | None | 2.4 µg/L | 2.4 x 10 -1 µg/L | 2.4 x 10 -2 µg/L |
153 | Vinyl chloride | 75-01-4 | Oral | Hepatic | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | Tumor | Female Wistar rats | Oral | Diet | Feron et al., 1981 | 7.2 x 10 -1 per mg/kg-day | No | 2.1 x 10 -5 per µg/L | No | LMS method | None | 4.8 µg/L | 4.8 x 10 -1 µg/L | 4.8 x 10 -2 µg/L |
154 | Vinyl chloride | 75-01-4 | Oral | Hepatic | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | Tumor | Female Wistar rats | Oral | Diet | Feron et al., 1981 | 7.5 x 10 -1 per mg/kg-day | No | 2.1 x 10 -5 per µg/L | No | LED 10/ linear method | None | 4.8 µg/L | 4.8 x 10 -1 µg/L | 4.8 x 10 -2 µg/L |
155 | Vinyl chloride | 75-01-4 | Oral | Hepatic | Total of liver angiosarcoma, hepatocellular carcinoma, and neoplastic nodules | Tumor | Female Wistar rats | Oral | Diet | Feron et al., 1981 | 1.4 per mg/kg-day | No | 4.2 x 10 -5 per µg/L | No | LMS method | None | 2.4 µg/L | 2.4 x 10 -1 µg/L | 2.4 x 10 -2 µg/L |
156 | Vinyl chloride | 75-01-4 | Inhalation | Hepatic | Liver angiosarcomas, angiomas, hepatomas, and neoplastic nodules | Tumor | Female Sprague-Dawley rats | Inhalation | None | Maltoni et al. (1981, 1984) | None | No | 8.8 x 10 -6 per µg/m3 | No | LED 10/ linear method | None | None | None | None |
157 | tert-Butyl Alcohol (tBA) | 75-65-0 | Oral | Endocrine, Urinary | Renal adenomas and carcinomas, thyroid adenomas | Tumor | Renal tumors in male rats F344 and tumors in male mice B63F1 | Oral | Drinking water | (NTP, 1995) | 5 x 10 -4 per mg/kg-day | No | None | No | None | None | None | None | None |
CHEMICAL NAME | CASRN | REVISION NUMBER | REVISION DATE | SECTIONS REVISED | REVISION DESCRIPTION | |
---|---|---|---|---|---|---|
1 | Acenaphthene | 83-32-9 | 1 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2 | Acenaphthene | 83-32-9 | 2 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
3 | Acenaphthene | 83-32-9 | 3 | Mar 11,2019 | Nanocancer RfD Clean | Corrected a typo on the RfD POD value and also removed the adjusted 05 settings on the data entry form by request from S.Rieth. |
4 | Acenaphthene | 83-32-9 | 4 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
5 | Acenaphthylene | 208-96-8 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
6 | Acephate | 30560-19-1 | 1 | Jul 15,2016 | Archiveed Assessment | IRIS working with OPP agreed to mark this pesticide chemical archived. |
7 | Acephate | 30560-19-1 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
8 | Acetaldehyde | 75-07-0 | 1 | None | None | |
9 | Acetaldehyde | 75-07-0 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
10 | Acetochlor | 34256-82-1 | 1 | Aug 1,1991 | I.A. | Oral RfD now under review |
11 | Acetochlor | 34256-82-1 | 2 | Aug 1,1991 | II. | Carcinogenicity assessment now under review |
12 | Acetochlor | 34256-82-1 | 3 | Sep 1,1993 | I.A. | Oral RfD on-line |
13 | Acetochlor | 34256-82-1 | 4 | Sep 1,1993 | VI.A. | Oral RfD references on-line |
14 | Acetochlor | 34256-82-1 | 5 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
15 | Acetochlor | 34256-82-1 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
16 | Acetochlor | 34256-82-1 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
17 | Acetone | 67-64-1 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
18 | Acetone | 67-64-1 | 2 | Jul 1,1989 | VI. | Bibliography on-line |
19 | Acetone | 67-64-1 | 3 | Jan 1,1990 | II. | Carcinogen assessment now under review |
20 | Acetone | 67-64-1 | 4 | Jul 1,1990 | II. | Carcinogen assessment on-line |
21 | Acetone | 67-64-1 | 5 | Jul 1,1990 | IV.F.1. | EPA contact changed |
22 | Acetone | 67-64-1 | 6 | Jul 1,1990 | VI.C. | Carcinogen references added |
23 | Acetone | 67-64-1 | 7 | Dec 1,1990 | I.A.2. | Text edited |
24 | Acetone | 67-64-1 | 8 | Dec 1,1990 | I.A.7. | Regulatory actions updated |
25 | Acetone | 67-64-1 | 9 | Dec 1,1990 | II.A.4. | Text edited |
26 | Acetone | 67-64-1 | 10 | Jan 1,1992 | IV. | Regulatory actions updated |
27 | Acetone | 67-64-1 | 11 | Aug 1,1993 | I.A. | Oral RfD noted as pending change |
28 | Acetone | 67-64-1 | 12 | Aug 1,1993 | I.A.6. | Work group review date added |
29 | Acetone | 67-64-1 | 13 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Piot Program replaced the workgroup functions beginning in September, 1995. |
30 | Acetone | 67-64-1 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
31 | Acetone | 67-64-1 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
32 | Acetonitrile | 75-05-8 | 1 | Jun 30,1988 | I.A.2. | Principal study clarified |
33 | Acetonitrile | 75-05-8 | 2 | Jul 1,1989 | I.B. | Inhalation RfD now under review |
34 | Acetonitrile | 75-05-8 | 3 | Aug 1,1989 | I.A. | Oral RfD summary noted as pending change |
35 | Acetonitrile | 75-05-8 | 4 | Feb 1,1990 | I.A. | Hazelton Labs, 1983 corrected to NTP, 1983 |
36 | Acetonitrile | 75-05-8 | 5 | Feb 1,1990 | I.A.2. | Text clarified (paragraph 4) |
37 | Acetonitrile | 75-05-8 | 6 | Feb 1,1990 | VI. | Bibliography on-line |
38 | Acetonitrile | 75-05-8 | 7 | Mar 1,1990 | VI.A. | NTP, 1983 - strain of rats and mice clarified |
39 | Acetonitrile | 75-05-8 | 8 | Jan 1,1992 | I.A.7. | Secondary contact changed |
40 | Acetonitrile | 75-05-8 | 9 | Jan 1,1992 | IV. | Regulatory actions updated |
41 | Acetonitrile | 75-05-8 | 10 | Feb 1,1996 | I.A.7. | Secondary contact deleted |
42 | Acetonitrile | 75-05-8 | 11 | Mar 3,1999 | I., II., VI. | RfD withdrawn, discussion added; new RfC and cancer assessment |
43 | Acetonitrile | 75-05-8 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
44 | Acetophenone | 98-86-2 | 1 | Aug 22,1988 | I.A. | oral RfD summary on-line |
45 | Acetophenone | 98-86-2 | 2 | Jan 1,1989 | I.A.7. | Contacts phone numbers corrected |
46 | Acetophenone | 98-86-2 | 3 | Aug 1,1989 | VI. | Bibliography on-line |
47 | Acetophenone | 98-86-2 | 4 | Dec 1,1990 | II. | Carcinogen assessment now under review |
48 | Acetophenone | 98-86-2 | 5 | Feb 1,1991 | II. | Carcinogenicity assessment on-line |
49 | Acetophenone | 98-86-2 | 6 | Feb 1,1991 | VI.C. | Carcinogen references added |
50 | Acetophenone | 98-86-2 | 7 | Sep 1,1991 | I.B. | Inhalation RfC now under review |
51 | Acetophenone | 98-86-2 | 8 | Jan 1,1992 | I.A.7. | Secondary contact changed |
52 | Acetophenone | 98-86-2 | 9 | Jan 1,1992 | IV. | Regulatory Action section on-line |
53 | Acetophenone | 98-86-2 | 10 | Aug 1,1992 | I.B. | Work group review meeting date added |
54 | Acetophenone | 98-86-2 | 11 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
55 | Acetophenone | 98-86-2 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Office for this information. |
56 | Acetophenone | 98-86-2 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
57 | Acetyl chloride | 75-36-5 | 1 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
58 | Acetyl chloride | 75-36-5 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
59 | Acetyl chloride | 75-36-5 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
60 | Acetyl chloride | 75-36-5 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
61 | Acetyl chloride | 75-36-5 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
62 | Acifluorfen, sodium | 62476-59-9 | 1 | Dec 1,1988 | I.A.2. | Text revised |
63 | Acifluorfen, sodium | 62476-59-9 | 2 | Nov 1,1989 | VI. | Bibliography on-line |
64 | Acifluorfen, sodium | 62476-59-9 | 3 | Oct 1,1990 | III.A. | Health Advisory on-line |
65 | Acifluorfen, sodium | 62476-59-9 | 4 | Oct 1,1990 | VI.D. | Health Advisory references added |
66 | Acifluorfen, sodium | 62476-59-9 | 5 | Nov 1,1993 | II. | Work group review date added |
67 | Acifluorfen, sodium | 62476-59-9 | 6 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
68 | Acifluorfen, sodium | 62476-59-9 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
69 | Acrolein | 107-02-8 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
70 | Acrolein | 107-02-8 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
71 | Acrolein | 107-02-8 | 3 | Jul 1,1989 | I.B. | Inhalation RfD now under review |
72 | Acrolein | 107-02-8 | 4 | Mar 1,1990 | II.A.4. | Citations clarified (3rd paragraph) |
73 | Acrolein | 107-02-8 | 5 | Mar 1,1990 | VI. | Bibliography on-line |
74 | Acrolein | 107-02-8 | 6 | May 1,1990 | VI.C. | Hemminki et al., 1980 citation corrected |
75 | Acrolein | 107-02-8 | 7 | Oct 1,1991 | I.B. | Inhalation RfC summary on-line |
76 | Acrolein | 107-02-8 | 8 | Oct 1,1991 | I.B. | Inhalation RfC references added |
77 | Acrolein | 107-02-8 | 9 | Jan 1,1992 | IV. | Regulatory Action section on-line |
78 | Acrolein | 107-02-8 | 10 | Jul 1,1993 | I.B.1. | LOAEL (ADJ) corrected |
79 | Acrolein | 107-02-8 | 11 | Feb 1,1994 | II.D.3. | Secondary contact's phone number changed |
80 | Acrolein | 107-02-8 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
81 | Acrolein | 107-02-8 | 13 | Mar 11,2019 | Nanocancer RfD Clean | Removed Adjusted and 05 from the RfD table, per request from S. Rieth. |
82 | Acrolein | 107-02-8 | 14 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
83 | Acrylamide | 79-06-1 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
84 | Acrylamide | 79-06-1 | 2 | Sep 26,1988 | II. | Carcionogen summary on-line |
85 | Acrylamide | 79-06-1 | 3 | Jun 1,1989 | II.D.2. | Work group review date added |
86 | Acrylamide | 79-06-1 | 4 | Sep 1,1990 | II. | Text edited |
87 | Acrylamide | 79-06-1 | 5 | Sep 1,1990 | III.A. | Health Advisory on-line |
88 | Acrylamide | 79-06-1 | 6 | Sep 1,1990 | VI. | Bibliography on-line |
89 | Acrylamide | 79-06-1 | 7 | Oct 1,1990 | I.B. | Not verified data inadequate |
90 | Acrylamide | 79-06-1 | 8 | Nov 1,1990 | I.B. | Inhalation RfC message on-line |
91 | Acrylamide | 79-06-1 | 9 | Nov 1,1990 | VI.B. | Inhalation RfC references on-line |
92 | Acrylamide | 79-06-1 | 10 | Jan 1,1991 | II. | Text edited |
93 | Acrylamide | 79-06-1 | 11 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
94 | Acrylamide | 79-06-1 | 12 | Mar 1,1991 | I.A.5. | Database corrected to medium text revised |
95 | Acrylamide | 79-06-1 | 13 | Aug 1,1991 | VI.C. | References clarified |
96 | Acrylamide | 79-06-1 | 14 | Jan 1,1992 | IV. | Regulatory Action section on-line |
97 | Acrylamide | 79-06-1 | 15 | Jul 1,1993 | II.D.1. | Source document and review statement clarified |
98 | Acrylamide | 79-06-1 | 16 | Aug 1,1995 | II.D.2 | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
99 | Acrylamide | 79-06-1 | 17 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
100 | Acrylamide | 79-06-1 | 18 | Feb 22,2001 | I., II. | This chemical is being reassessed under the IRIS Program. |
101 | Acrylamide | 79-06-1 | 19 | Mar 16,2010 | I., II., VI. | RfD and cancer assessment sections updated, RfC assessment added. |
102 | Acrylamide | 79-06-1 | 20 | Mar 9,2011 | NA | Corrections that were made to Table 3-2 of the Toxicological Review of Acrylamide: 1. Some of the superscripts were missing or wrong. 2. The species "hamster" should be "humans". 3. Citaion "j" Fennell et al 2005 should be Fennell et al 2006 4. All citations for Hartmann et al., 2008, 224480 should be Kopp and Dekant, 2009, 224532 |
103 | Acrylamide | 79-06-1 | 21 | Jul 10,2018 | Key Values Table | A footnote was added for ADAF. |
104 | Acrylamide | 79-06-1 | 22 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
105 | Acrylic acid | 79-10-7 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
106 | Acrylic acid | 79-10-7 | 2 | Mar 31,1987 | I.A.6. | Documentation corrected |
107 | Acrylic acid | 79-10-7 | 3 | Mar 1,1988 | I.A.2. | Paragraph 3 deleted |
108 | Acrylic acid | 79-10-7 | 4 | Aug 1,1989 | VI. | Bibliography on-line |
109 | Acrylic acid | 79-10-7 | 5 | Sep 1,1990 | I.B. | Inhalation RfC now under review |
110 | Acrylic acid | 79-10-7 | 6 | Oct 1,1990 | I.B. | Inhalation RfC summary on-line |
111 | Acrylic acid | 79-10-7 | 7 | Oct 1,1990 | VI.B. | Inhalation RfC references added |
112 | Acrylic acid | 79-10-7 | 8 | Jan 1,1992 | I.A.7. | Primary contact changed |
113 | Acrylic acid | 79-10-7 | 9 | Jan 1,1992 | IV. | Regulatory actions updated |
114 | Acrylic acid | 79-10-7 | 10 | Mar 1,1994 | I.A. | Withdrawn; new oral RfD verified (in preparation) |
115 | Acrylic acid | 79-10-7 | 11 | Mar 1,1994 | I.B. | Withdrawn; new inhalation RfC verified (in preparation) |
116 | Acrylic acid | 79-10-7 | 12 | Mar 1,1994 | VI. | Bibliography withdrawn |
117 | Acrylic acid | 79-10-7 | 13 | Apr 1,1994 | I.A. | Oral RfD summary replaced; new RfD |
118 | Acrylic acid | 79-10-7 | 14 | Apr 1,1994 | I.B. | Inhalation RfC summary replaced; new RfC |
119 | Acrylic acid | 79-10-7 | 15 | Apr 1,1994 | VI.A. | Oral RfD references replaced |
120 | Acrylic acid | 79-10-7 | 16 | Apr 1,1994 | VI.B. | Inhalation RfC references replaced |
121 | Acrylic acid | 79-10-7 | 17 | May 1,1994 | I.A.2. | Note moved from Add. Com. Sec. to Prin. Sup. Stud. Sec |
122 | Acrylic acid | 79-10-7 | 18 | May 1,1994 | I.B.1. | Note moved from Add. Com. Sec. to Prin. Sup. Stud. Sec |
123 | Acrylic acid | 79-10-7 | 19 | May 1,1995 | I.B.4. | Text edited (9th paragraph) |
124 | Acrylic acid | 79-10-7 | 20 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
125 | Acrylic acid | 79-10-7 | 21 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
126 | Acrylonitrile | 107-13-1 | 1 | Mar 1,1988 | II.B.4. | Confidence statement revised |
127 | Acrylonitrile | 107-13-1 | 2 | Feb 1,1989 | II.D.3 | Secondary contact's phone number corrected |
128 | Acrylonitrile | 107-13-1 | 3 | Jul 1,1989 | II. | Citations for Quast et al. clarified |
129 | Acrylonitrile | 107-13-1 | 4 | Jul 1,1989 | VI. | Bibliography on-line |
130 | Acrylonitrile | 107-13-1 | 5 | Jun 1,1990 | IV.A.1. | Area code for EPA contact corrected |
131 | Acrylonitrile | 107-13-1 | 6 | Jun 1,1990 | IV.F.1. | EPA contact changed |
132 | Acrylonitrile | 107-13-1 | 7 | Jan 1,1991 | I.B. | Inhalation RfC now under review |
133 | Acrylonitrile | 107-13-1 | 8 | Jan 1,1991 | II. | Text edited |
134 | Acrylonitrile | 107-13-1 | 9 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
135 | Acrylonitrile | 107-13-1 | 10 | Nov 1,1991 | I.B. | Inhalation RfC summary on-line |
136 | Acrylonitrile | 107-13-1 | 11 | Nov 1,1991 | VI.B. | Inhalation RfC references added |
137 | Acrylonitrile | 107-13-1 | 12 | Dec 1,1991 | I.B. | Text edited |
138 | Acrylonitrile | 107-13-1 | 13 | Jan 1,1992 | IV. | Regulatory actions updated |
139 | Acrylonitrile | 107-13-1 | 14 | Apr 1,1992 | IV.A.1. | CAA regulatory action withdrawn |
140 | Acrylonitrile | 107-13-1 | 15 | Aug 1,1992 | I.A. | Oral RfD now under review |
141 | Acrylonitrile | 107-13-1 | 16 | Jul 1,1993 | I.A. | Work group review date added |
142 | Acrylonitrile | 107-13-1 | 17 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by the Program replaced the workgroup functions beginning in September, 1995. |
143 | Acrylonitrile | 107-13-1 | 18 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
144 | Acrylonitrile | 107-13-1 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
145 | Adiponitrile | 111-69-3 | 1 | Feb 1,1991 | II. | Carcinogenicity assessment on-line |
146 | Adiponitrile | 111-69-3 | 2 | Feb 1,1991 | VI. | Bibliography on-line |
147 | Adiponitrile | 111-69-3 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
148 | Adiponitrile | 111-69-3 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
149 | Alachlor | 15972-60-8 | 1 | Mar 1,1988 | III.A. | Health Advisory added |
150 | Alachlor | 15972-60-8 | 2 | Dec 1,1988 | I.A.4. | Core graded added to studies 1, 3 and 4 |
151 | Alachlor | 15972-60-8 | 3 | Nov 1,1989 | VI. | Bibliography on-line |
152 | Alachlor | 15972-60-8 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
153 | Alachlor | 15972-60-8 | 5 | Sep 1,1993 | I.A. | Oral RfD revised; same study and number |
154 | Alachlor | 15972-60-8 | 6 | Nov 1,1993 | III.A.2. | Ten-day Health Advisory corrected |
155 | Alachlor | 15972-60-8 | 7 | Nov 1,1993 | III.A.9. | Documentation revised |
156 | Alachlor | 15972-60-8 | 8 | Nov 1,1993 | IV.B.2. | Discussion corrected |
157 | Alachlor | 15972-60-8 | 9 | Nov 1,1993 | VI. | Health Advisory references revised |
158 | Alachlor | 15972-60-8 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions,and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
159 | Alachlor | 15972-60-8 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
160 | Alar | 1596-84-5 | 1 | Aug 22,1988 | I.A.4. | Study 4 text revised |
161 | Alar | 1596-84-5 | 2 | Feb 1,1991 | I.B. | Incorrect message removed |
162 | Alar | 1596-84-5 | 3 | Jul 1,1991 | I.A. | Principal study clarified |
163 | Alar | 1596-84-5 | 4 | Jul 1,1991 | I.A.4. | Citations clarified |
164 | Alar | 1596-84-5 | 5 | Jul 1,1991 | VI. | Bibliography on-line |
165 | Alar | 1596-84-5 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
166 | Alar | 1596-84-5 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
167 | Alar | 1596-84-5 | 8 | Sep 27,2018 | Noncancer Critical | Updated the system from none to other so it would show up in the advanced search. |
168 | Alar | 1596-84-5 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
169 | Aldicarb | 116-06-3 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
170 | Aldicarb | 116-06-3 | 2 | Mar 1,1988 | I.A.7. | Primary contact changed |
171 | Aldicarb | 116-06-3 | 3 | Mar 1,1988 | III.A. | Health Advisory added |
172 | Aldicarb | 116-06-3 | 4 | Aug 22,1988 | II. | Carcinogen summary on-line |
173 | Aldicarb | 116-06-3 | 5 | May 1,1989 | I.A.5. | Confidence statement revised |
174 | Aldicarb | 116-06-3 | 6 | May 1,1989 | I.A.7. | Secondary contact changed |
175 | Aldicarb | 116-06-3 | 7 | Jun 1,1989 | II.D.2. | Work group review date added |
176 | Aldicarb | 116-06-3 | 8 | Aug 1,1989 | VI. | Bibliography on-line |
177 | Aldicarb | 116-06-3 | 9 | Jul 1,1990 | I.A. | Oral RfD summary noted as pending change |
178 | Aldicarb | 116-06-3 | 10 | Aug 1,1990 | I.A. | Withdrawn; new Oral RfD verified (in preparation) |
179 | Aldicarb | 116-06-3 | 11 | Aug 1,1990 | III.A.5. | DWEL & Lifetime HA withdrawn (RfD withdrawn) |
180 | Aldicarb | 116-06-3 | 12 | Aug 1,1990 | VI.A. | Oral RfD references withdrawn |
181 | Aldicarb | 116-06-3 | 13 | Mar 1,1991 | II.D.3 | Secondary contact changed |
182 | Aldicarb | 116-06-3 | 14 | Jul 1,1991 | I.A. | Oral RfD summary replaced; RfD changed |
183 | Aldicarb | 116-06-3 | 15 | Jul 1,1991 | III.A.5. | DWEL and Lifetime HA replaced |
184 | Aldicarb | 116-06-3 | 16 | Jul 1,1991 | VI.A. | Oral RfD references replaced |
185 | Aldicarb | 116-06-3 | 17 | Jul 1,1991 | III.A. | Section III.A.1-4 replaced |
186 | Aldicarb | 116-06-3 | 18 | Aug 1,1991 | I.A. | General edit |
187 | Aldicarb | 116-06-3 | 19 | Jan 1,1992 | IV. | Regulatory actions updated |
188 | Aldicarb | 116-06-3 | 20 | Oct 1,1992 | I.A. | Oral RfD summary noted as pending change |
189 | Aldicarb | 116-06-3 | 21 | Oct 1,1992 | I.A.6. | Work group review date added |
190 | Aldicarb | 116-06-3 | 22 | Dec 1,1992 | I.A.6. | Work group review date added |
191 | Aldicarb | 116-06-3 | 23 | Nov 1,1993 | I.A. | Oral RfD summary replaced; new RfD |
192 | Aldicarb | 116-06-3 | 24 | Nov 1,1993 | III.A. | Health Advisory withdrawn |
193 | Aldicarb | 116-06-3 | 25 | Nov 1,1993 | VI.A. | Oral RfD references replaced |
194 | Aldicarb | 116-06-3 | 26 | Nov 1,1993 | VI.D. | Health Advisory references withdrawn |
195 | Aldicarb | 116-06-3 | 27 | Jan 1,1994 | III.A. | Message revised to include contact's name and number |
196 | Aldicarb | 116-06-3 | 28 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS reveiw. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
197 | Aldicarb | 116-06-3 | 29 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or befroe April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
198 | Aldicarb | 116-06-3 | 30 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
199 | Aldicarb sulfone | 1646-88-4 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
200 | Aldicarb sulfone | 1646-88-4 | 2 | Feb 1,1989 | I.A.7. | Secondary contact's phone number corrected |
201 | Aldicarb sulfone | 1646-88-4 | 3 | Aug 1,1989 | I.A. | Citations clarified |
202 | Aldicarb sulfone | 1646-88-4 | 4 | Aug 1,1989 | VI. | Bibliography on-line |
203 | Aldicarb sulfone | 1646-88-4 | 5 | Jul 1,1990 | I.A. | Withdrawn; new RfD verified (in preparation) |
204 | Aldicarb sulfone | 1646-88-4 | 6 | Jul 1,1990 | VI. | Bibliography withdrawn |
205 | Aldicarb sulfone | 1646-88-4 | 7 | Sep 1,1990 | I.A. | Oral RfD summary replaced; RfD changed |
206 | Aldicarb sulfone | 1646-88-4 | 8 | Sep 1,1990 | VI. | Bibliography replaced |
207 | Aldicarb sulfone | 1646-88-4 | 9 | May 1,1990 | I.A. | Oral RfD withdrawn pending additional review |
208 | Aldicarb sulfone | 1646-88-4 | 10 | May 1,1991 | VI. | Bibliography withdrawn |
209 | Aldicarb sulfone | 1646-88-4 | 11 | Jan 1,1992 | IV. | Regulatory Action section on-line |
210 | Aldicarb sulfone | 1646-88-4 | 12 | Oct 1,1992 | I.A. | Work group review date added |
211 | Aldicarb sulfone | 1646-88-4 | 13 | Apr 1,1993 | I.A. | Oral RfD references replaced |
212 | Aldicarb sulfone | 1646-88-4 | 14 | Nov 1,1993 | I.A. | Oral RfD summary replaced; new RfD |
213 | Aldicarb sulfone | 1646-88-4 | 15 | Nov 1,1993 | VI.A. | Oral RfD references replaced |
214 | Aldicarb sulfone | 1646-88-4 | 16 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
215 | Aldicarb sulfone | 1646-88-4 | 17 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
216 | Aldrin | 309-00-2 | 1 | Sep 30,1987 | II. | Carcinogenicity section added |
217 | Aldrin | 309-00-2 | 2 | Mar 1,1988 | II.B.4 | Confidence statement revised |
218 | Aldrin | 309-00-2 | 3 | Dec 1,1988 | II.B.4. | Corrected slope factor in text |
219 | Aldrin | 309-00-2 | 4 | Sep 1,1989 | II.A.2. | Dirtaglia reference changed to Ditraglia et al. |
220 | Aldrin | 309-00-2 | 5 | Sep 1,1989 | II.A.3. | Deichmann reference changed to Deichmann et al. |
221 | Aldrin | 309-00-2 | 6 | Sep 1,1989 | II.B.3. | Body weight for mice corrected to kg |
222 | Aldrin | 309-00-2 | 7 | Sep 1,1989 | VI. | Bibliography on-line |
223 | Aldrin | 309-00-2 | 8 | Jan 1,1991 | II. | Text edited |
224 | Aldrin | 309-00-2 | 9 | Jan 1,1991 | II.C.1 | Inhalation slope factor removed (global change) |
225 | Aldrin | 309-00-2 | 10 | Jan 1,1992 | I.A.7. | Secondary contact changed |
226 | Aldrin | 309-00-2 | 11 | Jan 1,1992 | IV. | Regulatory actions updated |
227 | Aldrin | 309-00-2 | 12 | Jul 1,1993 | II.D.3. | Secondary contact's phone number changed |
228 | Aldrin | 309-00-2 | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementay data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Praogram Offices for this information. |
229 | Aldrin | 309-00-2 | 14 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
230 | Aldrin | 309-00-2 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
231 | Ally | 74223-64-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
232 | Allyl alcohol | 107-18-6 | 1 | Sep 30,1987 | V. | Supplementary Dta section added |
233 | Allyl alcohol | 107-18-6 | 2 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
234 | Allyl alcohol | 107-18-6 | 3 | Mar 1,1988 | I.A.2. | Text deleted |
235 | Allyl alcohol | 107-18-6 | 4 | Mar 1,1988 | I.A.4. | Text clarified |
236 | Allyl alcohol | 107-18-6 | 5 | Mar 1,1988 | I.A.5. | Confidence levels revised |
237 | Allyl alcohol | 107-18-6 | 6 | Aug 1,1989 | I.A.4. | Citations clarified |
238 | Allyl alcohol | 107-18-6 | 7 | Aug 1,1989 | VI. | Bibliography on-line |
239 | Allyl alcohol | 107-18-6 | 8 | Jan 1,1992 | I.A.7. | Primary contact changed |
240 | Allyl alcohol | 107-18-6 | 9 | Jan 1,1992 | IV. | Regulatory action updated |
241 | Allyl alcohol | 107-18-6 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS useres were directed to the appropriate EPA Program Offices for this information. |
242 | Allyl alcohol | 107-18-6 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
243 | Allyl chloride | 107-05-1 | 1 | Sep 1,1990 | II. | Carcinogen assessment on-line |
244 | Allyl chloride | 107-05-1 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
245 | Allyl chloride | 107-05-1 | 3 | Jan 1,1991 | I.B. | Inhalation RfC now under review |
246 | Allyl chloride | 107-05-1 | 4 | Aug 1,1991 | VI.C. | Eder et al. 1980 reference volume corrected |
247 | Allyl chloride | 107-05-1 | 5 | Dec 1,1991 | I.B. | Inhalation RfC on-line |
248 | Allyl chloride | 107-05-1 | 6 | Dec 1,1991 | VI.B. | Inhalation RfC references added |
249 | Allyl chloride | 107-05-1 | 7 | Jan 1,1992 | IV. | Regulatory Action section on-line |
250 | Allyl chloride | 107-05-1 | 8 | May 1,1995 | I.B. | Principal study author name corrected |
251 | Allyl chloride | 107-05-1 | 9 | May 1,1995 | VI.B. | Author name corrected |
252 | Allyl chloride | 107-05-1 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
253 | Allyl chloride | 107-05-1 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
254 | Aluminum phosphide | 20859-73-8 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
255 | Aluminum phosphide | 20859-73-8 | 2 | Mar 1,1988 | I.A.6. | Documentation revised |
256 | Aluminum phosphide | 20859-73-8 | 3 | Aug 1,1989 | VI. | Bibliography on-line |
257 | Aluminum phosphide | 20859-73-8 | 4 | Jan 1,1992 | I.A.7. | Primary contact changed |
258 | Aluminum phosphide | 20859-73-8 | 5 | Jan 1,1992 | IV. | Regulatory actions updated |
259 | Aluminum phosphide | 20859-73-8 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
260 | Aluminum phosphide | 20859-73-8 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
261 | Amdro | 67485-29-4 | 1 | Nov 1,1989 | VI. | Bibliography on-line |
262 | Amdro | 67485-29-4 | 2 | Jan 1,1992 | IV. | Regulatory Action section on-line |
263 | Amdro | 67485-29-4 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were direcetd to the appropriate EPA Program Office for this information. |
264 | Amdro | 67485-29-4 | 4 | Jul 15,2016 | Archived Assessment | IRIS working with OPP agreed to mark this pesticide chemical archived. |
265 | Amdro | 67485-29-4 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
266 | Ametryn | 834-12-8 | 1 | Mar 1,1988 | I.A.4. | Text clarified |
267 | Ametryn | 834-12-8 | 2 | Nov 1,1989 | I.A.4. | Species corrected in study 4 |
268 | Ametryn | 834-12-8 | 3 | Nov 1,1989 | VI. | Bibliography on-line |
269 | Ametryn | 834-12-8 | 4 | Oct 1,1990 | III.A. | Health Advisory on-line |
270 | Ametryn | 834-12-8 | 5 | Oct 1,1990 | VI.D. | Health Advisory references added |
271 | Ametryn | 834-12-8 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
272 | Ametryn | 834-12-8 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
273 | Ametryn | 834-12-8 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
274 | 4-Aminopyridine | 504-24-5 | 1 | Dec 1,1989 | II. | Carcinogen summary on-line |
275 | 4-Aminopyridine | 504-24-5 | 2 | Dec 1,1989 | VI. | Bibliography on-line |
276 | 4-Aminopyridine | 504-24-5 | 3 | Dec 1,1991 | II.A.1. | Basis statement replaced |
277 | 4-Aminopyridine | 504-24-5 | 4 | Dec 1,1991 | II.A.4. | Text replaced |
278 | 4-Aminopyridine | 504-24-5 | 5 | Dec 1,1991 | II.D.2. | Review date of 07/25/1991 added |
279 | 4-Aminopyridine | 504-24-5 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
280 | 4-Aminopyridine | 504-24-5 | 7 | Jul 1,1993 | II.D.1. | Source document year corrected |
281 | 4-Aminopyridine | 504-24-5 | 8 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
282 | 4-Aminopyridine | 504-24-5 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory ACtions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
283 | 4-Aminopyridine | 504-24-5 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
284 | Amitraz | 33089-61-1 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
285 | Amitraz | 33089-61-1 | 2 | Dec 1,1988 | I.A.4. | Core grades corrected |
286 | Amitraz | 33089-61-1 | 3 | Oct 1,1989 | VI. | Bibliography on-line |
287 | Amitraz | 33089-61-1 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
288 | Amitraz | 33089-61-1 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EP Program Offices for this information. |
289 | Amitraz | 33089-61-1 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
290 | Ammonia | 7664-41-7 | 1 | May 1,1991 | I.B. | Inhalation RfC summary on-line |
291 | Ammonia | 7664-41-7 | 2 | May 1,1991 | VI. | Bibliography on-line |
292 | Ammonia | 7664-41-7 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
293 | Ammonia | 7664-41-7 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this inforamation. |
294 | Ammonia | 7664-41-7 | 5 | Sep 20,2016 | I.B. | Update to the noncancer inhalation RfC key values. |
295 | Ammonia | 7664-41-7 | 6 | Jun 28,2018 | IRIS Summary | Renamed the IRIS Summary to Executive summary to match the attachment. |
296 | Ammonia | 7664-41-7 | 7 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
297 | Ammonium acetate | 631-61-8 | 1 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
298 | Ammonium acetate | 631-61-8 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
299 | Ammonium acetate | 631-61-8 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
300 | Ammonium acetate | 631-61-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. Iris users were directed to the appropriate EPA Program Offices for this information. |
301 | Ammonium acetate | 631-61-8 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
302 | Ammonium methacrylate | 16325-47-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
303 | Ammonium sulfamate | 7773-06-0 | 1 | Mar 1,1988 | I.A.1. | Critical effect identified, LOAEL specified |
304 | Ammonium sulfamate | 7773-06-0 | 2 | Mar 1,1988 | I.A.2. | Principal study citation corrected |
305 | Ammonium sulfamate | 7773-06-0 | 3 | Mar 1,1988 | I.A.2. | Text revised |
306 | Ammonium sulfamate | 7773-06-0 | 4 | Dec 1,1988 | I.A. | Withdrawn; new RfD verified (in preparation) |
307 | Ammonium sulfamate | 7773-06-0 | 5 | Jan 1,1989 | I.A. | Oral RfD summary replaced; RfD changed |
308 | Ammonium sulfamate | 7773-06-0 | 6 | Mar 1,1991 | I.A.4. | Citations added |
309 | Ammonium sulfamate | 7773-06-0 | 7 | Mar 1,1991 | III.A. | Health Advisory on-line |
310 | Ammonium sulfamate | 7773-06-0 | 8 | Mar 1,1991 | VI. | Bibliography on-line |
311 | Ammonium sulfamate | 7773-06-0 | 9 | Jun 1,1991 | III.A.4. | 70-kg 'child' corrected to 70-kg adult in assumptions |
312 | Ammonium sulfamate | 7773-06-0 | 10 | Jan 1,1992 | IV. | Regulatory actions updated |
313 | Ammonium sulfamate | 7773-06-0 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program offices for this information. |
314 | Ammonium sulfamate | 7773-06-0 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
315 | Aniline | 62-53-3 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
316 | Aniline | 62-53-3 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
317 | Aniline | 62-53-3 | 3 | Jun 1,1989 | II.D.2. | Work group review date added |
318 | Aniline | 62-53-3 | 4 | Aug 1,1989 | VI. | Bibliography on-line |
319 | Aniline | 62-53-3 | 5 | Oct 1,1990 | I.B. | Inhalation RfC now under review |
320 | Aniline | 62-53-3 | 6 | Nov 1,1990 | I.B. | Inhalation RfC summary on-line |
321 | Aniline | 62-53-3 | 7 | Nov 1,1990 | VI.B. | Inhalation RfC references added |
322 | Aniline | 62-53-3 | 8 | Nov 1,1991 | I.B.6. | Source Doc. & Other EPA Documentation corrected |
323 | Aniline | 62-53-3 | 9 | Jan 1,1992 | IV. | Regulatory Action section on-line |
324 | Aniline | 62-53-3 | 10 | Dec 1,1993 | I.B.1. | Critical effect clarified in study 1 |
325 | Aniline | 62-53-3 | 11 | Feb 1,1994 | II.D.3. | Secondary contact's phone number changed |
326 | Aniline | 62-53-3 | 12 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
327 | Aniline | 62-53-3 | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementarry Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
328 | Aniline | 62-53-3 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
329 | ortho-Anisidine | 90-04-0 | 1 | Sep 1,1991 | I.B. | Inhalation RfC now under review |
330 | ortho-Anisidine | 90-04-0 | 2 | Oct 1,1991 | I.B. | Inhalation RfC message on-line |
331 | ortho-Anisidine | 90-04-0 | 3 | Oct 1,1991 | VI. | Bibliography on-line |
332 | ortho-Anisidine | 90-04-0 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were direcetd to the appropriate EPA Program Offices for this information. |
333 | ortho-Anisidine | 90-04-0 | 5 | Dec 19,2018 | Archived Chemical | IRIS Program requested that we archive assessments with no values. |
334 | ortho-Anisidine | 90-04-0 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
335 | Anthracene | 120-12-7 | 1 | Sep 1,1990 | I.A. | Oral RfD summary on-line |
336 | Anthracene | 120-12-7 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
337 | Anthracene | 120-12-7 | 3 | Jan 1,1991 | II. | Carcinogen assessment on-line |
338 | Anthracene | 120-12-7 | 4 | Jan 1,1991 | VI.C. | Carcinogen assessment references added |
339 | Anthracene | 120-12-7 | 5 | Jul 1,1991 | I.A.7. | Primary and secondary contacts changed |
340 | Anthracene | 120-12-7 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
341 | Anthracene | 120-12-7 | 7 | Jul 1,1993 | I.A.6. | Source Document and Other EPA documentation clarified |
342 | Anthracene | 120-12-7 | 8 | Sep 1,1994 | I.B. | Inhalation RfD now under review |
343 | Anthracene | 120-12-7 | 9 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS reveiw. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
344 | Anthracene | 120-12-7 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplmentary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
345 | Anthracene | 120-12-7 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
346 | Antimony | 7440-36-0 | 1 | Aug 1,1989 | I.A. | Gross et al., (1955) citation clarified |
347 | Antimony | 7440-36-0 | 2 | Aug 1,1989 | VI. | Bibliography on-line |
348 | Antimony | 7440-36-0 | 3 | Feb 1,1991 | I.A.1. | Conversion factor revised |
349 | Antimony | 7440-36-0 | 4 | Feb 1,1991 | I.A.2. | Text added |
350 | Antimony | 7440-36-0 | 5 | Feb 1,1991 | I.A.4. | Paragraph 2 added |
351 | Antimony | 7440-36-0 | 6 | Feb 1,1991 | VI.A. | Dunn, 1928 and Monier-Williams, 1934 added |
352 | Antimony | 7440-36-0 | 7 | Jan 1,1992 | I.A.7. | Primary contact changed |
353 | Antimony | 7440-36-0 | 8 | Jan 1,1992 | IV. | Regulatory actions updated |
354 | Antimony | 7440-36-0 | 9 | Apr 1,1997 | III>, IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directeed to the appropriate EPA Program Offices for this information. |
355 | Antimony | 7440-36-0 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
356 | Antimony trioxide | 1309-64-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
357 | Apollo | 74115-24-5 | 1 | Mar 1,1988 | I.A.3. | Text revised |
358 | Apollo | 74115-24-5 | 2 | Mar 1,1988 | I.A.4. | Data gaps revised |
359 | Apollo | 74115-24-5 | 3 | Mar 1,1988 | I.A.4. | Study description added |
360 | Apollo | 74115-24-5 | 4 | Mar 1,1988 | I.A.4. | Data added to 'Other Data Reviewed' |
361 | Apollo | 74115-24-5 | 5 | Mar 1,1988 | I.A.5. | Confidence levels revised |
362 | Apollo | 74115-24-5 | 6 | Mar 1,1988 | I.A.6. | Dates corrected |
363 | Apollo | 74115-24-5 | 7 | Nov 1,1989 | I.A. | Principal study year corrected |
364 | Apollo | 74115-24-5 | 8 | Nov 1,1989 | VI. | Bibliography on-line |
365 | Apollo | 74115-24-5 | 9 | Mar 1,1990 | II. | Carcinogen assessment now under review |
366 | Apollo | 74115-24-5 | 10 | Jun 1,1991 | II. | Carcinogenicity assessment on-line |
367 | Apollo | 74115-24-5 | 11 | Jun 1,1991 | VI.C. | Carcinogenicity references added |
368 | Apollo | 74115-24-5 | 12 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone no. changed. |
369 | Apollo | 74115-24-5 | 13 | Aug 1,1995 | I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
370 | Apollo | 74115-24-5 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
371 | Apollo | 74115-24-5 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
372 | Aramite | 140-57-8 | 1 | Jun 1,1991 | II. | Carcinogenicity assessment on-line |
373 | Aramite | 140-57-8 | 2 | Jun 1,1991 | VI. | Bibliography on-line |
374 | Aramite | 140-57-8 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
375 | Aramite | 140-57-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
376 | Aramite | 140-57-8 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
377 | Aroclor 1016 | 12674-11-2 | 1 | Aug 1,1991 | I.A. | Oral RfD now under review |
378 | Aroclor 1016 | 12674-11-2 | 2 | Aug 1,1992 | I.A. | Work group review dates added |
379 | Aroclor 1016 | 12674-11-2 | 3 | Oct 1,1992 | I.A. | Work group review date added |
380 | Aroclor 1016 | 12674-11-2 | 4 | Dec 1,1992 | I.A. | Work group reveiw dates added |
381 | Aroclor 1016 | 12674-11-2 | 5 | Jan 1,1993 | I.A. | Oral RfD assessment on-line |
382 | Aroclor 1016 | 12674-11-2 | 6 | Jan 1,1993 | VI.A. | Oral RfD references on-line |
383 | Aroclor 1016 | 12674-11-2 | 7 | Feb 1,1993 | VI.A. | Oral RfD references corrected |
384 | Aroclor 1016 | 12674-11-2 | 8 | Mar 1,1993 | I.A.6. | Work group review date added |
385 | Aroclor 1016 | 12674-11-2 | 9 | Sep 1,1993 | I.A. | Oral RfD noted as going to be externally peer reviewed |
386 | Aroclor 1016 | 12674-11-2 | 10 | Nov 1,1993 | I.A. | Note revised |
387 | Aroclor 1016 | 12674-11-2 | 11 | May 1,1994 | I.A. | Peer review note removed; peer review May 24-25 |
388 | Aroclor 1016 | 12674-11-2 | 12 | Aug 1,1995 | I.A.6., I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
389 | Aroclor 1016 | 12674-11-2 | 13 | Nov 1,1996 | I.A.7. | Primary contact's office changed |
390 | Aroclor 1016 | 12674-11-2 | 14 | Apr 1,1997 | III., IV., V. | Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
391 | Aroclor 1016 | 12674-11-2 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
392 | Aroclor 1248 | 12672-29-6 | 1 | Sep 1,1992 | I.A. | Oral RfD now under review |
393 | Aroclor 1248 | 12672-29-6 | 2 | Dec 1,1992 | I.A. | Work group review date added |
394 | Aroclor 1248 | 12672-29-6 | 3 | Jul 1,1993 | I.A. | Work group review date added |
395 | Aroclor 1248 | 12672-29-6 | 4 | Aug 1,1993 | I.A. | Work group review date added |
396 | Aroclor 1248 | 12672-29-6 | 5 | Apr 1,1994 | I.A. | Oral RfD message on-line |
397 | Aroclor 1248 | 12672-29-6 | 6 | Apr 1,1994 | VI.A. | Oral RfD references on-line |
398 | Aroclor 1248 | 12672-29-6 | 7 | Nov 1,1996 | I.A. | Contact's office changed |
399 | Aroclor 1248 | 12672-29-6 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
400 | Aroclor 1248 | 12672-29-6 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
401 | Aroclor 1254 | 11097-69-1 | 1 | Jul 1,1993 | I.A. | Oral RfD now under review |
402 | Aroclor 1254 | 11097-69-1 | 2 | Sep 1,1993 | A11. | Monor edit |
403 | Aroclor 1254 | 11097-69-1 | 3 | Mar 1,1994 | I.A. | Work group review date added |
404 | Aroclor 1254 | 11097-69-1 | 4 | Oct 1,1994 | I.A. | Oral RfD summary on-line |
405 | Aroclor 1254 | 11097-69-1 | 5 | Oct 1,1994 | VI.A. | Oral RfD references on-line |
406 | Aroclor 1254 | 11097-69-1 | 6 | Nov 1,1996 | I.A.7. | Primary contact's office changed |
407 | Aroclor 1254 | 11097-69-1 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
408 | Aroclor 1254 | 11097-69-1 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
409 | Arsenic, Inorganic | 7440-38-2 | 1 | Jun 30,1988 | II.B. | Revised last paragraph |
410 | Arsenic, Inorganic | 7440-38-2 | 2 | Jun 30,1988 | II.C.1. | Inhalation slope factor changed |
411 | Arsenic, Inorganic | 7440-38-2 | 3 | Jun 30,1988 | II.C.3. | Paragraph 2 added |
412 | Arsenic, Inorganic | 7440-38-2 | 4 | Sep 7,1988 | II.B. | Major text changes |
413 | Arsenic, Inorganic | 7440-38-2 | 5 | Dec 1,1988 | II.A.2 | Mabuchi et al., citation year corrected |
414 | Arsenic, Inorganic | 7440-38-2 | 6 | Dec 1,1988 | II.A.3. | Pershagen et al., citation year corrected |
415 | Arsenic, Inorganic | 7440-38-2 | 7 | Sep 1,1989 | II.C.2. | Citations added to Anacondor smelter |
416 | Arsenic, Inorganic | 7440-38-2 | 8 | Sep 1,1989 | VI. | Bibliography on-line |
417 | Arsenic, Inorganic | 7440-38-2 | 9 | Jun 1,1990 | II.A.2. | 2nd and 3rd paragraph - Text revised |
418 | Arsenic, Inorganic | 7440-38-2 | 10 | Jun 1,1990 | II.A.4. | Text corrected |
419 | Arsenic, Inorganic | 7440-38-2 | 11 | Jun 1,1990 | II.C.1. | Inhalation slope factor removed (format change) |
420 | Arsenic, Inorganic | 7440-38-2 | 12 | Jun 1,1990 | IV.F.1. | EPA contact changed |
421 | Arsenic, Inorganic | 7440-38-2 | 13 | Jun 1,1990 | VI.C. | References added |
422 | Arsenic, Inorganic | 7440-38-2 | 14 | Dec 1,1990 | II.B. | Changed slope factor to "unit risk", 2nd paragraph, 1st sentence |
423 | Arsenic, Inorganic | 7440-38-2 | 15 | Feb 1,1991 | II.C.3. | Text edited |
424 | Arsenic, Inorganic | 7440-38-2 | 16 | Sep 1,1991 | I.A. | Oral RfD summary now on-line |
425 | Arsenic, Inorganic | 7440-38-2 | 17 | Sep 1,1991 | I.A. | Oral RfD bibliography added |
426 | Arsenic, Inorganic | 7440-38-2 | 18 | Oct 1,1991 | I.A.1. | Conversion factor text clarified |
427 | Arsenic, Inorganic | 7440-38-2 | 19 | Oct 1,1991 | IV.B.1. | MCLG noted as pending change |
428 | Arsenic, Inorganic | 7440-38-2 | 20 | Jan 1,1992 | IV. | Regulatory actions updated |
429 | Arsenic, Inorganic | 7440-38-2 | 21 | Aug 1,1992 | II. | Note added to indicate text in oral quant. estimate |
430 | Arsenic, Inorganic | 7440-38-2 | 22 | Oct 1,1992 | VI.C. | Missing reference added to bibliography |
431 | Arsenic, Inorganic | 7440-38-2 | 23 | Feb 1,1993 | I.A.4. | Citations added to second paragraph |
432 | Arsenic, Inorganic | 7440-38-2 | 24 | Feb 1,1993 | VI.A. | References added to bibliography |
433 | Arsenic, Inorganic | 7440-38-2 | 25 | Mar 1,1993 | VI.A. | Corrections to references |
434 | Arsenic, Inorganic | 7440-38-2 | 26 | Mar 1,1994 | II.D.2. | Work group review date added |
435 | Arsenic, Inorganic | 7440-38-2 | 27 | Jun 1,1994 | II. | Carcinogen assessment noted as pending change |
436 | Arsenic, Inorganic | 7440-38-2 | 28 | Jan 1,1995 | II. | Pending change note revised |
437 | Arsenic, Inorganic | 7440-38-2 | 29 | Jan 1,1995 | II.B. | Dates and document no. added to oral quant. estimate |
438 | Arsenic, Inorganic | 7440-38-2 | 30 | Jun 1,1995 | II. | Carcinogenicity assessment replaced |
439 | Arsenic, Inorganic | 7440-38-2 | 31 | Jun 1,1995 | VI.C. | Carcinogenicity references replaced |
440 | Arsenic, Inorganic | 7440-38-2 | 32 | Jul 1,1995 | II.D.1 | Documentation year corrected; review statement revised |
441 | Arsenic, Inorganic | 7440-38-2 | 33 | Jul 1,1995 | VI.C. | U.S. EPA, 1994 corrected to 1993 |
442 | Arsenic, Inorganic | 7440-38-2 | 34 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
443 | Arsenic, Inorganic | 7440-38-2 | 35 | Apr 1,1997 | III.,IV.,V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
444 | Arsenic, Inorganic | 7440-38-2 | 36 | Apr 10,1998 | II.B.3. | Added discussion on expert panel workshop |
445 | Arsenic, Inorganic | 7440-38-2 | 37 | Feb 11,2000 | II.C.2. | Corrected alignment of unit risks in table with corresponding studies |
446 | Arsenic, Inorganic | 7440-38-2 | 38 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
447 | Arsine | 7784-42-1 | 1 | Mar 1,1993 | I.B. | Inhalation RfC now under review |
448 | Arsine | 7784-42-1 | 2 | Mar 1,1994 | I.B. | Inhalation RfC on-line |
449 | Arsine | 7784-42-1 | 3 | Mar 1,1994 | VI.B. | Inhalation RfC references on-line |
450 | Arsine | 7784-42-1 | 4 | Apr 1,1997 | III.,IV.,V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
451 | Arsine | 7784-42-1 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
452 | Asbestos | 1332-21-4 | 1 | Sep 26,1988 | II. | Carcinogen summary on-line |
453 | Asbestos | 1332-21-4 | 2 | May 1,1989 | II. | Carcinogen summary noted as pending change |
454 | Asbestos | 1332-21-4 | 3 | Dec 1,1989 | VI. | Bibliography on-line |
455 | Asbestos | 1332-21-4 | 4 | Mar 1,1991 | II.A.1. | Text revised |
456 | Asbestos | 1332-21-4 | 5 | Jul 1,1991 | II.C.3 | Last paragraph units changed from ug/cu.m to fibers/ml |
457 | Asbestos | 1332-21-4 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
458 | Asbestos | 1332-21-4 | 7 | Jul 1,1993 | II.D.1. | EPA Documentation clarified |
459 | Asbestos | 1332-21-4 | 8 | Jul 1,1993 | VI.C. | References alphabetized correctly |
460 | Asbestos | 1332-21-4 | 9 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
461 | Asbestos | 1332-21-4 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
462 | Asbestos | 1332-21-4 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
463 | Assure | 76578-14-8 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
464 | Assure | 76578-14-8 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
465 | Assure | 76578-14-8 | 3 | Jun 1,1991 | II. | Carcinogenicity assessment on-line |
466 | Assure | 76578-14-8 | 4 | Jun 1,1991 | VI.C. | Carcinogenicity references added |
467 | Assure | 76578-14-8 | 5 | Jul 1,1991 | II.D.2. | Work group review date corrected |
468 | Assure | 76578-14-8 | 6 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone no. changed |
469 | Assure | 76578-14-8 | 7 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgropups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS pilot Program replaced the workgroup functions beginning in September, 1995. |
470 | Assure | 76578-14-8 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
471 | Assure | 76578-14-8 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
472 | Asulam | 3337-71-1 | 1 | Nov 1,1989 | VI. | Bibliography on-line |
473 | Asulam | 3337-71-1 | 2 | Jan 1,1992 | IV. | Regulatory action section on-line |
474 | Asulam | 3337-71-1 | 3 | Jan 1,1995 | I.A. | Oral RfD noted as pending change |
475 | Asulam | 3337-71-1 | 4 | Jan 1,1995 | I.A.6. | Work group reveiw date added |
476 | Asulam | 3337-71-1 | 5 | Aug 1,1995 | I.A.,I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reveiws that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
477 | Asulam | 3337-71-1 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
478 | Asulam | 3337-71-1 | 7 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
479 | Asulam | 3337-71-1 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
480 | Atrazine | 1912-24-9 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
481 | Atrazine | 1912-24-9 | 2 | Aug 22,1988 | I.A. | Withdrawn; new oral RfD in preparation |
482 | Atrazine | 1912-24-9 | 3 | Sep 7,1988 | I.A. | Revised oral RfD summary added |
483 | Atrazine | 1912-24-9 | 4 | Oct 1,1989 | VI. | Bibliography on-line |
484 | Atrazine | 1912-24-9 | 5 | Mar 1,1990 | I.A. | Withdrawn; new oral RfD in preparation |
485 | Atrazine | 1912-24-9 | 6 | Mar 1,1990 | VI.A. | Oral RfD references withdrawn |
486 | Atrazine | 1912-24-9 | 7 | May 1,1990 | I.A. | Oral RfD summary replaced; RfD unchanged |
487 | Atrazine | 1912-24-9 | 8 | May 1,1990 | VI.A. | Oral RfD references replaced |
488 | Atrazine | 1912-24-9 | 9 | Jan 1,1991 | I.A. | Text edited |
489 | Atrazine | 1912-24-9 | 10 | Jan 1,1991 | II. | Carcinogen assessment now under review |
490 | Atrazine | 1912-24-9 | 11 | Jan 1,1992 | IV. | Regulatory Action section on-line |
491 | Atrazine | 1912-24-9 | 12 | Dec 1,1992 | I.A. | Oral RfD summary noted as pending change |
492 | Atrazine | 1912-24-9 | 13 | Dec 1,1992 | I.A.6. | Work group review date added |
493 | Atrazine | 1912-24-9 | 14 | Jan 1,1993 | I.A. | Withdrawn; new oral RfD in preparation |
494 | Atrazine | 1912-24-9 | 15 | Jan 1,1993 | I.A. | Work group review date added |
495 | Atrazine | 1912-24-9 | 16 | Jan 1,1993 | VI.A. | Oral RfD references withdrawn |
496 | Atrazine | 1912-24-9 | 17 | Oct 1,1993 | I.A. | Oral RfD summary replaced; RfD changed |
497 | Atrazine | 1912-24-9 | 18 | Oct 1,1993 | VI.A. | Oral RfD references replaced |
498 | Atrazine | 1912-24-9 | 19 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning ing September, 1995. |
499 | Atrazine | 1912-24-9 | 20 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
500 | Atrazine | 1912-24-9 | 21 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
501 | Avermectin B1 | 65195-55-3 | 1 | Jul 1,1989 | I.A. | Oral RfD summary on-line |
502 | Avermectin B1 | 65195-55-3 | 2 | Jul 1,1989 | VI. | Bibliography on-line |
503 | Avermectin B1 | 65195-55-3 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Acions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
504 | Avermectin B1 | 65195-55-3 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
505 | Azobenzene | 103-33-3 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
506 | Azobenzene | 103-33-3 | 2 | Aug 1,1989 | VI. | Bibliography on-line |
507 | Azobenzene | 103-33-3 | 3 | Jan 1,1991 | II. | Text edited |
508 | Azobenzene | 103-33-3 | 4 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
509 | Azobenzene | 103-33-3 | 5 | Jul 1,1993 | II.D.3. | Secondary contact's phone number changed |
510 | Azobenzene | 103-33-3 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisoreis, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information |
511 | Azobenzene | 103-33-3 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
512 | Barium and Compounds | 7440-39-3 | 1 | Sep 30,1987 | IV. | Regulatory Action section added |
513 | Barium and Compounds | 7440-39-3 | 2 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
514 | Barium and Compounds | 7440-39-3 | 3 | Mar 1,1988 | I.A.3. | Text changed |
515 | Barium and Compounds | 7440-39-3 | 4 | Mar 1,1988 | I.A.7. | Secondary contact changed |
516 | Barium and Compounds | 7440-39-3 | 5 | Jun 30,1988 | I.A.7. | Contacts switched |
517 | Barium and Compounds | 7440-39-3 | 6 | Aug 1,1989 | VI. | Bibliography on-line |
518 | Barium and Compounds | 7440-39-3 | 7 | Jun 1,1990 | IV.F.1. | EPA contact changed |
519 | Barium and Compounds | 7440-39-3 | 8 | Jul 1,1990 | I.A. | Withdrawn; new RfD verified (in preparation) |
520 | Barium and Compounds | 7440-39-3 | 9 | Jul 1,1990 | VI. | Bibliography withdrawn |
521 | Barium and Compounds | 7440-39-3 | 10 | Aug 1,1990 | I.A. | Oral RfD summary replaced; RfD changed |
522 | Barium and Compounds | 7440-39-3 | 11 | Aug 1,1990 | VI. | Bibliography replaced |
523 | Barium and Compounds | 7440-39-3 | 12 | Dec 1,1990 | I.B. | Inhalation RfC now under review |
524 | Barium and Compounds | 7440-39-3 | 13 | Jan 1,1992 | IV. | Regulatory actions updated |
525 | Barium and Compounds | 7440-39-3 | 14 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
526 | Barium and Compounds | 7440-39-3 | 15 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
527 | Barium and Compounds | 7440-39-3 | 16 | Mar 30,1998 | I.A. | Oral RfD Assessment |
528 | Barium and Compounds | 7440-39-3 | 17 | Mar 30,1998 | I.B. | Inahalation RfC Assessment |
529 | Barium and Compounds | 7440-39-3 | 18 | Mar 30,1998 | II. | Carcinogenicity Assessment |
530 | Barium and Compounds | 7440-39-3 | 19 | Jan 21,1999 | I.A. | Minor revisions to RfD Assessment, revised critical effect |
531 | Barium and Compounds | 7440-39-3 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
532 | Barium cyanide | 542-62-1 | 1 | Mar 1,1988 | I.A.2. | Text revised paragraph 3 |
533 | Barium cyanide | 542-62-1 | 2 | Jan 1,1989 | I.A.1. | LOAEL dose rate units corrected |
534 | Barium cyanide | 542-62-1 | 3 | Mar 1,1991 | VI. | Bibliography withdrawn |
535 | Barium cyanide | 542-62-1 | 4 | Nov 1,1989 | VI. | Bibliography on-line |
536 | Barium cyanide | 542-62-1 | 5 | Mar 1,1991 | I.A. | Oral RfD withdrawn pending additional review |
537 | Barium cyanide | 542-62-1 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
538 | Barium cyanide | 542-62-1 | 7 | Aug 1,1993 | I.A. | Oral RfD withdrawn pending addditional review |
539 | Barium cyanide | 542-62-1 | 8 | Aug 1,1993 | I.A. | EPA contact changed |
540 | Barium cyanide | 542-62-1 | 9 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
541 | Barium cyanide | 542-62-1 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
542 | Barium cyanide | 542-62-1 | 11 | Dec 19,2018 | Archived Chemical | IRIS Program requested that we archive assessments with no values. |
543 | Barium cyanide | 542-62-1 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
544 | Baygon | 114-26-1 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
545 | Baygon | 114-26-1 | 2 | Mar 31,1987 | IV.A. | Pesticide AI data added |
546 | Baygon | 114-26-1 | 3 | Nov 1,1989 | VI. | Bibliography on-line |
547 | Baygon | 114-26-1 | 4 | Oct 1,1990 | III.A. | Health Advisory on-line |
548 | Baygon | 114-26-1 | 5 | Oct 1,1990 | VI.D. | Health Advisory references added |
549 | Baygon | 114-26-1 | 6 | Jan 1,1992 | IV. | Regulatory action updated |
550 | Baygon | 114-26-1 | 7 | Jul 1,1992 | I.A.4. | Study 5 citation corrected |
551 | Baygon | 114-26-1 | 8 | Apr 1,1997 | III., IV., V., VI.D. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS useres were directed to the appropriate EPA Program Offices for this information. |
552 | Baygon | 114-26-1 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
553 | Bayleton | 43121-43-3 | 1 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
554 | Bayleton | 43121-43-3 | 2 | Mar 1,1988 | I.A.4. | Core grades added |
555 | Bayleton | 43121-43-3 | 3 | Nov 1,1989 | VI. | Bibliography on-line |
556 | Bayleton | 43121-43-3 | 4 | Jan 1,1992 | IV. | Regulatory action on-line |
557 | Bayleton | 43121-43-3 | 5 | Apr 1,1987 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS useres were directed to the appropriate EPA Program Offices for this information. |
558 | Bayleton | 43121-43-3 | 6 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
559 | Bayleton | 43121-43-3 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
560 | Baythroid | 68359-37-5 | 1 | Nov 1,1989 | VI. | Bibliography on-line |
561 | Baythroid | 68359-37-5 | 2 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
562 | Baythroid | 68359-37-5 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
563 | Benefin | 1861-40-1 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
564 | Benefin | 1861-40-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
565 | Benomyl | 17804-35-2 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
566 | Benomyl | 17804-35-2 | 2 | Mar 1,1989 | I.A. | Major text revisions |
567 | Benomyl | 17804-35-2 | 3 | Jul 1,1989 | VI. | Bibliography on-line |
568 | Benomyl | 17804-35-2 | 4 | Jan 1,1992 | IV. | Regulatory action updated |
569 | Benomyl | 17804-35-2 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
570 | Benomyl | 17804-35-2 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
571 | Bentazon (Basagran) | 25057-89-0 | 1 | Apr 1,1989 | III. | Health Advisory on-line |
572 | Bentazon (Basagran) | 25057-89-0 | 2 | Nov 1,1989 | VI. | Bibliography on-line |
573 | Bentazon (Basagran) | 25057-89-0 | 3 | May 1,1991 | I.A. | Oral RfD Summary noted as pending change |
574 | Bentazon (Basagran) | 25057-89-0 | 4 | Jan 1,1992 | IV. | Regulatory action section on-line |
575 | Bentazon (Basagran) | 25057-89-0 | 5 | Jan 1,1995 | I.A.6. | Workgroup review date added |
576 | Bentazon (Basagran) | 25057-89-0 | 6 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
577 | Bentazon (Basagran) | 25057-89-0 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
578 | Bentazon (Basagran) | 25057-89-0 | 8 | Mar 2,1998 | I.A., II., VI. | New RfD, cancer assessment |
579 | Bentazon (Basagran) | 25057-89-0 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
580 | Benz[a]anthracene | 56-55-3 | 1 | Dec 1,1990 | II. | Carcinogen assessment on-line |
581 | Benz[a]anthracene | 56-55-3 | 2 | Dec 1,1990 | VI. | Bibliography on-line |
582 | Benz[a]anthracene | 56-55-3 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
583 | Benz[a]anthracene | 56-55-3 | 4 | Sep 1,1993 | II. | Carcinogenicity assessment noted as pending change |
584 | Benz[a]anthracene | 56-55-3 | 5 | Sep 1,1993 | II.D.2. | Work group review date added |
585 | Benz[a]anthracene | 56-55-3 | 6 | Nov 1,1993 | II.D.2. | Work group reveiw date added |
586 | Benz[a]anthracene | 56-55-3 | 7 | Mar 1,1994 | II. | Pending change note removed; no change |
587 | Benz[a]anthracene | 56-55-3 | 8 | Mar 1,1994 | II.D.2. | Work group review date added |
588 | Benz[a]anthracene | 56-55-3 | 9 | Sep 1,1994 | I.B. | Inhalation RfC now under review |
589 | Benz[a]anthracene | 56-55-3 | 10 | Aug 1,1995 | I.B., II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
590 | Benz[a]anthracene | 56-55-3 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
591 | Benz[a]anthracene | 56-55-3 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
592 | Benzaldehyde | 100-52-7 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
593 | Benzaldehyde | 100-52-7 | 2 | Dec 1,1989 | VI. | Bibliography on-line |
594 | Benzaldehyde | 100-52-7 | 3 | Jan 1,1992 | I.A.7. | Secondary contact changed |
595 | Benzaldehyde | 100-52-7 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
596 | Benzaldehyde | 100-52-7 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
597 | Benzaldehyde | 100-52-7 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
598 | Benzene | 71-43-2 | 1 | Dec 1,1988 | II.A.4. | Anderson and Richardson citation year corrected |
599 | Benzene | 71-43-2 | 2 | Dec 1,1988 | II.A.4. | Kissling and Speck citation year corrected |
600 | Benzene | 71-43-2 | 3 | Jul 1,1989 | I.B. | Inhalation RfD now under review |
601 | Benzene | 71-43-2 | 4 | Feb 1,1990 | II. | Clarified citations |
602 | Benzene | 71-43-2 | 5 | Feb 1,1990 | II.A.3. | Corrected Maltoni, 1979 to Maltoni and Scarnato, 1979 |
603 | Benzene | 71-43-2 | 6 | Feb 1,1990 | II.A.3. | Corrected Maltoni, 1983 to Maltoni et al., 1983 |
604 | Benzene | 71-43-2 | 7 | Feb 1,1990 | II.A.3. | Corrected Synder et al., 1980 to 1981 |
605 | Benzene | 71-43-2 | 8 | Feb 1,1990 | VI. | Bibliography on-line |
606 | Benzene | 71-43-2 | 9 | Mar 1,1990 | VI.C. | Clarify Maltoni et al., 1983 and NTP, 1986 references |
607 | Benzene | 71-43-2 | 10 | Aug 1,1990 | III.A.10. | Primary contact changed |
608 | Benzene | 71-43-2 | 11 | Aug 1,1990 | IV.F.1. | EPA contact changed |
609 | Benzene | 71-43-2 | 12 | Jan 1,1991 | II. | Text edited |
610 | Benzene | 71-43-2 | 13 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
611 | Benzene | 71-43-2 | 14 | Jan 1,1992 | IV. | Regulatory actions updated |
612 | Benzene | 71-43-2 | 15 | Apr 1,1992 | II.B.2. | Text revised |
613 | Benzene | 71-43-2 | 16 | Feb 1,1994 | II.D.3. | Secondary contact's phone number changed |
614 | Benzene | 71-43-2 | 17 | Oct 16,1998 | II., VI. | Revised inhalation carcinogenicity section and references |
615 | Benzene | 71-43-2 | 18 | Jan 19,2000 | II., VI. | Revised oral carcinogenicity section and references |
616 | Benzene | 71-43-2 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
617 | Benzidine | 92-87-5 | 1 | Mar 1,1988 | II.B.4. | Confidence statement revised |
618 | Benzidine | 92-87-5 | 2 | Mar 1,1988 | II.C.4. | Confidence statement revised |
619 | Benzidine | 92-87-5 | 3 | Mar 1,1988 | II.D.3. | Contacts switched |
620 | Benzidine | 92-87-5 | 4 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
621 | Benzidine | 92-87-5 | 5 | Jan 1,1989 | I.A.1. | LOAEL and RfD corrected |
622 | Benzidine | 92-87-5 | 6 | Jan 1,1989 | I.A.2. | Dose levels corrected |
623 | Benzidine | 92-87-5 | 7 | Jan 1,1990 | I.A.2. | Clarify text |
624 | Benzidine | 92-87-5 | 8 | Jan 1,1990 | II.A.2. | Corrected Zavon et al. (1973) to Zavon (1973) |
625 | Benzidine | 92-87-5 | 9 | Jan 1,1990 | II.A.4. | Corrected Parodi, 1983 to Parodi et al., 1983 |
626 | Benzidine | 92-87-5 | 10 | Jan 1,1990 | VI. | Bibliography on-line |
627 | Benzidine | 92-87-5 | 11 | May 1,1991 | I.B. | Inhalation RfC now under review |
628 | Benzidine | 92-87-5 | 12 | Jul 1,1991 | I.B. | Inhalation RfC message on-line |
629 | Benzidine | 92-87-5 | 13 | Jul 1,1991 | VI.B. | Inhalation RfC references added |
630 | Benzidine | 92-87-5 | 14 | Jan 1,1992 | I.A.7. | Secondary contact changed |
631 | Benzidine | 92-87-5 | 15 | Jan 1,1992 | IV. | Regulatory actions updated |
632 | Benzidine | 92-87-5 | 16 | Jul 1,1993 | II.D.1. | Zavon, 1973 reference removed from EPA Documentation |
633 | Benzidine | 92-87-5 | 17 | Feb 1,1995 | I.A.7. | Secondary contact's name changed |
634 | Benzidine | 92-87-5 | 18 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
635 | Benzidine | 92-87-5 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
636 | Benzo[a]pyrene (BaP) | 50-32-8 | 1 | Aug 1,1989 | VI. | Bibliography on-line |
637 | Benzo[a]pyrene (BaP) | 50-32-8 | 2 | Jan 1,1992 | II. | Carcinogen assessment noted as pending change |
638 | Benzo[a]pyrene (BaP) | 50-32-8 | 3 | Jan 1,1992 | IV. | Regulatory actions updated |
639 | Benzo[a]pyrene (BaP) | 50-32-8 | 4 | Apr 1,1992 | II. | Summary revised oral quantitative section added |
640 | Benzo[a]pyrene (BaP) | 50-32-8 | 5 | Apr 1,1992 | VI.C. | Carcinogen assessment references revised |
641 | Benzo[a]pyrene (BaP) | 50-32-8 | 6 | May 1,1992 | II.D.2. | Work group review and verification date corrected |
642 | Benzo[a]pyrene (BaP) | 50-32-8 | 7 | Jul 1,1992 | II. | Text revised in Note |
643 | Benzo[a]pyrene (BaP) | 50-32-8 | 8 | Jul 1,1992 | II.B. | Range of slope factors corrected |
644 | Benzo[a]pyrene (BaP) | 50-32-8 | 9 | Jul 1,1992 | II.B.1. | Slope factor and risks corrected |
645 | Benzo[a]pyrene (BaP) | 50-32-8 | 10 | Jul 1,1992 | II.B.2. | Data table heading corrected |
646 | Benzo[a]pyrene (BaP) | 50-32-8 | 11 | Jul 1,1992 | II.B.3. | Slope factor corrected last paragraph |
647 | Benzo[a]pyrene (BaP) | 50-32-8 | 12 | Jul 1,1992 | II.D.3. | Secondary contact changed |
648 | Benzo[a]pyrene (BaP) | 50-32-8 | 13 | Sep 1,1993 | II. | Carcinogenicity assessment noted as pending change |
649 | Benzo[a]pyrene (BaP) | 50-32-8 | 14 | Sep 1,1993 | II.D.2. | Work group review date added |
650 | Benzo[a]pyrene (BaP) | 50-32-8 | 15 | Dec 1,1993 | VI.C. | Reference revised - U.S. EPA, 1991b |
651 | Benzo[a]pyrene (BaP) | 50-32-8 | 16 | Feb 1,1994 | II.D.3. | Primary contact's phone number changed |
652 | Benzo[a]pyrene (BaP) | 50-32-8 | 17 | Mar 1,1994 | II.D.2. | Work group review date added |
653 | Benzo[a]pyrene (BaP) | 50-32-8 | 18 | Jul 1,1994 | II.D.2. | Work group review date added |
654 | Benzo[a]pyrene (BaP) | 50-32-8 | 19 | Nov 1,1994 | II.B.1. | Slope factor clarified changed O to %220%22 |
655 | Benzo[a]pyrene (BaP) | 50-32-8 | 20 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
656 | Benzo[a]pyrene (BaP) | 50-32-8 | 21 | Mar 1,1994 | II. | Pending change note removed no change |
657 | Benzo[a]pyrene (BaP) | 50-32-8 | 22 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
658 | Benzo[a]pyrene (BaP) | 50-32-8 | 23 | Jan 19,2017 | All | EPA completed a reassessment, updating all values. |
659 | Benzo[a]pyrene (BaP) | 50-32-8 | 24 | May 11,2018 | TR Supplemental Info | An error was corrected in Table E-1 of the supplemental information document based on a comment from the IRIS hotline. See errata sheet for additional details. |
660 | Benzo[a]pyrene (BaP) | 50-32-8 | 25 | Aug 2,2018 | Key Values WOE Note | Added a note regarding ADAF to both the OSF and IUR entries to further explain what is in the tox review. |
661 | Benzo[a]pyrene (BaP) | 50-32-8 | 26 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
662 | Benzo[b]fluoranthene | 205-99-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
663 | Benzo[g,h,i]perylene | 191-24-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
664 | Benzo[k]fluoranthene | 207-08-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
665 | Benzoic acid | 65-85-0 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system from none to other so it would show up in the advanced search. |
666 | Benzoic acid | 65-85-0 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
667 | Benzotrichloride | 98-07-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
668 | Benzyl chloride | 100-44-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
669 | Beryllium and compounds | 7440-41-7 | 1 | Mar 1,1988 | I.A.1. | Reference dose table clarified |
670 | Beryllium and compounds | 7440-41-7 | 2 | Mar 1,1988 | I.A.2. | Text added |
671 | Beryllium and compounds | 7440-41-7 | 3 | Sep 7,1988 | II. | Carcinogen summary on-line |
672 | Beryllium and compounds | 7440-41-7 | 4 | Jan 1,1990 | II.A.2. | References clarified |
673 | Beryllium and compounds | 7440-41-7 | 5 | Jan 1,1990 | II.A.3. | Text revised |
674 | Beryllium and compounds | 7440-41-7 | 6 | Jan 1,1990 | II.B. | Quanititative estimate for oral exposure section added |
675 | Beryllium and compounds | 7440-41-7 | 7 | Jan 1,1990 | II.C.3. | Text revised |
676 | Beryllium and compounds | 7440-41-7 | 8 | Jan 1,1990 | II.D.2. | Work group review dates and verification date added |
677 | Beryllium and compounds | 7440-41-7 | 9 | Jan 1,1990 | VI. | Bibliography on-line |
678 | Beryllium and compounds | 7440-41-7 | 10 | Feb 1,1990 | VI.A. | Puzanova et al. 1978 citation corrected |
679 | Beryllium and compounds | 7440-41-7 | 11 | Feb 1,1990 | VI.C. | Wagner et al. 1969 citation corrected |
680 | Beryllium and compounds | 7440-41-7 | 12 | Sep 1,1990 | I.A. | Morgareidge ref. now Cox (same study-authors reversed) |
681 | Beryllium and compounds | 7440-41-7 | 13 | Sep 1,1990 | IV.F.1. | EPA contact changed |
682 | Beryllium and compounds | 7440-41-7 | 14 | Sep 1,1990 | VI.A. | Morgareidge ref. now Cox (same study-authors reversed) |
683 | Beryllium and compounds | 7440-41-7 | 15 | Jan 1,1991 | II. | Text edited |
684 | Beryllium and compounds | 7440-41-7 | 16 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
685 | Beryllium and compounds | 7440-41-7 | 17 | Jan 1,1992 | IV. | Regulatory actions updated |
686 | Beryllium and compounds | 7440-41-7 | 18 | Sep 1,1992 | II.A.3. | U.S. EPA citation year corrected, paragraph 3 |
687 | Beryllium and compounds | 7440-41-7 | 19 | Sep 1,1992 | II.D.1. | Source document year corrected |
688 | Beryllium and compounds | 7440-41-7 | 20 | Sep 1,1992 | II.D.1. | Review statement revised |
689 | Beryllium and compounds | 7440-41-7 | 21 | Sep 1,1992 | VI.C. | U.S. EPA reference year corrected |
690 | Beryllium and compounds | 7440-41-7 | 22 | Feb 1,1993 | I.A.7. | Primary contact changed |
691 | Beryllium and compounds | 7440-41-7 | 23 | Apr 3,1998 | I.A. | Oral RfD Assessment |
692 | Beryllium and compounds | 7440-41-7 | 24 | Apr 3,1998 | I.B. | Inhalation RfC Assessment |
693 | Beryllium and compounds | 7440-41-7 | 25 | Apr 3,1998 | II. | Carcinogenicity Assessment |
694 | Beryllium and compounds | 7440-41-7 | 26 | Aug 1,1995 | II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. the IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
695 | Beryllium and compounds | 7440-41-7 | 27 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were remvoed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
696 | Beryllium and compounds | 7440-41-7 | 28 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
697 | Bidrin | 141-66-2 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
698 | Bidrin | 141-66-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
699 | Biphenthrin | 82657-04-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
700 | Biphenyl | 92-52-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
701 | Bis(2-chloro-1-methylethyl) ether | 108-60-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
702 | Bis(2-chloroethoxy)methane | 111-91-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
703 | Bis(chloroethyl)ether (BCEE) | 111-44-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
704 | Bis(chloromethyl)ether (BCME) | 542-88-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
705 | Bisphenol A | 80-05-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
706 | Boron and Compounds | 7440-42-8 | 1 | None | None | |
707 | Boron and Compounds | 7440-42-8 | 2 | I.A., I.B., II | Revised RfD, added RfC discussion and added carcinogenicity assessment. | |
708 | Boron and Compounds | 7440-42-8 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
709 | Bromate | 15541-45-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
710 | Brominated dibenzofurans | None | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
711 | Bromobenzene | 108-86-1 | 1 | Sep 30,2009 | I., II. | File first on-line. |
712 | Bromobenzene | 108-86-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
713 | Bromochloromethane | 74-97-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
714 | Bromodichloromethane | 75-27-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
715 | p-Bromodiphenyl ether | 101-55-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
716 | Bromoform | 75-25-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
717 | Bromomethane | 74-83-9 | 1 | Sep 30,1987 | I.A.1. | MF changed to UF -- no change in RfD |
718 | Bromomethane | 74-83-9 | 2 | Sep 30,1987 | I.A.2. | Text changes |
719 | Bromomethane | 74-83-9 | 3 | Sep 30,1987 | I.A.3. | Text changes |
720 | Bromomethane | 74-83-9 | 4 | Sep 30,1987 | I.A.4. | Study descriptions added |
721 | Bromomethane | 74-83-9 | 5 | Sep 30,1987 | I.A.5. | Text change |
722 | Bromomethane | 74-83-9 | 6 | Sep 30,1987 | I.A.6. | Secondary contact changed |
723 | Bromomethane | 74-83-9 | 7 | Mar 1,1988 | I.A.1. | Critical effect added |
724 | Bromomethane | 74-83-9 | 8 | Jun 30,1988 | I.A. | Withdrawn; new RfD verified (in preparation) |
725 | Bromomethane | 74-83-9 | 9 | Sep 26,1988 | I.A. | Oral RfD summary replaced |
726 | Bromomethane | 74-83-9 | 10 | May 1,1989 | II. | Carcinogen assessment now under review |
727 | Bromomethane | 74-83-9 | 11 | Jun 1,1989 | II. | Carcinogen summary on-line |
728 | Bromomethane | 74-83-9 | 12 | Jun 1,1989 | VI. | Bibliography on-line |
729 | Bromomethane | 74-83-9 | 13 | Aug 1,1989 | VI.A. | Oral RfD references added |
730 | Bromomethane | 74-83-9 | 14 | Oct 1,1989 | I.B. | Inhalation RfC now under review |
731 | Bromomethane | 74-83-9 | 15 | Jun 1,1990 | I.A.2. | Dosing clarified |
732 | Bromomethane | 74-83-9 | 16 | Jun 1,1990 | IV.F.1. | EPA contact changed |
733 | Bromomethane | 74-83-9 | 17 | Aug 1,1990 | I.A. | Text edited |
734 | Bromomethane | 74-83-9 | 18 | Aug 1,1990 | II. | Text edited |
735 | Bromomethane | 74-83-9 | 19 | Aug 1,1990 | III.A. | Health Advisory on-line |
736 | Bromomethane | 74-83-9 | 20 | Aug 1,1990 | VI.D. | Health Advisory references added |
737 | Bromomethane | 74-83-9 | 21 | Jul 1,1991 | I.A.7. | Secondary contact changed |
738 | Bromomethane | 74-83-9 | 22 | Jan 1,1992 | IV. | Regulatory actions updated |
739 | Bromomethane | 74-83-9 | 23 | Apr 1,1992 | I.B. | Inhalation RfC summary on-line |
740 | Bromomethane | 74-83-9 | 24 | Apr 1,1992 | VI.B. | Inhalation RfC references added |
741 | Bromomethane | 74-83-9 | 25 | May 1,1992 | I.B.6. | Deleted incorrect work group review date |
742 | Bromomethane | 74-83-9 | 26 | Oct 1,1992 | I.B.1. | "NOAEL" corrected to LOAEL |
743 | Bromomethane | 74-83-9 | 27 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
744 | Bromomethane | 74-83-9 | 28 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
745 | Bromotrichloromethane | 75-62-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
746 | Bromoxynil | 1689-84-5 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system from none to other so it would show up in the advanced search. |
747 | Bromoxynil | 1689-84-5 | 2 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
748 | Bromoxynil | 1689-84-5 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
749 | Bromoxynil octanoate | 1689-99-2 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system from none to other so it would show up in the advanced search. |
750 | Bromoxynil octanoate | 1689-99-2 | 2 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
751 | Bromoxynil octanoate | 1689-99-2 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
752 | 1,3-Butadiene | 106-99-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
753 | Butyl benzyl phthalate (BBP) | 85-68-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
754 | Butylate | 2008-41-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
755 | t-Butylchloride | 507-20-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
756 | Butylphthalyl butylglycolate (BPBG) | 85-70-1 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system from none to other so it would show up in the advanced search. |
757 | Butylphthalyl butylglycolate (BPBG) | 85-70-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
758 | Cacodylic acid | 75-60-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
759 | Cadmium | 7440-43-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
760 | Calcium cyanide | 592-01-8 | 1 | Sep 28,2010 | I.A. | Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment |
761 | Calcium cyanide | 592-01-8 | 2 | Sep 27,2018 | n | Updated the system value to other so it would show up in the advanced search. |
762 | Calcium cyanide | 592-01-8 | 3 | Oct 3,2018 | I.A. | Updated the system value to reproductive. |
763 | Calcium cyanide | 592-01-8 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
764 | Caprolactam | 105-60-2 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
765 | Caprolactam | 105-60-2 | 2 | Nov 1,1989 | VI. | Bibliography on-line |
766 | Caprolactam | 105-60-2 | 3 | Sep 1,1994 | I.B. | Inhalation RfC under review and message on-line |
767 | Caprolactam | 105-60-2 | 4 | Sep 1,1994 | VI.B. | Inhalation RfC references on-line |
768 | Caprolactam | 105-60-2 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
769 | Caprolactam | 105-60-2 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
770 | Captafol | 2425-06-1 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
771 | Captafol | 2425-06-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
772 | Captan | 133-06-2 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
773 | Captan | 133-06-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
774 | Carbaryl | 63-25-2 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
775 | Carbaryl | 63-25-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
776 | Carbofuran | 1563-66-2 | 1 | None | None | |
777 | Carbofuran | 1563-66-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
778 | Carbon disulfide | 75-15-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
779 | Carbon tetrachloride | 56-23-5 | 30 | Mar 31,2010 | I., II., VI. | RfD and cancer assessment sections updated RfC assessment added. |
780 | Carbon tetrachloride | 56-23-5 | 31 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
781 | Carbonyl sulfide | 463-58-1 | 1 | Dec 19,2018 | Archived Chemical | IRIS Program requested that we archive assessments with no values. |
782 | Carbonyl sulfide | 463-58-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
783 | Carbosulfan | 55285-14-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
784 | Carboxin | 5234-68-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
785 | Cerium Oxide and Cerium Compounds | 1306-38-3 | 1 | Sep 29,2009 | I., II. | RfD, RfC, and cancer assessment first on-line |
786 | Cerium Oxide and Cerium Compounds | 1306-38-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
787 | Chloral hydrate | 302-17-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
788 | Chloramben | 133-90-4 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
789 | Chloramben | 133-90-4 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
790 | Chlordane (Technical) | 12789-03-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
791 | Chlordecone (Kepone) | 143-50-0 | 1 | Sep 22,2009 | I., II. | RfD, RfC, and cancer assessment first on line |
792 | Chlordecone (Kepone) | 143-50-0 | 2 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
793 | Chlordecone (Kepone) | 143-50-0 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
794 | Chlorimuron-ethyl | 90982-32-4 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
795 | Chlorimuron-ethyl | 90982-32-4 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
796 | Chlorine | 7782-50-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
797 | Chlorine cyanide | 506-77-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
798 | Chlorine dioxide | 10049-04-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
799 | Chlorite (sodium salt) | 7758-19-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
800 | 1-Chloro-1,1-difluoroethane | 75-68-3 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
801 | 1-Chloro-1,1-difluoroethane | 75-68-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
802 | 2-Chloroacetophenone | 532-27-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
803 | p-Chloroaniline | 106-47-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
804 | Chlorobenzene | 108-90-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
805 | Chlorobenzilate | 510-15-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
806 | 1-Chlorobutane | 109-69-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
807 | 2-Chlorobutane | 78-86-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
808 | Chlorocyclopentadiene | 41851-50-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
809 | Chlorodifluoromethane | 75-45-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
810 | Chloroform | 67-66-3 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
811 | Chloromethyl methyl ether (CMME) | 107-30-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
812 | beta-Chloronaphthalene | 91-58-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
813 | 2-Chlorophenol | 95-57-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
814 | p-Chlorophenyl methyl sulfide | 123-09-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
815 | p-Chlorophenyl methyl sulfone | 98-57-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
816 | p-Chlorophenyl methyl sulfoxide | 934-73-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
817 | Chloroprene | 126-99-8 | 1 | Sep 30,2010 | I, II, VI, VII, VIII | RfC, and cancer assessment added |
818 | Chloroprene | 126-99-8 | 2 | Jul 10,2018 | Key Values Table | A footnote was added for ADAF. |
819 | Chloroprene | 126-99-8 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
820 | Chlorothalonil | 1897-45-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
821 | o-Chlorotoluene | 95-49-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
822 | Chlorpropham | 101-21-3 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
823 | Chlorpropham | 101-21-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
824 | Chlorpyrifos | 2921-88-2 | 1 | Mar 1,1988 | I.A.5. | Core grades added |
825 | Chlorpyrifos | 2921-88-2 | 2 | Nov 1,1989 | VI. | Bibliography on-line |
826 | Chlorpyrifos | 2921-88-2 | 3 | Jan 1,1992 | IV. | Regulatory actions updated |
827 | Chlorpyrifos | 2921-88-2 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
828 | Chlorpyrifos | 2921-88-2 | 5 | Mar 14,2018 | Archived Assessment | IRIS working with OPP agreed to mark this pesticide chemical archived. |
829 | Chlorpyrifos | 2921-88-2 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
830 | Chlorsulfuron | 64902-72-3 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
831 | Chlorsulfuron | 64902-72-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
832 | Chromium(III), insoluble salts | 16065-83-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
833 | Chromium(VI) | 18540-29-9 | 1 | Sep 30,1987 | II.A.1. | Citation corrected |
834 | Chromium(VI) | 18540-29-9 | 2 | Mar 1,1988 | II.C.4. | Confidence statement revised |
835 | Chromium(VI) | 18540-29-9 | 3 | Mar 1,1988 | II.D.3. | Contacts switched |
836 | Chromium(VI) | 18540-29-9 | 4 | Mar 1,1988 | III.A. | Health Advisory added |
837 | Chromium(VI) | 18540-29-9 | 5 | Dec 1,1989 | I.B. | Inhalation RfD now under review |
838 | Chromium(VI) | 18540-29-9 | 6 | Jun 1,1990 | II.A.1. | Basis - text revised |
839 | Chromium(VI) | 18540-29-9 | 7 | Jun 1,1990 | II.B. | Text revised |
840 | Chromium(VI) | 18540-29-9 | 8 | Jun 1,1990 | IV.A.1. | Area code for EPA contact corrected |
841 | Chromium(VI) | 18540-29-9 | 9 | Jun 1,1990 | IV.F.1 | EPA contact changed |
842 | Chromium(VI) | 18540-29-9 | 10 | Jun 1,1990 | VI. | Bibliography on-line |
843 | Chromium(VI) | 18540-29-9 | 11 | Jan 1,1991 | II. | Text edited |
844 | Chromium(VI) | 18540-29-9 | 12 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
845 | Chromium(VI) | 18540-29-9 | 13 | Mar 1,1991 | II.A.1. | Text Revised |
846 | Chromium(VI) | 18540-29-9 | 14 | Mar 1,1991 | II.A.4. | Text revised |
847 | Chromium(VI) | 18540-29-9 | 15 | Mar 1,1991 | II.B. | Text revised |
848 | Chromium(VI) | 18540-29-9 | 16 | Jan 1,1992 | I.A.7. | Secondary contact changed |
849 | Chromium(VI) | 18540-29-9 | 17 | Jan 1,1992 | IV. | Regulatory actions updated |
850 | Chromium(VI) | 18540-29-9 | 18 | Apr 1,1992 | IV.A.1. | CAA regulatory action withdrawn |
851 | Chromium(VI) | 18540-29-9 | 19 | Jun 1,1992 | All | CASRN corrected from 7440-47-3 to 18540-29-9 |
852 | Chromium(VI) | 18540-29-9 | 20 | Sep 1,1994 | I.A.6. | Work group review date added |
853 | Chromium(VI) | 18540-29-9 | 21 | Feb 1,1995 | I.A. | RfD noted as pending change: Work Grp Mtg on 8/3/1994 |
854 | Chromium(VI) | 18540-29-9 | 22 | Aug 1,1995 | I.A., I.A.6., I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in 1995. Chemical substance reviews that were not completed by September May 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
855 | Chromium(VI) | 18540-29-9 | 23 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
856 | Chromium(VI) | 18540-29-9 | 24 | Dec 1,1996 | I.A.7. | Secondary contact removed |
857 | Chromium(VI) | 18540-29-9 | 25 | Sep 3,1998 | I., II., VI. | Revised RfD, RfC, carcinogenicity assessment, and refs. |
858 | Chromium(VI) | 18540-29-9 | 26 | Jul 18,2019 | RFC Particulates | Made a correction to the labels in the table for the POD to match the IRIS Summary. |
859 | Chromium(VI) | 18540-29-9 | 27 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
860 | Chrysene | 218-01-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
861 | Cobalt and Cobalt Compounds | 1307-96-6 | 1 | Jun 24,2022 | None | EPA announced the cobalt assessment in the program Outlook (Jun 2022). |
862 | Cobalt and Cobalt Compounds | 1307-96-6 | 2 | Nov 14,2022 | None | IRIS released the IAP |
863 | Cobalt and Cobalt Compounds | 1307-96-6 | 3 | Dec 13,2022 | None | IRIS announced the public science meeting registration was open for the Jan 11, 2023 meeting. |
864 | Coke oven emissions | None | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
865 | Copper | 7440-50-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
866 | Copper cyanide | 544-92-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
867 | Creosote | 8001-58-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
868 | Crotonaldehyde | 123-73-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
869 | Cumene | 98-82-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
870 | Cyanazine | 21725-46-2 | 1 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
871 | Cyanazine | 21725-46-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
872 | Cyanide, free | 57-12-5 | 1 | Sep 28,2010 | I.A. | Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment |
873 | Cyanide, free | 57-12-5 | 2 | Mar 31,1987 | IV.B. | RQ - new rationale text |
874 | Cyanide, free | 57-12-5 | 3 | Mar 1,1988 | I.A.5. | Confidence levels revised |
875 | Cyanide, free | 57-12-5 | 4 | Mar 1,1988 | III.A. | Health Advisory added |
876 | Cyanide, free | 57-12-5 | 5 | Sep 7,1988 | II. | Carcinogen summary on-line |
877 | Cyanide, free | 57-12-5 | 6 | Jan 1,1990 | VI. | Bibliography on-line |
878 | Cyanide, free | 57-12-5 | 7 | Aug 1,1990 | III.A.10 | Primary contact changed |
879 | Cyanide, free | 57-12-5 | 8 | Sep 27,2018 | Noncancer Critical | Updated the system value to other so it would show up in the advanced search. |
880 | Cyanide, free | 57-12-5 | 10 | Oct 3,2018 | I.A. | Updated the RfD system value to reproductive. |
881 | Cyanide, free | 57-12-5 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
882 | Cyanogen | 460-19-5 | 1 | None | None | |
883 | Cyanogen | 460-19-5 | 2 | Sep 28,2010 | I.A. | Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment |
884 | Cyanogen | 460-19-5 | 3 | Sep 27,2018 | Noncancer Critical | Updated the system value to other so it would show up in the advanced search. |
885 | Cyanogen | 460-19-5 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
886 | Cyanogen bromide | 506-68-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
887 | Cyclohexane | 110-82-7 | 1 | all | IRIS summary first posted. | |
888 | Cyclohexane | 110-82-7 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
889 | Cyclohexanone | 108-94-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
890 | Cyclohexylamine | 108-91-8 | 1 | None | None | |
891 | Cyclohexylamine | 108-91-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
892 | Cyhalothrin/Karate | 68085-85-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
893 | Cypermethrin | 52315-07-8 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
894 | Cypermethrin | 52315-07-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
895 | Cyromazine | 66215-27-8 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
896 | Cyromazine | 66215-27-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
897 | Dacthal | 1861-32-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
898 | Dalapon, sodium salt | 75-99-0 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
899 | Dalapon, sodium salt | 75-99-0 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
900 | Danitol | 39515-41-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
901 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | 1 | Jun 30,2008 | I., II., VI. | RfD, RfC, and cancer assessment sections updated. |
902 | 2,2',3,3',4,4',5,5',6,6'-Decabromodiphenyl ether (BDE-209) | 1163-19-5 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
903 | Demeton | 8065-48-3 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
904 | Demeton | 8065-48-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
905 | Di (2-ethylhexyl)phthalate (DEHP) | 117-81-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
906 | Di(2-ethylhexyl)adipate | 103-23-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
907 | 2,4-Diaminotoluene | 95-80-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
908 | Diazomethane | 334-88-3 | 1 | Dec 19,2018 | Archive Chemical | IRIS Program requested that we archive assessments with no values. |
909 | Diazomethane | 334-88-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
910 | Dibenz[a,h]anthracene | 53-70-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
911 | Dibenzofuran | 132-64-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
912 | 1,2-Dibromo-3-chloropropane (DBCP) | 96-12-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
913 | 1,4-Dibromobenzene | 106-37-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
914 | Dibromochloromethane | 124-48-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
915 | Dibromodichloromethane | 594-18-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
916 | p,p'-Dibromodiphenyl ether | 2050-47-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
917 | 1,2-Dibromoethane | 106-93-4 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
918 | Dibutyl phthalate (DBP) | 84-74-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
919 | Dicamba | 1918-00-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
920 | Dichloroacetic acid | 79-43-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
921 | 1,4-Dichlorobenzene | 106-46-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
922 | 1,3-Dichlorobenzene | 541-73-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
923 | 1,2-Dichlorobenzene | 95-50-1 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
924 | 1,2-Dichlorobenzene | 95-50-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
925 | 3,3'-Dichlorobenzidine | 91-94-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
926 | Dichlorodifluoromethane | 75-71-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
927 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
928 | p,p'-Dichlorodiphenyl dichloroethane (DDD) | 72-54-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
929 | p,p'-Dichlorodiphenyldichloroethylene (DDE) | 72-55-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
930 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 1 | Sep 30,1987 | I.A.6. | Documentation changed |
931 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 2 | Aug 22,1988 | II. | Carcinogen summary on-line |
932 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 3 | Jan 1,1991 | II. | Text edited |
933 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 4 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
934 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 5 | May 1,1991 | II.A.3. | Change Lehman, 1952 to '1951' |
935 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 6 | May 1,1991 | VI. | Bibliography on-line |
936 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 7 | Jan 1,1992 | I.A.7. | Secondary contact changed |
937 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 8 | Jan 1,1992 | IV. | Regulatory actions updated |
938 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 9 | Feb 1,1996 | I.A.7. | Contact changed |
939 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Office. |
940 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 11 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
941 | p,p'-Dichlorodiphenyltrichloroethane (DDT) | 50-29-3 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
942 | 1,2-Dichloroethane | 107-06-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
943 | 1,1-Dichloroethane | 75-34-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
944 | cis-1,2-Dichloroethylene | 156-59-2 | 1 | Dec 1,1990 | II. | Carcinogen assessment on-line |
945 | cis-1,2-Dichloroethylene | 156-59-2 | 2 | Dec 1,1990 | VI. | Bibliography on-line |
946 | cis-1,2-Dichloroethylene | 156-59-2 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
947 | cis-1,2-Dichloroethylene | 156-59-2 | 4 | Feb 1,1995 | II.D.3. | Primary contact changed |
948 | cis-1,2-Dichloroethylene | 156-59-2 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
949 | cis-1,2-Dichloroethylene | 156-59-2 | 6 | Dec 3,2002 | II.D.2. | Screening-Level Literature Review Findings message has been added. |
950 | cis-1,2-Dichloroethylene | 156-59-2 | 7 | Sep 30,2010 | I., II., VI. | RfD assessment added; RfC and cancer assessment sections revised. |
951 | cis-1,2-Dichloroethylene | 156-59-2 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
952 | trans-1,2-Dichloroethylene | 156-60-5 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
953 | trans-1,2-Dichloroethylene | 156-60-5 | 2 | Jan 1,1989 | I.A.7. | Contact phone number corrected |
954 | trans-1,2-Dichloroethylene | 156-60-5 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
955 | trans-1,2-Dichloroethylene | 156-60-5 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
956 | trans-1,2-Dichloroethylene | 156-60-5 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
957 | trans-1,2-Dichloroethylene | 156-60-5 | 6 | Dec 3,2002 | I.A.6. | Screening-Level Literature Review Findings message has been added |
958 | trans-1,2-Dichloroethylene | 156-60-5 | 7 | Sep 30,2010 | I., II., VI. | RfD assessment added; RfC and cancer assessment sections revised. |
959 | trans-1,2-Dichloroethylene | 156-60-5 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
960 | 1,1-Dichloroethylene (1,1-DCE) | 75-35-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
961 | Dichloromethane | 75-09-2 | 1 | Nov 18,2011 | I., II, VI. | RfD and cancer assessment updated. RfC added. |
962 | Dichloromethane | 75-09-2 | 2 | Apr 20,1987 | II.C.1. | Unit Risk corrected from 4.1E-4 to 4.1E-6 |
963 | Dichloromethane | 75-09-2 | 3 | May 21,1987 | II.A.2. | Missing text replaced in 3rd paragraph |
964 | Dichloromethane | 75-09-2 | 4 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
965 | Dichloromethane | 75-09-2 | 5 | Mar 1,1988 | I.A.2. | Text revised |
966 | Dichloromethane | 75-09-2 | 6 | Mar 1,1988 | II.B.3. | Text revised |
967 | Dichloromethane | 75-09-2 | 7 | Mar 1,1988 | II.B.4. | Confidence statement revised |
968 | Dichloromethane | 75-09-2 | 8 | Mar 1,1988 | II.C.3. | Text revised |
969 | Dichloromethane | 75-09-2 | 9 | Mar 1,1988 | II.C.4. | Confidence statement revised |
970 | Dichloromethane | 75-09-2 | 10 | Mar 1,1988 | II.D.3. | Primary contact changed |
971 | Dichloromethane | 75-09-2 | 11 | Mar 1,1988 | III.A. | Health Advisory added |
972 | Dichloromethane | 75-09-2 | 12 | Jan 1,1989 | II. | Carcinogen summary noted as pending change |
973 | Dichloromethane | 75-09-2 | 13 | Oct 1,1989 | II.B.3. | Inhalation rate corrected in paragraph 1 |
974 | Dichloromethane | 75-09-2 | 14 | Oct 1,1989 | II.C.2. | Dose corrections in mg/kg/day |
975 | Dichloromethane | 75-09-2 | 15 | Oct 1,1989 | II.C.3. | Inhalation rate corrected in paragraph 1 |
976 | Dichloromethane | 75-09-2 | 16 | Oct 1,1989 | II.D.3. | Contacts phone number changed |
977 | Dichloromethane | 75-09-2 | 17 | Aug 1,1990 | IV.F.1. | EPA contact changed |
978 | Dichloromethane | 75-09-2 | 18 | Sep 1,1990 | II. | Carcinogen assessment revised following re-evaluation |
979 | Dichloromethane | 75-09-2 | 19 | Sep 1,1990 | II.C.1. | Inhalation unit risk changed |
980 | Dichloromethane | 75-09-2 | 20 | Sep 1,1990 | VI. | Bibliography on-line |
981 | Dichloromethane | 75-09-2 | 21 | Jan 1,1991 | II.C.1. | Paragraph moved to II.C.3. |
982 | Dichloromethane | 75-09-2 | 22 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
983 | Dichloromethane | 75-09-2 | 23 | Aug 1,1991 | VI.C. | Citations clarified |
984 | Dichloromethane | 75-09-2 | 24 | Sep 1,1991 | I.B. | Inhalation RfC now under review |
985 | Dichloromethane | 75-09-2 | 25 | Jan 1,1992 | IV. | Regulatory actions updated |
986 | Dichloromethane | 75-09-2 | 26 | Feb 1,1995 | II.D.3. | Primary contact changed |
987 | Dichloromethane | 75-09-2 | 27 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
988 | Dichloromethane | 75-09-2 | 28 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
989 | Dichloromethane | 75-09-2 | 29 | Dec 3,2002 | I.A.6., II.D.2. | Screening-Level Literature Review Findings message has been added. |
990 | Dichloromethane | 75-09-2 | 30 | Apr 29,2003 | II.D.2. | Screening Level Literature Review findings revised. |
991 | Dichloromethane | 75-09-2 | 31 | Jul 30,2003 | I., II. | This chemical is being reassessed under the IRIS Program. |
992 | Dichloromethane | 75-09-2 | 32 | Jul 10,2018 | Key Values Table | A footnote was added for ADAF. |
993 | Dichloromethane | 75-09-2 | 33 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
994 | 2,4-Dichlorophenol | 120-83-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
995 | 4-(2,4-Dichlorophenoxy)butyric acid (2,4-DB) | 94-82-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
996 | 2,4-Dichlorophenoxyacetic acid (2,4-D) | 94-75-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
997 | 1,2-Dichloropropane | 78-87-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
998 | 2,3-Dichloropropanol | 616-23-9 | 1 | None | None | |
999 | 2,3-Dichloropropanol | 616-23-9 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1000 | 1,3-Dichloropropene | 542-75-6 | 1 | Sep 26,1988 | II. | Carcinogen summary on-line |
1001 | 1,3-Dichloropropene | 542-75-6 | 2 | Dec 1,1988 | II.B.3. | Text added |
1002 | 1,3-Dichloropropene | 542-75-6 | 3 | Mar 1,1989 | II.A.1. | Text added |
1003 | 1,3-Dichloropropene | 542-75-6 | 4 | Mar 1,1989 | II.A.3. | Text added |
1004 | 1,3-Dichloropropene | 542-75-6 | 5 | Oct 1,1989 | II.B. | Oral quantitative risk estimate has been withdrawn |
1005 | 1,3-Dichloropropene | 542-75-6 | 6 | Oct 1,1989 | VI. | Bibliography on-line |
1006 | 1,3-Dichloropropene | 542-75-6 | 7 | Sep 1,1990 | I.B. | Inhalation RfC assessment now under review |
1007 | 1,3-Dichloropropene | 542-75-6 | 8 | Oct 1,1990 | I.A. | Text edited |
1008 | 1,3-Dichloropropene | 542-75-6 | 9 | Oct 1,1990 | II. | Text edited |
1009 | 1,3-Dichloropropene | 542-75-6 | 10 | Jan 1,1991 | I.B. | Inhalation RfC summary on-line |
1010 | 1,3-Dichloropropene | 542-75-6 | 11 | Jan 1,1991 | VI.B. | Inhalation RfC references added |
1011 | 1,3-Dichloropropene | 542-75-6 | 12 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1012 | 1,3-Dichloropropene | 542-75-6 | 13 | Feb 1,1993 | III.A. | Health Advisory on-line |
1013 | 1,3-Dichloropropene | 542-75-6 | 14 | Feb 1,1993 | VI.D. | Health Advisory references on-line |
1014 | 1,3-Dichloropropene | 542-75-6 | 15 | Sep 1,1993 | II. | Carcinogenicity assessment noted as pending change |
1015 | 1,3-Dichloropropene | 542-75-6 | 16 | Sep 1,1993 | II.D.2. | Work group review date added |
1016 | 1,3-Dichloropropene | 542-75-6 | 17 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone number changed |
1017 | 1,3-Dichloropropene | 542-75-6 | 18 | Aug 1,1995 | II., II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1018 | 1,3-Dichloropropene | 542-75-6 | 19 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Office for this information. |
1019 | 1,3-Dichloropropene | 542-75-6 | 20 | May 25,2000 | I.A. | Revised RfD |
1020 | 1,3-Dichloropropene | 542-75-6 | 21 | May 25,2000 | I.B. | Revised RfC |
1021 | 1,3-Dichloropropene | 542-75-6 | 22 | May 25,2000 | II. | Revised carcinogen summary |
1022 | 1,3-Dichloropropene | 542-75-6 | 23 | May 25,2000 | II.A. | Added oral cancer potency |
1023 | 1,3-Dichloropropene | 542-75-6 | 24 | May 25,2000 | II.B. | Added inhalation cancer potency |
1024 | 1,3-Dichloropropene | 542-75-6 | 25 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1025 | Dichlorvos | 62-73-7 | 1 | Mar 1,1988 | I.A. | NOAEL reevaluated-RfD changed |
1026 | Dichlorvos | 62-73-7 | 2 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1027 | Dichlorvos | 62-73-7 | 3 | Dec 1,1988 | I.A.1. | Converted dose for NOEL added |
1028 | Dichlorvos | 62-73-7 | 4 | Dec 1,1988 | I.A.4. | Study 2) NOEL clarified |
1029 | Dichlorvos | 62-73-7 | 5 | Oct 1,1989 | II. | Carcinogen summary on-line |
1030 | Dichlorvos | 62-73-7 | 6 | Dec 1,1989 | II.A.3. | Correct Kettering Lab (1974) to Shell Chemical (1967) |
1031 | Dichlorvos | 62-73-7 | 7 | Dec 1,1989 | II.A.4. | Correct spelling: Setervaick to 'Segerbaeck' |
1032 | Dichlorvos | 62-73-7 | 8 | Dec 1,1989 | II.B.2. | Correct reference citations |
1033 | Dichlorvos | 62-73-7 | 9 | Dec 1,1989 | VI. | Bibliography on-line |
1034 | Dichlorvos | 62-73-7 | 10 | Jan 1,1992 | II. | Carcinogen assessment noted as pending change |
1035 | Dichlorvos | 62-73-7 | 11 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1036 | Dichlorvos | 62-73-7 | 12 | Jul 1,1992 | I.A. | Withdrawn; new RfD verified (in preparation) |
1037 | Dichlorvos | 62-73-7 | 13 | Jul 1,1992 | VI.A. | Oral RfD references withdrawn |
1038 | Dichlorvos | 62-73-7 | 14 | Dec 1,1992 | I.B. | Inhalation RfC now under review |
1039 | Dichlorvos | 62-73-7 | 15 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone number changed |
1040 | Dichlorvos | 62-73-7 | 16 | Nov 1,1993 | I.A. | Oral RfD summary replaced; RfD changed |
1041 | Dichlorvos | 62-73-7 | 17 | Nov 1,1993 | VI.A. | Oral RfD references replaced |
1042 | Dichlorvos | 62-73-7 | 18 | Jun 1,1994 | I.B. | Inhalation RfC on-line |
1043 | Dichlorvos | 62-73-7 | 19 | Jun 1,1994 | VI.B. | Inhalation RfC references on-line |
1044 | Dichlorvos | 62-73-7 | 20 | Dec 1,1994 | II.A.3. | Animal strain clarified in NCI, 1977 study |
1045 | Dichlorvos | 62-73-7 | 21 | Jun 1,1995 | VI.C. | NTP, 1986a,b reference year corrected |
1046 | Dichlorvos | 62-73-7 | 22 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1047 | Dichlorvos | 62-73-7 | 23 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1048 | Dichlorvos | 62-73-7 | 24 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1049 | Dicofol | 115-32-2 | 1 | Aug 22,1988 | II. | Carcinogen summary on-line |
1050 | Dicofol | 115-32-2 | 2 | Jan 1,1990 | VI. | Bibliography on-line |
1051 | Dicofol | 115-32-2 | 3 | Jan 1,1992 | II. | Carcinogen assessment noted as pending change |
1052 | Dicofol | 115-32-2 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1053 | Dicofol | 115-32-2 | 5 | Apr 1,1992 | II. | Carcinogen assessment withdrawn pending further review |
1054 | Dicofol | 115-32-2 | 6 | Apr 1,1992 | IV. | Withdrawn; no assessments on-line |
1055 | Dicofol | 115-32-2 | 7 | Apr 1,1992 | VI. | Bibliography withdrawn; no assessments on-line |
1056 | Dicofol | 115-32-2 | 8 | Jul 1,1992 | II. | Work gropu review dates added |
1057 | Dicofol | 115-32-2 | 9 | Jul 1,1993 | II. | EPA contact changed |
1058 | Dicofol | 115-32-2 | 10 | Aug 1,1995 | II., IV., VI. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1059 | Dicofol | 115-32-2 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1060 | Dicofol | 115-32-2 | 12 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
1061 | Dicofol | 115-32-2 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1062 | Dieldrin | 60-57-1 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1063 | Dieldrin | 60-57-1 | 2 | Sep 7,1988 | II. | Carcinogen summary on-line |
1064 | Dieldrin | 60-57-1 | 3 | Mar 1,1990 | II.A.2. | Ditraglia citation clarified |
1065 | Dieldrin | 60-57-1 | 4 | Mar 1,1990 | II.A.3. | Reuber citation year and Deichman spelling corrected |
1066 | Dieldrin | 60-57-1 | 5 | Mar 1,1990 | II.A.4. | Shirasu citation year corrected |
1067 | Dieldrin | 60-57-1 | 6 | Mar 1,1990 | II.B.2. | Reuber citation year corrected |
1068 | Dieldrin | 60-57-1 | 7 | Mar 1,1990 | VI. | Bibliography on-line |
1069 | Dieldrin | 60-57-1 | 8 | Apr 1,1990 | VI.C. | Treon and Cleveland, 1955 citation corrected |
1070 | Dieldrin | 60-57-1 | 9 | Sep 1,1990 | I.A. | Text edited |
1071 | Dieldrin | 60-57-1 | 10 | Sep 1,1990 | II. | Text edited |
1072 | Dieldrin | 60-57-1 | 11 | Sep 1,1990 | III.A. | Health Advisory on-line |
1073 | Dieldrin | 60-57-1 | 12 | Sep 1,1990 | VI. | Health Advisory references on-line |
1074 | Dieldrin | 60-57-1 | 13 | Jan 1,1991 | II. | Text edited |
1075 | Dieldrin | 60-57-1 | 14 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
1076 | Dieldrin | 60-57-1 | 15 | Jan 1,1991 | IV. | Regulatory Action section on-line |
1077 | Dieldrin | 60-57-1 | 16 | Jul 1,1993 | II.D.3. | Secondary contact's phone number changed |
1078 | Dieldrin | 60-57-1 | 17 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1079 | Dieldrin | 60-57-1 | 18 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
1080 | Dieldrin | 60-57-1 | 19 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1081 | Diesel engine exhaust | None | 1 | Jul 1,1992 | I.B. | Inhalation RfC now under review |
1082 | Diesel engine exhaust | None | 2 | Aug 1,1992 | I.B.6. | Work group review date added |
1083 | Diesel engine exhaust | None | 3 | Jun 1,1993 | I.B. | Inhalation RfC on-line |
1084 | Diesel engine exhaust | None | 4 | Jun 1,1993 | VI.B. | Inhalation RfC references on-line |
1085 | Diesel engine exhaust | None | 5 | Jul 1,1993 | VI.B. | Minor correction made |
1086 | Diesel engine exhaust | None | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1087 | Diesel engine exhaust | None | 7 | Feb 28,2003 | All | Complete revision based on new health assessment document |
1088 | Diesel engine exhaust | None | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1089 | Diethyl phthalate (DEP) | 84-66-2 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
1090 | Diethyl phthalate (DEP) | 84-66-2 | 2 | Aug 1,1989 | VI. | Bibliography on-line |
1091 | Diethyl phthalate (DEP) | 84-66-2 | 3 | Aug 1,1991 | I.A.7. | Primary and secondary contects changed |
1092 | Diethyl phthalate (DEP) | 84-66-2 | 4 | Aug 1,1991 | II.D.3. | Primary and secondary contacts changed |
1093 | Diethyl phthalate (DEP) | 84-66-2 | 5 | Aug 1,1991 | IV.F.1. | EPA contact changed |
1094 | Diethyl phthalate (DEP) | 84-66-2 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
1095 | Diethyl phthalate (DEP) | 84-66-2 | 7 | Feb 1,1993 | I.A.7. | Primary contact changed |
1096 | Diethyl phthalate (DEP) | 84-66-2 | 8 | Feb 1,1993 | II.D.3. | Primary contact changed |
1097 | Diethyl phthalate (DEP) | 84-66-2 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1098 | Diethyl phthalate (DEP) | 84-66-2 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1099 | Diethyl sulfate | 64-67-5 | 1 | Oct 1,1991 | I.B. | Inhalation RfC now under review |
1100 | Diethyl sulfate | 64-67-5 | 2 | Nov 1,1991 | I.B. | Inhalation RfC message on-line |
1101 | Diethyl sulfate | 64-67-5 | 3 | Nov 1,1991 | VI.B. | Inhalation RfC references added |
1102 | Diethyl sulfate | 64-67-5 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1103 | Diethyl sulfate | 64-67-5 | 5 | Dec 19,2018 | Archive Chemical | IRIS Program requested that we archive assessments with no values. |
1104 | Diethyl sulfate | 64-67-5 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1105 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 1 | Oct 1,1991 | II. | Carcinogenicy assessment now under review |
1106 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 2 | Oct 1,1992 | II. | Carcinogenicity assessment on-line |
1107 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 3 | Oct 1,1992 | VI.C. | Carcinogenicity references on-line |
1108 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 4 | Nov 1,1992 | VI.C. | Spelling correction |
1109 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 5 | Jul 1,1993 | II.D.1. | Other EPA Documentation heading removed |
1110 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 6 | Dec 1,1996 | II.D.3. | Secondary contact removed |
1111 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1112 | Diethyl-p-nitrophenylphosphate | 311-45-5 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1113 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 1 | Jul 1,1992 | II. | Carcinogenicity assessment summary now under review |
1114 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 2 | Feb 1,1993 | II. | Carcinogenicity assessment on-line |
1115 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 3 | Feb 1,1993 | VI.C. | Carcinogenicity assessment references on-line |
1116 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 4 | Mar 1,1993 | VI.C. | Minor correction |
1117 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 5 | Jul 1,1993 | II.D.1. | Other EPA Documentation heading removed |
1118 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1119 | Diethylene glycol dinitrate (DEGDN) | 693-21-0 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1120 | Difenzoquat | 43222-48-6 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
1121 | Difenzoquat | 43222-48-6 | 2 | Dec 1,1989 | VI. | Bibliography on-line |
1122 | Difenzoquat | 43222-48-6 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1123 | Difenzoquat | 43222-48-6 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1124 | Difenzoquat | 43222-48-6 | 5 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1125 | Difenzoquat | 43222-48-6 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1126 | Diflubenzuron | 35367-38-5 | 1 | Sep 1,1990 | I.A. | Principal study clarified |
1127 | Diflubenzuron | 35367-38-5 | 2 | Sep 1,1990 | I.A.4. | Citations added |
1128 | Diflubenzuron | 35367-38-5 | 3 | Sep 1,1990 | VI. | Bibliography on-line |
1129 | Diflubenzuron | 35367-38-5 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
1130 | Diflubenzuron | 35367-38-5 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1131 | Diflubenzuron | 35367-38-5 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1132 | 1,1-Difluoroethane | 75-37-6 | 1 | Oct 1,1992 | I.B. | Inhalation RfC now under review |
1133 | 1,1-Difluoroethane | 75-37-6 | 2 | Sep 1,1994 | I.B. | Inhalation RfC on-line |
1134 | 1,1-Difluoroethane | 75-37-6 | 3 | Sep 1,1994 | VI.B. | Inhalation RfD references on-line |
1135 | 1,1-Difluoroethane | 75-37-6 | 4 | Oct 1,1994 | VI.B. | Aviado and Belej, 1974 page number corrected |
1136 | 1,1-Difluoroethane | 75-37-6 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1137 | 1,1-Difluoroethane | 75-37-6 | 6 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
1138 | 1,1-Difluoroethane | 75-37-6 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1139 | Diisobutyl phthalate (DIBP) | 84-69-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1140 | Diisononyl phthalate (DINP) | 28553-12-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1141 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 1 | Mar 1,1989 | II. | Carcinogen summary on-line |
1142 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 2 | Apr 1,1989 | I.A. | Oral RfD summary on-line |
1143 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 3 | Apr 1,1989 | II.A.4. | Citation year added |
1144 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 4 | Apr 1,1989 | II.D.1. | Corrected EPA citation year |
1145 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 5 | Apr 1,1989 | II.D.1. | Citation added |
1146 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 6 | Jul 1,1989 | VI. | Bibliography on-line |
1147 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 7 | Jun 1,1990 | I.A. | Text edited |
1148 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 8 | Jun 1,1990 | I.A.7. | Primary contact changed |
1149 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 9 | Jun 1,1990 | II.A.2. | Text added |
1150 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 10 | Dec 1,1990 | III.A. | Health Advisory on-line |
1151 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 11 | Dec 1,1990 | VI.D. | Health Advisory references added |
1152 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 12 | Sep 1,1992 | II.D.3. | Primary contact changed |
1153 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 13 | Feb 1,1993 | I.A.7. | Primary contact changed |
1154 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 14 | Feb 1,1993 | II.D.3. | Primary contact changed |
1155 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 15 | Feb 1,1993 | II.A.10. | Primary contact changed |
1156 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 16 | Jul 1,1993 | II.D.1. | EPA Documentation clarified |
1157 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 17 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1158 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 18 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
1159 | Diisopropyl methylphosphonate (DIMP) | 1445-75-6 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1160 | Dimethipin | 55290-64-7 | 1 | Aug 22,1988 | II. | Carcinogen summary on-line |
1161 | Dimethipin | 55290-64-7 | 2 | Mar 1,1990 | I.A. | NOTE added; assessment reevaluated - no RfD change |
1162 | Dimethipin | 55290-64-7 | 3 | May 1,1990 | I.A. | Reevaluated Oral RfD on-line - no RfD change |
1163 | Dimethipin | 55290-64-7 | 4 | May 1,1990 | VI. | Bibliography on-line |
1164 | Dimethipin | 55290-64-7 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1165 | Dimethipin | 55290-64-7 | 6 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone number changed |
1166 | Dimethipin | 55290-64-7 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the approrpriate EPA Program Offices for this information. |
1167 | Dimethipin | 55290-64-7 | 8 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1168 | Dimethipin | 55290-64-7 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1169 | Dimethoate | 60-51-5 | 1 | Mar 1,1988 | I.A.4. | New data entered |
1170 | Dimethoate | 60-51-5 | 2 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1171 | Dimethoate | 60-51-5 | 3 | Mar 1,1988 | I.A.6. | Review dates added |
1172 | Dimethoate | 60-51-5 | 4 | Mar 1,1988 | I.A.6. | Documentation added |
1173 | Dimethoate | 60-51-5 | 5 | Jun 30,1988 | I.A. | RfD withdrawn |
1174 | Dimethoate | 60-51-5 | 6 | Aug 22,1988 | I.A. | Revised oral RfD summary added |
1175 | Dimethoate | 60-51-5 | 7 | Sep 1,1990 | I.A.4. | Citations added |
1176 | Dimethoate | 60-51-5 | 8 | Sep 1,1990 | IV.F.1. | EPA contact changed |
1177 | Dimethoate | 60-51-5 | 9 | Sep 1,1990 | VI. | Bibliography on-line |
1178 | Dimethoate | 60-51-5 | 10 | Jan 1,1992 | IV. | Regulatory actions updated |
1179 | Dimethoate | 60-51-5 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1180 | Dimethoate | 60-51-5 | 12 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1181 | Dimethoate | 60-51-5 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1182 | Dimethyl phthalate | 131-11-3 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
1183 | Dimethyl phthalate | 131-11-3 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
1184 | Dimethyl phthalate | 131-11-3 | 3 | Mar 1,1990 | VI. | Bibliography on-line |
1185 | Dimethyl phthalate | 131-11-3 | 4 | Sep 1,1990 | I.B. | Not verified; data inadequate |
1186 | Dimethyl phthalate | 131-11-3 | 5 | Oct 1,1990 | I.B. | Inhalation RfC text modified |
1187 | Dimethyl phthalate | 131-11-3 | 6 | Oct 1,1990 | VI.B. | Bibliography on-line |
1188 | Dimethyl phthalate | 131-11-3 | 7 | Aug 1,1991 | II.D.3. | Primary and secondary contacts changed |
1189 | Dimethyl phthalate | 131-11-3 | 8 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1190 | Dimethyl phthalate | 131-11-3 | 9 | Feb 1,1993 | II.D.3. | Primary contact changed |
1191 | Dimethyl phthalate | 131-11-3 | 10 | Mar 1,1994 | I.A. | Work group review date added |
1192 | Dimethyl phthalate | 131-11-3 | 11 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinured in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1193 | Dimethyl phthalate | 131-11-3 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1194 | Dimethyl phthalate | 131-11-3 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1195 | Dimethyl sulfate | 77-78-1 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
1196 | Dimethyl sulfate | 77-78-1 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
1197 | Dimethyl sulfate | 77-78-1 | 3 | Mar 1,1990 | VI. | Bibliography on-line |
1198 | Dimethyl sulfate | 77-78-1 | 4 | Oct 1,1991 | I.B. | Inhalation RfD now under review |
1199 | Dimethyl sulfate | 77-78-1 | 5 | Jan 1,1992 | I.B. | Inhalation RfC on-line |
1200 | Dimethyl sulfate | 77-78-1 | 6 | Jan 1,1992 | VI.B. | Inhalation RfC reference added |
1201 | Dimethyl sulfate | 77-78-1 | 7 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1202 | Dimethyl sulfate | 77-78-1 | 8 | Feb 1,1994 | II.D.3. | Secondary contact's phone number changed |
1203 | Dimethyl sulfate | 77-78-1 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1204 | Dimethyl sulfate | 77-78-1 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1205 | Dimethyl terephthalate (DMT) | 120-61-6 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1206 | Dimethyl terephthalate (DMT) | 120-61-6 | 2 | Aug 1,1989 | VI. | Biliography on-line |
1207 | Dimethyl terephthalate (DMT) | 120-61-6 | 3 | Jan 1,1992 | I.A.7. | Secondary contact changed |
1208 | Dimethyl terephthalate (DMT) | 120-61-6 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1209 | Dimethyl terephthalate (DMT) | 120-61-6 | 5 | Feb 1,1995 | I.A.7. | Secondary contact's name changed |
1210 | Dimethyl terephthalate (DMT) | 120-61-6 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1211 | Dimethyl terephthalate (DMT) | 120-61-6 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1212 | Dimethylamine | 124-40-3 | 1 | Jul 1,1990 | I.B. | Inhalation RfC summary on-line |
1213 | Dimethylamine | 124-40-3 | 2 | Jul 1,1990 | VI. | Bibliography on-line |
1214 | Dimethylamine | 124-40-3 | 3 | Jan 1,1991 | I.B. | Wtihdrawn; new inhalation RfC verified (in preparation) |
1215 | Dimethylamine | 124-40-3 | 4 | Jan 1,1991 | VI. | Bibliography withdrawn |
1216 | Dimethylamine | 124-40-3 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1217 | Dimethylamine | 124-40-3 | 6 | Aug 1,1995 | I.B., VI. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in Septermber, 1995. |
1218 | Dimethylamine | 124-40-3 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1219 | Dimethylamine | 124-40-3 | 8 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
1220 | Dimethylamine | 124-40-3 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1221 | N-N-Dimethylaniline | 121-69-7 | 1 | Aug 1,1989 | VI. | Bibliography on-line |
1222 | N-N-Dimethylaniline | 121-69-7 | 2 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1223 | N-N-Dimethylaniline | 121-69-7 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1224 | 3,3-Dimethylbenzidine | 119-93-7 | 1 | Jul 1,1991 | I.B. | Inhalation RfC message on-line |
1225 | 3,3-Dimethylbenzidine | 119-93-7 | 2 | Jul 1,1991 | VI. | Bibliography on-line |
1226 | 3,3-Dimethylbenzidine | 119-93-7 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1227 | 3,3-Dimethylbenzidine | 119-93-7 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1228 | 3,3-Dimethylbenzidine | 119-93-7 | 5 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
1229 | 3,3-Dimethylbenzidine | 119-93-7 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1230 | N,N-Dimethylformamide | 68-12-2 | 1 | Oct 1,1990 | I.B. | Inhalation RfC summary on-line |
1231 | N,N-Dimethylformamide | 68-12-2 | 2 | Oct 1,1990 | VI. | Bibliography on-line |
1232 | N,N-Dimethylformamide | 68-12-2 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1233 | N,N-Dimethylformamide | 68-12-2 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1234 | 2,4-Dimethylphenol | 105-67-9 | 1 | Nov 1,1990 | I.A. | Oral RfD summary on-line |
1235 | 2,4-Dimethylphenol | 105-67-9 | 2 | Nov 1,1990 | VI. | Bibliography on-line |
1236 | 2,4-Dimethylphenol | 105-67-9 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1237 | 2,4-Dimethylphenol | 105-67-9 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appriopriate EPA Program Offices for this information. |
1238 | 2,4-Dimethylphenol | 105-67-9 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1239 | 2,6-Dimethylphenol | 576-26-1 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1240 | 2,6-Dimethylphenol | 576-26-1 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
1241 | 2,6-Dimethylphenol | 576-26-1 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1242 | 2,6-Dimethylphenol | 576-26-1 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1243 | 3,4-Dimethylphenol | 95-65-8 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1244 | 3,4-Dimethylphenol | 95-65-8 | 2 | Jan 1,1989 | I.A.7. | Contacts phone numbers corrected |
1245 | 3,4-Dimethylphenol | 95-65-8 | 3 | Jun 1,1991 | VI. | Bibliography on-line |
1246 | 3,4-Dimethylphenol | 95-65-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1247 | 3,4-Dimethylphenol | 95-65-8 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1248 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
1249 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 2 | Jan 1,1989 | I.A.7. | Contacts phone numbers corrected |
1250 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
1251 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 4 | Jan 1,1992 | I.A.7. | Secondary contact changed |
1252 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1253 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1254 | 4,6-Dinitro-o-cyclohexyl phenol | 131-89-5 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1255 | o-Dinitrobenzene | 528-29-0 | 1 | May 1,1992 | II. | Carcinogenicity assessment now under review |
1256 | o-Dinitrobenzene | 528-29-0 | 2 | Jun 1,1992 | Synonyms | Synonyms added |
1257 | o-Dinitrobenzene | 528-29-0 | 3 | Sep 1,1992 | II. | Carcinogenicity assessment on-line |
1258 | o-Dinitrobenzene | 528-29-0 | 4 | Sep 1,1992 | VI. | Bibliography on-line |
1259 | o-Dinitrobenzene | 528-29-0 | 5 | Jul 1,1993 | II.D.1. | Other EPA Documentation heading removed |
1260 | o-Dinitrobenzene | 528-29-0 | 6 | Dec 1,1996 | II.D.3. | Primary contact removed |
1261 | o-Dinitrobenzene | 528-29-0 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1262 | o-Dinitrobenzene | 528-29-0 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1263 | m-Dinitrobenzene | 99-65-0 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
1264 | m-Dinitrobenzene | 99-65-0 | 2 | Jul 1,1990 | II. | Carcinogen assessment now under review |
1265 | m-Dinitrobenzene | 99-65-0 | 3 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
1266 | m-Dinitrobenzene | 99-65-0 | 4 | Mar 1,1991 | VI. | Bibliography on-line |
1267 | m-Dinitrobenzene | 99-65-0 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1268 | m-Dinitrobenzene | 99-65-0 | 6 | Feb 1,1993 | II.D.3. | Primary contact changed |
1269 | m-Dinitrobenzene | 99-65-0 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1270 | m-Dinitrobenzene | 99-65-0 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1271 | 2,4-Dinitrophenol | 51-28-5 | 1 | Mar 1,1988 | I.A.3. | Text corrected |
1272 | 2,4-Dinitrophenol | 51-28-5 | 2 | Mar 1,1990 | I.A.2. | U.S. EPA, 1980 citation added |
1273 | 2,4-Dinitrophenol | 51-28-5 | 3 | Mar 1,1990 | VI. | Bibliography on-line |
1274 | 2,4-Dinitrophenol | 51-28-5 | 4 | Jul 1,1991 | I.A. | Oral RfD summary noted as pending change |
1275 | 2,4-Dinitrophenol | 51-28-5 | 5 | Jul 1,1991 | I.B. | Inhalation RfC now under review |
1276 | 2,4-Dinitrophenol | 51-28-5 | 6 | Oct 1,1991 | I.B. | Inhalation RfC message on-line |
1277 | 2,4-Dinitrophenol | 51-28-5 | 7 | Oct 1,1991 | VI.B. | Inhalation RfC references added |
1278 | 2,4-Dinitrophenol | 51-28-5 | 8 | Jan 1,1992 | I.A.7. | Secondary contact changed |
1279 | 2,4-Dinitrophenol | 51-28-5 | 9 | Jan 1,1992 | IV. | Regulatory actions updated |
1280 | 2,4-Dinitrophenol | 51-28-5 | 10 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1281 | 2,4-Dinitrophenol | 51-28-5 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1282 | 2,4-Dinitrophenol | 51-28-5 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1283 | 2,4-Dinitrotoluene | 121-14-2 | 1 | Mar 1,1991 | I.B. | Inhalation RfC message on-line |
1284 | 2,4-Dinitrotoluene | 121-14-2 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
1285 | 2,4-Dinitrotoluene | 121-14-2 | 3 | Sep 1,1991 | I.A. | Oral RfD now under review |
1286 | 2,4-Dinitrotoluene | 121-14-2 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1287 | 2,4-Dinitrotoluene | 121-14-2 | 5 | Jun 1,1992 | I.A. | Oral RfD summary on-line |
1288 | 2,4-Dinitrotoluene | 121-14-2 | 6 | Jun 1,1992 | VI.A. | Oral RfD references added |
1289 | 2,4-Dinitrotoluene | 121-14-2 | 7 | Feb 1,1993 | I.A.7. | Primary contact changed |
1290 | 2,4-Dinitrotoluene | 121-14-2 | 8 | Mar 1,1993 | VI.D. | Health Advisory on-line |
1291 | 2,4-Dinitrotoluene | 121-14-2 | 9 | Mar 1,1993 | III.A. | Heatlh Advisory references on-line |
1292 | 2,4-Dinitrotoluene | 121-14-2 | 10 | Apr 1,1993 | VI.A. | Oral RfD references corrected |
1293 | 2,4-Dinitrotoluene | 121-14-2 | 11 | Sep 1,1990 | II. | Carcinogen assessment on-line |
1294 | 2,4-Dinitrotoluene | 121-14-2 | 12 | Sep 1,1990 | VI. | Bibliography on-line |
1295 | 2,4-Dinitrotoluene | 121-14-2 | 13 | Aug 1,1991 | VI.C. | Citations clarified |
1296 | 2,4-Dinitrotoluene | 121-14-2 | 14 | Aug 1,1991 | I.A. | Oral RfD now under reivew |
1297 | 2,4-Dinitrotoluene | 121-14-2 | 15 | Sep 1,1991 | I.A. | Oral RfD will be isomer-specific |
1298 | 2,4-Dinitrotoluene | 121-14-2 | 16 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1299 | 2,4-Dinitrotoluene | 121-14-2 | 17 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1300 | 2,4-Dinitrotoluene | 121-14-2 | 18 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1301 | 2,4-Dinitrotoluene | 121-14-2 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1302 | 2,4-/2,6-Dinitrotoluene mixture | Various | 1 | Sep 1,1990 | II. | Carcinogen assessment on-line |
1303 | 2,4-/2,6-Dinitrotoluene mixture | Various | 2 | Sep 1,1990 | VI. | Bibliography on-line |
1304 | 2,4-/2,6-Dinitrotoluene mixture | Various | 3 | Aug 1,1991 | VI.C. | Citations clarified |
1305 | 2,4-/2,6-Dinitrotoluene mixture | Various | 4 | Aug 1,1991 | I.A. | Oral RfD now under reivew |
1306 | 2,4-/2,6-Dinitrotoluene mixture | Various | 5 | Sep 1,1991 | I.A. | Oral RfD will be isomer-specific |
1307 | 2,4-/2,6-Dinitrotoluene mixture | Various | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1308 | 2,4-/2,6-Dinitrotoluene mixture | Various | 7 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1309 | 2,4-/2,6-Dinitrotoluene mixture | Various | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1310 | 2,4-/2,6-Dinitrotoluene mixture | Various | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1311 | Dinoseb | 88-85-7 | 1 | Jun 1,1989 | I.A.6. | Work group review dates added |
1312 | Dinoseb | 88-85-7 | 2 | Jun 1,1989 | II. | Carcinogen assessment now under review |
1313 | Dinoseb | 88-85-7 | 3 | Aug 1,1989 | I.A. | Principal study citation corrected |
1314 | Dinoseb | 88-85-7 | 4 | Aug 1,1989 | I.A.4. | Citations added |
1315 | Dinoseb | 88-85-7 | 5 | Aug 1,1989 | II. | Carcinogen summary on-line |
1316 | Dinoseb | 88-85-7 | 6 | Aug 1,1989 | VI. | Bibliography on-line |
1317 | Dinoseb | 88-85-7 | 7 | Jun 1,1990 | I.A. | Text edited |
1318 | Dinoseb | 88-85-7 | 8 | Jun 1,1990 | II. | Text edited |
1319 | Dinoseb | 88-85-7 | 9 | Mar 1,1991 | II.D.3. | Secondary contact changed |
1320 | Dinoseb | 88-85-7 | 10 | Mar 1,1991 | IV.F.1. | EPA contact changed |
1321 | Dinoseb | 88-85-7 | 11 | Jan 1,1992 | IV. | Regulatory actions updated |
1322 | Dinoseb | 88-85-7 | 12 | Jul 1,1993 | II.D.2. | Missing work group review date added |
1323 | Dinoseb | 88-85-7 | 13 | Aug 1,1995 | I.A.6., II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by Septmber 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1324 | Dinoseb | 88-85-7 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1325 | Dinoseb | 88-85-7 | 15 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
1326 | Dinoseb | 88-85-7 | 16 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1327 | 1,4-Dioxane | 123-91-1 | 1 | Aug 22,1988 | II. | Carcinogen summary on-line |
1328 | 1,4-Dioxane | 123-91-1 | 10 | Aug 11,2010 | I., II., VI. | RfD and cancer assessment updated RfC discussion added. |
1329 | 1,4-Dioxane | 123-91-1 | 11 | Aug 11,2010 | NA | %3Ca href=%22http://cfpub.epa.gov/ncea/iris_drafts/archiveDrafts.cfm#D_form%22%3EArchived review drafts and comments from the development of the oral assessment%3C/a%3E are available. |
1330 | 1,4-Dioxane | 123-91-1 | 12 | Sep 20,2013 | None | Added RfC and inhalation cancer assessment. |
1331 | 1,4-Dioxane | 123-91-1 | 13 | Sep 20,2013 | NA | Archived review drafts and comments from the development of this assessment are available. Archived version of the 2010 final oral assessment is available (%3Ca href=%22http://hero.epa.gov/index.cfm?action=search.view&reference_id=625580%22%3EU.S. EPA, 2010%3C/a%3E). |
1332 | 1,4-Dioxane | 123-91-1 | 14 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1333 | Diphenamid | 957-51-7 | 1 | Apr 1,1989 | III. | Health Advisory on-line |
1334 | Diphenamid | 957-51-7 | 2 | Mar 1,1991 | I.A. | Principal study year corrected |
1335 | Diphenamid | 957-51-7 | 3 | Mar 1,1991 | I.A.4. | Citations added |
1336 | Diphenamid | 957-51-7 | 4 | Mar 1,1991 | III.A.5. | Principal study year corrected |
1337 | Diphenamid | 957-51-7 | 5 | Mar 1,1991 | VI. | Bibliography on-line |
1338 | Diphenamid | 957-51-7 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1339 | Diphenamid | 957-51-7 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1340 | Diphenamid | 957-51-7 | 8 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
1341 | Diphenamid | 957-51-7 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1342 | Diphenylamine | 122-39-4 | 1 | Sep 30,1987 | All | CASRN corrected |
1343 | Diphenylamine | 122-39-4 | 2 | Sep 1,1990 | I.A.4. | Citations added |
1344 | Diphenylamine | 122-39-4 | 3 | Sep 1,1990 | IV.F.1. | EPA contact changed |
1345 | Diphenylamine | 122-39-4 | 4 | Sep 1,1990 | VI. | Bibliography on-line |
1346 | Diphenylamine | 122-39-4 | 5 | Jan 1,1992 | IV. | Regulatory actions updated |
1347 | Diphenylamine | 122-39-4 | 6 | Jul 1,1992 | II. | Carcinogen assessment summary now under review |
1348 | Diphenylamine | 122-39-4 | 7 | Mar 1,1993 | III.A. | Health Advisory on-line |
1349 | Diphenylamine | 122-39-4 | 8 | Mar 1,1993 | VI.D. | Health Advisory references on-line |
1350 | Diphenylamine | 122-39-4 | 9 | Apr 1,1993 | VI.A. | Oral RfD reference corrected |
1351 | Diphenylamine | 122-39-4 | 10 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1352 | Diphenylamine | 122-39-4 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1353 | Diphenylamine | 122-39-4 | 12 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1354 | Diphenylamine | 122-39-4 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1355 | 1,2-Diphenylhydrazine | 122-66-7 | 1 | Mar 31,1987 | IV. | RQ added |
1356 | 1,2-Diphenylhydrazine | 122-66-7 | 2 | Mar 1,1988 | II.B.1. | Number rounded off |
1357 | 1,2-Diphenylhydrazine | 122-66-7 | 3 | Mar 1,1988 | II.B.3. | Text revised |
1358 | 1,2-Diphenylhydrazine | 122-66-7 | 4 | Mar 1,1988 | II.B.4. | Confidence statement revised |
1359 | 1,2-Diphenylhydrazine | 122-66-7 | 5 | Mar 1,1988 | II.C.1. | Number rounded off |
1360 | 1,2-Diphenylhydrazine | 122-66-7 | 6 | Mar 1,1988 | II.C.4. | Text revised |
1361 | 1,2-Diphenylhydrazine | 122-66-7 | 7 | Mar 1,1988 | II.D.3. | Primary contact changed |
1362 | 1,2-Diphenylhydrazine | 122-66-7 | 8 | Aug 1,1989 | VI. | Bibliography on-line |
1363 | 1,2-Diphenylhydrazine | 122-66-7 | 9 | Jan 1,1991 | II. | Text edited |
1364 | 1,2-Diphenylhydrazine | 122-66-7 | 10 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
1365 | 1,2-Diphenylhydrazine | 122-66-7 | 11 | Oct 1,1991 | I.B. | Inhalation RfC now under review |
1366 | 1,2-Diphenylhydrazine | 122-66-7 | 12 | Nov 1,1991 | I.B. | Inhalation RfC message on-line |
1367 | 1,2-Diphenylhydrazine | 122-66-7 | 13 | Nov 1,1991 | VI.B. | Inhalation references added |
1368 | 1,2-Diphenylhydrazine | 122-66-7 | 14 | Jan 1,1992 | IV. | Regulatory actions updated |
1369 | 1,2-Diphenylhydrazine | 122-66-7 | 15 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1370 | 1,2-Diphenylhydrazine | 122-66-7 | 16 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1371 | Diquat | 2764-72-9 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1372 | Diquat | 2764-72-9 | 2 | Sep 1,1989 | II. | Carcinogen assessment now under review |
1373 | Diquat | 2764-72-9 | 3 | Sep 1,1990 | I.A. | Principal study clarified |
1374 | Diquat | 2764-72-9 | 4 | Sep 1,1990 | I.A.4. | Citations added |
1375 | Diquat | 2764-72-9 | 5 | Sep 1,1990 | VI. | Bibliography on-line |
1376 | Diquat | 2764-72-9 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
1377 | Diquat | 2764-72-9 | 7 | Feb 1,1994 | I.A.1. | Critical dose and NOAEL(ADJ) corrected |
1378 | Diquat | 2764-72-9 | 8 | Jan 1,1995 | I.A. | Oral RfD noted as pending change |
1379 | Diquat | 2764-72-9 | 9 | Jan 1,1995 | I.A.6. | Work group review date added |
1380 | Diquat | 2764-72-9 | 10 | Aug 1,1995 | I.A., I.A.6., II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1381 | Diquat | 2764-72-9 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1382 | Diquat | 2764-72-9 | 12 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1383 | Diquat | 2764-72-9 | 13 | Sep 29,2020 | CASRN | Based on a request from CCTE and OLEM, the IRIS program updated the CASRN from 85-00-7 to 2764-72-9, and updated the IRIS Summary to correct an error with the original summary page. Also corrected the Chemicals Dashboard link. |
1384 | Disulfoton | 298-04-4 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1385 | Disulfoton | 298-04-4 | 2 | Feb 1,1990 | VI. | Bibliography on-line |
1386 | Disulfoton | 298-04-4 | 3 | Jan 1,1992 | IV. | Regulatory actions updated |
1387 | Disulfoton | 298-04-4 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1388 | Disulfoton | 298-04-4 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1389 | 1,4-Dithiane | 505-29-3 | 1 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
1390 | 1,4-Dithiane | 505-29-3 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
1391 | 1,4-Dithiane | 505-29-3 | 3 | Aug 1,1992 | I.A. | Oral RfD now under review |
1392 | 1,4-Dithiane | 505-29-3 | 4 | Feb 1,1993 | II.D.3. | Primary contact changed |
1393 | 1,4-Dithiane | 505-29-3 | 5 | Mar 1,1993 | I.A. | Oral RfD summary on-line |
1394 | 1,4-Dithiane | 505-29-3 | 6 | Mar 1,1993 | III.A. | Health Advisory on-line |
1395 | 1,4-Dithiane | 505-29-3 | 7 | Mar 1,1993 | VI.A. | Oral RfD references on-line |
1396 | 1,4-Dithiane | 505-29-3 | 8 | Mar 1,1993 | VI.D. | Health Advisory references on-line |
1397 | 1,4-Dithiane | 505-29-3 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1398 | 1,4-Dithiane | 505-29-3 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1399 | Diuron | 330-54-1 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1400 | Diuron | 330-54-1 | 2 | Aug 22,1988 | I.A.1. | Oral RfD corrected |
1401 | Diuron | 330-54-1 | 3 | Dec 1,1989 | VI. | Bibliography on-line |
1402 | Diuron | 330-54-1 | 4 | Oct 1,1990 | III.A. | Health Advisory on-line |
1403 | Diuron | 330-54-1 | 5 | Oct 1,1990 | VI.D. | Health Advisory references added |
1404 | Diuron | 330-54-1 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
1405 | Diuron | 330-54-1 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1406 | Diuron | 330-54-1 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1407 | Dodine | 2439-10-3 | 1 | Sep 1,1990 | I.A.4. | Citations added |
1408 | Dodine | 2439-10-3 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
1409 | Dodine | 2439-10-3 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1410 | Dodine | 2439-10-3 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1411 | Dodine | 2439-10-3 | 5 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1412 | Dodine | 2439-10-3 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1413 | Endosulfan | 115-29-7 | 1 | Jul 1,1989 | I.A.2. | MRID numbers added to principal study |
1414 | Endosulfan | 115-29-7 | 2 | Jul 1,1989 | I.A.4. | Citations added |
1415 | Endosulfan | 115-29-7 | 3 | Jul 1,1989 | VI. | Bibliography on-line |
1416 | Endosulfan | 115-29-7 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
1417 | Endosulfan | 115-29-7 | 5 | Dec 1,1992 | I.A. | Withdrawn; new Oral RfD verified (in preparation) |
1418 | Endosulfan | 115-29-7 | 6 | Dec 1,1992 | VI.A. | Oral RfD references withdrawn |
1419 | Endosulfan | 115-29-7 | 7 | May 1,1993 | I.A. | Work group review date added |
1420 | Endosulfan | 115-29-7 | 8 | Jul 1,1994 | II. | Carcinogenicity assessment now under review |
1421 | Endosulfan | 115-29-7 | 9 | Oct 1,1994 | I.A. | Oral RfD summary replaced; new RfD |
1422 | Endosulfan | 115-29-7 | 10 | Oct 1,1994 | VI.A. | Oral RfD references replaced |
1423 | Endosulfan | 115-29-7 | 11 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1424 | Endosulfan | 115-29-7 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1425 | Endosulfan | 115-29-7 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1426 | Endothall | 145-73-3 | 1 | Mar 1,1991 | I.A.4. | Citations added |
1427 | Endothall | 145-73-3 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
1428 | Endothall | 145-73-3 | 3 | Sep 1,1991 | II. | Carcinogenicity assessment now under review |
1429 | Endothall | 145-73-3 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1430 | Endothall | 145-73-3 | 5 | Jul 1,1992 | III.A. | Health Advisory on-line |
1431 | Endothall | 145-73-3 | 6 | Jul 1,1992 | VI.D. | Health Advisory references on-line |
1432 | Endothall | 145-73-3 | 7 | Aug 1,1992 | III.A.5. | Text clarified |
1433 | Endothall | 145-73-3 | 8 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1434 | Endothall | 145-73-3 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1435 | Endothall | 145-73-3 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1436 | Endrin | 72-20-8 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1437 | Endrin | 72-20-8 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
1438 | Endrin | 72-20-8 | 3 | Aug 1,1989 | VI. | Bibliography on-line |
1439 | Endrin | 72-20-8 | 4 | Oct 1,1989 | II. | Carcinogen summary on-line |
1440 | Endrin | 72-20-8 | 5 | Oct 1,1989 | VI.C. | Carcinogen references added |
1441 | Endrin | 72-20-8 | 6 | Apr 1,1991 | I.A. | Secondary contact changed |
1442 | Endrin | 72-20-8 | 7 | Apr 1,1991 | II. | Primary contact changed |
1443 | Endrin | 72-20-8 | 8 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1444 | Endrin | 72-20-8 | 9 | Jul 1,1993 | II.D.1. | EPA Documentation clarified |
1445 | Endrin | 72-20-8 | 10 | Jul 1,1993 | VI.C. | EPA references clarified |
1446 | Endrin | 72-20-8 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1447 | Endrin | 72-20-8 | 12 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
1448 | Endrin | 72-20-8 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1449 | Epichlorohydrin | 106-89-8 | 1 | Sep 30,1987 | V. | Supplementary Data section added |
1450 | Epichlorohydrin | 106-89-8 | 2 | Mar 1,1988 | I.A.1. | Dose conversion factor corrected |
1451 | Epichlorohydrin | 106-89-8 | 3 | Mar 1,1988 | I.A.2. | Text clarified |
1452 | Epichlorohydrin | 106-89-8 | 4 | Mar 1,1988 | II.B.1. | Number rounded off |
1453 | Epichlorohydrin | 106-89-8 | 5 | Mar 1,1988 | II.B.3. | Text revised |
1454 | Epichlorohydrin | 106-89-8 | 6 | Mar 1,1988 | II.B.4. | Confidence statement revised |
1455 | Epichlorohydrin | 106-89-8 | 7 | Mar 1,1988 | II.C. | Slope factor changed |
1456 | Epichlorohydrin | 106-89-8 | 8 | Mar 1,1988 | II.C.1. | Number rounded off |
1457 | Epichlorohydrin | 106-89-8 | 9 | Mar 1,1988 | II.C.3. | Text revised |
1458 | Epichlorohydrin | 106-89-8 | 10 | Mar 1,1988 | II.C.4. | Confidence statement revised |
1459 | Epichlorohydrin | 106-89-8 | 11 | Mar 1,1988 | III.A. | Health Advisory added |
1460 | Epichlorohydrin | 106-89-8 | 12 | Jun 30,1988 | II.D.1. | Documentation corrected |
1461 | Epichlorohydrin | 106-89-8 | 13 | Jun 1,1989 | I.A.6. | Work group review date added |
1462 | Epichlorohydrin | 106-89-8 | 14 | Oct 1,1989 | I.B. | Inhalation RfC now under review |
1463 | Epichlorohydrin | 106-89-8 | 15 | Feb 1,1990 | II.A.2. | Shellenberger et al., 1979 spelling corrected |
1464 | Epichlorohydrin | 106-89-8 | 16 | Feb 1,1990 | VI. | Bibliography on-line |
1465 | Epichlorohydrin | 106-89-8 | 17 | Jun 1,1990 | IV.A.1. | Area code for EPA contact corrected |
1466 | Epichlorohydrin | 106-89-8 | 18 | Aug 1,1990 | III.A.10. | Primary contact changed |
1467 | Epichlorohydrin | 106-89-8 | 19 | Jan 1,1991 | II. | Text edited |
1468 | Epichlorohydrin | 106-89-8 | 20 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
1469 | Epichlorohydrin | 106-89-8 | 21 | Sep 1,1991 | I.A. | Oral RfD summary noted as pending change |
1470 | Epichlorohydrin | 106-89-8 | 22 | Jan 1,1992 | I.A.7. | Secondary contact changed |
1471 | Epichlorohydrin | 106-89-8 | 23 | Jan 1,1992 | IV. | Regulatory actions updated |
1472 | Epichlorohydrin | 106-89-8 | 24 | Apr 1,1992 | I.A. | Oral RfD summary withdrawn pending further review |
1473 | Epichlorohydrin | 106-89-8 | 25 | Apr 1,1992 | I.B. | Inhalation RfC summary on-line |
1474 | Epichlorohydrin | 106-89-8 | 26 | Apr 1,1992 | IV.A.1. | CAA regulatory action withdrawn |
1475 | Epichlorohydrin | 106-89-8 | 27 | Apr 1,1992 | VI.A. | Oral RfD references withdrawn |
1476 | Epichlorohydrin | 106-89-8 | 28 | Apr 1,1992 | VI.B. | Inhalation RfC references added |
1477 | Epichlorohydrin | 106-89-8 | 29 | Jun 1,1992 | III.A.5. | DWEL withdrawn |
1478 | Epichlorohydrin | 106-89-8 | 30 | Feb 1,1994 | II.D.3. | Secondary contact's phone number changed |
1479 | Epichlorohydrin | 106-89-8 | 31 | Aug 1,1995 | I.A., I.A.6., VI.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1480 | Epichlorohydrin | 106-89-8 | 32 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1481 | Epichlorohydrin | 106-89-8 | 33 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1482 | 1,2-Epoxybutane (EBU) | 106-88-7 | 1 | Jan 1,1992 | I.B. | Inhalation RfC now under review |
1483 | 1,2-Epoxybutane (EBU) | 106-88-7 | 2 | May 1,1992 | I.B. | Inhalation RfC on-line |
1484 | 1,2-Epoxybutane (EBU) | 106-88-7 | 3 | May 1,1992 | VI.B. | Bibliography on-line |
1485 | 1,2-Epoxybutane (EBU) | 106-88-7 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1486 | 1,2-Epoxybutane (EBU) | 106-88-7 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1487 | Ethephon | 16672-87-0 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
1488 | Ethephon | 16672-87-0 | 2 | Mar 1,1991 | I.A.4. | Citations added |
1489 | Ethephon | 16672-87-0 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
1490 | Ethephon | 16672-87-0 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1491 | Ethephon | 16672-87-0 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1492 | Ethephon | 16672-87-0 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1493 | Ethion | 563-12-2 | 1 | Feb 1,1989 | I.A. | Critical study citation year added |
1494 | Ethion | 563-12-2 | 2 | Jun 1,1989 | I.A. | Withdrawn; new Oral RfD verified (in preparation) |
1495 | Ethion | 563-12-2 | 3 | Sep 1,1989 | I.A. | Oral RfD summary on-line; RfD changed |
1496 | Ethion | 563-12-2 | 4 | Sep 1,1989 | VI. | Bibliography on-line |
1497 | Ethion | 563-12-2 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1498 | Ethion | 563-12-2 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1499 | Ethion | 563-12-2 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1500 | 2-Ethoxyethanol | 110-80-5 | 1 | May 1,1991 | I.B. | Inhalation RfC summary on-line |
1501 | 2-Ethoxyethanol | 110-80-5 | 2 | May 1,1991 | VI. | Bibliography on-line |
1502 | 2-Ethoxyethanol | 110-80-5 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1503 | 2-Ethoxyethanol | 110-80-5 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1504 | 2-Ethoxyethanol | 110-80-5 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1505 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1506 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | 2 | Aug 13,2021 | All | EPA completed a reassessment, updating all values. There is no value for cancer oral as there was inadequate evidence to derive a value. |
1507 | Ethyl Tertiary Butyl Ether (ETBE) | 637-92-3 | 3 | Aug 16,2021 | All | Correction edits to the values after release. |
1508 | Ethyl acetate | 141-78-6 | 1 | Aug 1,1989 | VI. | Bibliography on-line |
1509 | Ethyl acetate | 141-78-6 | 2 | Jan 1,1992 | I.A.7. | Primary contact changed |
1510 | Ethyl acetate | 141-78-6 | 3 | Jan 1,1992 | IV. | Regulatory actions updated |
1511 | Ethyl acetate | 141-78-6 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1512 | Ethyl acetate | 141-78-6 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1513 | Ethyl carbamate | 51-79-6 | 1 | Jan 1,1992 | I.B. | Inhalation RfC now under review |
1514 | Ethyl carbamate | 51-79-6 | 2 | Apr 1,1992 | I.B. | Inhalation RfC message on-line |
1515 | Ethyl carbamate | 51-79-6 | 3 | Apr 1,1992 | VI. | Bibliography on-line |
1516 | Ethyl carbamate | 51-79-6 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1517 | Ethyl carbamate | 51-79-6 | 5 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
1518 | Ethyl carbamate | 51-79-6 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1519 | Ethyl chloride | 75-00-3 | 1 | Apr 1,1991 | I.B. | Inhalation RfC summary on-line |
1520 | Ethyl chloride | 75-00-3 | 2 | Apr 1,1991 | VI. | Bibliography on-line |
1521 | Ethyl chloride | 75-00-3 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1522 | Ethyl chloride | 75-00-3 | 4 | Jan 1,1995 | II. | Carcinogenicity assessment now under review |
1523 | Ethyl chloride | 75-00-3 | 5 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken our os IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in Septermber, 1995. |
1524 | Ethyl chloride | 75-00-3 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1525 | Ethyl chloride | 75-00-3 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1526 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | 1 | Sep 1,1990 | I.A.4. | Citations added |
1527 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
1528 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1529 | S-Ethyl dipropylthiocarbamate (EPTC) | 759-94-4 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1530 | Ethyl ether | 60-29-7 | 1 | Sep 1,1990 | I.A. | Oral RfD summary on-line |
1531 | Ethyl ether | 60-29-7 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
1532 | Ethyl ether | 60-29-7 | 3 | Jul 1,1991 | I.A.7. | Primary and secondary contacts changed |
1533 | Ethyl ether | 60-29-7 | 4 | Jul 1,1993 | I.A.6. | Source Document and Other EPA Documentation clarified |
1534 | Ethyl ether | 60-29-7 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1535 | Ethyl ether | 60-29-7 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1536 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | 1 | Mar 1,1991 | I.A.4. | Citations added |
1537 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
1538 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | 3 | Apr 1,1991 | VI.A. | MRID numbers added to citations |
1539 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
1540 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1541 | Ethyl p-nitrophenyl phenylphosphorothioate (EPN) | 2104-64-5 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1542 | Ethylbenzene | 100-41-4 | 1 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
1543 | Ethylbenzene | 100-41-4 | 2 | Mar 1,1988 | I.A.6. | Documentation revised |
1544 | Ethylbenzene | 100-41-4 | 3 | Mar 1,1988 | III.A. | Health Advisory added |
1545 | Ethylbenzene | 100-41-4 | 4 | Sep 7,1988 | II. | Carcinogen summary on-line |
1546 | Ethylbenzene | 100-41-4 | 5 | Aug 1,1989 | VI. | Bibliography on-line |
1547 | Ethylbenzene | 100-41-4 | 6 | Aug 1,1990 | IV.F.1. | EPA contact changed |
1548 | Ethylbenzene | 100-41-4 | 7 | Oct 1,1990 | I.B. | Inhalation RfC now under review |
1549 | Ethylbenzene | 100-41-4 | 8 | Mar 1,1991 | I.B. | Inhalation RfC summary on-line |
1550 | Ethylbenzene | 100-41-4 | 9 | Mar 1,1991 | VI.B. | Inhalation RfC references added |
1551 | Ethylbenzene | 100-41-4 | 10 | Jun 1,1991 | I.A.7. | Primary contact changed |
1552 | Ethylbenzene | 100-41-4 | 11 | Aug 1,1991 | II.D.3. | Secondary contact changed |
1553 | Ethylbenzene | 100-41-4 | 12 | Jan 1,1992 | I.A.7. | Secondary contact changed |
1554 | Ethylbenzene | 100-41-4 | 13 | Jan 1,1992 | IV. | Regulatory actions updated |
1555 | Ethylbenzene | 100-41-4 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1556 | Ethylbenzene | 100-41-4 | 15 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1557 | Ethylbenzene | 100-41-4 | 16 | Dec 20,2018 | All | EPA suspended the development of this assessment. |
1558 | Ethylbenzene | 100-41-4 | 17 | Jun 28,2021 | All | EPA removed the suspension and restarted the development of an update of this assessment. |
1559 | Ethylene diamine | 107-15-3 | 1 | May 1,1991 | I.B. | Inhalation RfC message on-line |
1560 | Ethylene diamine | 107-15-3 | 2 | May 1,1991 | VI. | Bibliography on-line |
1561 | Ethylene diamine | 107-15-3 | 3 | Sep 1,1991 | II. | Carcinogenicity assessment now under review |
1562 | Ethylene diamine | 107-15-3 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1563 | Ethylene diamine | 107-15-3 | 5 | Nov 1,1992 | II. | Carcinogenicity assessment on-line |
1564 | Ethylene diamine | 107-15-3 | 6 | Nov 1,1992 | VI.C. | Carcinogenicity references on-line |
1565 | Ethylene diamine | 107-15-3 | 7 | Dec 1,1992 | VI.C. | Slesinski reference clarified |
1566 | Ethylene diamine | 107-15-3 | 8 | Jul 1,1993 | II.D.1. | Other EPA Documentation heading removed |
1567 | Ethylene diamine | 107-15-3 | 9 | Dec 1,1996 | II.D.3. | Secondary contact removed |
1568 | Ethylene diamine | 107-15-3 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1569 | Ethylene diamine | 107-15-3 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1570 | Ethylene glycol | 107-21-1 | 1 | Sep 1,1989 | I.A. | Clarified DePass (1986) & DePass et al. (1986) refs |
1571 | Ethylene glycol | 107-21-1 | 2 | Sep 1,1989 | VI. | Bibliography on-line |
1572 | Ethylene glycol | 107-21-1 | 3 | Jan 1,1992 | I.A.7. | Secondary contact changed |
1573 | Ethylene glycol | 107-21-1 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1574 | Ethylene glycol | 107-21-1 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1575 | Ethylene glycol | 107-21-1 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1576 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | 1 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advirsories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1577 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | 2 | Dec 30,1999 | I...VI | RfD, RfC, and carcinogenicity assessment first on line |
1578 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | 5 | Mar 31,2010 | I., II., VI. | RfD, RfC, and cancer assessment sections updated. |
1579 | Ethylene glycol monobutyl ether (EGBE) (2-Butoxyethanol) | 111-76-2 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1580 | Ethylene oxide | 75-21-8 | 1 | May 16,2018 | WOE Footnote | Added the ADAF footnote to the WOE basis decription. |
1581 | Ethylene oxide | 75-21-8 | 2 | Jun 28,2018 | IRIS Summary | Renamed the IRIS Summary to Executive summary to match the attachment. |
1582 | Ethylene oxide | 75-21-8 | 3 | Jul 10,2018 | Key Values Table | A footnote was added for ADAF. |
1583 | Ethylene oxide | 75-21-8 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1584 | Ethylene thiourea (ETU) | 96-45-7 | 1 | May 1,1991 | I.A. | Oral RfD summary now on-line |
1585 | Ethylene thiourea (ETU) | 96-45-7 | 2 | May 1,1991 | VI. | Bibliography on-line |
1586 | Ethylene thiourea (ETU) | 96-45-7 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1587 | Ethylene thiourea (ETU) | 96-45-7 | 4 | Jul 1,1992 | I.A.6. | Oral RfD source references corrected |
1588 | Ethylene thiourea (ETU) | 96-45-7 | 5 | Jul 1,1992 | VI.A. | Oral RfD references corrected |
1589 | Ethylene thiourea (ETU) | 96-45-7 | 6 | Sep 1,1992 | I.B. | Inhalation RfC now under review |
1590 | Ethylene thiourea (ETU) | 96-45-7 | 7 | Sep 1,1993 | II. | Carcinogenicity assessment now under review |
1591 | Ethylene thiourea (ETU) | 96-45-7 | 8 | Feb 1,1994 | I.A.1. | NOAEL and LOAEL were reversed; corrected |
1592 | Ethylene thiourea (ETU) | 96-45-7 | 9 | Aug 1,1995 | I.B., II. | EPA's RfD/RFC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS reivew. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1593 | Ethylene thiourea (ETU) | 96-45-7 | 10 | Nov 1,1996 | I.A.7. | Primary contact's office changed |
1594 | Ethylene thiourea (ETU) | 96-45-7 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1595 | Ethylene thiourea (ETU) | 96-45-7 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1596 | Ethyleneimine | 151-56-4 | 1 | Jan 1,1992 | I.B. | Inhalation RfC now under review |
1597 | Ethyleneimine | 151-56-4 | 2 | Apr 1,1992 | I.B. | Inhalation RfC message on-line |
1598 | Ethyleneimine | 151-56-4 | 3 | Apr 1,1992 | VI. | Bibliography on-line |
1599 | Ethyleneimine | 151-56-4 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1600 | Ethyleneimine | 151-56-4 | 5 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
1601 | Ethyleneimine | 151-56-4 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1602 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | 1 | Aug 1,1989 | VI. | Bibliography on-line |
1603 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | 2 | May 1,1991 | I.A.4. | Text edited |
1604 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | 3 | Feb 1,1995 | I.A.7. | Secondary contact's name changed |
1605 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1606 | Ethylphthalyl ethylglycolate (EPEG) | 84-72-0 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1607 | Express | 101200-48-0 | 1 | Jan 1,1989 | I.A. | Oral RfD summary on-line |
1608 | Express | 101200-48-0 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
1609 | Express | 101200-48-0 | 3 | Apr 1,1990 | I.A.2. | Text edited |
1610 | Express | 101200-48-0 | 4 | Feb 1,1991 | II. | Carcinogen assessment now under review |
1611 | Express | 101200-48-0 | 5 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1612 | Express | 101200-48-0 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1613 | Express | 101200-48-0 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1614 | Fenamiphos | 22224-92-6 | 1 | Sep 1,1990 | I.A. | Principal study citation corrected |
1615 | Fenamiphos | 22224-92-6 | 2 | Sep 1,1990 | I.A.4. | Citations added |
1616 | Fenamiphos | 22224-92-6 | 3 | Sep 1,1990 | VI. | Bibliography on-line |
1617 | Fenamiphos | 22224-92-6 | 4 | Oct 1,1990 | III.A. | Health Advisory on-line |
1618 | Fenamiphos | 22224-92-6 | 5 | Oct 1,1990 | VI.D. | Health Advisory references added |
1619 | Fenamiphos | 22224-92-6 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
1620 | Fenamiphos | 22224-92-6 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1621 | Fenamiphos | 22224-92-6 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1622 | Fluometuron | 2164-17-2 | 1 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
1623 | Fluometuron | 2164-17-2 | 2 | Sep 1,1990 | I.A.2. | Text edited |
1624 | Fluometuron | 2164-17-2 | 3 | Sep 1,1990 | I.A.4. | Citations added |
1625 | Fluometuron | 2164-17-2 | 4 | Sep 1,1990 | III.A. | Health Advisory on-line |
1626 | Fluometuron | 2164-17-2 | 5 | Sep 1,1990 | VI. | Bibliography on-line |
1627 | Fluometuron | 2164-17-2 | 6 | Jan 1,1992 | IV. | Regulatory action updated |
1628 | Fluometuron | 2164-17-2 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1629 | Fluometuron | 2164-17-2 | 8 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
1630 | Fluometuron | 2164-17-2 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1631 | Fluoranthene | 206-44-0 | 1 | Sep 1,1990 | I.A. | Oral RfD summary on-line |
1632 | Fluoranthene | 206-44-0 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
1633 | Fluoranthene | 206-44-0 | 3 | Dec 1,1990 | II. | Carcinogen assessment on-line |
1634 | Fluoranthene | 206-44-0 | 4 | Dec 1,1990 | VI.C. | Carcinogen assessment references added |
1635 | Fluoranthene | 206-44-0 | 5 | Jul 1,1991 | I.A.7. | Primary and secondary contacts changed |
1636 | Fluoranthene | 206-44-0 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1637 | Fluoranthene | 206-44-0 | 7 | Jul 1,1993 | I.A.6. | Other EPA Documentation added |
1638 | Fluoranthene | 206-44-0 | 8 | Sep 1,1994 | I.B. | Inhalation RfC now under review |
1639 | Fluoranthene | 206-44-0 | 9 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replace the workgroup functions beginning in September, 1995. |
1640 | Fluoranthene | 206-44-0 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1641 | Fluoranthene | 206-44-0 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1642 | Fluorene | 86-73-7 | 1 | Nov 1,1990 | I.A. | Oral RfD summary on-line |
1643 | Fluorene | 86-73-7 | 2 | Nov 1,1990 | VI. | Bibliography on-line |
1644 | Fluorene | 86-73-7 | 3 | Dec 1,1990 | II. | Carcinogen assessment on-line |
1645 | Fluorene | 86-73-7 | 4 | Dec 1,1990 | VI.C. | Carcinogen assessment references added |
1646 | Fluorene | 86-73-7 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1647 | Fluorene | 86-73-7 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1648 | Fluorene | 86-73-7 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1649 | Fluorine (soluble fluoride) | 7782-41-4 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
1650 | Fluorine (soluble fluoride) | 7782-41-4 | 2 | Jun 30,1988 | I.A.7. | Contacts switched |
1651 | Fluorine (soluble fluoride) | 7782-41-4 | 3 | Apr 1,1989 | V. | Supplementary data on-line |
1652 | Fluorine (soluble fluoride) | 7782-41-4 | 4 | Jun 1,1989 | I.A.6. | Work group review dates corrected |
1653 | Fluorine (soluble fluoride) | 7782-41-4 | 5 | Aug 1,1989 | VI. | Bibliography on-line |
1654 | Fluorine (soluble fluoride) | 7782-41-4 | 6 | Jan 1,1992 | I.A.7. | Seconday contact changed |
1655 | Fluorine (soluble fluoride) | 7782-41-4 | 7 | Jan 1,1992 | IV. | Regulatory actions updated |
1656 | Fluorine (soluble fluoride) | 7782-41-4 | 8 | Aug 1,1995 | I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1657 | Fluorine (soluble fluoride) | 7782-41-4 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1658 | Fluorine (soluble fluoride) | 7782-41-4 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1659 | Fluridone | 59756-60-4 | 1 | Aug 22,1988 | I.A. | Oral RfD summary replaced; RfD not changed |
1660 | Fluridone | 59756-60-4 | 2 | Sep 1,1990 | I.A.4. | Citations added |
1661 | Fluridone | 59756-60-4 | 3 | Sep 1,1990 | VI. | Bibliography on-line |
1662 | Fluridone | 59756-60-4 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1663 | Fluridone | 59756-60-4 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1664 | Flurprimidol | 56425-91-3 | 1 | Jul 1,1989 | I.A. | Oral RfD summary on-line |
1665 | Flurprimidol | 56425-91-3 | 2 | Jul 1,1989 | VI. | Bibliography on-line |
1666 | Flurprimidol | 56425-91-3 | 3 | Apr 1,1990 | All | CASRN corrected |
1667 | Flurprimidol | 56425-91-3 | 4 | Apr 1,1990 | I.A. | Text edited |
1668 | Flurprimidol | 56425-91-3 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1669 | Flurprimidol | 56425-91-3 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1670 | Flutolanil | 66332-96-5 | 1 | May 1,1989 | I.A. | Oral RfD summary on-line |
1671 | Flutolanil | 66332-96-5 | 2 | Jul 1,1989 | VI. | Bibliography on-line |
1672 | Flutolanil | 66332-96-5 | 3 | May 1,1990 | I.A.2. | Text edited |
1673 | Flutolanil | 66332-96-5 | 4 | May 1,1990 | I.A.4. | Text edited |
1674 | Flutolanil | 66332-96-5 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1675 | Flutolanil | 66332-96-5 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1676 | Fluvalinate | 69409-94-5 | 1 | Mar 1,1991 | I.A.4. | Citations added |
1677 | Fluvalinate | 69409-94-5 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
1678 | Fluvalinate | 69409-94-5 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1679 | Fluvalinate | 69409-94-5 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1680 | Fluvalinate | 69409-94-5 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1681 | Folpet | 133-07-3 | 1 | Aug 22,1988 | II. | Carcinogen summary on-line |
1682 | Folpet | 133-07-3 | 2 | Mar 1,1991 | I.A.4. | Citations added |
1683 | Folpet | 133-07-3 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
1684 | Folpet | 133-07-3 | 4 | Apr 1,1991 | VI.C. | Carcinogen references added |
1685 | Folpet | 133-07-3 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1686 | Folpet | 133-07-3 | 6 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone no. changed |
1687 | Folpet | 133-07-3 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1688 | Folpet | 133-07-3 | 8 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1689 | Folpet | 133-07-3 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1690 | Fomesafen | 72178-02-0 | 1 | Aug 22,1988 | II. | Carcinogen summary on-line |
1691 | Fomesafen | 72178-02-0 | 2 | Jan 1,1989 | All | CASRN corrected |
1692 | Fomesafen | 72178-02-0 | 3 | Jun 1,1992 | II.A.3. | Citation years corrected |
1693 | Fomesafen | 72178-02-0 | 4 | Jun 1,1992 | II.B.2. | Citation year corrected |
1694 | Fomesafen | 72178-02-0 | 5 | Jun 1,1992 | VI. | Bibliography on-line |
1695 | Fomesafen | 72178-02-0 | 6 | Oct 1,1993 | II.D.3. | Primary contact changed |
1696 | Fomesafen | 72178-02-0 | 7 | Apr 1,1997 | III., IV. V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1697 | Fomesafen | 72178-02-0 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1698 | Fonofos | 944-22-9 | 1 | Mar 1,1991 | I.A.1. | MRID No. corrected |
1699 | Fonofos | 944-22-9 | 2 | Mar 1,1991 | I.A.4. | Citations added |
1700 | Fonofos | 944-22-9 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
1701 | Fonofos | 944-22-9 | 4 | Apr 1,1991 | V.B. | Missing field added (Haz. Decomp. or Byproducts) |
1702 | Fonofos | 944-22-9 | 5 | Jan 1,1992 | IV. | Regulatory actions updated |
1703 | Fonofos | 944-22-9 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1704 | Fonofos | 944-22-9 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1705 | Formaldehyde | 50-00-0 | 1 | Oct 1,1989 | II. | Carcinogen summary on-line |
1706 | Formaldehyde | 50-00-0 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
1707 | Formaldehyde | 50-00-0 | 3 | Dec 1,1989 | I.A. | Oral RfD now under review |
1708 | Formaldehyde | 50-00-0 | 4 | Feb 1,1990 | VI. | Supplementary data on-line |
1709 | Formaldehyde | 50-00-0 | 5 | Sep 1,1990 | I.A. | Oral RfD summary on-line |
1710 | Formaldehyde | 50-00-0 | 6 | Sep 1,1990 | II. | Text edited |
1711 | Formaldehyde | 50-00-0 | 7 | Sep 1,1990 | VI.A. | Oral RfD references added |
1712 | Formaldehyde | 50-00-0 | 8 | Jan 1,1991 | II. | Text edited |
1713 | Formaldehyde | 50-00-0 | 9 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
1714 | Formaldehyde | 50-00-0 | 10 | May 1,1991 | II.C.1. | Corrected units in risk level concentrations |
1715 | Formaldehyde | 50-00-0 | 11 | Aug 1,1991 | VI.A.&C. | Citations clarified |
1716 | Formaldehyde | 50-00-0 | 12 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1717 | Formaldehyde | 50-00-0 | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1718 | Formaldehyde | 50-00-0 | 14 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1719 | Formic acid | 64-18-6 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
1720 | Formic acid | 64-18-6 | 2 | Mar 1,1988 | I.A.1. | Critical effect revised |
1721 | Formic acid | 64-18-6 | 3 | Mar 1,1988 | I.A.2. | Text added paragraph 1 |
1722 | Formic acid | 64-18-6 | 4 | Dec 1,1990 | I.A. | Oral RfD withdrawn pending further review |
1723 | Formic acid | 64-18-6 | 5 | Oct 1,1991 | II. | Carcinogenicity assessment now under review |
1724 | Formic acid | 64-18-6 | 6 | Jan 1,1992 | IV. | Regulatory action updated |
1725 | Formic acid | 64-18-6 | 7 | Aug 1,1995 | I.A., II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1726 | Formic acid | 64-18-6 | 8 | Feb 1,1996 | I.A. | Contact changed |
1727 | Formic acid | 64-18-6 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1728 | Formic acid | 64-18-6 | 10 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
1729 | Formic acid | 64-18-6 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1730 | Fosetyl-al | 39148-24-8 | 1 | Aug 22,1988 | II. | Carcinogen summary on-line |
1731 | Fosetyl-al | 39148-24-8 | 2 | Mar 1,1991 | I.A.1. | MRID No. added |
1732 | Fosetyl-al | 39148-24-8 | 3 | Mar 1,1991 | I.A.4. | Citations added |
1733 | Fosetyl-al | 39148-24-8 | 4 | Mar 1,1991 | VI. | Bibliography on-line |
1734 | Fosetyl-al | 39148-24-8 | 5 | Apr 1,1991 | VI.C. | Citations clarified |
1735 | Fosetyl-al | 39148-24-8 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1736 | Fosetyl-al | 39148-24-8 | 7 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone no. changed |
1737 | Fosetyl-al | 39148-24-8 | 8 | Jul 1,1994 | II. | Carcinogenicity assessment noted as pending change |
1738 | Fosetyl-al | 39148-24-8 | 9 | Aug 1,1995 | II., II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
1739 | Fosetyl-al | 39148-24-8 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1740 | Fosetyl-al | 39148-24-8 | 11 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1741 | Fosetyl-al | 39148-24-8 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1742 | Furan | 110-00-9 | 1 | None | None | |
1743 | Furan | 110-00-9 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1744 | Furfural | 98-01-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1745 | Furmecyclox | 60568-05-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1746 | Glufosinate-ammonium | 77182-82-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1747 | Glycidaldehyde | 765-34-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1748 | Glyphosate | 1071-83-6 | 1 | Apr 16,2019 | Related Links | Removed the archived REDs link from top list because they can get to the documents from the new tab. |
1749 | Glyphosate | 1071-83-6 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1750 | Haloxyfop-methyl | 69806-40-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1751 | Harmony | 79277-27-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1752 | Heptachlor | 76-44-8 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
1753 | Heptachlor | 76-44-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1754 | Heptachlor epoxide | 1024-57-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1755 | n-Heptane | 142-82-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1756 | Hexabromobenzene | 87-82-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1757 | Hexabromocyclododecane (HBCD) | 3194-55-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1758 | Hexabromodiphenyl ether | 36483-60-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1759 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | 1 | Jun 30,2008 | I., II. | RfD, RfC, and cancer assessment first on line. |
1760 | 2,2',4,4',5,5'-Hexabromodiphenyl ether (BDE-153) | 68631-49-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1761 | Hexachlorobenzene | 118-74-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1762 | Hexachlorobutadiene | 87-68-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1763 | alpha-Hexachlorocyclohexane (alpha-HCH) | 319-84-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1764 | beta-Hexachlorocyclohexane (beta-HCH) | 319-85-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1765 | delta-Hexachlorocyclohexane (delta-HCH) | 319-86-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1766 | epsilon-Hexachlorocyclohexane (epsilon-HC) | 6108-10-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1767 | gamma-Hexachlorocyclohexane (gamma-HCH) | 58-89-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1768 | technical Hexachlorocyclohexane (t-HCH) | 608-73-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1769 | Hexachlorocyclopentadiene (HCCPD) | 77-47-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1770 | Hexachlorodibenzo-p-dioxin (HxCDD), mixture of 1,2,3,6,7,8-HxCDD and 1,2,3,7,8,9-HxCDD | 57653-85-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1771 | Hexachloroethane | 67-72-1 | 1 | Sep 30,1987 | I.A. | Oral RfD assessment on-line |
1772 | Hexachloroethane | 67-72-1 | 2 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1773 | Hexachloroethane | 67-72-1 | 3 | Mar 1,1988 | II.B.3. | Text clarified |
1774 | Hexachloroethane | 67-72-1 | 4 | Mar 1,1988 | II.B.4. | Confidence statement revised |
1775 | Hexachloroethane | 67-72-1 | 5 | Mar 1,1988 | II.C.4. | Confidence statement revised |
1776 | Hexachloroethane | 67-72-1 | 6 | Jan 1,1991 | II. | Text edited |
1777 | Hexachloroethane | 67-72-1 | 7 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
1778 | Hexachloroethane | 67-72-1 | 8 | Apr 1,1991 | I.A. | Text edited |
1779 | Hexachloroethane | 67-72-1 | 9 | Apr 1,1991 | I.A.7. | Secondary contact changed |
1780 | Hexachloroethane | 67-72-1 | 10 | Apr 1,1991 | II. | Text edited |
1781 | Hexachloroethane | 67-72-1 | 11 | Apr 1,1991 | VI. | Bibliography on-line |
1782 | Hexachloroethane | 67-72-1 | 12 | Dec 1,1991 | I.B. | Inhalation RfC now under review |
1783 | Hexachloroethane | 67-72-1 | 13 | Dec 1,1991 | IV.F.1. | EPA contact changed |
1784 | Hexachloroethane | 67-72-1 | 14 | Jan 1,1992 | IV. | Regulatory actions updated |
1785 | Hexachloroethane | 67-72-1 | 15 | Dec 1,1992 | I.B. | Work group review date added |
1786 | Hexachloroethane | 67-72-1 | 16 | Feb 1,1994 | II.D.3. | Secondary contact's phone number changed |
1787 | Hexachloroethane | 67-72-1 | 17 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemicalsubstance reviews that were not completed by September 1995 were taken out of IRISreview. The IRIS Pilot Program replaced the workgroup functions beginning inSeptember, 1995. |
1788 | Hexachloroethane | 67-72-1 | 18 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Datawere removed from IRIS on or before April 1997. IRIS users were directed to theappropriate EPA Program Offices for this information. |
1789 | Hexachloroethane | 67-72-1 | 19 | Sep 23,2011 | I, II, VI, VIII | RfD and cancer assessments updated. RfC added. |
1790 | Hexachloroethane | 67-72-1 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1791 | Hexachlorophene | 70-30-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1792 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | 1 | Aug 30,2018 | Updates to Key Value | After a rigorous peer review, the IRIS Program update the noncancer RfD value (not enough data was available to update the RfC), and the weight of evidence (woe) oral unit risk value (not enough data was available to update the inhalation unit risk value. |
1793 | Hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) | 121-82-4 | 2 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1794 | 1,6-Hexamethylene diisocyanate | 822-06-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1795 | n-Hexane | 110-54-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1796 | 2-Hexanone | 591-78-6 | 1 | Sep 25,2009 | I., II. | RfD, RfC, and cancer assessment first on-line |
1797 | 2-Hexanone | 591-78-6 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1798 | Hexazinone | 51235-04-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1799 | Hydrazine/Hydrazine sulfate | 302-01-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1800 | Hydrogen Cyanide and Cyanide Salts | Various | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
1801 | Hydrogen Cyanide and Cyanide Salts | Various | 2 | Mar 1,1988 | I.A.2. | Text revised |
1802 | Hydrogen Cyanide and Cyanide Salts | Various | 3 | Mar 1,1988 | III.A. | Health Advisory added |
1803 | Hydrogen Cyanide and Cyanide Salts | Various | 4 | Aug 1,1990 | IV.F.1. | EPA contact changed |
1804 | Hydrogen Cyanide and Cyanide Salts | Various | 5 | Jun 1,1991 | VI. | Bibliography on-line |
1805 | Hydrogen Cyanide and Cyanide Salts | Various | 6 | Jan 1,1992 | I.A.7. | Primary contact changed |
1806 | Hydrogen Cyanide and Cyanide Salts | Various | 7 | Jan 1,1992 | IV. | Regulatory actions updated |
1807 | Hydrogen Cyanide and Cyanide Salts | Various | 8 | Feb 1,1993 | I.A.7. | Minor text change |
1808 | Hydrogen Cyanide and Cyanide Salts | Various | 9 | Mar 1,1993 | I.B. | Inhalation RfC now under review |
1809 | Hydrogen Cyanide and Cyanide Salts | Various | 10 | Sep 1,1994 | I.B. | Inhalation RfC on-line |
1810 | Hydrogen Cyanide and Cyanide Salts | Various | 11 | Sep 1,1994 | VI.B. | Inhalation RfC references on-line |
1811 | Hydrogen Cyanide and Cyanide Salts | Various | 12 | Nov 1,1994 | VI.B. | Osuntokun, 1981 reference clarified |
1812 | Hydrogen Cyanide and Cyanide Salts | Various | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1813 | Hydrogen Cyanide and Cyanide Salts | Various | 14 | Jan 9,2002 | I., II. | This chemical is being reassessed under the IRIS Program |
1814 | Hydrogen Cyanide and Cyanide Salts | Various | 15 | Sep 28,2010 | I., II., VI. | RfD and RfC assessment updated cancer assessment added. |
1815 | Hydrogen Cyanide and Cyanide Salts | Various | 16 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1816 | Hydrogen chloride | 7647-01-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1817 | Hydrogen sulfide | 7783-06-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1818 | Hydroquinone | 123-31-9 | 1 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
1819 | Hydroquinone | 123-31-9 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1820 | Imazalil | 35554-44-0 | 1 | Jul 15,2016 | Archived Key Values | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1821 | Imazalil | 35554-44-0 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1822 | Imazaquin | 81335-37-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1823 | Indeno[1,2,3-cd]pyrene | 193-39-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1824 | Iprodione | 36734-19-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1825 | Isobutyl alcohol | 78-83-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1826 | Isophorone | 78-59-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1827 | Isopropalin | 33820-53-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1828 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
1829 | Isopropyl methyl phosphonic acid (IMPA) | 1832-54-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1830 | Isoxaben | 82558-50-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1831 | Lactofen | 77501-63-4 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
1832 | Lactofen | 77501-63-4 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1833 | Lead and compounds (inorganic) | 7439-92-1 | 1 | Sep 26,1988 | II. | Carcinogen summary on-line |
1834 | Lead and compounds (inorganic) | 7439-92-1 | 2 | Feb 1,1989 | IV.B.1. | Effect level corrected in discussion |
1835 | Lead and compounds (inorganic) | 7439-92-1 | 3 | Jun 1,1989 | II.D.3. | Primary contact changed |
1836 | Lead and compounds (inorganic) | 7439-92-1 | 4 | Jun 1,1989 | IV.A.1. | Reference corrected - changed number for part in CFR |
1837 | Lead and compounds (inorganic) | 7439-92-1 | 5 | Dec 1,1989 | II.A.3. | Last paragraph - correct Van Esch 1969 citation |
1838 | Lead and compounds (inorganic) | 7439-92-1 | 6 | Dec 1,1989 | VI. | Bibliography on-line |
1839 | Lead and compounds (inorganic) | 7439-92-1 | 7 | Jul 1,1990 | I.A. | Changed contact J. Cohen's office and telephone number |
1840 | Lead and compounds (inorganic) | 7439-92-1 | 8 | Jul 1,1990 | IV.F.1. | EPA contact chenged |
1841 | Lead and compounds (inorganic) | 7439-92-1 | 9 | Feb 1,1991 | I.A. | Message revised to include new EPA document |
1842 | Lead and compounds (inorganic) | 7439-92-1 | 10 | Feb 1,1991 | I.A. | EPA contacts changed |
1843 | Lead and compounds (inorganic) | 7439-92-1 | 11 | May 1,1991 | II.A. | Text edited |
1844 | Lead and compounds (inorganic) | 7439-92-1 | 12 | Jan 1,1992 | IV. | Regulatory actions updated |
1845 | Lead and compounds (inorganic) | 7439-92-1 | 13 | Jun 1,1992 | IV.B.2. | MCL monitoring reqs. and BAT corrected |
1846 | Lead and compounds (inorganic) | 7439-92-1 | 14 | Jul 1,1993 | II.D.3. | Secondary contact's phone number changed |
1847 | Lead and compounds (inorganic) | 7439-92-1 | 15 | Jul 1,1993 | VI.C. | References alphabetized correctly |
1848 | Lead and compounds (inorganic) | 7439-92-1 | 16 | Nov 1,1993 | II.D.1. | U.S.EPA 1987 replaced with 1989; rev. state. revised |
1849 | Lead and compounds (inorganic) | 7439-92-1 | 17 | Nov 1,1993 | VI.C. | U.S.EPA 1987 deleted; U.S.EPA 1989 added |
1850 | Lead and compounds (inorganic) | 7439-92-1 | 18 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1851 | Lead and compounds (inorganic) | 7439-92-1 | 19 | I.A., I.Bl, II. | Previous reference value discussions replaced with links to EPA websites containing regulatory information and other websites with risk assessment information; cancer discussion retained, added links to agencies conducting reviews of lead carcinogenicity. | |
1852 | Lead and compounds (inorganic) | 7439-92-1 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1853 | Libby Amphibole Asbestos | 1318-09-8 | 1 | Nov 17,2014 | IB, II, VI. | RfC and cancer assessment added |
1854 | Libby Amphibole Asbestos | 1318-09-8 | 2 | Jun 19,2020 | CASRN | Added CASRN, DTXSID number (as alternate CASRN) and related link from/to the Chemistry Dashboard. |
1855 | Libby Amphibole Asbestos | 1318-09-8 | 3 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
1856 | d-Limonene | 5989-27-5 | 1 | Nov 1,1993 | I.B. | Inhalation RfC now under review |
1857 | d-Limonene | 5989-27-5 | 2 | Dec 1,1993 | I.B. | Inhalation RfC message on-line |
1858 | d-Limonene | 5989-27-5 | 3 | Dec 1,1991 | VI.B. | Inhalation RfC references on-line |
1859 | d-Limonene | 5989-27-5 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1860 | d-Limonene | 5989-27-5 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1861 | Linuron | 330-55-2 | 1 | May 1,1989 | II. | Carcinogen assessment now under review |
1862 | Linuron | 330-55-2 | 2 | Aug 1,1989 | II. | Carcinogen summary on-line |
1863 | Linuron | 330-55-2 | 3 | Aug 1,1989 | VI. | Bibliography on-line |
1864 | Linuron | 330-55-2 | 4 | Aug 1,1990 | I.A. | Text edited |
1865 | Linuron | 330-55-2 | 5 | Aug 1,1990 | II. | Text edited |
1866 | Linuron | 330-55-2 | 6 | Aug 1,1990 | VI.A. | RfD references added |
1867 | Linuron | 330-55-2 | 7 | Jan 1,1992 | IV. | Regulatory actions updated |
1868 | Linuron | 330-55-2 | 8 | Oct 1,1993 | II.D.3. | Secondary actions updated |
1869 | Linuron | 330-55-2 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1870 | Linuron | 330-55-2 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1871 | Londax | 83055-99-6 | 1 | Sep 30,1987 | All | CASRN added to file |
1872 | Londax | 83055-99-6 | 2 | Mar 1,1988 | I.A.2. | LEL text clarified |
1873 | Londax | 83055-99-6 | 3 | Jun 30,1988 | I.A. | Withdrawn; new RfD verified (in preparation) |
1874 | Londax | 83055-99-6 | 4 | Sep 7,1988 | I.A. | Revised oral RfD summary added |
1875 | Londax | 83055-99-6 | 5 | Sep 1,1990 | I.A.4. | Citations added |
1876 | Londax | 83055-99-6 | 6 | Sep 1,1990 | VI. | Bibliography on-line |
1877 | Londax | 83055-99-6 | 7 | Apr 1,1991 | I.A. | Text edited |
1878 | Londax | 83055-99-6 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1879 | Londax | 83055-99-6 | 9 | Aug 1,2018 | POD Value Update | Made a correction on the POD on the Oral RfD from 1.99 to 19.9 to match the tox review. |
1880 | Londax | 83055-99-6 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1881 | Malathion | 121-75-5 | 1 | Mar 1,1988 | All | CASRN corrected |
1882 | Malathion | 121-75-5 | 2 | Aug 1,1991 | I.B. | Inhalation RfC now under review |
1883 | Malathion | 121-75-5 | 3 | Jan 1,1992 | I.A.4. | Citations added |
1884 | Malathion | 121-75-5 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
1885 | Malathion | 121-75-5 | 5 | Jan 1,1992 | VI. | Bibliography on-line |
1886 | Malathion | 121-75-5 | 6 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workshops were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken oout of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
1887 | Malathion | 121-75-5 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1888 | Malathion | 121-75-5 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1889 | Maleic anhydride | 108-31-6 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
1890 | Maleic anhydride | 108-31-6 | 2 | Sep 26,1988 | All | CASRN corrected |
1891 | Maleic anhydride | 108-31-6 | 3 | Apr 1,1991 | I.A. | Text edited |
1892 | Maleic anhydride | 108-31-6 | 4 | Apr 1,1991 | I.A.7. | Secondary contact changed |
1893 | Maleic anhydride | 108-31-6 | 5 | Aug 1,1991 | I.A. | All citations clarified - changed to U.S. EPA |
1894 | Maleic anhydride | 108-31-6 | 6 | Aug 1,1991 | VI. | Bibliography on-ine |
1895 | Maleic anhydride | 108-31-6 | 7 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1896 | Maleic anhydride | 108-31-6 | 8 | Jul 1,1993 | I.A.6. | Other EPA Documentation clarified |
1897 | Maleic anhydride | 108-31-6 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1898 | Maleic anhydride | 108-31-6 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1899 | Maleic hydrazide | 123-33-1 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
1900 | Maleic hydrazide | 123-33-1 | 2 | Jan 1,1992 | IV. | Regulatory actions updated |
1901 | Maleic hydrazide | 123-33-1 | 3 | May 1,1992 | I.A.7. | Primary contact changed |
1902 | Maleic hydrazide | 123-33-1 | 4 | May 1,1992 | VI.A. | Bibliography on-line |
1903 | Maleic hydrazide | 123-33-1 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information |
1904 | Maleic hydrazide | 123-33-1 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1905 | Maneb | 12427-38-2 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1906 | Maneb | 12427-38-2 | 2 | Apr 1,1991 | I.A. | Text edited |
1907 | Maneb | 12427-38-2 | 3 | Jan 1,1992 | I.A.4. | Citations added |
1908 | Maneb | 12427-38-2 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1909 | Maneb | 12427-38-2 | 5 | Jan 1,1992 | VI. | Bibliography on-line |
1910 | Maneb | 12427-38-2 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1911 | Maneb | 12427-38-2 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1912 | Manganese | 7439-96-5 | 1 | Sep 26,1988 | II. | Carcinogen summary on-line |
1913 | Manganese | 7439-96-5 | 2 | Sep 1,1989 | VI. | Bibliography on-line |
1914 | Manganese | 7439-96-5 | 3 | Jun 1,1990 | I.A. | Oral RfD now under review |
1915 | Manganese | 7439-96-5 | 4 | Aug 1,1990 | I.A. | Oral RfD summary on-line |
1916 | Manganese | 7439-96-5 | 5 | Aug 1,1990 | II. | Text edited |
1917 | Manganese | 7439-96-5 | 6 | Aug 1,1990 | VI. | Oral RfD references added |
1918 | Manganese | 7439-96-5 | 7 | Sep 1,1990 | I.B. | Inhalation RfC now under review |
1919 | Manganese | 7439-96-5 | 8 | Dec 6,1990 | I.B. | Inhalation RfC on-line |
1920 | Manganese | 7439-96-5 | 9 | Dec 6,1990 | VI.B. | Inhalation RfC references added |
1921 | Manganese | 7439-96-5 | 10 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1922 | Manganese | 7439-96-5 | 11 | Jun 1,1992 | VI.B. | Iregren, 1990 and Nishiyama et al., 1975 pages corrected |
1923 | Manganese | 7439-96-5 | 12 | Aug 1,1992 | I.A. | Oral RfD noted as pending change |
1924 | Manganese | 7439-96-5 | 13 | Aug 1,1992 | I.A.6. | Work group review date added |
1925 | Manganese | 7439-96-5 | 14 | Oct 1,1992 | I.A. | Oral RfD withdrawn; new summary in preparation |
1926 | Manganese | 7439-96-5 | 15 | Oct 1,1992 | I.A.6. | Work group review date added |
1927 | Manganese | 7439-96-5 | 16 | Oct 1,1992 | VI.A. | Oral RfD references withdrawn |
1928 | Manganese | 7439-96-5 | 17 | Jan 1,1993 | I.A. | Oral RfD replaced (RfD changed) |
1929 | Manganese | 7439-96-5 | 18 | Jan 1,1993 | VI.A. | Oral RfD references replaced |
1930 | Manganese | 7439-96-5 | 19 | May 1,1993 | I.A. | Work group review date added |
1931 | Manganese | 7439-96-5 | 20 | Jul 1,1993 | II.A.3. | 'Inadequate' added to first paragraph |
1932 | Manganese | 7439-96-5 | 21 | Jul 1,1993 | II.D.1. | EPA Documentation clarified |
1933 | Manganese | 7439-96-5 | 22 | Nov 1,1993 | I.B. | Inhalation RfC noted as pending changed |
1934 | Manganese | 7439-96-5 | 23 | Nov 1,1993 | I.B.6. | Work group review date added |
1935 | Manganese | 7439-96-5 | 24 | Dec 1,1993 | I.B. | Inhalation RfC replaced; RfC changed |
1936 | Manganese | 7439-96-5 | 25 | Dec 1,1993 | VI.B. | Inhalation RfC references replaced |
1937 | Manganese | 7439-96-5 | 26 | Jan 1,1994 | I.A. | Oral RfD noted as pending change |
1938 | Manganese | 7439-96-5 | 27 | Jan 1,1994 | I.A.6. | Work group review date added |
1939 | Manganese | 7439-96-5 | 28 | Mar 1,1994 | II.D.3. | Primary contact changed |
1940 | Manganese | 7439-96-5 | 29 | Apr 1,1994 | I.A.2. | Text revised |
1941 | Manganese | 7439-96-5 | 30 | Apr 1,1994 | I.A.3. | Test revised |
1942 | Manganese | 7439-96-5 | 31 | Apr 1,1994 | I.A.4. | Text revised |
1943 | Manganese | 7439-96-5 | 32 | Apr 1,1994 | I.A.5. | Text revised |
1944 | Manganese | 7439-96-5 | 33 | Apr 1,1994 | VI.A. | Oral RfD references revised |
1945 | Manganese | 7439-96-5 | 34 | Jun 1,1995 | I.A. | Oral RfD noted as pending change |
1946 | Manganese | 7439-96-5 | 35 | Jun 1,1995 | I.A.6. | Work group review date added |
1947 | Manganese | 7439-96-5 | 36 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot PRogram replaced the workgroup functions beginning in September 1995. |
1948 | Manganese | 7439-96-5 | 37 | Nov 1,1995 | I.A. | Oral RfD assessment replaced |
1949 | Manganese | 7439-96-5 | 38 | Nov 1,1995 | VI.A. | Oral RfD references replaced |
1950 | Manganese | 7439-96-5 | 39 | May 1,1996 | I.A.7. | Secondary contact's phone number changed |
1951 | Manganese | 7439-96-5 | 40 | Dec 1,1996 | II.D.3. | Primary contact removed |
1952 | Manganese | 7439-96-5 | 41 | Apr 1,1997 | III., IV., V. | Drinking Wate Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1953 | Manganese | 7439-96-5 | 43 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1954 | Mepiquat chloride | 24307-26-4 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
1955 | Mepiquat chloride | 24307-26-4 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
1956 | Mepiquat chloride | 24307-26-4 | 3 | Apr 1,1991 | I.A. | text edited |
1957 | Mepiquat chloride | 24307-26-4 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1958 | Mepiquat chloride | 24307-26-4 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1959 | Mepiquat chloride | 24307-26-4 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1960 | Mercuric chloride (HgCl2) | 7487-94-7 | 1 | Apr 1,1994 | I.B. | Inhalation RfC noted as under review on 3/22/1990 |
1961 | Mercuric chloride (HgCl2) | 7487-94-7 | 2 | Apr 1,1994 | II. | Carcinogenicity assessment now under review |
1962 | Mercuric chloride (HgCl2) | 7487-94-7 | 3 | May 1,1995 | I.A. | Oral RfD summary on-line |
1963 | Mercuric chloride (HgCl2) | 7487-94-7 | 4 | May 1,1995 | II. | Carcinogenicity assessment summary on-line |
1964 | Mercuric chloride (HgCl2) | 7487-94-7 | 5 | May 1,1995 | VI. | Bibliography on-line |
1965 | Mercuric chloride (HgCl2) | 7487-94-7 | 6 | Jun 1,1995 | II.B. | Text revised; first paragraph |
1966 | Mercuric chloride (HgCl2) | 7487-94-7 | 7 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by Setember 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
1967 | Mercuric chloride (HgCl2) | 7487-94-7 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were direced to the appropriate EPA Program Offices for this information. |
1968 | Mercuric chloride (HgCl2) | 7487-94-7 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1969 | Mercury, elemental | 7439-97-6 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
1970 | Mercury, elemental | 7439-97-6 | 2 | Sep 1,1989 | VI. | Bibliography on-line |
1971 | Mercury, elemental | 7439-97-6 | 3 | Dec 1,1989 | I.B. | Inhalation RfD now under review |
1972 | Mercury, elemental | 7439-97-6 | 4 | May 1,1991 | II.A.3. | Text edited |
1973 | Mercury, elemental | 7439-97-6 | 5 | Jan 1,1992 | IV. | Regulatory Action Section on-line |
1974 | Mercury, elemental | 7439-97-6 | 6 | Apr 1,1994 | II. | Carcinogenicity assessment noted as pending change |
1975 | Mercury, elemental | 7439-97-6 | 7 | Apr 1,1994 | II.D.2. | Work group review date added |
1976 | Mercury, elemental | 7439-97-6 | 8 | May 1,1995 | All | Name changed from mercury (inorganic) |
1977 | Mercury, elemental | 7439-97-6 | 9 | May 1,1995 | II. | Carcinogen assessment replaced |
1978 | Mercury, elemental | 7439-97-6 | 10 | May 1,1995 | VI.C. | Carcinogen assessment references replaced |
1979 | Mercury, elemental | 7439-97-6 | 11 | Jun 1,1995 | I.B. | Inhalation RfC summary on-line |
1980 | Mercury, elemental | 7439-97-6 | 12 | Jun 1,1995 | VI.B. | Inhalation RfC references on-line |
1981 | Mercury, elemental | 7439-97-6 | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
1982 | Mercury, elemental | 7439-97-6 | 14 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1983 | Merphos | 150-50-5 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1984 | Merphos | 150-50-5 | 2 | Jan 1,1989 | All | CASRN corrected |
1985 | Merphos | 150-50-5 | 3 | Apr 1,1991 | I.A. | Text edited |
1986 | Merphos | 150-50-5 | 4 | Apr 1,1992 | I.A.4. | Citations added |
1987 | Merphos | 150-50-5 | 5 | Apr 1,1992 | VI. | Bibliography on-line |
1988 | Merphos | 150-50-5 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
1989 | Merphos | 150-50-5 | 7 | Aug 1,1992 | I.B. | Inhalation RfC now under review |
1990 | Merphos | 150-50-5 | 8 | Nov 1,1992 | I.B. | Not verified; data inadequate |
1991 | Merphos | 150-50-5 | 9 | Nov 1,1992 | VI.B. | No references available |
1992 | Merphos | 150-50-5 | 10 | Apr 1,1997 | III., IV.,V. | Dring Water Health Advisories, EPA Regulatory Actions, and Supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program offices for this information. |
1993 | Merphos | 150-50-5 | 11 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
1994 | Merphos | 150-50-5 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
1995 | Merphos oxide | 78-48-8 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
1996 | Merphos oxide | 78-48-8 | 2 | Apr 1,1991 | I.A. | Text edited |
1997 | Merphos oxide | 78-48-8 | 3 | Apr 1,1991 | I.A.4. | Citations added |
1998 | Merphos oxide | 78-48-8 | 4 | Apr 1,1991 | VI. | Bibliography on-line |
1999 | Merphos oxide | 78-48-8 | 5 | Aug 1,1992 | I.B. | Inhalation RfC now under review |
2000 | Merphos oxide | 78-48-8 | 6 | Nov 1,1992 | I.B. | Not verified; data inadequate |
2001 | Merphos oxide | 78-48-8 | 7 | Nov 1,1992 | VI.B. | No references available |
2002 | Merphos oxide | 78-48-8 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Halth Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2003 | Merphos oxide | 78-48-8 | 9 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2004 | Merphos oxide | 78-48-8 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2005 | Metalaxyl | 57837-19-1 | 1 | Mar 1,1987 | IV. | Regulatory Action section on-line |
2006 | Metalaxyl | 57837-19-1 | 2 | Mar 1,1991 | I.A.4. | Citations added |
2007 | Metalaxyl | 57837-19-1 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
2008 | Metalaxyl | 57837-19-1 | 4 | Jan 1,1992 | IV. | Regulatory action updated |
2009 | Metalaxyl | 57837-19-1 | 5 | Jan 1,1995 | I.A. | Oral RfD noted as pending |
2010 | Metalaxyl | 57837-19-1 | 6 | Jan 1,1995 | I.A.6. | Work group review date added |
2011 | Metalaxyl | 57837-19-1 | 7 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2012 | Metalaxyl | 57837-19-1 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water HEalth Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2013 | Metalaxyl | 57837-19-1 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2014 | Methacrylonitrile | 126-98-7 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
2015 | Methacrylonitrile | 126-98-7 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
2016 | Methacrylonitrile | 126-98-7 | 3 | Sep 1,1989 | VI. | Bibliography on-line |
2017 | Methacrylonitrile | 126-98-7 | 4 | Jan 1,1991 | I.A. | Text edited |
2018 | Methacrylonitrile | 126-98-7 | 5 | Jan 1,1992 | I.A.7. | Secondary contact changed |
2019 | Methacrylonitrile | 126-98-7 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2020 | Methacrylonitrile | 126-98-7 | 7 | Feb 1,1996 | I.A.7. | Secondary contact deleted |
2021 | Methacrylonitrile | 126-98-7 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplemetary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2022 | Methacrylonitrile | 126-98-7 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2023 | Methamidophos | 10265-92-6 | 1 | Mar 1,1988 | I.A.4. | Text deleted |
2024 | Methamidophos | 10265-92-6 | 2 | Mar 1,1991 | I.A.4. | Citations added |
2025 | Methamidophos | 10265-92-6 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
2026 | Methamidophos | 10265-92-6 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2027 | Methamidophos | 10265-92-6 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2028 | Methamidophos | 10265-92-6 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2029 | Methanol | 67-56-1 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
2030 | Methanol | 67-56-1 | 2 | Oct 1,1989 | I.B. | Inhalation RfD now under review |
2031 | Methanol | 67-56-1 | 3 | Nov 1,1989 | VI. | Bibliography on-line |
2032 | Methanol | 67-56-1 | 4 | Jan 1,1991 | I.A. | Text edited |
2033 | Methanol | 67-56-1 | 5 | Jan 1,1992 | I.A.7. | Secondary contact changed |
2034 | Methanol | 67-56-1 | 6 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2035 | Methanol | 67-56-1 | 7 | Jul 1,1993 | I.A.6. | Other EPA Documnetation added |
2036 | Methanol | 67-56-1 | 8 | Aug 1,1995 | .B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2037 | Methanol | 67-56-1 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA PRogram Offices for this information. |
2038 | Methanol | 67-56-1 | 10 | Sep 30,2013 | I., VI., VIII. | RfD assessment updated. RfC added. |
2039 | Methanol | 67-56-1 | 11 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2040 | Methidathion | 950-37-8 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
2041 | Methidathion | 950-37-8 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
2042 | Methidathion | 950-37-8 | 3 | May 1,1989 | II. | Carcinogen summary on-line |
2043 | Methidathion | 950-37-8 | 4 | Dec 1,1989 | II.A.3. | Paragraph 1: Citation corrected |
2044 | Methidathion | 950-37-8 | 5 | Dec 1,1989 | II.A.3. | Paragraph 2: Citation corrected |
2045 | Methidathion | 950-37-8 | 6 | Dec 1,1989 | VI. | Bibliography on-line |
2046 | Methidathion | 950-37-8 | 7 | Aug 1,1990 | I.A. | Text edited |
2047 | Methidathion | 950-37-8 | 8 | Aug 1,1990 | II. | Text edited |
2048 | Methidathion | 950-37-8 | 9 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2049 | Methidathion | 950-37-8 | 10 | Jul 1,1993 | II.D.1. | EPA Documentation clarified |
2050 | Methidathion | 950-37-8 | 11 | Jul 1,1993 | VI.C. | EPA reference year clarified |
2051 | Methidathion | 950-37-8 | 12 | Oct 1,1993 | II.D.3. | Secondary contact changed |
2052 | Methidathion | 950-37-8 | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices. |
2053 | Methidathion | 950-37-8 | 14 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2054 | Methidathion | 950-37-8 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2055 | Methomyl | 16752-77-5 | 1 | Mar 31,1987 | IV. | Regulatory Action section on-line |
2056 | Methomyl | 16752-77-5 | 2 | Dec 1,1988 | I.A.4. | Core grades added to studies 1, 3 and 4 |
2057 | Methomyl | 16752-77-5 | 3 | Mar 1,1991 | I.A.4. | Citations added |
2058 | Methomyl | 16752-77-5 | 4 | Mar 1,1991 | III.A. | Health Advisory on-line |
2059 | Methomyl | 16752-77-5 | 5 | Mar 1,1991 | VI. | Bibliography on-line |
2060 | Methomyl | 16752-77-5 | 6 | Oct 1,1991 | II. | Carcinogenicity assessment now under review |
2061 | Methomyl | 16752-77-5 | 7 | Jan 1,1992 | IV. | Regulatory actions updated |
2062 | Methomyl | 16752-77-5 | 8 | Aug 1,1992 | II. | EPA's RfD/RfC and Crave workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of the IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2063 | Methomyl | 16752-77-5 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplemntary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2064 | Methomyl | 16752-77-5 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2065 | Methoxychlor | 72-43-5 | 1 | Sep 7,1988 | II. | Carcinogen summary on-line |
2066 | Methoxychlor | 72-43-5 | 2 | Feb 1,1989 | II.D.3. | Primary contact's phone number corrected |
2067 | Methoxychlor | 72-43-5 | 3 | Jun 1,1989 | II.D.3. | Secondary contact deleted |
2068 | Methoxychlor | 72-43-5 | 4 | Dec 1,1989 | VI. | Bibliography on-line |
2069 | Methoxychlor | 72-43-5 | 5 | May 1,1990 | I.A. | Oral RfD now under review |
2070 | Methoxychlor | 72-43-5 | 6 | Sep 1,1990 | I.A. | Oral RfD summary on-line |
2071 | Methoxychlor | 72-43-5 | 7 | Sep 1,1990 | III.A. | Health Advisory on-line |
2072 | Methoxychlor | 72-43-5 | 8 | Sep 1,1990 | VI.A. | Oral RfD references added |
2073 | Methoxychlor | 72-43-5 | 9 | Sep 1,1990 | VI.D. | Health Advisory references added |
2074 | Methoxychlor | 72-43-5 | 10 | Oct 1,1990 | II. | Text edited |
2075 | Methoxychlor | 72-43-5 | 11 | Aug 1,1991 | I.A.4. | Khera citation year corrected |
2076 | Methoxychlor | 72-43-5 | 12 | Aug 1,1991 | VI.A. | Khera reference year corrected |
2077 | Methoxychlor | 72-43-5 | 13 | Dec 1,1991 | I.B. | Inhalation RfC now under review |
2078 | Methoxychlor | 72-43-5 | 14 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2079 | Methoxychlor | 72-43-5 | 15 | Apr 1,1992 | I.B. | Inhalation RfC message on-line |
2080 | Methoxychlor | 72-43-5 | 16 | Apr 1,1992 | VI.B. | Inhalation RfC references added |
2081 | Methoxychlor | 72-43-5 | 17 | Dec 1,1993 | I.B. | Replaced with expanded assessment |
2082 | Methoxychlor | 72-43-5 | 18 | Dec 1,1993 | III.A. | Health Advisory withdrawn |
2083 | Methoxychlor | 72-43-5 | 19 | Dec 1,1993 | VI.B. | References revised |
2084 | Methoxychlor | 72-43-5 | 20 | Dec 1,1993 | VI.D. | Health Advisory references withdrawn |
2085 | Methoxychlor | 72-43-5 | 21 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2086 | Methoxychlor | 72-43-5 | 22 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
2087 | Methoxychlor | 72-43-5 | 23 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2088 | 2-Methoxyethanol | 109-86-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2089 | Methyl acrylate | 96-33-3 | 1 | Dec 1,1990 | II. | Carcinogen assessment on-line |
2090 | Methyl acrylate | 96-33-3 | 2 | Dec 1,1990 | VI.C. | Bibliography on-line |
2091 | Methyl acrylate | 96-33-3 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2092 | Methyl acrylate | 96-33-3 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2093 | Methyl chloride | 74-87-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2094 | Methyl chlorocarbonate | 79-22-1 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
2095 | Methyl chlorocarbonate | 79-22-1 | 2 | Apr 1,1989 | V. | Supplementary data on-line |
2096 | Methyl chlorocarbonate | 79-22-1 | 3 | May 1,1989 | I.A. | Withdrawn pending further review |
2097 | Methyl chlorocarbonate | 79-22-1 | 4 | Oct 1,1991 | II. | Carcinogenicity assessment now under review |
2098 | Methyl chlorocarbonate | 79-22-1 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2099 | Methyl chlorocarbonate | 79-22-1 | 6 | Aug 1,1995 | I.A., II. | EPAs RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2100 | Methyl chlorocarbonate | 79-22-1 | 7 | Feb 1,1996 | I.A. | Contact changed |
2101 | Methyl chlorocarbonate | 79-22-1 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA PROgram Offices for this information. |
2102 | Methyl chlorocarbonate | 79-22-1 | 9 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2103 | Methyl chlorocarbonate | 79-22-1 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2104 | Methyl ethyl ketone (MEK) | 78-93-3 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
2105 | Methyl ethyl ketone (MEK) | 78-93-3 | 2 | Mar 1,1988 | I.A.2. | Paragraph 2 clarified |
2106 | Methyl ethyl ketone (MEK) | 78-93-3 | 3 | Jul 1,1989 | II. | Carcinogen assessment now under review |
2107 | Methyl ethyl ketone (MEK) | 78-93-3 | 4 | Jul 1,1989 | VI. | Bibliography on-line |
2108 | Methyl ethyl ketone (MEK) | 78-93-3 | 5 | Dec 1,1989 | II. | Carcinogen assessment on-line |
2109 | Methyl ethyl ketone (MEK) | 78-93-3 | 6 | Dec 1,1989 | VI.C. | Carcinogen references added |
2110 | Methyl ethyl ketone (MEK) | 78-93-3 | 7 | Apr 1,1990 | I.B. | Inhalation RfC now under review |
2111 | Methyl ethyl ketone (MEK) | 78-93-3 | 8 | Jun 1,1990 | I.A. | Oral RfD summary noted as pending change |
2112 | Methyl ethyl ketone (MEK) | 78-93-3 | 9 | Jun 1,1990 | IV.F.1. | EPA contact changed |
2113 | Methyl ethyl ketone (MEK) | 78-93-3 | 10 | Aug 1,1991 | I.A. | Withdrawn pending further review |
2114 | Methyl ethyl ketone (MEK) | 78-93-3 | 11 | Aug 1,1991 | VI.A. | Oral RfD references withdrawn |
2115 | Methyl ethyl ketone (MEK) | 78-93-3 | 12 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2116 | Methyl ethyl ketone (MEK) | 78-93-3 | 13 | Jul 1,1992 | I.B. | Inhalation RfC on-line |
2117 | Methyl ethyl ketone (MEK) | 78-93-3 | 14 | Jul 1,1992 | VI.B. | Inhalation RfC references on-line |
2118 | Methyl ethyl ketone (MEK) | 78-93-3 | 15 | Aug 1,1992 | VI.B. | Inhalation RfC references clarified |
2119 | Methyl ethyl ketone (MEK) | 78-93-3 | 16 | Oct 1,1992 | I.A. | Work group review date added |
2120 | Methyl ethyl ketone (MEK) | 78-93-3 | 17 | Dec 1,1992 | I.A. | Work group review date added |
2121 | Methyl ethyl ketone (MEK) | 78-93-3 | 18 | May 1,1993 | I.A. | Oral RfD summary replaced; RfD changed |
2122 | Methyl ethyl ketone (MEK) | 78-93-3 | 19 | May 1,1993 | VI.A. | Oral RfD references replaced |
2123 | Methyl ethyl ketone (MEK) | 78-93-3 | 20 | Jun 1,1993 | VI.C. | Minor correction |
2124 | Methyl ethyl ketone (MEK) | 78-93-3 | 21 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS user were directed to the appropriate EPA Program Offices for this information. |
2125 | Methyl ethyl ketone (MEK) | 78-93-3 | 22 | Jan 9,2002 | I., II. | This chemical is being reassessed under the IRIS Program. |
2126 | Methyl ethyl ketone (MEK) | 78-93-3 | 23 | I., II., VI. | RfD, RfC, and cancer sections updated | |
2127 | Methyl ethyl ketone (MEK) | 78-93-3 | 24 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2128 | Methyl iodide | 74-88-4 | 1 | Sep 1,1992 | I.B. | inhalation RfC now under review |
2129 | Methyl iodide | 74-88-4 | 2 | Mar 1,1994 | II. | Carcinogenicity assessment now under review |
2130 | Methyl iodide | 74-88-4 | 3 | Oct 1,1994 | All | CASRN corrected |
2131 | Methyl iodide | 74-88-4 | 4 | Aug 1,1995 | I.B., II. | EPA's RfD/RfC and Crave workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2132 | Methyl iodide | 74-88-4 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisries, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2133 | Methyl iodide | 74-88-4 | 6 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
2134 | Methyl iodide | 74-88-4 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2135 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 1 | Mar 1,1988 | I.A.2. | Text revised |
2136 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 2 | Jul 1,1989 | VI. | Bibliography on-line |
2137 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 3 | Apr 1,1990 | I.B. | Inhalation RfD now under review |
2138 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 4 | Mar 1,1991 | I.A. | Oral RfD withdrawn pending additional review |
2139 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 5 | Mar 1,1991 | VI. | Bibliography on-line |
2140 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
2141 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 7 | Aug 1,1993 | I.A. | Work group review date added |
2142 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 8 | Aug 1,1993 | I.A. | EPA contact changed |
2143 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 9 | Aug 1,1995 | I.A., I.B., VI. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2144 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2145 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 11 | Dec 10,1998 | I., II. | This chemical is being reassessed under the IRIS Program. |
2146 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 12 | I., II., VI. | RfD, RfC and cancer sections updated | |
2147 | Methyl isobutyl ketone (MIBK) | 108-10-1 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2148 | Methyl isocyanate | 624-83-9 | 1 | Mar 1,1991 | I.B. | Inhalation RfC message on-line |
2149 | Methyl isocyanate | 624-83-9 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
2150 | Methyl isocyanate | 624-83-9 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2151 | Methyl isocyanate | 624-83-9 | 4 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2152 | Methyl isocyanate | 624-83-9 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2153 | Methyl methacrylate | 80-62-6 | 1 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementart Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2154 | Methyl methacrylate | 80-62-6 | 2 | Mar 2,1998 | I.A., I.B., II., VI. | New RfD, RfC, cancer assessments |
2155 | Methyl methacrylate | 80-62-6 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2156 | Methyl parathion | 298-00-0 | 1 | Mar 1,1991 | I.A.4. | Citations added |
2157 | Methyl parathion | 298-00-0 | 2 | Mar 1,1991 | III.A. | Health Advisory on-line |
2158 | Methyl parathion | 298-00-0 | 3 | Mar 1,1991 | VI. | Bibliography on-line |
2159 | Methyl parathion | 298-00-0 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
2160 | Methyl parathion | 298-00-0 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1995. IRIS users were directed to the appropriate EPA Program Offices for this information |
2161 | Methyl parathion | 298-00-0 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2162 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 1 | Aug 1,1991 | I.B. | Inhalation RfC now under review |
2163 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 2 | Dec 1,1991 | I.B. | Inhalation RfC on-line |
2164 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 3 | Dec 1,1991 | VI. | Bibliography on-line |
2165 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 4 | Mar 1,1993 | I.A. | Oral RfD now under review |
2166 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 5 | May 1,1993 | I.B. | Inhalation RfC noted as pending change |
2167 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 6 | May 1,1993 | I.B.6. | Work group review date added |
2168 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 7 | Aug 1,1993 | I.B. | Withdrawn; new RfC verified (in preparation) |
2169 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 8 | Aug 1,1993 | I.B.6. | Work group review date added |
2170 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 9 | Aug 1,1993 | I.B.7. | EPA contact changed |
2171 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 10 | Aug 1,1993 | VI. | Bibliography withdrawn |
2172 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 11 | Sep 1,1993 | I.B. | Inhalation RfC replaced; RfC changed |
2173 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 12 | Sep 1,1993 | VI.B. | Inhalation RfC refereences on-line |
2174 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 13 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2175 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2176 | Methyl tert-butyl ether (MTBE) | 1634-04-4 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2177 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | 1 | Sep 29,1988 | I.A. | Oral RfD summary on-line |
2178 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | 2 | Dec 1,1990 | I.A.2. | Text edited |
2179 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2180 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | 4 | Jul 1,1992 | VI.A. | Oral RfD references on-line |
2181 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2182 | 4-(2-Methyl-4-chlorophenoxy) butyric acid (MCPB) | 94-81-5 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2183 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 1 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
2184 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 2 | Dec 1,1988 | I.A. | Withdrawn; new RfD verified (in preparation) |
2185 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 3 | Jan 1,1989 | I.A. | Oral RfD summary replaced; RfD changed |
2186 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 4 | Dec 1,1989 | VI. | Bibliography on-line |
2187 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 5 | Aug 1,1990 | I.A. | Text edited |
2188 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2189 | 2-(2-Methyl-4-chlorophenoxy)propionic acid (MCPP) | 93-65-2 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2190 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 1 | Aug 28,1987 | I.A. | New Study - RfD changed |
2191 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 2 | Mar 1,1988 | I.A.6. | Verification date changed |
2192 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 3 | Sep 26,1988 | I.A.1. | Citation corrected |
2193 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 4 | Sep 26,1988 | I.A.2. | Text revised |
2194 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 5 | Sep 26,1988 | I.A.3. | UF text revised |
2195 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 6 | Sep 26,1988 | I.A.4. | Study descriptions revised |
2196 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 7 | Sep 26,1988 | I.A.5. | Confidence levels revised |
2197 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 8 | Jan 1,1991 | I.A. | Text edited |
2198 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 9 | Mar 1,1991 | VI. | Bibliography on-line |
2199 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 10 | Jan 1,1992 | IV. | Regulatory action updated |
2200 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2201 | 2-Methyl-4-chlorophenoxyacetic acid (MCPA) | 94-74-6 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2202 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 1 | Aug 1,1991 | I.B. | Inhalation RfC now under review |
2203 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 2 | Mar 1,1993 | I.B. | Work group review date added |
2204 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 3 | May 1,1994 | I.B. | Inhalation RfC now on-line |
2205 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 4 | May 1,1994 | VI.B. | Inhalation RfC references on-line |
2206 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2207 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 6 | Feb 7,1998 | I.B., II., VI. | Revised RfC, new carcinogenicity assessment |
2208 | Methylene Diphenyl Diisocyanate (monomeric MDI) and polymeric MDI (PMDI) | 101-68-8 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2209 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | 1 | Aug 1,1989 | II. | Carcinogen summary on-line |
2210 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | 2 | Aug 1,1989 | VI. | Bibliography on-line |
2211 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | 3 | Aug 1,1990 | II. | Text edited |
2212 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | 4 | Jul 1,1993 | VI.C. | References alphabetized correctly |
2213 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2214 | 4,4'-Methylene bis(N,N'-dimethyl)aniline | 101-61-1 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2215 | Methylmercury (MeHg) | 22967-92-6 | 1 | Dec 1,1988 | I.A. | Principal study citations added |
2216 | Methylmercury (MeHg) | 22967-92-6 | 2 | Feb 1,1989 | I.A. | Oral RfD summary is being reevaluated |
2217 | Methylmercury (MeHg) | 22967-92-6 | 3 | Aug 1,1991 | VI. | Bibliography on-line |
2218 | Methylmercury (MeHg) | 22967-92-6 | 4 | Jan 1,1992 | I.A.7. | Secondary contact changed |
2219 | Methylmercury (MeHg) | 22967-92-6 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2220 | Methylmercury (MeHg) | 22967-92-6 | 6 | Mar 1,1994 | I.A.6. | Work group review date added |
2221 | Methylmercury (MeHg) | 22967-92-6 | 7 | Apr 1,1994 | II. | Carcinogenicity assessment now under review |
2222 | Methylmercury (MeHg) | 22967-92-6 | 8 | Sep 1,1994 | I.A.6. | Work group review date added |
2223 | Methylmercury (MeHg) | 22967-92-6 | 9 | Oct 1,1994 | I.A.6. | Work group review dates added |
2224 | Methylmercury (MeHg) | 22967-92-6 | 10 | Nov 1,1994 | I.A.6. | Work group review date added |
2225 | Methylmercury (MeHg) | 22967-92-6 | 11 | Dec 1,1994 | I.A.6. | Work group review date added |
2226 | Methylmercury (MeHg) | 22967-92-6 | 12 | May 1,1995 | I.A. | Oral RfD summary replaced; new RfD |
2227 | Methylmercury (MeHg) | 22967-92-6 | 13 | May 1,1995 | VI.A. | Oral RfD references replaced |
2228 | Methylmercury (MeHg) | 22967-92-6 | 14 | May 1,1995 | II. | Carcinogenicity assessment on-line |
2229 | Methylmercury (MeHg) | 22967-92-6 | 15 | May 1,1995 | VI.C. | Carcinogenicity assessment references on-line |
2230 | Methylmercury (MeHg) | 22967-92-6 | 16 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2231 | Methylmercury (MeHg) | 22967-92-6 | 17 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2232 | 2-Methylnaphthalene | 91-57-6 | 1 | All | First IRIS RfD, cancer assessment | |
2233 | 2-Methylnaphthalene | 91-57-6 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2234 | 4-Methylphenol | 106-44-5 | 1 | Aug 22,1988 | I.A. | Oral RfD summary on-line |
2235 | 4-Methylphenol | 106-44-5 | 2 | Jan 1,1989 | I.A.6. | Review statement deleted |
2236 | 4-Methylphenol | 106-44-5 | 3 | Nov 1,1989 | II. | Carcinogen assessment now under review |
2237 | 4-Methylphenol | 106-44-5 | 4 | Nov 1,1989 | VI. | Bibliography on-line |
2238 | 4-Methylphenol | 106-44-5 | 5 | Sep 1,1990 | I.A. | Text edited |
2239 | 4-Methylphenol | 106-44-5 | 6 | Sep 1,1990 | II. | Carcinogen assessment on-line |
2240 | 4-Methylphenol | 106-44-5 | 7 | Sep 1,1990 | VI.C. | Carcinogen references added |
2241 | 4-Methylphenol | 106-44-5 | 8 | Aug 1,1991 | I.A. | Withdrawn pending further review |
2242 | 4-Methylphenol | 106-44-5 | 9 | Aug 1,1991 | II.A.3. | Kaiser reference year corrected |
2243 | 4-Methylphenol | 106-44-5 | 10 | Aug 1,1991 | All | Name changed from p-Cresol |
2244 | 4-Methylphenol | 106-44-5 | 11 | Aug 1,1991 | VI.A. | Oral RfD references withdrawn |
2245 | 4-Methylphenol | 106-44-5 | 12 | Aug 1,1991 | VI.C. | Kaiser reference year corrected |
2246 | 4-Methylphenol | 106-44-5 | 13 | Aug 1,1991 | VI.C. | Citations corrected |
2247 | 4-Methylphenol | 106-44-5 | 14 | Jan 1,1992 | I.B. | Inhalation RfC now under review |
2248 | 4-Methylphenol | 106-44-5 | 15 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2249 | 4-Methylphenol | 106-44-5 | 16 | Apr 1,1992 | I.B. | Inhalation RfC now under review |
2250 | 4-Methylphenol | 106-44-5 | 17 | Apr 1,1992 | VI.B. | Inhalation RfC references added |
2251 | 4-Methylphenol | 106-44-5 | 18 | Aug 1,1993 | I.A. | Work group review date added |
2252 | 4-Methylphenol | 106-44-5 | 19 | Aug 1,1993 | I.A. | EPA contact changed |
2253 | 4-Methylphenol | 106-44-5 | 20 | Aug 1,1995 | I.A., VI.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2254 | 4-Methylphenol | 106-44-5 | 21 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2255 | 4-Methylphenol | 106-44-5 | 22 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2256 | 3-Methylphenol | 108-39-4 | 1 | Aug 22,1988 | I.A. | ORal RfD summary on-line |
2257 | 3-Methylphenol | 108-39-4 | 2 | Jan 1,1989 | I.A.6. | Review statement deleted |
2258 | 3-Methylphenol | 108-39-4 | 3 | Nov 1,1989 | II. | Carcinogen assessment now under review |
2259 | 3-Methylphenol | 108-39-4 | 4 | Nov 1,1989 | VI. | Bibliography on-line |
2260 | 3-Methylphenol | 108-39-4 | 5 | Sep 1,1990 | I.A. | Text edited |
2261 | 3-Methylphenol | 108-39-4 | 6 | Sep 1,1990 | II. | Carcinogen assessment on-line |
2262 | 3-Methylphenol | 108-39-4 | 7 | Sep 1,1990 | VI.C. | Carcinogen references added |
2263 | 3-Methylphenol | 108-39-4 | 8 | Aug 1,1991 | II.A.3. | Kaiser reference year corrected |
2264 | 3-Methylphenol | 108-39-4 | 9 | Aug 1,1991 | VI.C. | Kaiser reference year corrected |
2265 | 3-Methylphenol | 108-39-4 | 10 | Aug 1,1991 | VI.C. | Citations corrected |
2266 | 3-Methylphenol | 108-39-4 | 11 | Aug 1,1991 | All | Name changed from m-Cresol |
2267 | 3-Methylphenol | 108-39-4 | 12 | Jan 1,1992 | I.A.7. | Secondary contact changed |
2268 | 3-Methylphenol | 108-39-4 | 13 | Jan 1,1992 | I.B. | Inhalation RfC now under review |
2269 | 3-Methylphenol | 108-39-4 | 14 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2270 | 3-Methylphenol | 108-39-4 | 15 | Apr 1,1992 | I.B. | Inhalation RfD message on-line |
2271 | 3-Methylphenol | 108-39-4 | 16 | Apr 1,1992 | VI.B. | Inhalation RfC references added |
2272 | 3-Methylphenol | 108-39-4 | 17 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2273 | 3-Methylphenol | 108-39-4 | 18 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2274 | 2-Methylphenol | 95-48-7 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
2275 | 2-Methylphenol | 95-48-7 | 2 | Jan 1,1989 | I.A.7. | Contacts phone numbers corrected |
2276 | 2-Methylphenol | 95-48-7 | 3 | Apr 1,1989 | V. | Supplementary data on-line |
2277 | 2-Methylphenol | 95-48-7 | 4 | Jan 1,1989 | II. | Carcinogen assessment now under review |
2278 | 2-Methylphenol | 95-48-7 | 5 | Nov 1,1989 | VI. | Bibliography on-line |
2279 | 2-Methylphenol | 95-48-7 | 6 | Sep 1,1990 | I.A. | Text edited |
2280 | 2-Methylphenol | 95-48-7 | 7 | Sep 1,1990 | II. | Carcinogen assessment on-line |
2281 | 2-Methylphenol | 95-48-7 | 8 | Sep 1,1990 | VI.C. | Carcinogen references added |
2282 | 2-Methylphenol | 95-48-7 | 9 | Aug 1,1991 | II.A.3. | Kaiser reference year corrected |
2283 | 2-Methylphenol | 95-48-7 | 10 | Aug 1,1991 | VI.C. | Kaiser reference year corrected |
2284 | 2-Methylphenol | 95-48-7 | 11 | Aug 1,1991 | VI.C. | Citations corrected |
2285 | 2-Methylphenol | 95-48-7 | 12 | Aug 1,1991 | All | Name changed from o-Cresol |
2286 | 2-Methylphenol | 95-48-7 | 13 | Jan 1,1992 | I.A.7. | Secondary contact changed |
2287 | 2-Methylphenol | 95-48-7 | 14 | Jan 1,1992 | I.B. | Inhalation RfC now under review |
2288 | 2-Methylphenol | 95-48-7 | 15 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2289 | 2-Methylphenol | 95-48-7 | 16 | Apr 1,1992 | I.B. | Inhalation RfC message on-line |
2290 | 2-Methylphenol | 95-48-7 | 17 | Apr 1,1992 | VI.B. | Inhalation references added |
2291 | 2-Methylphenol | 95-48-7 | 18 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Date were removed from IRIS on or before April 1997. IRIS users were directed to the appropirate EPA Program Offices for this information. |
2292 | 2-Methylphenol | 95-48-7 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2293 | Metolachlor | 51218-45-2 | 1 | Mar 31,1987 | IV. | regulatory Action section on-line |
2294 | Metolachlor | 51218-45-2 | 2 | Mar 1,1988 | I.A.5. | Confidence levels revised |
2295 | Metolachlor | 51218-45-2 | 3 | Jun 30,1988 | I.A. | Withdrawn pending further review |
2296 | Metolachlor | 51218-45-2 | 4 | Aug 22,1988 | II. | Carcinogen summary on-line |
2297 | Metolachlor | 51218-45-2 | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added |
2298 | Metolachlor | 51218-45-2 | 6 | Dec 1,1988 | I.A.1. | Clarified effect |
2299 | Metolachlor | 51218-45-2 | 7 | Feb 1,1989 | II.D.3. | Secondary contact's area code corrected |
2300 | Metolachlor | 51218-45-2 | 8 | Oct 1,1990 | I.A.1 | Oral RfD corrected |
2301 | Metolachlor | 51218-45-2 | 9 | Feb 1,1991 | I.A. | Text edited |
2302 | Metolachlor | 51218-45-2 | 10 | Feb 1,1991 | II. | Text edited |
2303 | Metolachlor | 51218-45-2 | 11 | Feb 1,1991 | VI. | bibliography on-line |
2304 | Metolachlor | 51218-45-2 | 12 | Mar 1,1991 | III.A. | Health Advisory on-line |
2305 | Metolachlor | 51218-45-2 | 13 | Mar 1,1991 | VI.D. | Health Advisory on-line |
2306 | Metolachlor | 51218-45-2 | 14 | Jan 1,1992 | IV. | Regulatory actions updated |
2307 | Metolachlor | 51218-45-2 | 15 | Oct 1,1993 | II.D.3. | Primary contact changed; secondary's phone no. changed |
2308 | Metolachlor | 51218-45-2 | 16 | Jan 1,1994 | I.A. | Oral RfD noted as pending change |
2309 | Metolachlor | 51218-45-2 | 17 | Jan 1,1994 | I.A.6. | Work group review date added |
2310 | Metolachlor | 51218-45-2 | 18 | Aug 1,1995 | .A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2311 | Metolachlor | 51218-45-2 | 19 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2312 | Metolachlor | 51218-45-2 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2313 | Metribuzin | 21087-64-9 | 1 | Mar 31,1987 | IV. | Regulatory Action section on-line |
2314 | Metribuzin | 21087-64-9 | 2 | Mar 1,1988 | I.A.5. | Confidence levels revised |
2315 | Metribuzin | 21087-64-9 | 3 | Mar 1,1991 | I.A.4. | Citations added |
2316 | Metribuzin | 21087-64-9 | 4 | Mar 1,1991 | III.A. | Health Advisory on-line |
2317 | Metribuzin | 21087-64-9 | 5 | Mar 1,1991 | VI. | Bibliography on-line |
2318 | Metribuzin | 21087-64-9 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
2319 | Metribuzin | 21087-64-9 | 7 | Mar 1,1993 | II. | Carcinogenicty assessment now under review |
2320 | Metribuzin | 21087-64-9 | 8 | Dec 1,1993 | II. | Carcinogenicity assessment on-line |
2321 | Metribuzin | 21087-64-9 | 9 | Dec 1,1993 | VI.C. | Carcinogenicity assessment references on-line |
2322 | Metribuzin | 21087-64-9 | 10 | Mar 1,1994 | I.A. | Oral RfD noted as pending change |
2323 | Metribuzin | 21087-64-9 | 11 | Mar 1,1994 | I.A.6. | Work group review date added |
2324 | Metribuzin | 21087-64-9 | 12 | Jan 1,1995 | I.A.6. | Work group review date added |
2325 | Metribuzin | 21087-64-9 | 13 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2326 | Metribuzin | 21087-64-9 | 14 | Dec 1,1996 | II.D.3. | Primary contact removed |
2327 | Metribuzin | 21087-64-9 | 15 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. The IRIS users were directed to the appropriate EPA Program Offices for this information. |
2328 | Metribuzin | 21087-64-9 | 16 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2329 | Mirex | 2385-85-5 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
2330 | Mirex | 2385-85-5 | 2 | Apr 1,1991 | I.A.4. | Citations added |
2331 | Mirex | 2385-85-5 | 3 | Apr 1,1991 | VI. | Bibliography on-line |
2332 | Mirex | 2385-85-5 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
2333 | Mirex | 2385-85-5 | 5 | Aug 1,1992 | I.A. | Withdrawn; new oral RfD verified (in preparation) |
2334 | Mirex | 2385-85-5 | 6 | Aug 1,1992 | IV. | Regulatory actions withdrawn |
2335 | Mirex | 2385-85-5 | 7 | Aug 1,1992 | VI.A. | Bibliography withdrawn |
2336 | Mirex | 2385-85-5 | 8 | Oct 1,1992 | I.A. | Oral RfD summary replaced; RfD changed |
2337 | Mirex | 2385-85-5 | 9 | Oct 1,1992 | IV. | Regulatory actions returned in conjunction with RfD |
2338 | Mirex | 2385-85-5 | 10 | Oct 1,1992 | VI.A. | Bibliography replaced |
2339 | Mirex | 2385-85-5 | 11 | Jul 1,1993 | II. | Carcinogenicity assessment now under review |
2340 | Mirex | 2385-85-5 | 12 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substances that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2341 | Mirex | 2385-85-5 | 13 | Apr 1,1997 | III., IV.,V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2342 | Mirex | 2385-85-5 | 14 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
2343 | Mirex | 2385-85-5 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2344 | Molinate | 2212-67-1 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
2345 | Molinate | 2212-67-1 | 2 | Feb 1,1991 | I.A. | Text edited |
2346 | Molinate | 2212-67-1 | 3 | Feb 1,1991 | VI. | Biblioraphy on-line |
2347 | Molinate | 2212-67-1 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2348 | Molinate | 2212-67-1 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2349 | Molybdenum | 7439-98-7 | 1 | Aug 1,1991 | I.A. | Oral RfD now under review |
2350 | Molybdenum | 7439-98-7 | 2 | Nov 1,1992 | I.A. | Oral RfD summary on-line |
2351 | Molybdenum | 7439-98-7 | 3 | Nov 1,1992 | VI.A. | Oral RfD references on-line |
2352 | Molybdenum | 7439-98-7 | 4 | Aug 1,1993 | I.A.2. | Transposed number corrected in para. 1, line 13 |
2353 | Molybdenum | 7439-98-7 | 5 | Apr 1,1997 | III., IV.,V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA PRogram Offices for this information. |
2354 | Molybdenum | 7439-98-7 | 6 | Jun 19,2020 | CASRN | Added DTXSID and related links from/to Chemistry Dashboard and ATSDR. |
2355 | Molybdenum | 7439-98-7 | 7 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2356 | Monochloramine | 10599-90-3 | 1 | Aug 1,1992 | I.A. | Oral RfD now under review |
2357 | Monochloramine | 10599-90-3 | 2 | Nov 1,1992 | I.A. | Oral RfD summary on-line |
2358 | Monochloramine | 10599-90-3 | 3 | Nov 1,1992 | VI.A. | Oral RfD references on-line |
2359 | Monochloramine | 10599-90-3 | 4 | Nov 1,1992 | II. | Carcinogenicity assessment now under review |
2360 | Monochloramine | 10599-90-3 | 5 | Jan 1,1993 | II.D.2. | Work group review date added |
2361 | Monochloramine | 10599-90-3 | 6 | Dec 1,1993 | I.A.6. | Work group review date added |
2362 | Monochloramine | 10599-90-3 | 7 | Dec 1,1993 | II. | Carcinogenicity assessment on-line |
2363 | Monochloramine | 10599-90-3 | 8 | Dec 1,1993 | VI.C. | Carcinogenicity references on-line |
2364 | Monochloramine | 10599-90-3 | 9 | Jan 1,1994 | I.A. | Oral RfD noted as pending change |
2365 | Monochloramine | 10599-90-3 | 10 | Jan 1,1994 | I.A.6. | Work group reiew date added |
2366 | Monochloramine | 10599-90-3 | 11 | Mar 1,1994 | I.A. | Oral RfD revised; study and number unchanged |
2367 | Monochloramine | 10599-90-3 | 12 | Mar 1,1994 | VI.A. | Oral RfD references revised |
2368 | Monochloramine | 10599-90-3 | 13 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Actions were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2369 | Monochloramine | 10599-90-3 | 14 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
2370 | Monochloramine | 10599-90-3 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2371 | Naled | 300-76-5 | 1 | Sep 30,1987 | I.A.4. | Study description added (number 2.) |
2372 | Naled | 300-76-5 | 2 | Sep 30,1987 | IV. | Pesticide Registration Standard added |
2373 | Naled | 300-76-5 | 3 | Jun 1,1989 | I.A.6. | Work group review date added |
2374 | Naled | 300-76-5 | 4 | Mar 1,1991 | I.A.4. | Citations added |
2375 | Naled | 300-76-5 | 5 | Mar 1,1991 | VI. | Bibliography on-line |
2376 | Naled | 300-76-5 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
2377 | Naled | 300-76-5 | 7 | Jan 1,1995 | I.A. | Oral RfD noted as pending change |
2378 | Naled | 300-76-5 | 8 | Jan 1,1995 | I.A.6. | Work group review date added |
2379 | Naled | 300-76-5 | 9 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2380 | Naled | 300-76-5 | 10 | Apr 1,1997 | III., IV.,V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2381 | Naled | 300-76-5 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2382 | Naphthalene | 91-20-3 | 1 | Dec 1,1990 | II. | Carcinogen assessment on-line |
2383 | Naphthalene | 91-20-3 | 2 | Dec 1,1990 | VI. | Bibliography on-line |
2384 | Naphthalene | 91-20-3 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2385 | Naphthalene | 91-20-3 | 4 | Sep 1,1992 | II. | Classification noted as pending change |
2386 | Naphthalene | 91-20-3 | 5 | Sep 1,1992 | II.D.2. | Work group review date added |
2387 | Naphthalene | 91-20-3 | 6 | Nov 1,1993 | I.A. | Work group review date added |
2388 | Naphthalene | 91-20-3 | 7 | Sep 1,1994 | I.A. | Work group review date added |
2389 | Naphthalene | 91-20-3 | 8 | May 1,1995 | II. | Pending change note replaced |
2390 | Naphthalene | 91-20-3 | 9 | May 1,1995 | II.D.2. | Work group review date added |
2391 | Naphthalene | 91-20-3 | 10 | Jul 1,1995 | II. | Pending change note replaced; see new note |
2392 | Naphthalene | 91-20-3 | 11 | Aug 1,1995 | I.A, II., II.D.2. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2393 | Naphthalene | 91-20-3 | 12 | Aug 1,1995 | II. | Note revised |
2394 | Naphthalene | 91-20-3 | 13 | Aug 1,1995 | II.A.3. | Paragraph 1 revised |
2395 | Naphthalene | 91-20-3 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2396 | Naphthalene | 91-20-3 | 15 | Sep 17,1998 | I., II., VI. | Revised RfD, RfC, carcinogenicity assessments |
2397 | Naphthalene | 91-20-3 | 16 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2398 | Naphthalene | 91-20-3 | 17 | Jun 28,2021 | All | EPA removed the suspension and restarted the development of an update of this assessment. |
2399 | Naphthalene | 91-20-3 | 18 | Dec 20,2018 | All | EPA suspended the development of this assessment. |
2400 | Napropamide | 15299-99-7 | 1 | Jul 1,1989 | I.A. | Oral RfD summary on-line |
2401 | Napropamide | 15299-99-7 | 2 | Jul 1,1989 | VI. | Bibliography on-line |
2402 | Napropamide | 15299-99-7 | 3 | May 1,1990 | I.A.2. | Text edited |
2403 | Napropamide | 15299-99-7 | 4 | May 1,1990 | I.A.4. | Text edited |
2404 | Napropamide | 15299-99-7 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices. |
2405 | Napropamide | 15299-99-7 | 6 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2406 | Napropamide | 15299-99-7 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2407 | Nickel carbonyl | 13463-39-3 | 1 | Dec 1,1989 | VI. | Bibliography on-line |
2408 | Nickel carbonyl | 13463-39-3 | 2 | Jun 1,1990 | IV.A.1. | Area code for EPA contact corrected |
2409 | Nickel carbonyl | 13463-39-3 | 3 | Mar 1,1991 | II.A.1. | Text edited |
2410 | Nickel carbonyl | 13463-39-3 | 4 | Jan 1,1992 | IV. | Regulatory actions updated |
2411 | Nickel carbonyl | 13463-39-3 | 5 | Apr 1,1992 | IV.A.1. | CAA regulatory action withdrawn |
2412 | Nickel carbonyl | 13463-39-3 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2413 | Nickel carbonyl | 13463-39-3 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2414 | Nickel refinery dust | None | 1 | Jun 1,1990 | II.A.3. | Text revised |
2415 | Nickel refinery dust | None | 2 | Jun 1,1990 | VI. | Bibliography on-line |
2416 | Nickel refinery dust | None | 3 | Jan 1,1991 | II. | Text edited |
2417 | Nickel refinery dust | None | 4 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
2418 | Nickel refinery dust | None | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2419 | Nickel refinery dust | None | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Adivsories, EPA Regulatory Actions, and Supplementary Data were removed on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2420 | Nickel refinery dust | None | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2421 | Nickel subsulfide | 12035-72-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2422 | Nickel, soluble salts | Various | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2423 | Nitrapyrin | 1929-82-4 | 1 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
2424 | Nitrapyrin | 1929-82-4 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2425 | Nitrate | 14797-55-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2426 | Nitric oxide | 10102-43-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2427 | Nitrite | 14797-65-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2428 | Nitrobenzene | 98-95-3 | 1 | Feb 6,2009 | I., II. | Revised the RfD; added an RfC; revised the cancer assessment. |
2429 | Nitrobenzene | 98-95-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2430 | Nitrogen dioxide | 10102-44-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2431 | Nitroguanidine | 556-88-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2432 | p-Nitrophenol | 100-02-7 | 1 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
2433 | p-Nitrophenol | 100-02-7 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2434 | 2-Nitropropane | 79-46-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2435 | N-Nitroso-N-methylethylamine | 10595-95-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2436 | N-Nitroso-di-n-butylamine | 924-16-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2437 | N-Nitrosodi-N-propylamine | 621-64-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2438 | N-Nitrosodiethanolamine | 1116-54-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2439 | N-Nitrosodiethylamine | 55-18-5 | 1 | Mar 31,1987 | IV. | RQ added |
2440 | N-Nitrosodiethylamine | 55-18-5 | 2 | Sep 30,1987 | IV. | Water Quality Criteria added |
2441 | N-Nitrosodiethylamine | 55-18-5 | 3 | Mar 1,1988 | II.A.1. | Text clarified |
2442 | N-Nitrosodiethylamine | 55-18-5 | 4 | Mar 1,1988 | II.B.1. | Number rounded off |
2443 | N-Nitrosodiethylamine | 55-18-5 | 5 | Mar 1,1988 | II.B.3. | Text revised |
2444 | N-Nitrosodiethylamine | 55-18-5 | 6 | Mar 1,1988 | II.B.4. | Confidence statement revised |
2445 | N-Nitrosodiethylamine | 55-18-5 | 7 | Mar 1,1988 | II.C.1. | Number rounded off |
2446 | N-Nitrosodiethylamine | 55-18-5 | 8 | Mar 1,1988 | II.C.4. | Confidence statement revised |
2447 | N-Nitrosodiethylamine | 55-18-5 | 9 | Mar 1,1988 | II.D.3. | Secondary contact changed |
2448 | N-Nitrosodiethylamine | 55-18-5 | 10 | Feb 1,1990 | II.A.3. | Rajewsky et al., 1966 spelling corrected |
2449 | N-Nitrosodiethylamine | 55-18-5 | 11 | Feb 1,1990 | VI. | Bibliography on-line |
2450 | N-Nitrosodiethylamine | 55-18-5 | 12 | Mar 1,1990 | VI.C. | Druckrey, Peto and Mohr reference titles clarified |
2451 | N-Nitrosodiethylamine | 55-18-5 | 13 | Jan 1,1991 | II. | Text edited |
2452 | N-Nitrosodiethylamine | 55-18-5 | 14 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
2453 | N-Nitrosodiethylamine | 55-18-5 | 15 | Jan 1,1992 | IV. | Regulatory actions updated |
2454 | N-Nitrosodiethylamine | 55-18-5 | 16 | Jul 1,1993 | II.D.3. | Secondary contact's phone number changed |
2455 | N-Nitrosodiethylamine | 55-18-5 | 17 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2456 | N-Nitrosodiethylamine | 55-18-5 | 18 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2457 | N-Nitrosodimethylamine | 62-75-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2458 | N-Nitrosodiphenylamine | 86-30-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2459 | N-Nitrosopyrrolidine | 930-55-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2460 | Nonabromodiphenyl ether | 63936-56-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2461 | Norflurazon | 27314-13-2 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2462 | Norflurazon | 27314-13-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2463 | NuStar | 85509-19-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2464 | Octabromodiphenyl ether | 32536-52-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2465 | Octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine (HMX) | 2691-41-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2466 | Oryzalin | 19044-88-3 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2467 | Oryzalin | 19044-88-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2468 | Oxadiazon | 19666-30-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2469 | Oxamyl | 23135-22-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2470 | Oxyfluorfen | 42874-03-3 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2471 | Oxyfluorfen | 42874-03-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2472 | Paclobutrazol | 76738-62-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2473 | Paraquat | 1910-42-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2474 | Parathion | 56-38-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2475 | Pendimethalin | 40487-42-1 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2476 | Pendimethalin | 40487-42-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2477 | Pentabromodiphenyl ether | 32534-81-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2478 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | 1 | Jun 30,2008 | I., II. | RfD, RfC, and cancer assessment first on line. |
2479 | 2,2',4,4',5-Pentabromodiphenyl ether (BDE-99) | 60348-60-9 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2480 | Pentachlorobenzene | 608-93-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2481 | Pentachlorocyclopentadiene | 25329-35-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2482 | Pentachloronitrobenzene (PCNB) | 82-68-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2483 | Pentachlorophenol | 87-86-5 | 1 | Sep 30,2010 | I., II., VI. | RfD and cancer assessment sections updated. RfC discussion added. |
2484 | Pentachlorophenol | 87-86-5 | 2 | Mar 1,1988 | III.A. | Health Advisory added |
2485 | Pentachlorophenol | 87-86-5 | 3 | Jun 30,1988 | I.A.6. | Documentation year corrected |
2486 | Pentachlorophenol | 87-86-5 | 4 | Jan 1,1990 | II. | Carcinogen assessment now under review |
2487 | Pentachlorophenol | 87-86-5 | 5 | Jan 1,1990 | VI. | Bibliography on-line |
2488 | Pentachlorophenol | 87-86-5 | 6 | Apr 1,1990 | I.A.2. | NOEL corrected to NOAEL in last sentence, 1st paragraph |
2489 | Pentachlorophenol | 87-86-5 | 7 | Jul 1,1990 | I.B. | Inhalation RfC now under Review |
2490 | Pentachlorophenol | 87-86-5 | 8 | Jul 1,1990 | IV.F.1. | EPA contact changed |
2491 | Pentachlorophenol | 87-86-5 | 9 | Aug 1,1990 | III.A.10 | Primary contact changed |
2492 | Pentachlorophenol | 87-86-5 | 10 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
2493 | Pentachlorophenol | 87-86-5 | 11 | Mar 1,1991 | VI.C. | Carcinogenicity references added |
2494 | Pentachlorophenol | 87-86-5 | 12 | Jan 1,1992 | I.A.7. | Primary contact changed |
2495 | Pentachlorophenol | 87-86-5 | 13 | Jan 1,1992 | IV. | Regulatory actions updated |
2496 | Pentachlorophenol | 87-86-5 | 14 | Feb 1,1993 | I.A.7. | Minor text change |
2497 | Pentachlorophenol | 87-86-5 | 15 | Jul 1,1993 | II.D.3. | Primary contact's phone number changed |
2498 | Pentachlorophenol | 87-86-5 | 16 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2499 | Pentachlorophenol | 87-86-5 | 17 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2500 | Pentachlorophenol | 87-86-5 | 18 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2501 | Pentafluoroethane | 354-33-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2502 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | 1 | Feb 18,2005 | All | IRIS assessment for Perchlorate and Perchlorate Salts added to the database. |
2503 | Perchlorate (ClO4) and Perchlorate Salts | 7790-98-9 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2504 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2505 | Perfluorobutanoic Acid (PFBA) | 375-22-4 | 2 | Feb 10,2022 | Supporting document | Added a link to the peer review meeting at the request of the public & program (DS). |
2506 | Perfluorodecanoic Acid (PFDA) | 335-76-2 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2507 | Perfluorohexanesulfonic Acid (PFHxS) | 355-46-4 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2508 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2509 | Perfluorohexanoic Acid (PFHxA) | 307-24-4 | 2 | Apr 10,2023 | All | Released the final report and key values. |
2510 | Perfluorononanoic Acid (PFNA) | 375-95-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2511 | Permethrin | 52645-53-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2512 | Phenanthrene | 85-01-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2513 | Phenmedipham | 13684-63-4 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
2514 | Phenmedipham | 13684-63-4 | 2 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2515 | Phenmedipham | 13684-63-4 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2516 | Phenol | 108-95-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2517 | m-Phenylenediamine | 108-45-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2518 | Phenylmercuric acetate | 62-38-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2519 | Phosalone | 2310-17-0 | 1 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
2520 | Phosalone | 2310-17-0 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2521 | Phosgene | 75-44-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2522 | Phosmet | 732-11-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2523 | Phosphine | 7803-51-2 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
2524 | Phosphine | 7803-51-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2525 | Phosphoric acid | 7664-38-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2526 | Phthalic anhydride | 85-44-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2527 | Picloram | 1918-02-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2528 | Pirimiphos-methyl | 29232-93-7 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2529 | Pirimiphos-methyl | 29232-93-7 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2530 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 1 | May 1,1989 | II. | Carcinogen summary on-line |
2531 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 2 | Jan 1,1990 | II. | Text edited |
2532 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 3 | Jan 1,1990 | VI. | Bibliography on-line |
2533 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2534 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 5 | Jun 1,1994 | I.A. | Message only |
2535 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 6 | Jan 1,1996 | II. | Note added to assessment |
2536 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 7 | Oct 1,1996 | II. | File replaced; cancer potency of mixtures addressed |
2537 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 8 | Nov 1,1996 | VI.C. | References revised |
2538 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 9 | Jun 1,1997 | II.C.3. | Units corrected in Upper-bound Unit Risk |
2539 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2540 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 11 | May 16,2018 | Footnotes to WOE | Notes were added to the WOE-Oral and WOE-inhalation table to further explain these numbers. Additional updates were made to the inhalation unit risk and extrapolation method descriptions. |
2541 | Polychlorinated Biphenyls (PCBs) | 1336-36-3 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2542 | Polycyclic aromatic hydrocarbon (PAH) mixtures | Various | 1 | Sep 27,2019 | CASRN | Set to various |
2543 | Polycyclic aromatic hydrocarbon (PAH) mixtures | Various | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2544 | Potassium cyanide | 151-50-8 | 1 | Sep 28,2010 | I.A. | Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment |
2545 | Potassium cyanide | 151-50-8 | 2 | Sep 27,2018 | Noncancer Critical | Updated the system value to other so it would show up in the advanced search. |
2546 | Potassium cyanide | 151-50-8 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2547 | Potassium silver cyanide | 506-61-6 | 1 | Sep 28,2010 | I.A. | Updated RfD with data from Hydrogen Cyanide and Cyanide Salts Assessment |
2548 | Potassium silver cyanide | 506-61-6 | 2 | Sep 27,2018 | Noncancer Critical | Updated the system value to other so it would show up in the advanced search. |
2549 | Potassium silver cyanide | 506-61-6 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2550 | Prochloraz | 67747-09-5 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
2551 | Prochloraz | 67747-09-5 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2552 | Prometon | 1610-18-0 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
2553 | Prometon | 1610-18-0 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2554 | Prometryn | 7287-19-6 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2555 | Prometryn | 7287-19-6 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2556 | Pronamide | 23950-58-5 | 1 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
2557 | Pronamide | 23950-58-5 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2558 | Propachlor | 1918-16-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2559 | Propanil | 709-98-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2560 | Propargite | 2312-35-8 | 1 | May 1,1990 | I.A. | Oral RfD summary on-line |
2561 | Propargite | 2312-35-8 | 2 | May 1,1990 | VI. | Bibliography on-line |
2562 | Propargite | 2312-35-8 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2563 | Propargite | 2312-35-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2564 | Propargite | 2312-35-8 | 5 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2565 | Propargite | 2312-35-8 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2566 | Propargyl alcohol | 107-19-7 | 1 | Nov 1,1990 | I.A. | Oral RfD summary on-line |
2567 | Propargyl alcohol | 107-19-7 | 2 | Nov 1,1990 | VI. | Bibliography on-line |
2568 | Propargyl alcohol | 107-19-7 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2569 | Propargyl alcohol | 107-19-7 | 4 | Jul 1,1993 | I.A.6. | Other EPA documentation added |
2570 | Propargyl alcohol | 107-19-7 | 5 | Jan 1,1994 | I.A.1. | Citation year changed to 1987 |
2571 | Propargyl alcohol | 107-19-7 | 6 | Jan 1,1994 | I.A.2. | Citation year changed to 1987 |
2572 | Propargyl alcohol | 107-19-7 | 7 | Jan 1,1994 | I.A.6. | Citation year changed to 1987 |
2573 | Propargyl alcohol | 107-19-7 | 8 | Jan 1,1994 | VI.A. | Reference year changed to 1987 |
2574 | Propargyl alcohol | 107-19-7 | 9 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2575 | Propargyl alcohol | 107-19-7 | 10 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2576 | Propazine | 139-40-2 | 1 | Aug 28,1987 | I.A. | UF reevaluated - RfD changed |
2577 | Propazine | 139-40-2 | 2 | Oct 1,1990 | I.A.4. | Citations added |
2578 | Propazine | 139-40-2 | 3 | Oct 1,1990 | III.A. | Health advisory on-line |
2579 | Propazine | 139-40-2 | 4 | Oct 1,1990 | VI. | Bibliography on-line |
2580 | Propazine | 139-40-2 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2581 | Propazine | 139-40-2 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2582 | Propazine | 139-40-2 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2583 | Propham | 122-42-9 | 1 | Dec 1,1989 | VI. | Bibliography on-line |
2584 | Propham | 122-42-9 | 2 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2585 | Propham | 122-42-9 | 3 | Feb 1,1993 | III.A. | Health Advisory on-line |
2586 | Propham | 122-42-9 | 4 | Feb 1,1993 | VI.D. | Health Advisory references on-line |
2587 | Propham | 122-42-9 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2588 | Propham | 122-42-9 | 6 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
2589 | Propham | 122-42-9 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2590 | Propiconazole | 60207-90-1 | 1 | Aug 22,1988 | I.A.1. | Dose conversion factor changed; RfD changed |
2591 | Propiconazole | 60207-90-1 | 2 | Aug 22,1988 | I.A.2. | Dose levels changed; reflects altered conversion factor |
2592 | Propiconazole | 60207-90-1 | 3 | Feb 1,1991 | II. | Carcinogen assessment now under review |
2593 | Propiconazole | 60207-90-1 | 4 | Jan 1,1992 | I.A.4. | Citations added |
2594 | Propiconazole | 60207-90-1 | 5 | Jan 1,1992 | VI. | Bibliography on-line |
2595 | Propiconazole | 60207-90-1 | 6 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May 1995. Chemical substance reviews that were not completed by September, 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2596 | Propiconazole | 60207-90-1 | 7 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2597 | Propiconazole | 60207-90-1 | 8 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2598 | Propiconazole | 60207-90-1 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2599 | beta-Propiolactone | 57-57-8 | 1 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2600 | beta-Propiolactone | 57-57-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2601 | Propionaldehyde | 123-38-6 | 1 | Sep 30,2008 | I., II. | RfD, RfC, and cancer assessment first on line. |
2602 | Propionaldehyde | 123-38-6 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2603 | Propylene glycol | 57-55-6 | 1 | Jun 1,1991 | I.B. | Inhalation RfC message on-line |
2604 | Propylene glycol | 57-55-6 | 2 | Jun 1,1991 | VI. | Bibliography on-line |
2605 | Propylene glycol | 57-55-6 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2606 | Propylene glycol | 57-55-6 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2607 | Propylene glycol | 57-55-6 | 5 | Dec 10,2018 | Archived Values | Requested by the IRIS Program to archive the chemicals with null values. |
2608 | Propylene glycol | 57-55-6 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2609 | Propylene glycol monoethyl ether | 52125-53-8 | 1 | Jun 1,1991 | I.B. | Inhalation RfC message on-line |
2610 | Propylene glycol monoethyl ether | 52125-53-8 | 2 | Jun 1,1991 | VI. | Bibliography on-line |
2611 | Propylene glycol monoethyl ether | 52125-53-8 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2612 | Propylene glycol monoethyl ether | 52125-53-8 | 4 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2613 | Propylene glycol monoethyl ether | 52125-53-8 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2614 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | 1 | Jul 1,1991 | I.B. | Inhalation RfC summary on-line |
2615 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | 2 | Jul 1,1991 | VI. | Bibliography on-line |
2616 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | 3 | Jul 1,1993 | I.B.1. | 'E' notation added |
2617 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2618 | Propylene glycol monomethyl ether (PGME) | 107-98-2 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2619 | Propylene oxide | 75-56-9 | 1 | Oct 1,1990 | II. | Carcinogen assessment on-line |
2620 | Propylene oxide | 75-56-9 | 2 | Oct 1,1990 | VI. | Bibliography on-line |
2621 | Propylene oxide | 75-56-9 | 3 | Nov 1,1990 | I.B. | Inhalation RfC summary on-line |
2622 | Propylene oxide | 75-56-9 | 4 | Nov 1,1990 | VI.B. | Inhalation RfC references added |
2623 | Propylene oxide | 75-56-9 | 5 | Jan 1,1991 | II. | Text edited |
2624 | Propylene oxide | 75-56-9 | 6 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
2625 | Propylene oxide | 75-56-9 | 7 | Feb 1,1991 | II.C.3. | Information on extrapolation process included |
2626 | Propylene oxide | 75-56-9 | 8 | Aug 1,1991 | VI.C. | References clarified |
2627 | Propylene oxide | 75-56-9 | 9 | Jan 1,1991 | IV. | Regulatory Action section on-line |
2628 | Propylene oxide | 75-56-9 | 10 | Mar 1,1994 | II.D.3. | Contact's phone number changed |
2629 | Propylene oxide | 75-56-9 | 11 | Apr 1,1994 | II.D.3. | Contact changed |
2630 | Propylene oxide | 75-56-9 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2631 | Propylene oxide | 75-56-9 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2632 | Propyleneimine | 75-55-8 | 1 | Dec 1,1991 | I.B. | Inhalation RfC now under review |
2633 | Propyleneimine | 75-55-8 | 2 | Jan 1,1992 | I.B. | Inhalation RfC message on-line |
2634 | Propyleneimine | 75-55-8 | 3 | Jan 1,1992 | VI. | Bibliography on-line; no inhalation refs available |
2635 | Propyleneimine | 75-55-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2636 | Propyleneimine | 75-55-8 | 5 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2637 | Propyleneimine | 75-55-8 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2638 | Pursuit | 81335-77-5 | 1 | Jan 1,1990 | I.A. | Oral RfD summary on-line |
2639 | Pursuit | 81335-77-5 | 2 | Jan 1,1990 | VI. | Bibliography on-line |
2640 | Pursuit | 81335-77-5 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2641 | Pursuit | 81335-77-5 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2642 | Pydrin | 51630-58-1 | 1 | Jan 1,1992 | I.A.4. | Citations added |
2643 | Pydrin | 51630-58-1 | 2 | Jan 1,1992 | IV. | Regulatory Action section added |
2644 | Pydrin | 51630-58-1 | 3 | Jan 1,1992 | VI. | Bibliography on-line |
2645 | Pydrin | 51630-58-1 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2646 | Pydrin | 51630-58-1 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2647 | Pyrene | 129-00-0 | 1 | Sep 1,1990 | I.A. | Oral RfD summary on-line |
2648 | Pyrene | 129-00-0 | 2 | Sep 1,1990 | VI. | Bibliography on-line |
2649 | Pyrene | 129-00-0 | 3 | Jan 1,1991 | II. | Carcinogen assessment on-line |
2650 | Pyrene | 129-00-0 | 4 | Jan 1,1991 | VI.C. | Carcinogen assessment references added |
2651 | Pyrene | 129-00-0 | 5 | Jul 1,1991 | I.A.7. | Primary and secondary contacts changed |
2652 | Pyrene | 129-00-0 | 6 | Aug 1,1991 | VI.A. | U.S. EPA, 1989 citation clarified |
2653 | Pyrene | 129-00-0 | 7 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2654 | Pyrene | 129-00-0 | 8 | Jul 1,1993 | I.A.6. | Other EPA Documentation added |
2655 | Pyrene | 129-00-0 | 9 | Sep 1,1994 | I.B. | Inhalation RfC now under review |
2656 | Pyrene | 129-00-0 | 10 | Aug 1,1995 | I.B. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2657 | Pyrene | 129-00-0 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2658 | Pyrene | 129-00-0 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2659 | Pyridine | 110-86-1 | 1 | Mar 1,1988 | I.A.4. | Text clarified |
2660 | Pyridine | 110-86-1 | 2 | Jun 30,1988 | I.A.2. | Clarified principal study |
2661 | Pyridine | 110-86-1 | 3 | Sep 26,1988 | I.A.2. | Corrected citation |
2662 | Pyridine | 110-86-1 | 4 | Sep 26,1988 | I.A.4. | Corrected citation |
2663 | Pyridine | 110-86-1 | 5 | Jun 1,1989 | I.A.6. | Work group review date corrected |
2664 | Pyridine | 110-86-1 | 6 | Jan 1,1990 | VI. | Bibliography on-line |
2665 | Pyridine | 110-86-1 | 7 | Jan 1,1992 | I.A.7. | Primary contact changed |
2666 | Pyridine | 110-86-1 | 8 | Jan 1,1992 | IV. | Regulatory actions updated |
2667 | Pyridine | 110-86-1 | 9 | Aug 1,1995 | I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2668 | Pyridine | 110-86-1 | 10 | Apr 1,1987 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this infomation. |
2669 | Pyridine | 110-86-1 | 11 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2670 | Quinalphos | 13593-03-8 | 1 | Jan 1,1992 | I.A.4. | Citations added |
2671 | Quinalphos | 13593-03-8 | 2 | Jan 1,1992 | VI. | Bibiography on-line |
2672 | Quinalphos | 13593-03-8 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2673 | Quinalphos | 13593-03-8 | 4 | Sep 27,2018 | Noncancer Critical | Updated the system value from none to other so it would show up in the advanced search. |
2674 | Quinalphos | 13593-03-8 | 5 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
2675 | Quinalphos | 13593-03-8 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2676 | Quinoline | 91-22-5 | 1 | I.,II.,VI | Assessment first on-line | |
2677 | Quinoline | 91-22-5 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2678 | Quinone | 106-51-4 | 1 | Oct 1,1990 | I.B. | Inhalation RfC message on-line |
2679 | Quinone | 106-51-4 | 2 | Oct 1,1990 | VI. | Bibliography on-line |
2680 | Quinone | 106-51-4 | 3 | Mar 1,1995 | I.B. | Agency Work Group Review date corrected |
2681 | Quinone | 106-51-4 | 4 | Apr 1,1997 | III., IV, V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2682 | Quinone | 106-51-4 | 5 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2683 | Quinone | 106-51-4 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2684 | Radium 226,228 | Various | 1 | Jan 1,1989 | II. | Withdrawn pending further review |
2685 | Radium 226,228 | Various | 2 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2686 | Radium 226,228 | Various | 3 | Mar 1,1993 | II. | Work Group review date added |
2687 | Radium 226,228 | Various | 4 | May 1,1993 | II. | Work Group review date added |
2688 | Radium 226,228 | Various | 5 | Jul 1,1993 | II. | EPA contact changed |
2689 | Radium 226,228 | Various | 6 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2690 | Radium 226,228 | Various | 7 | Apr 1,1997 | II., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2691 | Radium 226,228 | Various | 8 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2692 | Radium 226,228 | Various | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2693 | Radon 222 | 14859-67-7 | 1 | Mar 1,1988 | II.A.1. | Classification clarified |
2694 | Radon 222 | 14859-67-7 | 2 | Mar 1,1988 | II.B.1. | Number rounded off |
2695 | Radon 222 | 14859-67-7 | 3 | Jun 30,1988 | II.D.3. | Contacts changed |
2696 | Radon 222 | 14859-67-7 | 4 | Jan 1,1989 | II. | Withdrawn pending further review |
2697 | Radon 222 | 14859-67-7 | 5 | Jul 1,1989 | II. | Withdrawn; new assessment verified (in preparation) |
2698 | Radon 222 | 14859-67-7 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
2699 | Radon 222 | 14859-67-7 | 7 | Nov 1,1992 | II. | Work group review date added |
2700 | Radon 222 | 14859-67-7 | 8 | Mar 1,1993 | II. | Work group review date added |
2701 | Radon 222 | 14859-67-7 | 9 | May 1,1993 | II. | Work group review date added |
2702 | Radon 222 | 14859-67-7 | 10 | Jul 1,1993 | II. | EPA contact changed |
2703 | Radon 222 | 14859-67-7 | 11 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2704 | Radon 222 | 14859-67-7 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2705 | Radon 222 | 14859-67-7 | 13 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2706 | Radon 222 | 14859-67-7 | 14 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2707 | Refractory ceramic fibers | None | 1 | Sep 1,1992 | II. | Carcinogenicity assessment under review on 03/31/1992 |
2708 | Refractory ceramic fibers | None | 2 | Sep 1,1992 | II. | Carcinogenicity assessment on-line |
2709 | Refractory ceramic fibers | None | 3 | Sep 1,1992 | VI. | Bibliography on-line |
2710 | Refractory ceramic fibers | None | 4 | Oct 1,1992 | VI.C. | Minor corrections to references |
2711 | Refractory ceramic fibers | None | 5 | Jul 1,1993 | II.D.1. | Other EPA Documentation heading removed |
2712 | Refractory ceramic fibers | None | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2713 | Refractory ceramic fibers | None | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2714 | Resmethrin | 10453-86-8 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
2715 | Resmethrin | 10453-86-8 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
2716 | Resmethrin | 10453-86-8 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2717 | Resmethrin | 10453-86-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2718 | Resmethrin | 10453-86-8 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2719 | Rotenone | 83-79-4 | 1 | Sep 7,1988 | I.A. | Oral RfD summary on-line |
2720 | Rotenone | 83-79-4 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
2721 | Rotenone | 83-79-4 | 3 | Jun 1,1991 | II. | Carcinogen assessment now under review |
2722 | Rotenone | 83-79-4 | 4 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2723 | Rotenone | 83-79-4 | 5 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2724 | Rotenone | 83-79-4 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2725 | Rotenone | 83-79-4 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2726 | Savey | 78587-05-0 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
2727 | Savey | 78587-05-0 | 2 | May 1,1989 | II. | Carcinogen assessment now under review |
2728 | Savey | 78587-05-0 | 3 | Oct 1,1989 | VI. | Bibliography on-line |
2729 | Savey | 78587-05-0 | 4 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2730 | Savey | 78587-05-0 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2731 | Savey | 78587-05-0 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2732 | Selenious acid | 7783-00-8 | 1 | May 1,1989 | I.A. | Oral RfD summary noted as pending change |
2733 | Selenious acid | 7783-00-8 | 2 | Jan 1,1990 | I.A.5. | Corrected citation year |
2734 | Selenious acid | 7783-00-8 | 3 | Jan 1,1990 | VI. | Bibliography on-line |
2735 | Selenious acid | 7783-00-8 | 4 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
2736 | Selenious acid | 7783-00-8 | 5 | Mar 1,1991 | VI.C. | Carcinogenicity references added |
2737 | Selenious acid | 7783-00-8 | 6 | May 1,1991 | I.A. | Withdrawn; new Oral RfD verfied (in preparation) |
2738 | Selenious acid | 7783-00-8 | 7 | May 1,1991 | VI.A. | Oral RfD references withdrawn |
2739 | Selenious acid | 7783-00-8 | 8 | Jun 1,1991 | I.A. | Oral RfD summary replaced; RfD changed |
2740 | Selenious acid | 7783-00-8 | 9 | Jun 1,1991 | VI.A. | Oral RfD references replaced |
2741 | Selenious acid | 7783-00-8 | 10 | Jul 1,1991 | I.A.6. | Work group review date added |
2742 | Selenious acid | 7783-00-8 | 11 | Jul 1,1991 | I.A.7. | Primary contact's phone number corrected |
2743 | Selenious acid | 7783-00-8 | 12 | Sep 1,1991 | I.A.3. | Text revised |
2744 | Selenious acid | 7783-00-8 | 13 | Sep 1,1991 | I.A.5. | Text revised |
2745 | Selenious acid | 7783-00-8 | 14 | Jan 1,1992 | IV. | Regulatory actions added |
2746 | Selenious acid | 7783-00-8 | 15 | Jul 1,1993 | II.D.3. | Primary contact's phone number changed |
2747 | Selenious acid | 7783-00-8 | 16 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2748 | Selenious acid | 7783-00-8 | 17 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2749 | Selenium and Compounds | 7782-49-2 | 1 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
2750 | Selenium and Compounds | 7782-49-2 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
2751 | Selenium and Compounds | 7782-49-2 | 3 | Jun 1,1991 | II.A.2. | Para 4: Correct Shamber&Willis to Shamberger&Willis |
2752 | Selenium and Compounds | 7782-49-2 | 4 | Jun 1,1991 | I.A. | Oral RfD summary on-line |
2753 | Selenium and Compounds | 7782-49-2 | 5 | Jun 1,1991 | VI.A. | Oral RfD references added |
2754 | Selenium and Compounds | 7782-49-2 | 6 | Sep 1,1991 | I.A.2. | Paragraph 2, line 2: number corrected to 5/349 |
2755 | Selenium and Compounds | 7782-49-2 | 7 | Sep 1,1991 | I.A.3. | Text revised |
2756 | Selenium and Compounds | 7782-49-2 | 8 | Sep 1,1991 | I.A.5. | Confidence in RfD changed; text revised |
2757 | Selenium and Compounds | 7782-49-2 | 9 | Jan 1,1992 | IV. | Regulatory section on-line |
2758 | Selenium and Compounds | 7782-49-2 | 10 | Jul 1,1993 | II.D.3. | Primary contact's phone number changed |
2759 | Selenium and Compounds | 7782-49-2 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2760 | Selenium and Compounds | 7782-49-2 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2761 | Selenium sulfide | 7446-34-6 | 1 | Mar 1,1991 | II. | Carcinogenicity assessment on-line |
2762 | Selenium sulfide | 7446-34-6 | 2 | Mar 1,1991 | VI. | Bibliography on-line |
2763 | Selenium sulfide | 7446-34-6 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2764 | Selenium sulfide | 7446-34-6 | 4 | Jul 1,1993 | II.D.3. | Primary contact's phone number changed |
2765 | Selenium sulfide | 7446-34-6 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2766 | Selenium sulfide | 7446-34-6 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2767 | Selenourea | 630-10-4 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
2768 | Selenourea | 630-10-4 | 2 | May 1,1989 | I.A. | Oral RfDsummary noted as pending change |
2769 | Selenourea | 630-10-4 | 3 | Dec 1,1989 | VI. | Bibliography on-line |
2770 | Selenourea | 630-10-4 | 4 | May 1,1991 | I.A. | Oral RfD withdrawn pending additional review |
2771 | Selenourea | 630-10-4 | 5 | May 1,1991 | VI. | Bibliography withdrawn |
2772 | Selenourea | 630-10-4 | 6 | Jan 1,1992 | IV. | Regulatory actions withdrawn |
2773 | Selenourea | 630-10-4 | 7 | Jun 1,1992 | I.A. | Work group review dates added |
2774 | Selenourea | 630-10-4 | 8 | Aug 1,1995 | I.A., VI. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed before September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2775 | Selenourea | 630-10-4 | 9 | Feb 1,1996 | I.A. | Contact changed |
2776 | Selenourea | 630-10-4 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2777 | Selenourea | 630-10-4 | 11 | Dec 19,2018 | Archived Key Values | Archived this assessment because there were null key values. |
2778 | Selenourea | 630-10-4 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2779 | Sethoxydim | 74051-80-2 | 1 | Mar 1,1988 | I.A.5. | Confidence levels revised |
2780 | Sethoxydim | 74051-80-2 | 2 | Jul 1,1989 | I.A. | Withdrawn; new Oral RfD verified (in preparation) |
2781 | Sethoxydim | 74051-80-2 | 3 | Nov 1,1989 | I.A. | Oral RfD summary replaced; RfD changed |
2782 | Sethoxydim | 74051-80-2 | 4 | Nov 1,1989 | VI. | Bibliography on-line |
2783 | Sethoxydim | 74051-80-2 | 5 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2784 | Sethoxydim | 74051-80-2 | 6 | Apr 1,1997 | II., IV., V. | Drinking Water Health Advisoies, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2785 | Sethoxydim | 74051-80-2 | 7 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
2786 | Sethoxydim | 74051-80-2 | 8 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2787 | Silver | 7440-22-4 | 1 | Mar 1,1988 | I.A.4. | Text revised |
2788 | Silver | 7440-22-4 | 2 | Mar 1,1988 | I.A.7. | Seconary contact changed |
2789 | Silver | 7440-22-4 | 3 | Jun 30,1988 | I.A.7. | Primary contact changed |
2790 | Silver | 7440-22-4 | 4 | Jun 1,1989 | II. | Carcinogen summary on-line |
2791 | Silver | 7440-22-4 | 5 | Jun 1,1989 | VI. | Bibliography on-line |
2792 | Silver | 7440-22-4 | 6 | Aug 1,1989 | VI.A. | Oral RfD references added |
2793 | Silver | 7440-22-4 | 7 | Mar 1,1991 | I.A. | Oral RfD summary noted as pending change |
2794 | Silver | 7440-22-4 | 8 | Aug 1,1991 | I.A. | Withdrawn; new oral RfD verified (in preparation) |
2795 | Silver | 7440-22-4 | 9 | Aug 1,1991 | VI.A. | Oral RfD references withdrawn |
2796 | Silver | 7440-22-4 | 10 | Dec 1,1991 | I.A. | Oral RfD summary replaced; RfD changed |
2797 | Silver | 7440-22-4 | 11 | Dec 1,1991 | VI.A. | Oral RfD references replaced |
2798 | Silver | 7440-22-4 | 12 | Jan 1,1992 | IV. | Regulatory actions updated |
2799 | Silver | 7440-22-4 | 13 | Dec 1,1996 | I.A.7. | Secondary contact removed |
2800 | Silver | 7440-22-4 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2801 | Silver | 7440-22-4 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2802 | Silver cyanide | 506-64-9 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
2803 | Silver cyanide | 506-64-9 | 2 | Mar 1,1988 | I.A.5. | Confidence levels raised |
2804 | Silver cyanide | 506-64-9 | 3 | Jan 1,1990 | I.A.2. | Add Philbrick et al. 1979 citation |
2805 | Silver cyanide | 506-64-9 | 4 | Jan 1,1990 | VI. | Bibliography on- line |
2806 | Silver cyanide | 506-64-9 | 5 | Jan 1,1992 | I.A.7. | Primary contact changed |
2807 | Silver cyanide | 506-64-9 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
2808 | Silver cyanide | 506-64-9 | 7 | Feb 1,1996 | I.A.7. | Contact changed |
2809 | Silver cyanide | 506-64-9 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2810 | Silver cyanide | 506-64-9 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2811 | Simazine | 122-34-9 | 1 | Mar 1,1988 | I.A.4. | Data gaps revised |
2812 | Simazine | 122-34-9 | 2 | Jul 1,1989 | I.A. | Withdrawn; new Oral RfD verified (in preparation) |
2813 | Simazine | 122-34-9 | 3 | Sep 1,1989 | II. | Carcinogen assessment now under review |
2814 | Simazine | 122-34-9 | 4 | Nov 1,1989 | I.A. | Oral RfD summary replaced; RfD changed |
2815 | Simazine | 122-34-9 | 5 | Nov 1,1989 | VI. | Bibliography on-line |
2816 | Simazine | 122-34-9 | 6 | Sep 1,1991 | I.A. | Withdrawn; new Oral RfD verified (in preparation) |
2817 | Simazine | 122-34-9 | 7 | Sep 1,1991 | VI.A. | Bibliography withdrawn |
2818 | Simazine | 122-34-9 | 8 | Jan 1,1992 | IV. | Regulatory actions updated |
2819 | Simazine | 122-34-9 | 9 | Sep 1,1993 | I.A. | Oral RfD summary replaced; RfD changed |
2820 | Simazine | 122-34-9 | 10 | Apr 1,1994 | I.A.1. | Study type corrected to 2-year |
2821 | Simazine | 122-34-9 | 11 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September 1995. |
2822 | Simazine | 122-34-9 | 12 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2823 | Simazine | 122-34-9 | 13 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2824 | Sodium azide | 26628-22-8 | 1 | Jan 1,1990 | VI. | Bibliography on-line |
2825 | Sodium azide | 26628-22-8 | 2 | Jan 1,1992 | I.A.7. | Primary contact changed |
2826 | Sodium azide | 26628-22-8 | 3 | Jan 1,1992 | IV. | Regulatory actions updated |
2827 | Sodium azide | 26628-22-8 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2828 | Sodium azide | 26628-22-8 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2829 | Sodium cyanide | 143-33-9 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
2830 | Sodium cyanide | 143-33-9 | 2 | Mar 1,1988 | III.A. | Health Advisory |
2831 | Sodium cyanide | 143-33-9 | 3 | Aug 1,1990 | IV.F.1. | EPA contact changed |
2832 | Sodium cyanide | 143-33-9 | 4 | Jun 1,1991 | VI. | Bibliography on-line |
2833 | Sodium cyanide | 143-33-9 | 5 | Jan 1,1992 | I.A.7. | Primary contact changed |
2834 | Sodium cyanide | 143-33-9 | 6 | Jan 1,1992 | IV. | Regulatory actions updated |
2835 | Sodium cyanide | 143-33-9 | 7 | Feb 1,1996 | I.A.7. | Contact changed |
2836 | Sodium cyanide | 143-33-9 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2837 | Sodium cyanide | 143-33-9 | 10 | Sep 27,2018 | Noncancer Critical | Updated the system value to other so it would show up in the advanced search. |
2838 | Sodium cyanide | 143-33-9 | 12 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2839 | Sodium diethyldithiocarbamate | 148-18-5 | 1 | Mar 1,1988 | I.A.1. | Dose conversion clarified |
2840 | Sodium diethyldithiocarbamate | 148-18-5 | 2 | Jan 1,1990 | VI. | Bibliography on-line |
2841 | Sodium diethyldithiocarbamate | 148-18-5 | 3 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2842 | Sodium diethyldithiocarbamate | 148-18-5 | 4 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2843 | Sodium fluoroacetate | 62-74-8 | 1 | May 1,1991 | I.A. | Oral RfD summary on-line |
2844 | Sodium fluoroacetate | 62-74-8 | 2 | May 1,1991 | VI. | Bibliography on-line |
2845 | Sodium fluoroacetate | 62-74-8 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2846 | Sodium fluoroacetate | 62-74-8 | 4 | Jul 1,1993 | I.A.6. | Other EPA Documentation added |
2847 | Sodium fluoroacetate | 62-74-8 | 5 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2848 | Sodium fluoroacetate | 62-74-8 | 6 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2849 | Strontium | 7440-24-6 | 1 | Aug 1,1991 | I.A. | Oral RfD now uder review |
2850 | Strontium | 7440-24-6 | 2 | Aug 1,1992 | I.A.6. | Work group review dates added |
2851 | Strontium | 7440-24-6 | 3 | Oct 1,1992 | I.A. | Oral RfD summary on-line |
2852 | Strontium | 7440-24-6 | 4 | Oct 1,1992 | VI.A. | Oral RfD references on-line |
2853 | Strontium | 7440-24-6 | 5 | Dec 1,1996 | I.A.7. | Primary contact removed |
2854 | Strontium | 7440-24-6 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2855 | Strontium | 7440-24-6 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2856 | Strychnine | 57-24-9 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected |
2857 | Strychnine | 57-24-9 | 2 | Mar 1,1988 | I.A.4. | Text deleted |
2858 | Strychnine | 57-24-9 | 3 | Jan 1,1990 | VI. | Bibliography on-line |
2859 | Strychnine | 57-24-9 | 4 | Jan 1,1992 | I.A.7. | Primary contact changed |
2860 | Strychnine | 57-24-9 | 5 | Jan 1,1992 | IV. | Regulatory actions updated |
2861 | Strychnine | 57-24-9 | 6 | Apr 1,1987 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2862 | Strychnine | 57-24-9 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2863 | Styrene | 100-42-5 | 1 | Jun 30,1988 | I.A.7. | cONTACTS CHANGED |
2864 | Styrene | 100-42-5 | 2 | Oct 1,1989 | I.B. | Inhalation RfD now under review |
2865 | Styrene | 100-42-5 | 3 | Feb 1,1990 | VI. | Bibliography on-line |
2866 | Styrene | 100-42-5 | 4 | May 1,1990 | I.A. | Oral RfD summary noted as pending change |
2867 | Styrene | 100-42-5 | 5 | May 1,1990 | II. | Carcinogen assessment now under review |
2868 | Styrene | 100-42-5 | 6 | Sep 1,1990 | I.A. | Text edited |
2869 | Styrene | 100-42-5 | 7 | Sep 1,1990 | III.A. | Health Advisory on-line |
2870 | Styrene | 100-42-5 | 8 | Sep 1,1990 | VI.D. | Health Advisory references added |
2871 | Styrene | 100-42-5 | 9 | Jan 1,1992 | IV. | Regulatory actions updated |
2872 | Styrene | 100-42-5 | 10 | Nov 1,1992 | I.B. | Inhalation RfC summary on-line |
2873 | Styrene | 100-42-5 | 11 | Nov 1,1992 | VI.B. | Inhalation RfC references on-line |
2874 | Styrene | 100-42-5 | 12 | Jul 1,1993 | I.B.1. | 'E' notation added |
2875 | Styrene | 100-42-5 | 13 | Aug 1,1995 | I.A., II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2876 | Styrene | 100-42-5 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2877 | Styrene | 100-42-5 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2878 | Systhane | 88671-89-0 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
2879 | Systhane | 88671-89-0 | 2 | Oct 1,1989 | VI. | Bibliography on-line |
2880 | Systhane | 88671-89-0 | 3 | Jan 1,1995 | I.A. | Oral RfD noted as pending change |
2881 | Systhane | 88671-89-0 | 4 | Jan 1,1995 | I.A.6. | Work group review date added |
2882 | Systhane | 88671-89-0 | 5 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2883 | Systhane | 88671-89-0 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April, 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2884 | Systhane | 88671-89-0 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2885 | Tebuthiuron | 34014-18-1 | 1 | Aug 22,1988 | I.A.1. | NOEL corrected; RfD changed |
2886 | Tebuthiuron | 34014-18-1 | 2 | Aug 22,1988 | I.A.2. | Text changed to reflect corrected dose levels |
2887 | Tebuthiuron | 34014-18-1 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2888 | Tebuthiuron | 34014-18-1 | 4 | Jul 1,1992 | I.A.1. | Short citation clarified |
2889 | Tebuthiuron | 34014-18-1 | 5 | Jul 1,1992 | I.A.2. | Principal study clarified |
2890 | Tebuthiuron | 34014-18-1 | 6 | Jul 1,1992 | I.A.4. | Citations added |
2891 | Tebuthiuron | 34014-18-1 | 7 | Jul 1,1992 | VI.A. | Oral RfD references on-line |
2892 | Tebuthiuron | 34014-18-1 | 8 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2893 | Tebuthiuron | 34014-18-1 | 9 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2894 | Terbacil | 5902-51-2 | 1 | Mar 31,1987 | IV. | Regulatory Action section on-line |
2895 | Terbacil | 5902-51-2 | 2 | Sep 1,1989 | I.A. | Oral RfD summary sheet revised |
2896 | Terbacil | 5902-51-2 | 3 | Sep 1,1989 | I.A.5. | Confidence levels changed |
2897 | Terbacil | 5902-51-2 | 4 | Sep 1,1989 | VI. | Bibliography on-line |
2898 | Terbacil | 5902-51-2 | 5 | Jan 1,1992 | IV. | Regulatory action updated |
2899 | Terbacil | 5902-51-2 | 6 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2900 | Terbacil | 5902-51-2 | 7 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2901 | Terbutryn | 886-50-0 | 1 | Sep 26,1988 | I.A. | Oral RfD summary on-line |
2902 | Terbutryn | 886-50-0 | 2 | Dec 1,1989 | VI. | Bibliography on-line |
2903 | Terbutryn | 886-50-0 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2904 | Terbutryn | 886-50-0 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2905 | Terbutryn | 886-50-0 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2906 | Tetrabromodiphenyl ether | 40088-47-9 | 1 | Aug 1,1990 | II. | Carcinogen assessment on-line |
2907 | Tetrabromodiphenyl ether | 40088-47-9 | 2 | Aug 1,1990 | VI. | Bibliography on-line |
2908 | Tetrabromodiphenyl ether | 40088-47-9 | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
2909 | Tetrabromodiphenyl ether | 40088-47-9 | 4 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2910 | Tetrabromodiphenyl ether | 40088-47-9 | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2911 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | 1 | Jun 30,2008 | I., II. | RfD, RfC, and cancer assessment first on line. |
2912 | 2,2',4,4'-Tetrabromodiphenyl ether (BDE-47) | 5436-43-1 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2913 | 1,2,4,5-Tetrachlorobenzene | 95-94-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2914 | Tetrachlorocyclopentadiene | 695-77-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2915 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | 1 | Feb 17,2012 | I.A. | RfD added |
2916 | 2,3,7,8-Tetrachlorodibenzo-p-dioxin | 1746-01-6 | 2 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2917 | 1,1,1,2-Tetrachloroethane | 630-20-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2918 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 1 | Mar 1,1988 | II.B.4. | Confidence statement revised |
2919 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 2 | Mar 1,1988 | II.C.4. | Confidence statement revised |
2920 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 3 | Mar 1,1988 | II.D.3. | Secondary contact changed |
2921 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 4 | Aug 1,1989 | I.A. | Oral RfD under review |
2922 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 5 | Aug 1,1989 | VI. | Bibliography on-line |
2923 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 6 | Jan 1,1991 | II. | Text edited |
2924 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 7 | Jan 1,1991 | II.C.1. | Inhalation slope factor removed (global change) |
2925 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 8 | Jan 1,1992 | IV. | Regulatory Actions updated |
2926 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 9 | Feb 1,1994 | II.D.3. | Primary contact's phone number changed |
2927 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 10 | Aug 1,1995 | I.A. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2928 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 11 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2929 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 12 | Dec 3,2002 | II.D.2. | Screening-Level Literature Review Findings message has been added. |
2930 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 13 | Mar 7,2005 | II.B.1. | Text edited |
2931 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 14 | Sep 30,2010 | I., II., VI. | RfD and cancer assessment updated RfC discussion added. |
2932 | 1,1,2,2-Tetrachloroethane | 79-34-5 | 15 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2933 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 1 | Dec 23,1987 | I.A. | RfD withdrawn pending further review |
2934 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 2 | Mar 1,1988 | I.A. | Revised Oral RfD summary added - RfD changed |
2935 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 3 | Mar 1,1988 | III.A. | Health Advisory added |
2936 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 4 | Jul 1,1989 | VI. | Bibliography on-line |
2937 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 5 | Jun 1,1990 | IV.A.1. | Area code for EPA contact corrected |
2938 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 6 | Jun 1,1990 | IV.F.1. | EPA contact changed |
2939 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 7 | Jan 1,1992 | IV. | Regulatory actions updated |
2940 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 8 | Apr 1,1992 | IV. | Regulatory action section withdrawn |
2941 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 9 | Aug 1,1995 | II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
2942 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 10 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
2943 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 11 | Feb 10,2012 | I., II., VI. | RfD updated. RfC and cancer assessment added. |
2944 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 12 | Oct 25,2017 | Updates Key Values | Removed the basis, POD and UF and added (see note) for users to refer to the IRIS Summary. On the RfD, a table of 4 rows was consolidated to 1 row with the same (see note) update. |
2945 | Tetrachloroethylene (Perchloroethylene) | 127-18-4 | 13 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2946 | 2,3,4,6-Tetrachlorophenol | 58-90-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2947 | Tetrachlorovinphos | 961-11-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2948 | Tetraethyl lead | 78-00-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2949 | Tetraethyldithiopyrophosphate | 3689-24-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2950 | 1,1,1,2-Tetrafluoroethane | 811-97-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2951 | Tetrahydrofuran | 109-99-9 | 1 | Dec 9,2011 | I., II, and VI. | RfD and RfC added, cancer assessment added. |
2952 | Tetrahydrofuran | 109-99-9 | 2 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
2953 | Tetrahydrofuran | 109-99-9 | 3 | Sep 25,2023 | RFC Value | The IRIS program requested a correction for the THF POD BMCL10 being represented incorrectly in the key values table on the chemical landing page. Request included removing the %E2%80%9C-12%E2%80%9D from the RFC value. |
2954 | Thallium (I), soluble salts | Various | 1 | Mar 31,1987 | I.A.6 | Documentation corrected. |
2955 | Thallium (I), soluble salts | Various | 2 | Mar 1,1988 | I.A. | RfD changed -- new study (thallium sulfate). |
2956 | Thallium (I), soluble salts | Various | 3 | Mar 1,1988 | I.A.6. | Verification date changed (thallium sulfate). |
2957 | Thallium (I), soluble salts | Various | 4 | Jun 30,1988 | I.A. | RfD withdrawn. |
2958 | Thallium (I), soluble salts | Various | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
2959 | Thallium (I), soluble salts | Various | 6 | Jun 1,1989 | I.A.6. | Work group review dates revised (thallium acetate, carbonate, chloride, nitrate). |
2960 | Thallium (I), soluble salts | Various | 7 | Sep 1,1990 | I.A. | Text edited. |
2961 | Thallium (I), soluble salts | Various | 8 | Sep 1,1990 | I.A.7. | Secondary contact changed. |
2962 | Thallium (I), soluble salts | Various | 9 | Sep 1,1990 | II. | Carcinogen assessment online. |
2963 | Thallium (I), soluble salts | Various | 10 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
2964 | Thallium (I), soluble salts | Various | 11 | Sep 1,1990 | VI. | Bibliography online. |
2965 | Thallium (I), soluble salts | Various | 12 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
2966 | Thallium (I), soluble salts | Various | 13 | Jan 1,1992 | IV. | Regulatory actions updated. |
2967 | Thallium (I), soluble salts | Various | 14 | Jun 1,1992 | V.B. | Chemical formula corrected (thallium carbonate). |
2968 | Thallium (I), soluble salts | Various | 15 | Apr 1,1997 | III., IV., V. | Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information. |
2969 | Thallium (I), soluble salts | Various | 16 | Dec 3,2002 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate). |
2970 | Thallium (I), soluble salts | Various | 17 | Oct 28,2003 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium acetate). |
2971 | Thallium (I), soluble salts | Various | 18 | Sep 30,2009 | I.A.6., II.D.2. | Screening-level literature review findings message removed. |
2972 | Thallium (I), soluble salts | Various | 19 | Sep 30,2009 | All | IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed. |
2973 | Thallium (I), soluble salts | Various | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2974 | Thallium acetate | 563-68-8 | 1 | Mar 31,1987 | I.A.6 | Documentation corrected. |
2975 | Thallium acetate | 563-68-8 | 2 | Mar 1,1988 | I.A. | RfD changed -- new study (thallium sulfate). |
2976 | Thallium acetate | 563-68-8 | 3 | Mar 1,1988 | I.A.6. | Verification date changed (thallium sulfate). |
2977 | Thallium acetate | 563-68-8 | 4 | Jun 30,1988 | I.A. | RfD withdrawn. |
2978 | Thallium acetate | 563-68-8 | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
2979 | Thallium acetate | 563-68-8 | 6 | Jun 1,1989 | I.A.6. | Work group review dates revised (thallium acetate, carbonate, chloride, nitrate). |
2980 | Thallium acetate | 563-68-8 | 7 | Sep 1,1990 | I.A. | Text edited. |
2981 | Thallium acetate | 563-68-8 | 8 | Sep 1,1990 | I.A.7. | Secondary contact changed. |
2982 | Thallium acetate | 563-68-8 | 9 | Sep 1,1990 | II. | Carcinogen assessment online. |
2983 | Thallium acetate | 563-68-8 | 10 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
2984 | Thallium acetate | 563-68-8 | 11 | Sep 1,1990 | VI. | Bibliography online. |
2985 | Thallium acetate | 563-68-8 | 12 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
2986 | Thallium acetate | 563-68-8 | 13 | Jan 1,1992 | IV. | Regulatory actions updated. |
2987 | Thallium acetate | 563-68-8 | 14 | Jun 1,1992 | V.B. | Chemical formula corrected (thallium carbonate). |
2988 | Thallium acetate | 563-68-8 | 15 | Apr 1,1997 | III., IV., V. | Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information. |
2989 | Thallium acetate | 563-68-8 | 16 | Dec 3,2002 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate). |
2990 | Thallium acetate | 563-68-8 | 17 | Oct 28,2003 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium acetate). |
2991 | Thallium acetate | 563-68-8 | 18 | Sep 30,2009 | I.A.6., II.D.2. | Screening-level literature review findings message removed. |
2992 | Thallium acetate | 563-68-8 | 19 | Sep 30,2009 | All | IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed. |
2993 | Thallium acetate | 563-68-8 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
2994 | Thallium carbonate | 6533-73-9 | 1 | Mar 31,1987 | I.A.6 | Documentation corrected. |
2995 | Thallium carbonate | 6533-73-9 | 2 | Mar 1,1988 | I.A. | RfD changed -- new study (thallium sulfate). |
2996 | Thallium carbonate | 6533-73-9 | 3 | Mar 1,1988 | I.A.6. | Verification date changed (thallium sulfate). |
2997 | Thallium carbonate | 6533-73-9 | 4 | Jun 30,1988 | I.A. | RfD withdrawn. |
2998 | Thallium carbonate | 6533-73-9 | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
2999 | Thallium carbonate | 6533-73-9 | 6 | Jun 1,1989 | I.A.6. | Work group review dates revised (thallium acetate, carbonate, chloride, nitrate). |
3000 | Thallium carbonate | 6533-73-9 | 7 | Sep 1,1990 | I.A. | Text edited. |
3001 | Thallium carbonate | 6533-73-9 | 8 | Sep 1,1990 | I.A.7. | Secondary contact changed. |
3002 | Thallium carbonate | 6533-73-9 | 9 | Sep 1,1990 | II. | Carcinogen assessment online. |
3003 | Thallium carbonate | 6533-73-9 | 10 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
3004 | Thallium carbonate | 6533-73-9 | 11 | Sep 1,1990 | VI. | Bibliography online. |
3005 | Thallium carbonate | 6533-73-9 | 12 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
3006 | Thallium carbonate | 6533-73-9 | 13 | Jan 1,1992 | IV. | Regulatory actions updated. |
3007 | Thallium carbonate | 6533-73-9 | 14 | Jun 1,1992 | V.B. | Chemical formula corrected (thallium carbonate). |
3008 | Thallium carbonate | 6533-73-9 | 15 | Apr 1,1997 | III., IV., V. | Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information. |
3009 | Thallium carbonate | 6533-73-9 | 16 | Dec 3,2002 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate). |
3010 | Thallium carbonate | 6533-73-9 | 17 | Oct 28,2003 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium acetate). |
3011 | Thallium carbonate | 6533-73-9 | 18 | Sep 30,2009 | I.A.6., II.D.2. | Screening-level literature review findings message removed. |
3012 | Thallium carbonate | 6533-73-9 | 19 | Sep 30,2009 | All | IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed. |
3013 | Thallium carbonate | 6533-73-9 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3014 | Thallium chloride | 7791-12-0 | 1 | Mar 31,1987 | I.A.6 | Documentation corrected. |
3015 | Thallium chloride | 7791-12-0 | 2 | Mar 1,1988 | I.A. | RfD changed -- new study (thallium sulfate). |
3016 | Thallium chloride | 7791-12-0 | 3 | Mar 1,1988 | I.A.6. | Verification date changed (thallium sulfate). |
3017 | Thallium chloride | 7791-12-0 | 4 | Jun 30,1988 | I.A. | RfD withdrawn. |
3018 | Thallium chloride | 7791-12-0 | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
3019 | Thallium chloride | 7791-12-0 | 6 | Jun 1,1989 | I.A.6. | Work group review dates revised (thallium acetate, carbonate, chloride, nitrate). |
3020 | Thallium chloride | 7791-12-0 | 7 | Sep 1,1990 | I.A. | Text edited. |
3021 | Thallium chloride | 7791-12-0 | 8 | Sep 1,1990 | I.A.7. | Secondary contact changed. |
3022 | Thallium chloride | 7791-12-0 | 9 | Sep 1,1990 | II. | Carcinogen assessment online. |
3023 | Thallium chloride | 7791-12-0 | 10 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
3024 | Thallium chloride | 7791-12-0 | 11 | Sep 1,1990 | VI. | Bibliography online. |
3025 | Thallium chloride | 7791-12-0 | 12 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
3026 | Thallium chloride | 7791-12-0 | 13 | Jan 1,1992 | IV. | Regulatory actions updated. |
3027 | Thallium chloride | 7791-12-0 | 14 | Jun 1,1992 | V.B. | Chemical formula corrected (thallium carbonate). |
3028 | Thallium chloride | 7791-12-0 | 15 | Apr 1,1997 | III., IV., V. | Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information. |
3029 | Thallium chloride | 7791-12-0 | 16 | Dec 3,2002 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate). |
3030 | Thallium chloride | 7791-12-0 | 17 | Oct 28,2003 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium acetate). |
3031 | Thallium chloride | 7791-12-0 | 18 | Sep 30,2009 | I.A.6., II.D.2. | Screening-level literature review findings message removed. |
3032 | Thallium chloride | 7791-12-0 | 19 | Sep 30,2009 | All | IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed. |
3033 | Thallium chloride | 7791-12-0 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3034 | Thallium nitrate | 10102-45-1 | 1 | Mar 31,1987 | I.A.6 | Documentation corrected. |
3035 | Thallium nitrate | 10102-45-1 | 2 | Mar 1,1988 | I.A. | RfD changed -- new study (thallium sulfate). |
3036 | Thallium nitrate | 10102-45-1 | 3 | Mar 1,1988 | I.A.6. | Verification date changed (thallium sulfate). |
3037 | Thallium nitrate | 10102-45-1 | 4 | Jun 30,1988 | I.A. | RfD withdrawn. |
3038 | Thallium nitrate | 10102-45-1 | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
3039 | Thallium nitrate | 10102-45-1 | 6 | Jun 1,1989 | I.A.6. | Work group review dates revised (thallium acetate, carbonate, chloride, nitrate). |
3040 | Thallium nitrate | 10102-45-1 | 7 | Sep 1,1990 | I.A. | Text edited. |
3041 | Thallium nitrate | 10102-45-1 | 8 | Sep 1,1990 | I.A.7. | Secondary contact changed. |
3042 | Thallium nitrate | 10102-45-1 | 9 | Sep 1,1990 | II. | Carcinogen assessment online. |
3043 | Thallium nitrate | 10102-45-1 | 10 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
3044 | Thallium nitrate | 10102-45-1 | 11 | Sep 1,1990 | VI. | Bibliography online. |
3045 | Thallium nitrate | 10102-45-1 | 12 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
3046 | Thallium nitrate | 10102-45-1 | 13 | Jan 1,1992 | IV. | Regulatory actions updated. |
3047 | Thallium nitrate | 10102-45-1 | 14 | Jun 1,1992 | V.B. | Chemical formula corrected (thallium carbonate). |
3048 | Thallium nitrate | 10102-45-1 | 15 | Apr 1,1997 | III., IV., V. | Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information. |
3049 | Thallium nitrate | 10102-45-1 | 16 | Dec 3,2002 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate). |
3050 | Thallium nitrate | 10102-45-1 | 17 | Oct 28,2003 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium acetate). |
3051 | Thallium nitrate | 10102-45-1 | 18 | Sep 30,2009 | I.A.6., II.D.2. | Screening-level literature review findings message removed. |
3052 | Thallium nitrate | 10102-45-1 | 19 | Sep 30,2009 | All | IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed. |
3053 | Thallium nitrate | 10102-45-1 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3054 | Thallium oxide | 1314-32-5 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected. |
3055 | Thallium oxide | 1314-32-5 | 2 | Jun 30,1988 | I.A. | RfD withdrawn. |
3056 | Thallium oxide | 1314-32-5 | 3 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
3057 | Thallium oxide | 1314-32-5 | 4 | May 1,1989 | I.A. | Oral RfD withdrawn pending further review. |
3058 | Thallium oxide | 1314-32-5 | 5 | Sep 1,1990 | II. | Carcinogen assessment online. |
3059 | Thallium oxide | 1314-32-5 | 6 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
3060 | Thallium oxide | 1314-32-5 | 7 | Sep 1,1990 | VI. | Bibliography online. |
3061 | Thallium oxide | 1314-32-5 | 8 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
3062 | Thallium oxide | 1314-32-5 | 9 | Jan 1,1992 | IV. | Regulatory actions updated. |
3063 | Thallium oxide | 1314-32-5 | 10 | Aug 1,1993 | I.A. | Work group review date added. |
3064 | Thallium oxide | 1314-32-5 | 11 | Aug 1,1993 | I.A. | EPA contact changed. |
3065 | Thallium oxide | 1314-32-5 | 12 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE work groups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS pilot program replaced the work group functions beginning in September 1995. |
3066 | Thallium oxide | 1314-32-5 | 13 | Jul 1,1996 | I.A. | WG review date corrected contact changed. |
3067 | Thallium oxide | 1314-32-5 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulated Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
3068 | Thallium oxide | 1314-32-5 | 15 | Dec 3,2002 | I.A., II.D.2. | Screening-Level Literature Review Findings message has been added. |
3069 | Thallium oxide | 1314-32-5 | 16 | Sep 30,2009 | All | RfD, RfC, and cancer sections updated. |
3070 | Thallium oxide | 1314-32-5 | 17 | Sep 30,2009 | All | Name of file changed from thallic oxide to thallium oxide. |
3071 | Thallium oxide | 1314-32-5 | 18 | Sep 30,2009 | I.A., II.D.2. | Screening-Level Literature Review Findings message removed. |
3072 | Thallium oxide | 1314-32-5 | 19 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3073 | Thallium selenite | 12039-52-0 | 1 | Mar 31,1987 | I.A.6. | Documentation corrected. |
3074 | Thallium selenite | 12039-52-0 | 2 | Jun 30,1988 | I.A. | RfD withdrawn. |
3075 | Thallium selenite | 12039-52-0 | 3 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
3076 | Thallium selenite | 12039-52-0 | 4 | May 1,1989 | I.A. | Oral RfD noted as pending change. |
3077 | Thallium selenite | 12039-52-0 | 5 | Jun 1,1989 | I.A.6. | Work group review dates revised. |
3078 | Thallium selenite | 12039-52-0 | 6 | Jun 1,1989 | I.A.7. | Secondary contact changed. |
3079 | Thallium selenite | 12039-52-0 | 7 | Sep 1,1990 | I.A. | Text edited. |
3080 | Thallium selenite | 12039-52-0 | 8 | Sep 1,1990 | II. | Carcinogen assessment online. |
3081 | Thallium selenite | 12039-52-0 | 9 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
3082 | Thallium selenite | 12039-52-0 | 10 | Sep 1,1990 | VI. | Bibliography online. |
3083 | Thallium selenite | 12039-52-0 | 11 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
3084 | Thallium selenite | 12039-52-0 | 12 | Jan 1,1992 | IV. | Regulatory actions updated. |
3085 | Thallium selenite | 12039-52-0 | 13 | Aug 1,1993 | I.A. | Withdrawn inadequate data. |
3086 | Thallium selenite | 12039-52-0 | 14 | Aug 1,1993 | I.A. | Work group review date added. |
3087 | Thallium selenite | 12039-52-0 | 15 | Aug 1,1993 | I.A. | EPA contact changed. |
3088 | Thallium selenite | 12039-52-0 | 16 | Aug 1,1993 | VI.A. | Oral RfD references withdrawn. |
3089 | Thallium selenite | 12039-52-0 | 17 | Aug 1,1995 | I.A., I.A.6. | EPA's RfD/RfC and CRAVE work groups were discontinued in May 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS pilot program replaced the work group functions beginning in September 1995. |
3090 | Thallium selenite | 12039-52-0 | 18 | Jul 1,1996 | I.A. | Contact changed. |
3091 | Thallium selenite | 12039-52-0 | 19 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulated Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
3092 | Thallium selenite | 12039-52-0 | 20 | Oct 28,2003 | I.A., II.D.2. | Screening-Level Literature Review Findings message has been added. |
3093 | Thallium selenite | 12039-52-0 | 21 | Sep 30,2009 | All | RfD, RfC, and cancer sections updated. |
3094 | Thallium selenite | 12039-52-0 | 22 | Sep 30,2009 | I.A., II.D.2. | Screening-Level Literature Review Findings message removed. |
3095 | Thallium selenite | 12039-52-0 | 23 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3096 | Thallium(I) sulfate | 7446-18-6 | 1 | Mar 31,1987 | I.A.6 | Documentation corrected. |
3097 | Thallium(I) sulfate | 7446-18-6 | 2 | Mar 1,1988 | I.A. | RfD changed -- new study (thallium sulfate). |
3098 | Thallium(I) sulfate | 7446-18-6 | 3 | Mar 1,1988 | I.A.6. | Verification date changed (thallium sulfate). |
3099 | Thallium(I) sulfate | 7446-18-6 | 4 | Jun 30,1988 | I.A. | RfD withdrawn. |
3100 | Thallium(I) sulfate | 7446-18-6 | 5 | Sep 7,1988 | I.A. | Revised oral RfD summary added. |
3101 | Thallium(I) sulfate | 7446-18-6 | 6 | Jun 1,1989 | I.A.6. | Work group review dates revised (thallium acetate, carbonate, chloride, nitrate). |
3102 | Thallium(I) sulfate | 7446-18-6 | 7 | Sep 1,1990 | I.A. | Text edited. |
3103 | Thallium(I) sulfate | 7446-18-6 | 8 | Sep 1,1990 | I.A.7. | Secondary contact changed. |
3104 | Thallium(I) sulfate | 7446-18-6 | 9 | Sep 1,1990 | II. | Carcinogen assessment online. |
3105 | Thallium(I) sulfate | 7446-18-6 | 10 | Sep 1,1990 | IV.F.1. | EPA contact changed. |
3106 | Thallium(I) sulfate | 7446-18-6 | 11 | Sep 1,1990 | VI. | Bibliography online. |
3107 | Thallium(I) sulfate | 7446-18-6 | 12 | Aug 1,1991 | VI.C. | Kada et al. (1980) citation corrected. |
3108 | Thallium(I) sulfate | 7446-18-6 | 13 | Jan 1,1992 | IV. | Regulatory actions updated. |
3109 | Thallium(I) sulfate | 7446-18-6 | 14 | Jun 1,1992 | V.B. | Chemical formula corrected (thallium carbonate). |
3110 | Thallium(I) sulfate | 7446-18-6 | 15 | Apr 1,1997 | III., IV., V. | Drinking water health advisories, EPA regulated actions, and supplementary data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA program offices for this information. |
3111 | Thallium(I) sulfate | 7446-18-6 | 16 | Dec 3,2002 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium sulfate, carbonate, chloride, nitrate). |
3112 | Thallium(I) sulfate | 7446-18-6 | 17 | Oct 28,2003 | I.A.6., II.D.2. | Screening-level literature review findings message has been added (thallium acetate). |
3113 | Thallium(I) sulfate | 7446-18-6 | 18 | Sep 30,2009 | I.A.6., II.D.2. | Screening-level literature review findings message removed. |
3114 | Thallium(I) sulfate | 7446-18-6 | 19 | Sep 30,2009 | All | IRIS Summaries for five thallium soluble salts combined into a single Summary. RfD, RfC, and cancer sections updated. RfD removed. |
3115 | Thallium(I) sulfate | 7446-18-6 | 20 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3116 | Thiobencarb | 28249-77-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3117 | Thiophanate-methyl | 23564-05-8 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
3118 | Thiophanate-methyl | 23564-05-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3119 | Thiram | 137-26-8 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
3120 | Thiram | 137-26-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3121 | Toluene | 108-88-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3122 | 2,4-/2,6-Toluene diisocyanate mixture (TDI) | 26471-62-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3123 | Toxaphene | 8001-35-2 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
3124 | Toxaphene | 8001-35-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3125 | Tralomethrin | 66841-25-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3126 | Triallate | 2303-17-5 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
3127 | Triallate | 2303-17-5 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3128 | Triasulfuron | 82097-50-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3129 | 1,2,4-Tribromobenzene | 615-54-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3130 | Tribromochloromethane | 594-15-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3131 | Tribromodiphenyl ether | 49690-94-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3132 | Tributyltin oxide (TBTO) | 56-35-9 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3133 | 1,1,2-Trichloro-1,2,2-trifluoroethane (CFC-113) | 76-13-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3134 | Trichloroacetic acid | 76-03-9 | 1 | Sep 30,2011 | I., II. | RfD and cancer assessment sections updated. RfC discussion added.%0A |
3135 | Trichloroacetic acid | 76-03-9 | 2 | Oct 1,1992 | I.A. | Oral RfD now under review |
3136 | Trichloroacetic acid | 76-03-9 | 3 | Mar 1,1993 | II. | Carcinogenicity assessment now under review |
3137 | Trichloroacetic acid | 76-03-9 | 4 | May 1,1993 | I.A., II. | Work group review date added |
3138 | Trichloroacetic acid | 76-03-9 | 5 | Jul 1,1993 | I.A. | Work group review date added |
3139 | Trichloroacetic acid | 76-03-9 | 6 | Sep 1,1993 | II. | Work group review date added |
3140 | Trichloroacetic acid | 76-03-9 | 7 | Jan 1,1994 | I.A. | Work group review date added |
3141 | Trichloroacetic acid | 76-03-9 | 8 | Aug 1,1995 | I.A., II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
3142 | Trichloroacetic acid | 76-03-9 | 9 | Feb 1,1996 | II. | Carcinogenicity assessment on-line |
3143 | Trichloroacetic acid | 76-03-9 | 10 | Feb 1,1996 | VI.C. | Carcinogenicity assessment references on-line |
3144 | Trichloroacetic acid | 76-03-9 | 11 | Mar 1,1996 | II.A.3. | Citation revised |
3145 | Trichloroacetic acid | 76-03-9 | 12 | Mar 1,1996 | II.D.3. | Primary contact changed |
3146 | Trichloroacetic acid | 76-03-9 | 13 | Mar 1,1996 | VI.C. | U.S. EPA, 1993 revised to DeAngelo, 1993 |
3147 | Trichloroacetic acid | 76-03-9 | 14 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
3148 | Trichloroacetic acid | 76-03-9 | 15 | Dec 3,2002 | II.D.2. | Screening-Level Literature Review Findings message has been added. |
3149 | Trichloroacetic acid | 76-03-9 | 16 | Jul 30,2003 | I., II. | This chemical is being reassessed under the IRIS Program. |
3150 | Trichloroacetic acid | 76-03-9 | 17 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3151 | 1,2,4-Trichlorobenzene | 120-82-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3152 | Trichlorocyclopentadiene | 77323-84-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3153 | 1,1,1-Trichloroethane | 71-55-6 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
3154 | 1,1,2-Trichloroethane | 79-00-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3155 | Trichloroethylene | 79-01-6 | 1 | Mar 1,1988 | II.B.3. | Text revised |
3156 | Trichloroethylene | 79-01-6 | 2 | Mar 1,1988 | II.B.4. | Confidence statement revised |
3157 | Trichloroethylene | 79-01-6 | 3 | Mar 1,1988 | II.C.2. | Text added |
3158 | Trichloroethylene | 79-01-6 | 4 | Mar 1,1988 | II.C.4. | Confidence statement revised |
3159 | Trichloroethylene | 79-01-6 | 5 | Mar 1,1988 | II.D.4. | Documentation corrected |
3160 | Trichloroethylene | 79-01-6 | 6 | May 1,1989 | II. | Carcinogen assessment summary noted as pending change |
3161 | Trichloroethylene | 79-01-6 | 7 | Jun 1,1989 | II.D.3. | Primary contact changed |
3162 | Trichloroethylene | 79-01-6 | 8 | Jul 1,1989 | II. | Withdrawn new assessment verified (in preparation) |
3163 | Trichloroethylene | 79-01-6 | 9 | Dec 1,1989 | I.B. | Inhalation RfD now under review |
3164 | Trichloroethylene | 79-01-6 | 10 | Jun 1,1990 | IV.A.1. | Area code for EPA contact corrected |
3165 | Trichloroethylene | 79-01-6 | 11 | Jun 1,1990 | IV.F.1. | EPA contact changed |
3166 | Trichloroethylene | 79-01-6 | 12 | Jan 1,1992 | IV. | Regulatory actions updated |
3167 | Trichloroethylene | 79-01-6 | 13 | Apr 1,1992 | IV.A.1. | CAA regulatory action withdrawn |
3168 | Trichloroethylene | 79-01-6 | 14 | Jul 1,1992 | II. | EPA contact changed work group review dates added |
3169 | Trichloroethylene | 79-01-6 | 15 | Aug 1,1992 | I.A. | Oral RfD now under review |
3170 | Trichloroethylene | 79-01-6 | 16 | Nov 1,1993 | II. | Work group review date added |
3171 | Trichloroethylene | 79-01-6 | 17 | Jul 1,1994 | II. | Work group review date added |
3172 | Trichloroethylene | 79-01-6 | 18 | Aug 1,1995 | I.A., I.B., II. | EPA's RfD/RfC and CRAVE workgroups were discontinued in May, 1995. Chemical substance reviews that were not completed by September 1995 were taken out of IRIS review. The IRIS Pilot Program replaced the workgroup functions beginning in September, 1995. |
3173 | Trichloroethylene | 79-01-6 | 19 | Apr 1,1997 | III., IV., V. | Drinking Water Health Advisories, EPA Regulatory Actions, and Supplementary Data were removed from IRIS on or before April 1997. IRIS users were directed to the appropriate EPA Program Offices for this information. |
3174 | Trichloroethylene | 79-01-6 | 20 | Jan 2,1998 | I., II. | This chemical is being reassessed under the IRIS Program. |
3175 | Trichloroethylene | 79-01-6 | 21 | Jun 5,2003 | Status of Data | Correction of administrative error concerning the date the carcinogenicity assessment (II.) was withdrawn from IRIS. |
3176 | Trichloroethylene | 79-01-6 | 22 | Jun 7,2004 | VIII | Text revised. |
3177 | Trichloroethylene | 79-01-6 | 23 | Sep 28,2011 | I., II., VI. | RfD, RfC, and Cancer assessment added. |
3178 | Trichloroethylene | 79-01-6 | 24 | Jul 10,2018 | Key Values Table | A footnote was added for ADAF. |
3179 | Trichloroethylene | 79-01-6 | 25 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3180 | Trichlorofluoromethane | 75-69-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3181 | 2,4,6-Trichlorophenol | 88-06-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3182 | 2,4,5-Trichlorophenol | 95-95-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3183 | 2(2,4,5-Trichlorophenoxy) propionic acid (2,4,5-TP) | 93-72-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3184 | 2,4,5-Trichlorophenoxyacetic acid (2,4,5-T) | 93-76-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3185 | 1,1,2-Trichloropropane | 598-77-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3186 | 1,2,3-Trichloropropane | 96-18-4 | 1 | Sep 30,2009 | I.A., I.B., II. | Revised RfD, added RfC and carcinogenicity assessments. |
3187 | 1,2,3-Trichloropropane | 96-18-4 | 2 | Jul 10,2018 | Key Values Table | A footnote was added for ADAF. |
3188 | 1,2,3-Trichloropropane | 96-18-4 | 3 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3189 | Tricresol | 1319-77-3 | 1 | Oct 24,2018 | Archived | Archived nulls at the request of the NCEA Center Director (T. Bahadori). |
3190 | Tricresol | 1319-77-3 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3191 | Tridiphane | 58138-08-2 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
3192 | Tridiphane | 58138-08-2 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3193 | Triethylamine | 121-44-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3194 | Triethylene glycol monobutyl ether | 143-22-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3195 | Triethylene glycol monoethyl ether | 112-50-5 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3196 | Trifluralin | 1582-09-8 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3197 | 1,3,5-Trimethylbenzene | 108-67-8 | 1 | Sep 9,2016 | All | RfD, RfC and carcinogenic assessment added. |
3198 | 1,3,5-Trimethylbenzene | 108-67-8 | 2 | Aug 2,2018 | Updates to Key Value | Added chronic/subchronic values into the key table to correspond with the Toxicological Review (TR). Made additional corrections to the system specific values based on input from the CM from the TR. |
3199 | 1,3,5-Trimethylbenzene | 108-67-8 | 3 | Aug 13,2018 | IRIS Summary | Renamed label to Executive Summary to match the linked document. |
3200 | 1,3,5-Trimethylbenzene | 108-67-8 | 4 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
3201 | 1,2,3-Trimethylbenzene | 526-73-8 | 1 | Sep 9,2016 | All | RfD, RfC, and cancer assessment added. |
3202 | 1,2,3-Trimethylbenzene | 526-73-8 | 2 | Aug 2,2018 | Updates to Key Value | Added chronic/subchronic values into the key table to correspond with the Toxicological Review (TR). Made additional corrections to the system specific values based on input from the CM from the TR. |
3203 | 1,2,3-Trimethylbenzene | 526-73-8 | 3 | Aug 13,2018 | IRIS Summary | Renamed label to Executive Summary to match the linked document. |
3204 | 1,2,3-Trimethylbenzene | 526-73-8 | 4 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
3205 | 1,2,4-Trimethylbenzene | 95-63-6 | 1 | Sep 9,2016 | All | RfD, RfC and cancer assessment added. |
3206 | 1,2,4-Trimethylbenzene | 95-63-6 | 4 | Aug 2,2018 | Updates to Key Value | Added chronic/subchronic values into the key table to correspond with the Toxicological Review (TR). Made additional corrections to the system specific values based on input from the CM from the TR. |
3207 | 1,2,4-Trimethylbenzene | 95-63-6 | 5 | Aug 13,2018 | IRIS Summary | Renamed label to Executive Summary to match the linked document. |
3208 | 1,2,4-Trimethylbenzene | 95-63-6 | 6 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
3209 | 2,2,4-Trimethylpentane | 540-84-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3210 | 1,3,5-Trinitrobenzene | 99-35-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3211 | 2,4,6-Trinitrotoluene (TNT) | 118-96-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3212 | Uranium, natural | 7440-61-1 | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
3213 | Uranium, natural | 7440-61-1 | 2 | Dec 20,2018 | All | EPA suspended the development of this assessment. |
3214 | Uranium, natural | 7440-61-1 | 3 | Jun 28,2021 | All | EPA removed the suspension and re-started this assessment. |
3215 | Uranium, soluble salts | Various | 1 | Oct 1,1989 | I.A. | Oral RfD summary on-line |
3216 | Uranium, soluble salts | Various | 2 | Oct 1,1989 | VI. | Bibliography on-line |
3217 | Uranium, soluble salts | Various | 3 | Jan 1,1992 | IV. | Regulatory Action section on-line |
3218 | Uranium, soluble salts | Various | 5 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3219 | Urea | 57-13-6 | 1 | Jul 13,2011 | I., II., VI. | RfD and RfC discussion added cancer assessment added. |
3220 | Urea | 57-13-6 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3221 | Vanadium and Compounds (Inhalation) | Various | 1 | May 28,2021 | Step 1 | EPA released the draft document, IRIS Assessment Plan (IAP) for Inhalation Exposure to Vanadium and Compounds, for a 30-day public review and comment period. |
3222 | Vanadium and Compounds (Oral) | Various | 1 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link and DTX SID number |
3223 | Vanadium pentoxide | 1314-62-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3224 | Vernam | 1929-77-7 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
3225 | Vernam | 1929-77-7 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3226 | Vinclozolin | 50471-44-8 | 1 | Jul 15,2016 | Archived Chemical | IRIS working with OPP agreed to mark this pesticide chemical archived. |
3227 | Vinclozolin | 50471-44-8 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3228 | Vinyl acetate | 108-05-4 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3229 | Vinyl bromide | 593-60-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3230 | Vinyl chloride | 75-01-4 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3231 | Warfarin | 81-81-2 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3232 | White phosphorus | 7723-14-0 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3233 | Xylenes | 1330-20-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3234 | Zinc and Compounds | 7440-66-6 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3235 | Zinc cyanide | 557-21-1 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3236 | Zinc phosphide | 1314-84-7 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3237 | Zineb | 12122-67-7 | 1 | May 15,2019 | Pesticide | Marked this chemical as a pesticide. %5BSR%5D |
3238 | Zineb | 12122-67-7 | 2 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3239 | n-Butanol | 71-36-3 | 1 | Jul 15,2020 | Related Topics | Added Chemicals Dashboard link |
3240 | tert-Butyl Alcohol (tBA) | 75-65-0 | 1 | Jul 19,2016 | Draft Document | EPA released the draft document (step 1) for public review and comment. This is a new assessment so a new chemical landing page (draft) was also launched. |
3241 | tert-Butyl Alcohol (tBA) | 75-65-0 | 2 | Jul 14,2020 | Related Topics | Added Chemicals Dashboard link |
3242 | tert-Butyl Alcohol (tBA) | 75-65-0 | 3 | Aug 13,2021 | All | EPA completed a reassessment, updating all values. |